
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="utf-8"?-->


     <title></title>
<meta http-equiv="Content-Type" content="text/html">

<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_SEEL_seelostx.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001017491 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_07A_XDX_seelos.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_Years_0_utr%2D%2DY -->

<div style="display: none">
<ix:header>
 <ix:hidden>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001017491</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0065" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0085" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0089" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0098" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0103" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0106" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0110" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0112" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0118" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0119" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0124" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0125" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0197" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0200" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0203" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0206" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0229" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0231" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0234" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0236" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0242" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0249" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0253" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0255" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0261" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0268" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0273" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0274" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0284" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0286" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0289" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0291" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0296" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0298" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0303" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0307" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0309" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0313" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0315" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0319" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0321" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0328" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0335" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0342" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0347" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0348" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0370" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0380" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0383" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0386" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0389" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0416" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0424" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0431" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0434" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0436" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0457" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0458" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0467" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0470" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0473" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0476" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0479" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0481" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0514" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0543" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0544" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0547" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0548" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0552" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0553" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0555" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0556" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0560" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0565" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0566" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0569" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0570" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0577" unitref="Pure" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0586" unitref="Pure" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0597" unitref="Pure" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0599" unitref="Pure" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0895" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0897" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0966" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0968" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0974" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0975" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1016" unitref="Pure" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1017" unitref="Pure" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric format="ixt:datemonthdayyear" id="xdx2ixbrl1075">12/31/2036</ix:nonnumeric>
  <ix:nonnumeric format="ixt:datemonthdayyear" id="xdx2ixbrl1078">12/31/2036</ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1085" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1089" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1103" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1104" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1134" unitref="Pure" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl1135" unitref="Pure" xs:nil="true"></ix:nonfraction>
  <ix:nonnumeric id="xdx2ixbrl1144">P292D</ix:nonnumeric>
  <ix:nonfraction id="xdx2ixbrl1149" unitref="USD" xs:nil="true"></ix:nonfraction>
  </ix:hidden>
 <ix:references>
  <link:schemaref xlink:href="seel-20211231.xsd" xlink:type="simple">
  </link:schemaref></ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember329729531">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-12-31_custom_NovemberAndDecember2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:NovemberAndDecember2021Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_December2020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:December2020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_September42020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September42020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-09-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_September42020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September42020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-09_custom_September42020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September42020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-012019-08-31_custom_August2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:August2019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-08-01</xbrli:startdate>
        <xbrli:enddate>2019-08-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-012019-08-30_custom_August2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:August2019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-08-01</xbrli:startdate>
        <xbrli:enddate>2019-08-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_May242021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May242021Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-24_custom_May242021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May242021Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_January282021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January282021Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-28_custom_January282021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January282021Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-012020-03-31_custom_March162020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:March162020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-03-01</xbrli:startdate>
        <xbrli:enddate>2020-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-16_custom_March162020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:March162020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-28_custom_February132020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:February132020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-02-01</xbrli:startdate>
        <xbrli:enddate>2020-02-28</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-13_custom_February132020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:February132020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-28_custom_February192020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:February192020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-02-01</xbrli:startdate>
        <xbrli:enddate>2020-02-28</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-19_custom_February192020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:February192020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_IXLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:IXLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-12-31_custom_IXLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:IXLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_IXLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:IXLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2022-01-01</xbrli:startdate>
        <xbrli:enddate>2022-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_January22020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January22020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_custom_May112020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May112020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-05-01</xbrli:startdate>
        <xbrli:enddate>2020-05-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-112020-12-31_custom_May112020Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:May112020Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-05-11</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_January242019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:January242019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_March72019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:March72019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_March72019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:March72019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-012016-09-30_custom_LicensefromLigandPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:LicensefromLigandPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2016-09-01</xbrli:startdate>
        <xbrli:enddate>2016-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_LicensefromLigandPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:LicensefromLigandPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-01-01</xbrli:startdate>
        <xbrli:enddate>2019-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:LicensefromLigandPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-012018-03-31_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2018-03-01</xbrli:startdate>
        <xbrli:enddate>2018-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-05-012018-05-31_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2018-05-01</xbrli:startdate>
        <xbrli:enddate>2018-05-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-01-31_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-01-01</xbrli:startdate>
        <xbrli:enddate>2019-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-01-01</xbrli:startdate>
        <xbrli:enddate>2019-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-10-31_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2019-10-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-04-30_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-04-01</xbrli:startdate>
        <xbrli:enddate>2020-04-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-07-01</xbrli:startdate>
        <xbrli:enddate>2020-07-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-09-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromVyeraPharmaceuticalsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-012019-08-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-08-01</xbrli:startdate>
        <xbrli:enddate>2019-08-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2022-01-01</xbrli:startdate>
        <xbrli:enddate>2022-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_WegLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:WegLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-012019-02-28_custom_AssetsfromBioblastPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromBioblastPharmaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-02-01</xbrli:startdate>
        <xbrli:enddate>2019-02-28</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-29_custom_AssetsfromBioblastPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromBioblastPharmaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-02-01</xbrli:startdate>
        <xbrli:enddate>2020-02-29</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_AssetsfromBioblastPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromBioblastPharmaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-01-01</xbrli:startdate>
        <xbrli:enddate>2019-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AssetsfromBioblastPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:AssetsfromBioblastPharmaMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_custom_UCRegentsLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:UCRegentsLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-03-01</xbrli:startdate>
        <xbrli:enddate>2019-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_UCRegentsLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:UCRegentsLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-01-01</xbrli:startdate>
        <xbrli:enddate>2019-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_UCRegentsLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:UCRegentsLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_DukeLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:DukeLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-06-01</xbrli:startdate>
        <xbrli:enddate>2019-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_custom_DukeLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:DukeLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-04-01</xbrli:startdate>
        <xbrli:enddate>2019-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_DukeLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">SEEL:DukeLicenseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-30_custom_Vovember2021LindSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">SEEL:Vovember2021LindSecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31_custom_December2021SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-12-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-02_custom_December2021SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_December2021SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">SEEL:December2021SPAsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_LindSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">SEEL:LindSecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_December17SPAsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">SEEL:December17SPAsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_custom_PPPLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">SEEL:PPPLoanMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-05-01</xbrli:startdate>
        <xbrli:enddate>2020-05-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-31_custom_PPPLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">SEEL:PPPLoanMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_September2020WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-012019-08-31_custom_September2020WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September2020WarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-08-01</xbrli:startdate>
        <xbrli:enddate>2019-08-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_September2020WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:September2020WarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_September2020WarrantsMember329739390">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:September2020WarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_August2019WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-012019-08-31_custom_August232019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:August232019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-08-01</xbrli:startdate>
        <xbrli:enddate>2019-08-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_August2019WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">SEEL:August2019WarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_August2019WarrantsMember329739468">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:August2019WarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">SEEL:SeriesAWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_WarrantDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">SEEL:WarrantDerivativeFinancialInstrumentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">SEEL:EmployeeStockPurchasePlanMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_InducementPlanof2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">SEEL:InducementPlanof2019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_InducementPlanof2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">SEEL:InducementPlanof2019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">SEEL:PSUtoExecutivesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">SEEL:PSUtoExecutivesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-01-01</xbrli:startdate>
        <xbrli:enddate>2019-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">SEEL:PSUtoExecutivesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember329742015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionsandDirectorOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">SEEL:StockOptionsandDirectorOptionsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">SEEL:StockOptionsandDirectorOptionsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">SEEL:StockOptionsandDirectorOptionsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_March2019LeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2019LeaseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_March2021LeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2021LeaseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_March2021LeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LeaseContractualTermAxis">SEEL:March2021LeaseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001017491</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitnumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitdenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Years">
      <xbrli:measure>utr:Y</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<hr style="border-width: 0px; color: Gray; background-color: Gray; height: 4px; width: 100%">

<hr style="border-width: 0px; color: Gray; background-color: Gray; height: 1px; width: 100%">

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><span style="font-size: 13.5pt"><b>UNITED
STATES<br>
SECURITIES AND EXCHANGE COMMISSION&nbsp;<br>
</b></span><b><span style="font-size: 10pt">Washington, D.C.&nbsp;20549&nbsp;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>____________________________</b></p>

<p style="font: 13.5pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>FORM <span id="xdx_906_edei--DocumentType_c20210101__20211231_zs1EWq0i35n6"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentType" inside-table="false" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt; width: 5%"><span style="font-family: Wingdings"><b><span id="xdx_901_edei--DocumentAnnualReport_c20210101__20211231_zP5BOwoFZBk2"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" inside-table="true" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">x</ix:nonnumeric></span></span></b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt; width: 95%"><span style="font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>For the Fiscal Year Ended
<span id="xdx_90C_edei--DocumentPeriodEndDate_c20210101__20211231_zsDUh97iqo96"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" inside-table="false" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span id="xdx_909_edei--CurrentFiscalYearEndDate_c20210101__20211231_zMawPcIXcefk"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" inside-table="false" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31</ix:nonnumeric></span></span>, 2021</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>or</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt; width: 5%"><span style="font-size: 10pt">&nbsp;</span><span style="font-family: Wingdings"><b><span id="xdx_907_edei--DocumentTransitionReport_c20210101__20211231_zvG39jGKffZ3"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" inside-table="true" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">o</ix:nonnumeric></span></span></b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0.75pt; width: 95%"><span style="font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>For the Transition Period
from&nbsp;<span style="text-decoration: underline">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>&nbsp;to&nbsp;<span style="text-decoration: underline">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">Commission File Number&nbsp;<span id="xdx_904_edei--EntityFileNumber_c20210101__20211231_zKlrE61d9wg9"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityFileNumber" inside-table="false" id="fact-identifier-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">000-22245</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>____________________________</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><span style="font-size: 10pt">&nbsp;</span><span style="font-size: 13.5pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20210101__20211231_zMJ3Dcur4tnl"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName" inside-table="false" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SEELOS
THERAPEUTICS, INC.</ix:nonnumeric></span></span><br>
</b></span><span style="font-size: 10pt">(Exact name of registrant as specified in its charter)</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 50%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20210101__20211231_z7NkkX4fFzv4"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nevada</ix:nonnumeric></span></span></b></span></td>
    <td style="padding: 0.75pt; width: 1%; text-align: center">&nbsp;</td>
    <td style="padding: 0.75pt; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20210101__20211231_zUCu7riOReZ3"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber" inside-table="true" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87-0449967</ix:nonnumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</span></td>
    <td style="padding: 0.75pt; text-align: center">&nbsp;</td>
    <td style="padding: 0.75pt; text-align: center"><span style="font-size: 10pt">(I.R.S.&nbsp;&nbsp;Employer Identification No.)</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20210101__20211231_zVmfnPztdNd5"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1" inside-table="false" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300 Park Avenue</ix:nonnumeric></span></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20210101__20211231_zqIvcJK8Jgak"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine2" inside-table="false" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2nd&nbsp;Floor</ix:nonnumeric></span></span>,
<span id="xdx_90F_edei--EntityAddressCityOrTown_c20210101__20211231_z21hEhIyHKkg"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown" inside-table="false" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">New York</ix:nonnumeric></span></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20210101__20211231_zbrKllg7HhW3"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressStateOrProvince" inside-table="false" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">NY</ix:nonnumeric></span></span> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20210101__20211231_z8Yx0qvFYr0i"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode" inside-table="false" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10022</ix:nonnumeric></span></span><br>
</b>(Address of principal executive offices and zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>(<span id="xdx_902_edei--CityAreaCode_c20210101__20211231_ztjPfyMoI1rf"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:CityAreaCode" inside-table="false" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">646</ix:nonnumeric></span></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20210101__20211231_zBdmrkegIoCb"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber" inside-table="false" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">293-2100</ix:nonnumeric></span></span><br>
</b>(Registrant's telephone number, including area code)</p>

<p style="font: 7.5pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>Securities registered pursuant
to Section&nbsp;12(b) of the Act:</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; width: 37%; text-align: center"><span style="font-size: 10pt">&nbsp;<b>Title of Each Class</b></span></td>
    <td style="padding: 0.75pt; width: 25%; text-align: center"><span style="font-size: 10pt">&nbsp;<b>Trading Symbol</b></span></td>
    <td style="padding: 0.75pt; width: 38%; text-align: center"><span style="font-size: 10pt"><b>Name of Each Exchange on Which Registered</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.75pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20210101__20211231_zbaGrSoYBqi9"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:Security12bTitle" inside-table="true" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Stock, par value $0.001 per share</ix:nonnumeric></span></span></span></td>
    <td style="padding: 0.75pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20210101__20211231_zkhJc3P68pu7"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:TradingSymbol" inside-table="true" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SEEL</ix:nonnumeric></span></span></span></td>
    <td style="padding: 0.75pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20210101__20211231_zrryacbmmhb8"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" inside-table="true" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Nasdaq Stock Market LLC</ix:nonnumeric></span></span></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>Securities registered pursuant
to section 12(g) of the Act: None.</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span style="font-size: 10pt">Indicate by check mark
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;Yes &nbsp;&nbsp;&nbsp;</span><span style="font-family: Wingdings">o</span><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;<span id="xdx_90F_edei--EntityWellKnownSeasonedIssuer_c20210101__20211231_zfpUlrIz6r21"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span>&nbsp;</span><span style="font-family: Wingdings">x</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span style="font-size: 10pt">Indicate by check mark
if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act. Yes &nbsp;&nbsp;&nbsp;</span><span style="font-family: Wingdings">o</span><span style="font-size: 10pt">&nbsp;&nbsp;<span id="xdx_907_edei--EntityVoluntaryFilers_c20210101__20211231_zl1KzAeMxKU1"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span>&nbsp;&nbsp;</span><span style="font-family: Wingdings">x</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span style="font-size: 10pt">Indicate by check mark
whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has
been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;<span id="xdx_901_edei--EntityCurrentReportingStatus_c20210101__20211231_zHuptyPxTi0e"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;&nbsp; </span><span style="font-family: Wingdings">x</span><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
</span><span style="font-family: Wingdings">o</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span style="font-size: 10pt">Indicate by check mark
whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (§&nbsp;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;<span id="xdx_90D_edei--EntityInteractiveDataCurrent_c20210101__20211231_ze0Qz97leW77"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;&nbsp;</span><span style="font-family: Wingdings">x</span><span style="font-size: 10pt">&nbsp;No&nbsp;&nbsp;</span><span style="font-family: Wingdings">o</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Indicate by check mark whether the registrant is
a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See
the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging
growth company" in Rule&nbsp;12b-2 of the Exchange Act:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 19%"><span style="font-size: 8pt">Large accelerated filer</span> <span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;<span style="font-family: Wingdings">¨</span></span></td>
    <td style="width: 16%"><span style="font-size: 8pt">Accelerated filer</span> <span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;<span style="font-family: Wingdings">¨</span></span></td>
    <td style="width: 19%"><span style="font-size: 8pt"><span id="xdx_90D_edei--EntityFilerCategory_c20210101__20211231_zn8K5zS7oO5a"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="true" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span></span> <span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;<span style="font-family: Wingdings">x</span></span></td>
    <td style="width: 24%"><span style="font-size: 8pt">Smaller reporting company</span> <span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;<span style="font-family: Wingdings"><span id="xdx_90D_edei--EntitySmallBusiness_c20210101__20211231_zjY8kof2oWe7"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" inside-table="true" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">x</ix:nonnumeric></span></span></span></span></td>
    <td style="width: 22%"><span style="font-size: 8pt">Emerging growth company  <span style="font-family: Segoe UI Symbol"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20210101__20211231_z9FoKJfZHTvk"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" inside-table="true" id="fact-identifier-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></span></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp; <span style="font-family: Segoe UI Symbol">☐
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Indicate by check mark whether the registrant has
filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its
audit report. &nbsp; <span style="font-family: Segoe UI Symbol"><span id="xdx_907_edei--IcfrAuditorAttestationFlag_c20210101__20211231_zLSKeRas1qQb"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag" inside-table="false" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span>
</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span style="font-size: 10pt">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</span><span style="font-family: Wingdings">o</span><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span id="xdx_909_edei--EntityShellCompany_c20210101__20211231_zDjY5ngMfdsj"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span>&nbsp;&nbsp;</span><span style="font-family: Wingdings">x</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of February 25, 2022, <span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_c20220304_zLa3cGASJdu4"><span><ix:nonfraction name="dei:EntityCommonStockSharesOutstanding" contextref="AsOf2022-03-04" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,506,695</ix:nonfraction></span></span>
shares of the common stock, par value $<span id="xdx_90E_edei--EntityListingParValuePerShare_c20210101__20211231_z9BclnGPimb1"><span><ix:nonfraction name="dei:EntityListingParValuePerShare" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></span>,
of the registrant were outstanding.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The aggregate market value of the voting stock held
by non-affiliates of the registrant the last business day of the registrant's most recently completed second fiscal quarter: $<span id="xdx_906_edei--EntityPublicFloat_iI_pn5n6_c20210630_zh6I3ff3itQf"><span><ix:nonfraction name="dei:EntityPublicFloat" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">261.5</ix:nonfraction></span></span> million
based upon the closing sale price of the registrant's common stock of $2.64 on that date. Shares of the registrant's common stock held
by each officer and director and by each person known to own in excess of 10% of outstanding shares of the registrant's common stock have
been excluded in that such persons may be deemed to be affiliates. The determination of affiliate status is not necessarily a conclusive
determination for other purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>DOCUMENTS INCORPORATED BY
REFERENCE</b></p>

<p id="xdx_98B_edei--DocumentsIncorporatedByReferenceTextBlock_c20210101__20211231_zX348GZGpTbg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Certain information required to be disclosed in Part
III of this report is incorporated by reference from the information contained in the registrant's Definitive Proxy Statement for the
2022 Annual Meeting of Stockholders, which Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after
the end of the fiscal year ended December 31, 2021.</ix:nonnumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>










<hr style="border-width: 0px; color: Gray; background-color: Gray; height: 1px; width: 100%">

<hr style="border-width: 0px; color: Gray; background-color: Gray; height: 4px; width: 100%">


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Table of Contents</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="width: 9%">&nbsp;</td>
    <td style="width: 86%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">Page</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>PART I.</b></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item1" tabindex="18">ITEM 1.</a></span></td>
    <td><span style="font-size: 10pt">BUSINESS</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item1a" tabindex="18">ITEM 1A.</a></span></td>
    <td><span style="font-size: 10pt">RISK FACTORS</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">21</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item1b" tabindex="18">ITEM 1B.</a></span></td>
    <td><span style="font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item2" tabindex="18">ITEM 2.</a></span></td>
    <td><span style="font-size: 10pt">PROPERTIES</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item3" tabindex="18">ITEM 3.</a></span></td>
    <td><span style="font-size: 10pt">LEGAL PROCEEDINGS</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item4" tabindex="18">ITEM 4.</a></span></td>
    <td><span style="font-size: 10pt">MINE SAFETY DISCLOSURES</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>PART II.</b></span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item5" tabindex="18">ITEM 5.</a></span></td>
    <td><span style="font-size: 10pt">MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
    SECURITIES</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">54</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item6" tabindex="18">ITEM 6.</a></span></td>
    <td><span style="font-size: 10pt">[RESERVED]</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">54</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item7" tabindex="18">ITEM 7.</a></span></td>
    <td><span style="font-size: 10pt">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">55</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item7a" tabindex="18">ITEM 7A.</a></span></td>
    <td><span style="font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">67</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item8" tabindex="18">ITEM 8.</a></span></td>
    <td><span style="font-size: 10pt">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">68</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item9" tabindex="18">ITEM 9.</a></span></td>
    <td><span style="font-size: 10pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">97</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item9a" tabindex="18">ITEM 9A.</a></span></td>
    <td><span style="font-size: 10pt">CONTROLS AND PROCEDURES</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">97</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item9b" tabindex="18">ITEM 9B.</a></span></td>
    <td><span style="font-size: 10pt">OTHER INFORMATION</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">98</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><a href="#item9c" tabindex="18">ITEM 9C.</a></span></td>
    <td><span style="font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></td>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">98</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr>
    <td style="text-align: right; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>PART III.</b></span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item10" tabindex="18">ITEM 10.</a></span></td>
    <td><span style="font-size: 10pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">98</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item11" tabindex="18">ITEM 11.</a></span></td>
    <td><span style="font-size: 10pt">EXECUTIVE COMPENSATION</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">98</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item12" tabindex="18">ITEM 12.</a></span></td>
    <td><span style="font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item13" tabindex="18">ITEM 13.</a></span></td>
    <td><span style="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item14" tabindex="18">ITEM 14.</a></span></td>
    <td><span style="font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>PART IV.</b></span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item15" tabindex="18">ITEM 15.</a></span></td>
    <td><span style="font-size: 10pt">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">99</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><a href="#item16" tabindex="18">ITEM 16.</a></span></td>
    <td><span style="font-size: 10pt">FORM 10-K SUMMARY</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">106</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">&nbsp;
    <!-- Field: Sequence; Type: Arabic; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><span style="text-decoration: underline">Cautionary Note Regarding
Forward-Looking Statements</span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">This report includes “forward-looking statements” within
the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”). Those statements include statements regarding the intent, belief or
current expectations of Seelos Therapeutics, Inc. and its subsidiaries (“we,” “us,” “our,” the “Company”
or “Seelos”) and our management team. Any such forward-looking statements are not guarantees of future performance and involve
risks and uncertainties, and actual results may differ materially from those projected in the forward-looking statements. These risks
and uncertainties include but are not limited to those risks and uncertainties set forth in Item&nbsp;1A of this Report.&nbsp;In light
of the significant risks and uncertainties inherent in the forward-looking statements included in this Report, the inclusion of such statements
should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Further, these forward-looking
statements reflect our view only as of the date of this report. Except as required by law, we undertake no obligations to update any forward-looking
statements and we disclaim any intent to update forward-looking statements after the date of this report to reflect subsequent developments.
Accordingly, you should also carefully consider the factors set forth in other reports or documents that we file from time to time with
the Securities and Exchange Commission (“SEC”).</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We have common law trademark rights in the unregistered marks “Seelos
Therapeutics, Inc.,” “Seelos” and the Seelos logo in certain jurisdictions. Vitaros is a registered trademark of Ferring
International Center S.A. (“Ferring”) in certain countries outside of the United States. This Annual Report on Form 10-K
also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks
and tradenames referred to in this Annual Report on Form 10-K appear without the <sup>®</sup> and <sup>™</sup> symbols, but
those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights
or that the applicable owner will not assert its rights, to these trademarks and tradenames.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><span id="item1"></span>ITEM 1. BUSINESS</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We are a clinical-stage biopharmaceutical company
focused on achieving efficient development of products that address significant unmet needs in Central Nervous System ("CNS")
disorders and other rare disorders.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Our business model is to advance multiple late-stage
therapeutic candidates as well as earlier stage assets with proven mechanisms of action or with strong scientific rationale that address
large markets with unmet medical needs and for which there is a strong economic and scientific rationale for development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">1</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our product development pipeline is as follows:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Product</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Indication</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Development
    Phase</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 42%; text-align: center"><span style="font-size: 10pt"><b>Development
    Status</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">SLS-002<br>
  Intranasal Racemic Ketamine</span></td>
  <td><span style="font-size: 10pt">&nbsp;<br>
  &nbsp;</span></td>
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Acute Suicidal Ideation and Behavior (ASIB) in Major
  Depressive Disorder (MDD)</span></td>
  <td><span style="font-size: 10pt">&nbsp; &nbsp;</span></td>
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Phase II<br>
  &nbsp;</span></td>
  <td><span style="font-size: 10pt">&nbsp;<br>
  &nbsp;</span></td>
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Completed open-label patient enrollment and announced
  the initial topline data from Part 1 of the proof-of-concept study on May 17, 2021 and initiated enrollment of Part 2 of a registration
  directed study&nbsp;</span></td>
</tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">SLS-005</span></p>
                                   <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">IV Trehalose</span></p></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Amyotrophic Lateral Sclerosis (ALS)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Phase II/III</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Startup activities completed; on February 28, 2022, we announced dosing
    of the first participants in the registrational study</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;Spinocerebellar Ataxia (SCA)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">Phase IIb/III</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">Startup activities initiated</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Sanfilippo Syndrome</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Phase II</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Obtaining natural history data</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">SLS-004</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Parkinson's Disease (PD)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Pre-IND</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical studies ongoing</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Gene Therapy</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">SLS-006</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Parkinson's Disease (PD)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Phase II/III</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Considering studies to advance into late stage trials</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Partial Dopamine Agonist</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">SLS-007</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Parkinson's Disease (PD)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Pre-IND</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical study ongoing</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Peptide Inhibitor</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"><b>Lead Programs</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Our lead programs are currently SLS-002 for the potential
treatment of Acute Suicidal Ideation and Behavior (“ASIB”) in patients with Major Depressive Disorder (“MDD”)
and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”).
SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-002</span></b>&nbsp;is intranasal racemic ketamine
with two investigational new drug applications (“INDs”). The lead program is focused on the treatment of ASIB in MDD. SLS-002
was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500
subjects. SLS-002 addresses an unmet need for an efficacious drug to treat suicidality in the United States. Traditionally, anti-depressants
have been used in this setting but many of the existing treatments are known to contribute to an increased risk of suicidal thoughts in
some circumstances, and if and when they are effective, it often takes weeks for the full therapeutic effect to be manifested. We believe
there is a large opportunity in the United States and European markets for products in this space. Based on information gathered from
the databases of the Agency for Healthcare Research and Quality, there were approximately 1,000,000 visits to emergency rooms for suicide
attempts in 2013 in the United States alone. Experimental studies suggest ketamine has the potential to be a rapid, effective treatment
for refractory depression and suicidality.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">The clinical development program for SLS-002 includes two
parallel healthy volunteer studies (Phase I). We announced interim data from our Phase I study of SLS-002 during the quarterly period
ended March 31, 2020. As a result, in March 2020, we completed a Type C meeting with the U.S. Food and Drug Administration (“FDA”)
and received guidance to conduct a Phase II proof of concept (“PoC”) study of SLS-002 for ASIB in patients with MDD, to support
the further clinical development of this product candidate, together with nonclinical data under development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">2</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">As a result of the Type C meeting and the Fast Track designation
for SLS-002 for the treatment of ASIB in patients with MDD, we believe we are well positioned to pursue the FDA's expedited programs for
drug development and review.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">On June 23, 2020, we announced the final safety data from
our Phase I pharmacokinetics/pharmacodynamics study of intranasal racemic ketamine (SLS-002) as well as the planned design of a Phase
II double blind, placebo-controlled PoC study for ASIB in subjects with MDD. We initiated this PoC study in two parts: Part 1 was an
open-label study of 17 subjects, and is being followed by Part 2, which is a double blind, placebo-controlled study of approximately
120 subjects. On January 15, 2021, we announced dosing of the first subjects in Part 1 of the PoC study. On March 5, 2021, we announced
the completion of open-label enrollment of subjects in Part 1 of the PoC study. On May 17, 2021, we announced positive topline data from
Part 1 of the POC study, the open-label cohort, of our study of SLS-002 (intranasal racemic ketamine), demonstrating a significant treatment
effect and a well-tolerated safety profile for ASIB in patients with MDD. This study enrolled 17 subjects diagnosed with MDD requiring
psychiatric hospitalization due to significant risk of suicide with a baseline score of ≥ 28 points on the Montgomery-Åsberg
Depression Rating Scale ("MADRS"), a score of 5 or 6 on MADRS Item-10, a score of ≥ 15 points on the Sheehan-Suicidality
Tracking Scale (S-STS) total score and a history of previous suicide attempt(s), as confirmed on the Columbia Suicide Severity Rating
Scale (C-SSRS) with a history of at least one actual attempt, or if the attempt was interrupted or aborted, is judged to have been serious
in intent. SLS-002 demonstrated a 76.5% response rate (response meaning 50% reduction from baseline) in the primary endpoint on MADRS
twenty-four hours after first dose, with a mean reduction in total score from 39.4 to 14.5 points.&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">On July 6, 2021, we announced dosing of the first subject
in Part 2 of the planned registration directed study. Based on feedback from a Type C meeting with the FDA in June 2021, we are planning
to increase the subjects in Part 2 to increase the sample size and power to support a potential marketing application.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-005</span></b> is IV trehalose, a protein stabilizer
that crosses the blood-brain-barrier and activates autophagy and the lysosomal pathway. Based on preclinical and in vitro studies, there
is a sound scientific rationale for developing trehalose for the treatment of ALS, SCA and other indications such as Sanfilippo Syndrome.
Trehalose is a low molecular weight disaccharide (0.342 kDa) that protects against pathological processes in cells. It has been shown
to penetrate muscle and cross the blood-brain-barrier. In animal models of several diseases associated with abnormal cellular protein
aggregation, it has been shown to reduce pathological aggregation of misfolded proteins as well as to activate autophagy pathways through
the activation of Transcription Factor EB ("TFEB"), a key factor in lysosomal and autophagy gene expression. Activation of TFEB
is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Trehalose 90.5 mg/mL IV solution has demonstrated promising
clinical potential in prior Phase II clinical development for oculopharyngeal muscular dystrophy ("OPMD") and spinocerebellar
ataxia type 3 ("SCA3"), also known as Machado Joseph disease, with no significant safety signals to date and encouraging efficacy
results. Pathological accumulation of protein aggregates within cells, whether in the CNS or in muscle, eventually leads to loss of function
and ultimately cell death. Prior preclinical studies indicate that this platform has the potential to prevent mutant protein aggregation
in other devastating PolyA/PolyQ diseases.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">We own three United States patents for parenteral
administration of trehalose for patients with OPMD and SCA3, all of which are expected to expire in 2034. In addition, Orphan Drug
Designation ("ODD") for OPMD and SCA3 has been secured in the United States and in the European Union ("EU"). In
February 2019, we assumed a collaborative agreement, turned subsequently into a research grant, with Team Sanfilippo Foundation
(“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome. On April 30,
2020, we were granted ODD for SLS-005 in Sanfilippo Syndrome from the FDA. SLS-005 was previously granted ODD from the FDA and
European Medicines Agency for SCA3 and OPMD as well as Fast Track designation for OPMD. On August 25, 2020, we were issued U.S.
patent number 10,751,353 titled "COMPOSITIONS AND METHODS FOR TREATING AN AGGREGATION DISEASE OR DISORDER" which relates to
trehalose (SLS-005). The issued patent covers the method of use for trehalose (SLS-005) formulation for treating a disease or
disorder selected from any one of the following: spinal and bulbar muscular atrophy, dentatombral-pallidoluysian atrophy,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">3</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia or parkinsonism linked to
chromosome 17. On May 15, 2020, we were granted Rare Pediatric Disease Designation ("RPDD") for SLS-005 in Sanfilippo Syndrome
from the FDA. RPDD is an incentive program created under the Federal Food, Drug, and Cosmetic Act to encourage the development of new
therapies for the prevention and treatment of certain rare pediatric diseases. On May 27, 2021, we announced that we were granted ODD
for SLS-005 in ALS from the European Medicines Agency. In December 2020, we announced the selection of SLS-005 for the Healey ALS platform
trial led by Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study multiple potential treatments for
ALS simultaneously. The platform trial model aims to greatly accelerate the study access, reduce costs and shorten development timelines.
On February 28, 2022, we announced the dosing of the first participants in the Healey ALS platform trial. In November 2021, we announced the
FDA acceptance of an IND and grant of Fast Track designation for SLS-005 for the treatment of SCA. We have begun the start up activities
for a Phase IIb/III study for SCA.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Additionally, we are developing several preclinical programs,
most of which have well-defined mechanisms of action, including SLS-004, licensed from Duke University, and SLS-007, licensed from The
Regents of the University of California, for the potential treatment of Parkinson’s Disease (“PD”), SLS-008, targeted
at chronic inflammation in asthma, atopic dermatitis and orphan indications such as pediatric esophagitis, SLS-010 in narcolepsy and related
disorders and SLS-012, an injectable therapy for post-operative pain management.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Strategy and Ongoing Programs</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-002:</span></b> The clinical development program for
SLS-002 includes two parallel healthy volunteer studies (Phase I). Following these Phase I studies, we completed a Type C meeting with
the FDA in March 2020 and received guidance to conduct a Phase II PoC study of SLS-002 for ASIB in subjects with MDD. We released topline
data for Part 1 of our open-label study on May 17, 2021. We initiated enrollment in Part 2 of the registration directed study on July
6, 2021.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-005</span></b>
is undergoing startup activities for clinical studies in ALS and SCA. In December 2020, we announced the selection of SLS-005 for
the Healey ALS platform trial led by Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study
multiple potential treatments for ALS simultaneously. The platform trial model aims to greatly accelerate the study access, reduce
costs, and shorten development timelines. On February 28, 2022, we announced dosing of the first participants in the Healey ALS
platform trial. In November 2021, we announced the FDA acceptance of an IND and grant of Fast Track designation for SLS-005 for the
treatment of SCA. We have begun the start up activities for a Phase IIb/III study for SCA. We are continuing to consider trials in
Sanfilippo Syndrome and are seeking more natural history data based on the guidance from regulatory agencies.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-004</span></b> is an all-in-one lentiviral vector,
targeted for gene editing through DNA methylation within intron 1 of the synuclein alpha ("SNCA") gene responsible for expressing
alpha-synuclein protein. SLS-004, when delivered to dopaminergic neurons derived from human induced pluripotent stem cells of a PD patient,
modified the expression on alpha-synuclein ("α-synuclein") and exhibited reversal of the disease-related cellular-phenotype
characteristics of the neurons. The role of mutated SNCA in PD pathogenesis and the need to maintain the normal physiological levels of
α-synuclein protein emphasize the yet unmet need to develop new therapeutic strategies, such as SLS-004, targeting the regulatory
mechanism of α-synuclein expression. On May 28, 2020, we announced the initiation of a preclinical study of SLS-004 in PD through
an all-in-one lentiviral vector targeting the SNCA gene. We are constructing a bimodular viral system harboring an endogenous α-synuclein
transgene and inducible regulated repressive CRISPR/Cas9-unit to achieve constitutive activation and inducible suppression of PD-related
pathologies. On July 7, 2021, we announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein expression under
this study.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">SLS-006</span></b> is a true partial dopamine agonist, originally developed
by Wyeth Pharmaceuticals, Inc., with previous clinical studies on 340 subjects in various Phase I and Phase II studies. It is a potent
D2/D3 agonist/antagonist that has shown promising efficacy with statistical significance in Phase II studies in early-stage PD patients
and an attractive safety profile. Moreover, it has also shown synergistic effect with reduced doses of L-DOPA. We are considering studies
to advance the product candidate into late-stage trials.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">4</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-007</span></b> is a rationally designed peptide-based
approach, targeting the nonamyloid component core ("NACore") of α-synuclein to inhibit the protein from aggregation. Recent
in vitro and cell culture research has shown that SLS-007 has the ability to stop the propagation and seeding of α- synuclein aggregates.
We will evaluate the potential for in vivo delivery of SLS-007 in a PD transgenic mice model. The goal will be to establish in vivo pharmacokinetics/pharmacodynamics
and target engagement parameters of SLS-007, a family of anti- α -synuclein peptidic inhibitors. On June 25, 2020, we announced
the initiation of a preclinical study of SLS-007 in PD delivered through an adeno associated viral ("AAV") vector targeting
the non-amyloid component core of α-synuclein. We have initiated an in vivo preclinical study of SLS-007 in rodents to assess the
ability of two specific novel peptides, S62 and S71, delivered via AAV1/2 viral vector, to protect dopaminergic function in the preformed
α-synuclein fibril rodent model of PD. Production of AAV1/2 vectors encoding each of the two novel peptides incorporating hemagglutinin
tags has already been completed. This preclinical study is designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles
and target engagement parameters of SLS-007.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">We intend to become a leading biopharmaceutical company focused
on neurological and psychiatric disorders, including orphan indications. Our business strategy includes:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">Advancing SLS-002 in ASIB in MDD and post-traumatic stress disorder;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">Advancing SLS-004 in PD;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">Advancing SLS-005 in ALS, SCA and Sanfilippo syndrome;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">Advancing SLS-007 in PD as a monotherapy; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">Acquiring synergistic assets in the CNS therapy space through licensing and partnerships.</td></tr></tbody></table>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">We also have two legacy product candidates: a product candidate
in the United States for the treatment of erectile dysfunction, which we in-licensed from Warner Chilcott Company, Inc., now a subsidiary
of Allergan plc; and a product candidate which has completed a Phase IIa clinical trial for the treatment of Raynaud’s Phenomenon,
secondary to scleroderma, for which we own worldwide rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>Impact of COVID-19</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">In March 2020, we began taking precautionary measures to protect
the health and safety of our employees and contractors and further assessing the actual and potential impact of the coronavirus (“COVID-19”)
pandemic on our business, financial condition and operations. COVID-19 infections have been reported throughout the United States, along
with other jurisdictions in which our suppliers, partners and collaborators operate. In addition, COVID-19 has caused disruption and volatility
in the global capital markets, and has led to an economic slowdown. Certain national, provincial, state and local governmental authorities
have issued proclamations and/or directives aimed at minimizing the spread of COVID-19 and additional, more restrictive proclamations
and/or directives may be issued in the future. Before the COVID-19 outbreak, most of our employees worked remotely. Up until the fourth
quarter of 2021, we had not experienced any significant delays with our past or ongoing clinical trials for SLS-002, nor our start up
activities for clinical trials for SLS-005. During the fourth quarter of 2021 and through the issuance of this report, we have experienced
a slowdown in patient enrollment primarily due to staffing issues at our study sites related to the spike in COVID-19 cases due to the
Omicron variant. Additionally, the pandemic has not materially affected our liquidity as we maintain our resources in the form of cash.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">In addition, although we do not currently expect the preventative
measures taken to date to have a material adverse impact on our business for the first quarter of 2022, the continued impact of the COVID-19
pandemic on our business, financial condition and results of operations is unknown and will depend on future developments and risks, which
are highly uncertain and cannot be predicted. These developments and risks include, among others, the duration and severity of the COVID-19
pandemic, the emergence or spread of new COVID-19 variants, the impact on the capital markets, the impact on our partners and the regulatory
agencies that oversee our sector and any additional preventative and protective actions that governmental authorities, or we, may implement,
any of which may result in an extended period of business disruption, including potential delays in commencing future clinical trials,
or in completing enrollment for any clinical trials we may commence or in the FDA or other regulatory agencies conducting in-person inspections
or accommodations for alternatives to in-person inspections. Any resulting financial impact cannot be reasonably estimated at this time,
but the COVID-19 pandemic may force us to make</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">5</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b>&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">adjustments to our business, our plans and our timeline for developing assets, including
our programs. In addition, the pandemic is currently not anticipated to have a material adverse impact on our business, financial condition
and results of operations, including our ability to raise additional capital, although, if the pandemic continues at its current rate
into the middle of 2022, it could have a material adverse impact on our business. See Part I, Item 1A, Risk Factors, for an additional
discussion of risks related to COVID-19.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>Merger</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">On January 24, 2019, our company (which was formerly named
“Apricus Biosciences, Inc.”) completed a business combination with Seelos Therapeutics, Inc., a Delaware corporation (“STI”),
in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into
on July 30, 2018. Pursuant to the Merger Agreement, (i) a former subsidiary of ours merged with and into STI, with STI (renamed “Seelos
Corporation”) continuing as a wholly-owned subsidiary of ours and the surviving corporation of the merger and (ii) our company
was renamed “Seelos Therapeutics, Inc.” (the “Merger”).&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>Acquisition of Assets from Bioblast Pharma Ltd. (“Bioblast”)</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 0.7pt 0 0">On February 15, 2019, we entered into an Asset Purchase
Agreement (the "Bioblast Asset Purchase Agreement") with Bioblast. Pursuant to the Bioblast Asset Purchase Agreement, we acquired
all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the "Bioblast Asset Purchase"). At the
closing of the Bioblast Asset Purchase (the "Bioblast Closing"), we paid to Bioblast $1.5 million in cash in February 2019 and
an additional $2.0 million in cash in February 2020. Accordingly, we recognized a $3.5 million charge to research and development expense
during the three months ended March 31, 2019. Under the terms of the Bioblast Asset Purchase Agreement, we agreed to pay additional consideration
to Bioblast upon the achievement of certain milestones in the future, as follows: (1) within 15 days following the completion of our or
our affiliate's first Phase II(b) clinical trial of Trehalose satisfying certain criteria, we will pay to Bioblast $8.5 million in cash;
and (2) within 15 days following the approval for commercialization by the FDA or the Health Products and Food Branch of Health Canada
of the first new drug application (an “NDA”) or New Drug Submission, respectively, of Trehalose filed by us or our affiliates,
we will pay to Bioblast $8.5 million in cash. In addition, we agreed to pay Bioblast a cash royalty equal to 1% of the net sales of Trehalose.
Under the terms of the Bioblast Asset Purchase, we assumed a collaborative agreement with TSF. On July 15, 2019, we amended the agreement
whereby we agreed to assume responsibility for a Phase II(b)/III clinical trial and TSF agreed to provide a grant of up to $1.5 million
towards the funding of the trial.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Acquisition of Assets from Vyera Pharmaceuticals, AG (“Vyera”)</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On March 6, 2018, we entered into an asset purchase agreement with
Vyera pursuant to which we acquired the assets (the “Vyera Assets”) and liabilities (the “Vyera Assumed Liabilities”)
of Vyera related to TUR-002 (intranasal ketamine), which is known as SLS-002. We are obligated to use commercially reasonable efforts
to seek regulatory approval in the United States for and commercialize SLS-002.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">As consideration for the Vyera Assets, we paid to Vyera a non-refundable
cash payment of $150,000 on May 21, 2018. As further consideration for the Vyera Assets, upon public announcement of the entry by us and
STI into the Merger Agreement, we paid to Vyera a non-refundable cash payment of $150,000. As further consideration for the Vyera Assets,
we issued to Vyera 191,529 shares of common stock and paid Vyera a non-refundable cash payment $1,000,000 on January 29, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">6</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Pursuant to the amendment to the asset purchase agreement entered
into with Vyera on October 15, 2019, we issued Vyera 1,809,845 registered shares of our common stock on January 2, 2020 and made cash
payments to Vyera in the amounts of $750,000, $750,000, $1.0 million and $1.0 million in October 2019, January 2020, April 2020 and July
2020, respectively.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Pursuant to the amendment to the asset purchase agreement entered
into with Vyera on February 15, 2021, we made cash payments to Vyera in the amount of $3.0 million in each of February 2021, June 2021
and September 2021 in exchange for a lower royalty percentage on potential net sales of SLS-002.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event that we sell, directly or indirectly,
all or substantially all of the Vyera Assets to a third party, then we must pay Vyera an amount equal to 4% of the net proceeds actually
received by us as an upfront payment in such sale.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We agreed to pay to Vyera certain one-time, non-refundable milestone
payments consisting of (i) $10.0 million upon approval by the FDA of an NDA, with respect to SLS-002, (ii) $5.0 million upon approval
by the European Medicines Agency (the “EMA”) of the foreign equivalent to an NDA with respect to SLS-002 in the EU (either
in its entirety or including at least one of France, Germany or, if at the time the United Kingdom is a member of the EU, the United Kingdom),
the United Kingdom, if at the time the United Kingdom is not a member of the EU, Japan or the People’s Republic of China (each,
a “Major Market”), (iii) $2.5 million upon approval by the EMA of the foreign equivalent to an NDA with respect to SLS-002
in a second Major Market, (iv) $5.0 million upon the achievement of $250.0 million in net sales of SLS-002, (v) $10.0 million upon the
achievement of $500.0 million in net sales of SLS-002, (vi) $15.0 million upon the achievement of $1.0 billion in net sales of SLS-002,
(vii) $20.0 million upon the achievement of $1.5 billion in net sales of SLS-002, and (viii) $25.0 million upon the achievement of $2.0
billion in net sales of SLS-002. We will also pay to Vyera a royalty percentage in the mid-single digits on aggregate annual net sales
of SLS-002.</p>

<p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Acquisition of License from Stuart Weg, MD</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On August 29, 2019, we entered into an amended and restated exclusive
license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which we were granted an exclusive worldwide
license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, we
paid an upfront license fee of $75,000 upon execution of the agreement. We agreed to pay additional consideration to Dr. Weg as follows:
(i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for
a product containing ketamine in any dosage on or before December 31, 2021, $0.2 million on January 2, 2022. We paid the required $0.1
million on January 2, 2020, $0.125 million on January 2, 2021, and $0.2 million on January 3, 2022. As further consideration, we agreed
to pay Dr. Weg certain milestone payments consisting of (i) $0.1 million and shares of common stock equal to $0.15 million divided by
the closing sales price of our common stock upon the issuance of the first patent directed to an anxiety indication, (ii) $0.5 million
after the locking of the database and unblinding the data for the statistically significant readout of a Phase III trial of an intranasal
racemic ketamine product that has been conducted for the submission under an NDA or equivalent seeking regulatory approval in the United
States, the United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory from the EMA in the EU, for such product
(the “Milestone Product”), (iii) $3.0 million upon FDA approval of an NDA for the Milestone Product, (iv) $2.0 million upon
regulatory approval by the EMA for the Milestone Product, and (v) $1.5 million upon regulatory approval in Japan for the Milestone Product;
provided, however, that the maximum amount to be paid by us under milestones (i)-(v) will be $6.6 million. We will also pay to Dr. Weg
a royalty percentage equal to 2.25% on the sale of each product containing ketamine in any dosage.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Acquisition of License from The Regents of the University of California</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On March 7, 2019, we entered into an exclusive license agreement (the
“UC Regents License Agreement”) with The Regents of the University of California (“The UC Regents”) pursuant to
which we were granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology that was created
by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed peptide
inhibitors that target the aggregation of α-synuclein. We plan to study this initial approach in PD and will further evaluate the
potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-007. Upon entry into the UC Regents
License Agreement, we paid to The UC Regents $0.1 million. Under the terms of the UC Regents License Agreement, we agreed to pay additional
consideration upon the achievement of certain milestones in the future, as follows: (i) within 90 days following dosing of the first patient
in a Phase I clinical trial, we will pay $50,000; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial,
we will pay $0.1 million; (iii) within 90 days following dosing of the first patient in a Phase III clinical trial, we</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">7</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">will pay $0.3 million;
(iv) within 90 days following the first commercial sales in the U.S., we will pay $1.0 million; (v) within 90 days following the first
commercial sales in any European market, we will pay $1.0 million; and (vi) within 90 days following $250 million in cumulative worldwide
net sales of a licensed product, we will pay $2.5 million. We are also obligated to pay a single digit royalty on sales of the product,
if any. In addition, if we fail to achieve certain milestones within a specified timeframe, The UC Regents may terminate the agreement
or reduce our license to a nonexclusive license.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Acquisition of License from Duke University</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On June 27, 2019, we entered into an exclusive license agreement (the
“Duke License Agreement”) with Duke University pursuant to which we were granted an exclusive license to a gene therapy program
targeting the regulation of the SNCA gene, which encodes α-synuclein expression. We plan to study this initial approach in PD and
will further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-004. Upon
entry into the Duke License Agreement, we paid to Duke University $0.1 million. We agreed to pay additional consideration to Duke University
upon the achievement of certain milestones in the future, as follows: (i) within 30 days following filing of an IND following the completion
of preclinical studies including comprehensive validation of the platform, we will pay $0.1 million; (ii) within 30 days following dosing
of the first patient in a Phase I clinical trial, we will pay $0.2 million; (iii) within 30 days following dosing of the first patient
in a Phase II clinical trial, we will pay $0.5 million; (iv) within 30 days following dosing of the first patient in a Phase III clinical
trial, we will pay $1.0 million; and (v) within 30 days following an NDA approval, we will pay $2.0 million. We are also obligated to
pay a single digit royalty on sales of the product, if any. In addition, if we fail to achieve certain milestones within a specified timeframe,
Duke University may terminate the agreement.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Acquisition of License from Ligand Pharmaceuticals Incorporated</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On September 21, 2016, we entered into a License Agreement (the “License
Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”), Neurogen Corporation and CyDex Pharmaceuticals, Inc.
(collectively, the “Licensors”), pursuant to which, among other things, the Licensors granted us an exclusive, perpetual,
irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related to a product known as Aplindore,
which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product to be administered by any method
in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen),
which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either or both of the Licensors’ two
proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the “Licensed Products”), and (ii)
copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto. We are obligated to use commercially
reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for the Licensed Products in the United States
or a Major Market, and (c) commercialize the Licensed Products in each country where regulatory approval is obtained. We have the exclusive
right and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical
trials and non-clinical studies we believe appropriate to obtain regulatory approvals for commercialization of the Licensed Products.
We also have the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">As partial consideration for the grant of the rights and licenses
under the License Agreement, we paid to Ligand a nominal option fee. As further partial consideration for the grant of the rights and
licenses to us under the License Agreement, we were obligated to pay to Ligand an aggregate of $1.3 million within 30 days after the closing
of the issuance and sale by us of debt and/or equity securities for gross proceeds to us of at least $7.5 million. In connection with
the closing of the Merger, we issued 392,307 shares of common stock to settle this obligation. As further partial consideration for the
grant of the rights and licenses to us by Ligand under the License Agreement, we agreed to pay to Ligand certain one-time, non-refundable
milestone payments upon the achievement of certain financing milestones, consisting of (i) the lesser of $3.5 million or 10% of the net
proceeds to us in the event of our initial public offering or a financing transaction consummated in connection with a transaction as
a result of which our business becomes owned or controlled by an existing issuer with a class of securities registered under the Exchange
Act and immediately after such transaction, our security holders as of immediately before such transaction own, as a result of such transaction,
at least 35% of the equity securities or voting power of such issuer, or (ii) the</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">8</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">lesser of $3.5 million or 10% of the net proceeds to
us in the event we are acquired. In connection with the closing of the Merger, we issued 408,946 shares of common stock to settle this
obligation.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">As further partial consideration for the grant of the rights and licenses
under the License Agreement, we agreed to pay Ligand certain one-time, non-refundable regulatory milestone payments in connection with
the Licensed Products, other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $750,000
upon submission of an application with the FDA or equivalent foreign body for a particular Licensed Product, (ii) $3.0 million upon FDA
approval of an application for a particular Licensed Product, (iii) $1.125 million upon regulatory approval in a Major Market for a particular
Licensed Product, and (iv) $1.125 million upon regulatory approval in a second Major Market for a particular Licensed Product.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">As further partial consideration for the grant of the rights and licenses
under the License Agreement, we agreed to pay to Ligand certain one-time, non-refundable regulatory milestone payments in connection with
the Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome, consisting of (i) $100,000 upon
submission of an application with the FDA or equivalent foreign body for a particular Licensed Product, (ii) $350,000 upon FDA approval
of an application for a particular Licensed Product, (iii) $125,000 upon regulatory approval in a Major Market for a particular Licensed
Product, and (iv) $125,000 upon regulatory approval in a second Major Market for a particular Licensed Product.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">As further partial consideration for the grant of the rights and licenses
under the License Agreement, we agreed to pay Ligand certain one-time, non-refundable commercial milestone payments in connection with
the Licensed Products, consisting of (i) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed
Products based upon Aplindore, (ii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products
based upon an H3 receptor antagonist, (iii) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed
Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered by any method in any
form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen),
(iv) $10.0 million upon the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists,
(v) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore, (vi)
$20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist,
(vii) $20.0 million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen
(as it may have been or may be modified for use in a product to be administered by any method in any form including, without limitation,
injection and intravenously, the sole active pharmaceutical ingredient of which is acetaminophen), and (viii) $20.0 million upon the achievement
of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We will also pay Ligand a royalty percentage in the mid-single digits
on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome
in a country where such Licensed Products are covered under a licensed patent and a tiered incremental royalty in the upper single digit
to lower double digit range on aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or
Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent. Additionally, we will pay Ligand
low single digit royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication
of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent and a tiered incremental
royalty in the lower single digit to middle single digit range on aggregate annual net sales of Licensed Products in connection with Aplindore
for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products are not covered under a licensed patent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">9</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>


<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Acquisition of License from iX Biopharma Europe Limited</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On November 24, 2021, we entered into an exclusive license agreement
(the “iX License Agreement”) with iX Biopharma Europe Limited (“iX Biopharma”) and a common stock purchase agreement
with iX Biopharma (the “Purchase Agreement”). Pursuant to the iX License Agreement, among other things, iX Biopharma granted
us an exclusive, sublicensable, perpetual, worldwide (excluding certain jurisdictions identified in the iX License Agreement) and irrevocable
right and license to certain of iX Biopharma’s licensed patents, know-how, and technological information, including access to iX
Biopharma’s research, development and manufacturing capabilities, to enable the further development, manufacture, promotion and
commercialization of Wafermine<sup>™</sup>&nbsp;and certain other existing and to be developed iX Biopharma wafer-based delivery technologies,
now known as SLS-003, in all cases for sublingual administration of ketamine. In addition, iX Biopharma will supply us with sufficient
product for the potential treatment of 400 patients, with further supplied amounts to be determined by the parties. We granted iX Biopharma
an exclusive license to exploit technology developed under the iX License Agreement outside of the licensed territory and to undertake
limited, non-exclusive research and development activities in the territory. We further agreed not to undertake certain activities with
respect to products competitive with those licensed under the iX License Agreement during the term of the iX License Agreement.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">As consideration for the license under the iX License Agreement, we
agreed to (i) pay iX Biopharma an upfront fee of $9.0 million, comprised of $3.5 million in cash and $5.5 million in restricted shares
(the “Shares”) of our common stock, calculated in accordance with the Purchase Agreement; and (ii) pay certain development,
regulatory and commercial milestones and royalty payments as further set out in the iX License Agreement.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Pursuant to the Purchase Agreement, we also agreed to reimburse iX
Biopharma for the difference in value (the “Shortfall Amount”) in the event the aggregate value of all of the Shares issued
to iX Biopharma at the time of registration and issuance is less than $5.5 million. The Shortfall Amount could be paid in cash, additional
shares of our common stock or a combination of the foregoing, depending on the size of the Shortfall Amount. We paid iX Biopharma a Shortfall
Amount of $1.2 million in cash in January 2022.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Legacy Pre-Merger Programs</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Pursuant to the Merger, we retained certain assets and technologies
that were assets and technologies of the company that was known as “Apricus Biosciences, Inc.” before the consummation of
the Merger (such assets, the “Legacy Apricus Assets”). Despite that our primary operations have, post-Merger, been those of
STI, and that we expect this to be the case on a going-forward basis, we may choose to monetize Legacy Apricus Assets in the future. We
may also seek to monetize such assets pursuant to certain contractual obligations. Prior to the closing of the Merger, in addition to
strategic efforts, we had been historically focused on the development of innovative product candidates in the areas of urology and rheumatology.
We have two legacy product candidates: a product candidate in the United States intended for the topical treatment of erectile dysfunction
(“ED”), which we in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (“Allergan”)
(the “CVR Product Candidate”); and a product candidate which has completed a Phase IIa clinical trial for the treatment of
Raynaud's Phenomenon, secondary to scleroderma, for which we own worldwide rights. At the closing of the Merger, we entered into a Contingent
Value Rights Agreement (the “CVR Agreement”) with STI, Richard Pascoe, as representative of holders of the contingent value
rights (“CVRs”), and a rights agent. Pursuant to the CVR Agreement, each of the pre-Merger stockholders of our company received
one CVR for each share of common stock held of record immediately prior to the closing of the Merger. Each CVR represents the right to
receive payments based on the CVR Product Candidate and certain related assets and technologies. In particular, the holders of the CVRs
will be entitled to receive 90% of any cash payments (or the fair market value of any non-cash payments) exceeding $500,000 received,
during a period of ten years from the closing of the Merger, based on the sale or out-licensing of the CVR Product Candidate or related
assets and technologies, including any milestone payments, less reasonable transaction expenses. We agreed to pay up to $500,000 of such
Contingent Payments that we receive to a third party pursuant to a settlement agreement between us and the third party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">10</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Patent Portfolio</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">As of <span style="background-color: White">February 25, 2022</span>,
we owned or in-licensed approximately 40 issued patents that relate to our core programs, which will expire from 2022 through 2037, approximately.
Also, as of that same date, we owned or in-licensed approximately 54 patent applications that relate to our core programs, which if ultimately
issued would expire as late as approximately 2043, based upon the potential expiration date of the last to expire of those patent applications.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">To further strengthen our global patent position on our proprietary
products under development and to expand the patent protection to other markets, we have filed foreign patent applications, many of which
correspond to our issued United States patents and pending United States patent applications. These foreign filings have resulted in numerous
issued patents and currently pending patent applications.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">While we have obtained patents and have patent applications pending,
the extent of effective patent protection in the United States and other countries is highly uncertain.&nbsp;No consistent policy addresses
the breadth of claims allowed in or the degree of protection afforded under patents of medical and pharmaceutical companies.&nbsp;Patents
we currently own or may obtain might not be sufficiently broad to protect us against competitors with similar technology.&nbsp;Any of
our patents could be invalidated or circumvented.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The holders of competing patents could determine to commence a lawsuit
against us and may even prevail in any such lawsuit.&nbsp;Litigation could result in substantial cost to and diversion of effort by us,
which may harm our business. In addition, our efforts to protect or defend our proprietary rights may not be successful or, even if successful,
may result in substantial cost to us.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Trademark Portfolio</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: White">As of February 25, 2022, we
owned approximately 5 registered trademarks and 2 pending trademark applications worldwide. We have common law trademark rights in
the unregistered marks “Seelos Therapeutics, Inc.,” “Seelos” and the Seelos logo in certain jurisdictions. Vitaros
is a registered trademark of Ferring in certain countries outside of the United States.</span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">While we have obtained registered trademarks, have trademark applications
pending and may have common law trademark rights where applicable, the extent of effective trademark protection in the United States and
other countries is highly uncertain.&nbsp;Trademarks we currently own or may obtain might not be sufficiently broad to protect us against
competitors.&nbsp;Any of our trademarks could be invalidated or circumvented.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Even where we have registered trademarks, competitors could seek to
invalidate these registrations.&nbsp;Any such litigation could result in substantial cost to and diversion of effort by us, which may
harm our business. In addition, our efforts to protect or defend our proprietary rights may not be successful or, even if successful,
may result in substantial cost to us.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Governmental Regulation</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Government authorities in the United States (including federal, state
and local authorities) and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development,
marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing and
export and import of pharmaceutical products, such as our products and product candidates. The process of obtaining regulatory approvals
and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
time and financial resources. Moreover, failure to comply with applicable regulatory requirements may result in, among other things, warning
letters, clinical holds, civil or criminal penalties, recall or seizure of products, injunction, disbarment, partial or total suspension
of production or withdrawal of the product from the market. Any agency or judicial enforcement action could have a material adverse effect
on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">11</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>United States Government Regulation</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In the United States, the FDA regulates drugs and medical devices
under the Federal Food, Drug, and Cosmetic Act (“FDCA”), and its implementing regulations. Drugs and devices are also subject
to other federal, state and local statutes and regulations. Our product candidates are subject to regulation as combination products,
which means that they are composed of both a drug product and device product. If marketed individually, each component would be subject
to different regulatory pathways and reviewed by different Centers within the FDA. A combination product, however, is assigned to a Center
that will have primary jurisdiction over its regulation based on a determination of the combination product’s primary mode of action,
which is the single mode of action that provides the most important therapeutic action. In the case of our product candidates, we believe
the primary mode of action is attributable to the drug component of the product, which means that the FDA’s Center for Drug Evaluation
and Research would have primary jurisdiction over the premarket development, review and approval of our product candidates. Accordingly,
we have and plan to continue to investigate our products through the IND framework and seek approval through the NDA pathway. Based on
our discussions with the FDA to date, we do not anticipate that the FDA will require a separate medical device authorization for the unit-dose
dispenser to be marketed together with our product candidates, though the device component will need to comply with certain requirements
applicable to devices. The process required by the FDA before our product candidates may be marketed in the United States generally involves
the following:</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>submission to the FDA of an IND which must become effective before human clinical trials may begin and must be updated annually;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA’s
Good Laboratory Practice regulations;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for
each proposed indication in accordance with good clinical practices (“GCPs”);</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>submission to the FDA of an NDA after completion of all pivotal clinical trials;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>a determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the active pharmaceutical ingredient
(“API”), and finished drug product are produced and tested to assess compliance with good manufacturing Practices (“cGMP”)
regulations; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>FDA review and approval of an NDA prior to any commercial marketing or sale of the drug in the United States.</td></tr></tbody></table>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">An IND is a request for authorization from the FDA to administer an
investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s)
for human studies. The IND also includes results of animal studies or other human studies, as appropriate, as well as manufacturing information,
analytical data and any available clinical data or literature to support the use of the investigational new drug. An IND must become effective
before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that
time the FDA raises concerns or questions related to the proposed clinical trials. In such a case, the IND may be placed on clinical hold
and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical trials can begin. Accordingly, submission
of an IND may or may not result in the FDA allowing clinical trials to commence.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Clinical trials involve the administration of the investigational
drug to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all
research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety, and the efficacy criteria
to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the
IND. Additionally, approval must also be obtained from each clinical trial site’s institutional review board (“IRB”)
before the trials may be initiated, and the IRB must monitor the study until completed. There are also requirements governing the reporting
of ongoing clinical trials and clinical trial results to public registries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">12</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The clinical investigation of a drug is generally divided into three
phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The three phases of an investigation
are as follows:</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>Phase I. Phase I includes the initial introduction of an investigational new drug into humans. Phase I clinical trials are typically
closely monitored and may be conducted in patients with the target disease or condition or in healthy volunteers. These studies are designed
to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the investigational drug in humans, the side effects
associated with increasing doses, and if possible, to gain early evidence on effectiveness. During Phase I clinical trials, sufficient
information about the investigational drug’s pharmacokinetics and pharmacological effects may be obtained to permit the design of
well-controlled and scientifically valid Phase II clinical trials. The total number of participants included in Phase I clinical trials
varies, but is generally in the range of 20 to 80.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>Phase II. Phase II includes controlled clinical trials conducted to preliminarily or further evaluate the effectiveness of the investigational
drug for a particular indication(s) in patients with the disease or condition under study, to determine dosage tolerance and optimal dosage,
and to identify possible adverse side effects and safety risks associated with the drug. Phase II clinical trials are typically well-controlled,
closely monitored, and conducted in a limited patient population, usually involving no more than several hundred participants.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>Phase III. Phase III clinical trials are generally controlled clinical trials conducted in an expanded patient population generally
at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the drug has
been obtained, and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship
of the investigational drug product, and to provide an adequate basis for product approval. Phase III clinical trials usually involve
several hundred to several thousand participants.</td></tr></tbody></table>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">A pivotal study is a clinical study which adequately meets regulatory
agency requirements for the evaluation of a drug candidate’s efficacy and safety such that it can be used to justify the approval
of the product. Generally, pivotal studies are also Phase III studies but may be Phase II studies if the trial design provides a well-controlled
and reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The FDA, the IRB or the clinical trial sponsor may suspend or terminate
a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health
risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor,
known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at
designated check points based on access to certain data from the study. We may also suspend or terminate a clinical trial based on evolving
business objectives and/or competitive climate.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Assuming successful completion of all required testing in accordance
with all applicable regulatory requirements, detailed investigational drug product information is submitted to the FDA in the form of
an NDA requesting approval to market the product for one or more indications. The application includes all relevant data available from
pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed
information relating to the product’s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come
from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative
sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality
and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Once the NDA submission has been accepted for filing, within 60 days
following submission, the FDA’s goal is to review applications for new molecular entities within ten months of the filing date or,
if the application relates to a serious or life-threatening indication and demonstrates the potential to provide a significant improvement
in safety or effectiveness over currently marketed therapies, six months from the filing date. The review process is often significantly
extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review,
evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory
committee, but it typically follows such recommendations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">13</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">After the FDA evaluates the NDA and conducts inspections of manufacturing
facilities where the drug product and/or its active pharmaceutical ingredient will be produced, it may issue an approval letter or a complete
response letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.
A complete response letter indicates that the review cycle of the application is complete and the application is not ready for approval.
A complete response letter may require additional clinical data and/or an additional pivotal Phase III clinical trial(s), and/or other
significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such
additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could
also approve the NDA with a risk evaluation and mitigation strategy to mitigate risks, which could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and
specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase
IV clinical trials and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization.
Regulatory approval of oncology products often requires that patients in clinical trials be followed for long periods to determine the
overall survival benefit of the drug.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">After regulatory approval of a drug product is obtained, manufacturers
are required to comply with a number of post-approval requirements. The holder of an approved NDA must report, among other things, certain
adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements
concerning advertising and promotional labeling for the approved product. Also, quality control and manufacturing procedures must continue
to conform to cGMP after approval to ensure and preserve the long-term stability of the drug product and compliance with relevant manufacturing
requirements applicable to the device component. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP,
which imposes extensive procedural, substantive and record keeping requirements. In addition, changes to the manufacturing process are
strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations
also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and
any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in
the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We rely, and expect to continue to rely, on third parties for the
production of clinical and commercial quantities of our product candidates. Future FDA and state inspections may identify compliance issues
at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial
resources to correct. In addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements
may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal or recall of the product from
the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Newly discovered or developed
safety or effectiveness data may require changes to a product’s approved labeling, including the addition of new warnings and contraindications,
and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting
from new legislation, may be established, or the FDA’s policies may change, which could delay or prevent regulatory approval of
our products under development.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>The Hatch-Waxman Amendments</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>ANDA Approval Process</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The Hatch-Waxman Act, established abbreviated FDA approval procedures
for drugs that are shown to be equivalent to proprietary drugs previously approved by the FDA through its NDA process. Approval to market
and distribute these drugs is obtained by filing an abbreviated new drug application (“ANDA”) with the FDA. An ANDA is a comprehensive
submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation,
specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control
procedures. Premarket applications for generic drugs are termed abbreviated because they generally do not include preclinical and clinical
data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator
drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">14</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In certain situations, an applicant may obtain ANDA approval of a
generic product with a strength or dosage form that differs from a referenced innovator drug pursuant to the filing and approval of an
ANDA Suitability Petition. The FDA will approve the generic product as suitable for an ANDA application if it finds that the generic product
does not raise new questions of safety and effectiveness as compared to the innovator product. A product is not eligible for ANDA approval
if the FDA determines that it is not equivalent to the referenced innovator drug, if it is intended for a different use, or if it is not
subject to an approved Suitability Petition. However, such a product might be approved under an NDA, with supportive data from clinical
trials.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>505(b)(2) NDAs</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">As an alternative path to FDA approval for modifications to formulations
or uses of products previously approved by the FDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2)
was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least some of the information required for
approval comes from studies not conducted by, or for, the applicant or for which the applicant has not obtained a right of reference.
If the 505(b)(2) applicant can establish that reliance on FDA’s previous findings of safety and effectiveness is scientifically
appropriate, it may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require
companies to perform additional studies or measurements, including clinical trials, to support the change from the approved branded reference
drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the branded reference drug
has been approved, as well as for any new indication sought by the 505(b)(2) applicant. We anticipate filing 505(b)(2) NDAs for our lead
product candidates, which would rely, in part, on the FDA’s previous findings of safety and efficacy of the active ingredient.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Orange Book Listing</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In seeking approval for a drug through an NDA, including a 505(b)(2)
NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant’s product. Upon approval of an
NDA, each of the patents listed in the application for the drug is then published in the Orange Book. Any applicant who files an ANDA
seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the
Orange Book must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been
submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not
be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification
is known as a paragraph IV certification. A notice of the paragraph IV certification must be provided to each owner of the patent that
is the subject of the certification and to the holder of the approved NDA to which the ANDA or 505(b)(2) application refers. The applicant
may also elect to submit a ‘‘section viii’’ statement certifying that its proposed label does not contain (or
carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the reference NDA
holder and patent owners assert a patent challenge directed to one of the Orange Book listed patents within 45 days of the receipt of
the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30 months from the receipt
of the paragraph IV certification expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable
to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the
Orange Book for the branded reference drug has expired as described in further detail below.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">15</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Non-Patent Exclusivity</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In addition to patent exclusivity, the holder of the NDA for the listed
drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA or 505(b)(2) application that
relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity upon NDA approval
of a new chemical entity (“NCE”), which is a drug that contains an active moiety that has not been approved by FDA in any
other NDA. An ‘‘active moiety’’ is defined as the molecule or ion responsible for the drug substance’s physiological
or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA seeking approval of a generic
version of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA’s findings regarding that drug,
except that FDA may accept an application for filing after four years if the follow-on applicant makes a paragraph IV certification. A
drug, including one approved under Section 505(b)(2), may obtain a three-year period of exclusivity for a particular condition of approval,
or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other
than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant.
Should this occur, the FDA would be precluded from approving any ANDA or 505(b)(2) application for the protected modification until after
that three-year exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process
during the exclusivity period.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Europe/Rest of World Government Regulation</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In addition to regulations in the United States, we may be subject
to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution
of our product candidates.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Whether or not we obtain FDA approval for a product, we must obtain
the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of
the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of
a clinical trial application much like the IND prior to the commencement of human clinical trials. In Europe, for example, a clinical
trial application (“CTA”) must be submitted to each country’s national health authority and an independent ethics committee,
much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country’s requirements, clinical trial development
may proceed. The requirements and process governing the conduct of clinical trials,
product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance
with cGCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">To obtain regulatory approval of an investigational drug under EU
regulatory systems, we must submit a marketing authorization application. The application used to file the NDA in the United States is
similar to that required in Europe, with the exception of, among other things, country-specific document requirements.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">For other countries outside of the EU, such as countries in Eastern
Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement
vary from country to country. In all cases, again, the clinical trials are conducted in accordance with cGCPs and the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">If we fail to comply with applicable foreign regulatory requirements,
we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products,
operating restrictions and criminal prosecution.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Authorization Procedures in the European Union</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Medicines can be authorized in the EU by using either the centralized
authorization procedure or national authorization procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">16</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>Centralized Procedure. Under the Centralized Procedure a so-called Community Marketing Authorization is issued by the European Commission,
based on the opinion of the Committee for Medicinal Products for Human Use of the EMA. The Community Marketing Authorization is valid
throughout the entire territory of the European Economic Area (“EEA”) (which includes the 27 Member States of the EU plus
Norway, Liechtenstein and Iceland). The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal
products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders,
diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet
authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the
interest of public health in the EU.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized
marketing authorization to the EMA, as long as the medicine concerned is a significant therapeutic, scientific or technical innovation,
or if its authorization would be in the interest of public health.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>National Authorization Procedures. There are also two other possible routes to authorize medicinal products in several countries,
which are available for investigational drug products that fall outside the scope of the centralized procedure:</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">◦</td><td>Decentralized Procedure. Using the Decentralized Procedure, an applicant may apply for simultaneous authorization in more than one
EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of
the centralized procedure. Under the Decentralized Procedure the applicant chooses one country as Reference Member State. The regulatory
authority of the Reference Member State will then be in charge of leading the assessment of the marketing authorization application.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">◦</td><td>Mutual Recognition Procedure. In the Mutual Recognition Procedure, a medicine is first authorized in one EU Member State, in accordance
with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries in
a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.</td></tr></tbody></table>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In the EU, upon receiving marketing authorization, new chemical entities
generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents
regulatory authorities in the EU from referencing the innovator’s data to assess a generic application. During the additional two-year
period of market exclusivity, a generic marketing authorization can be submitted, and the innovator’s data may be referenced, but
no generic product can be marketed until the expiration of the market exclusivity. However, there is no guarantee that a product will
be considered by the EU’s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Other Health Care Laws</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We may also be subject to healthcare regulation and enforcement by
the federal government and the states and foreign governments where we may market our product candidates, if approved.&nbsp; These laws
include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, physician sunshine and privacy and security
laws and regulations.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The federal Anti-Kickback Statute prohibits, among other things, any
person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either
the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made
under federal healthcare programs such as the Medicare and Medicaid programs.&nbsp; The Anti-Kickback Statute is subject to evolving interpretations.
In the past, the government has enforced the Anti-Kickback Statute to reach large settlements with healthcare companies based on sham
consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute
or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including
items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes
of the federal False Claims Act. The majority of states also have anti-kickback laws which establish similar prohibitions and in some
cases may apply to items or services reimbursed by any third-party payor, including commercial insurers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">17</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Additionally, the civil False Claims Act prohibits knowingly presenting
or causing the presentation of a false, fictitious or fraudulent claim for payment to the United States government. Actions under the
False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government.
Violations of the False Claims Act can result in very significant monetary penalties and treble damages. The federal government is using
the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and
biotechnology companies throughout the United States, for example, in connection with the promotion of products for unapproved uses and
other sales and marketing practices.&nbsp; The government has obtained multi-million and multi-billion dollar settlements under the False
Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and
potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers'
and manufacturers' compliance with applicable fraud and abuse laws.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The federal Health Insurance Portability and Accountability Act of
1996 (“HIPAA”) also created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully
embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback
Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed
a violation.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">There has also been a recent trend of increased federal and state
regulation of payments made to physicians and other healthcare providers. The Patient Protection and Affordable Care Act, as amended by
the Health Care and Education Reconciliation Act, (collectively, “the Affordable Care Act”), among other things, imposed new
reporting requirements on drug manufacturers for payments made by them to physicians and teaching hospitals, as well as ownership and
investment interests held by physicians and their immediate family members.&nbsp; Failure to submit timely, accurately and completely
the required information may result in civil monetary penalties of up to an aggregate of approximately $0.2 million per year (or up to
an aggregate of $1.1 million per year for “knowing failures”), for all payments, transfers of value or ownership or investment
interests that are not timely, accurately and completely reported in an annual submission.&nbsp; Drug manufacturers are required to submit
reports to the government by the 90th day of each calendar year.&nbsp; Certain states also mandate implementation of compliance programs,
impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of marketing expenditures and pricing
information as well as gifts, compensation and other remuneration to physicians.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We may also be subject to data privacy and security regulation by
both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology and
Clinical Health Act (“HITECH”), and their respective implementing regulations, including the final omnibus rule published
on January 25, 2013, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health
information. Among other things, HITECH makes HIPAA’s privacy and security standards directly applicable to “business associates,”
defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information
in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that
may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority
to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney’s fees and
costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in
certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">18</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Coverage and Reimbursement</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Sales of our product candidates, once approved, will depend, in part,
on the extent to which the costs of our products will be covered by third-party payors, such as government health programs, private health
insurers and managed care organizations. Third-party payors generally decide which drugs they will cover and establish certain reimbursement
levels for such drugs. In particular, in the United States, private health insurers and other third-party payors often provide reimbursement
for products and services based on the level at which the government (through the Medicare or Medicaid programs) provides reimbursement
for such treatments. Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally
rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless
coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of our products and
product candidates, if approved, will therefore depend substantially on the extent to which the costs of products and our product candidates
will be paid by third-party payors. Additionally, the market for our products and product candidates will depend significantly on access
to third-party payors’ formularies without prior authorization, step therapy, or other limitations such as approved lists of treatments
for which third-party payors provide coverage and reimbursement. Additionally, coverage and reimbursement for therapeutic products can
differ significantly from payor to payor. One third-party payor’s decision to cover a particular medical product or service does
not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement
rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products
to each payor separately and will be a time-consuming process.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In addition, the United States government, state legislatures and
foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement
and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more
restrictive policies in jurisdictions with existing controls and measures, could further limit our future net revenue and results. Decreases
in third-party reimbursement for our products and product candidates or a decision by a third-party payor to not cover our products or
product candidates could reduce physician usage of our products and product candidates, if approved, and have a material adverse effect
on our sales, results of operations and financial condition.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Health Care Reform</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In the United States and foreign jurisdictions, there have been a
number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. There have been
and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In particular, in the United States, the Affordable Care Act has had,
and is expected to continue to have, a significant impact on the healthcare industry. The Affordable Care Act was designed to expand coverage
for the uninsured while at the same time containing overall healthcare costs. The Affordable Care Act, among other things, addressed a
new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate
Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes
on manufacturers of certain branded prescription drugs, and established a new Medicare Part D coverage gap discount program, in which
manufacturers must agree to offer 50% point-of-sale discounts, which, through subsequent legislative amendments, was increased to 70%,
off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s
outpatient drugs to be covered under Medicare Part D. Substantial new provisions affecting compliance were also enacted, which may require
us to modify our business practices with healthcare providers and entities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">19</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Since its enactment, there have been judicial and Congressional challenges
to certain aspects of the Affordable Care Act. Most recently, the Tax Cuts and Jobs Act was enacted, which, among other things, removes
penalties for not complying with Affordable Care Act’s individual mandate to carry health insurance. There is still uncertainty
with respect to the impact President Biden’s administration and the U.S. Congress may have, if any, and any changes will likely
take time to unfold, and could have an impact on coverage and reimbursement for healthcare items and services covered by plans that were
authorized by the Affordable Care Act.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">In addition, other legislative changes have been proposed and adopted
since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal
year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through
2025 unless additional Congressional action is taken. Additionally, in January 2013, the American Taxpayer Relief Act of 2012 was signed
into law, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations
period for the government to recover overpayments to providers from three to five years. Recently there has been heightened governmental
scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries
and proposed bills designed to, among other things, reform government program reimbursement methodologies. <span style="color: #231F20">Individual
states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span>We expect
that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates
or additional pricing pressures.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Employees</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">As of February 25, 2022, we had 16 employees, 15 of which are full-time
employees, and all of whom are in the United States. <span id="a_Hlk3799803"></span>Our <span style="background-color: white">organization
will rely primarily on outsourcing research, development and clinical trial activities, and manufacturing operations, as well as other
functions critical to our business. We believe this approach enhances our ability to focus on our core product opportunities, allocate
resources efficiently to different projects and allocate internal resources more effectively. </span>None of our employees are represented
by a collective bargaining agreement.&nbsp;We believe that we have a good relationship with our employees.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Corporate Information</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We were incorporated under the laws of the State of Nevada in 1987,
as NexMed, Inc. On September 10, 2010, we changed our name to "Apricus Biosciences, Inc." On January 24, 2019, we completed
the Merger with STI (formerly known as Seelos Therapeutics, Inc.), a Delaware corporation, and, upon completion of the Merger, we changed
our name to "Seelos Therapeutics, Inc." Shares of our common stock commenced trading on the Nasdaq Capital Market under the
ticker symbol "SEEL" as of market open on January 24, 2019.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Available Information</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We file annual, quarterly and current reports, proxy statements and
other information with the SEC, and we have an Internet website address at <span style="text-decoration: underline">http://www.seelostherapeutics.com</span>. We make available
free of charge on our Internet website address our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form
8-K, and amendments to those reports filed or furnished pursuant to Sections&nbsp;13(a) or 15(d) of the Exchange Act as well as our proxy
statements as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.&nbsp;You may
also obtain copies of such documents from the SEC’s website at <span style="text-decoration: underline">http://www.sec.gov</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">20</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item1a"></span>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>We operate in a dynamic and rapidly changing environment that involves
numerous risks and uncertainties. Certain factors may have a material adverse effect on our business, prospects, financial condition and
results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the
following discussion of risk factors, in its entirety, in addition to other information contained in this Annual Report on Form 10-K and
our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also
affect our business, prospects, financial condition and results of operations.</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risk Factor Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Below is a summary of the principal factors that make
an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion
of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered,
together with all of the other information appearing in or incorporated by reference into this Annual Report on Form 10-K, or this Form
10-K, and our other public filings with the SEC before making an investment decision regarding our common stock. Other events that we
do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0; text-align: justify">We are a clinical-stage company, we have a very limited operating history, are not currently
profitable, do not expect to become profitable in the near future and may never become profitable.</li>

<li style="margin: 0; text-align: justify">We are dependent on the success of one or more of our current product candidates and we cannot
be&nbsp;certain that any of them will receive regulatory approval or be commercialized.</li>

<li style="margin: 0; text-align: justify">If development of our product candidates does not produce favorable results, or encounters
challenges, we and our collaborators, if&nbsp;any, may be unable to commercialize these products.</li>

<li style="margin: 0; text-align: justify">We expect to continue to incur significant research and development expenses, which may make
it difficult for us to attain profitability.</li>

<li style="margin: 0; text-align: justify">Given our lack of current cash flow, we may need to raise additional capital; however, it may
be unavailable&nbsp;to us or, even if capital is obtained, may cause dilution or place significant restrictions on our ability to&nbsp;operate
our business. If we fail to raise the necessary additional capital, we may be unable to complete the development and commercialization
of our product candidates, or continue our development programs.</li>

<li style="margin: 0; text-align: justify">Our product candidates may cause undesirable side effects that could delay or prevent their
regulatory approval&nbsp;or commercialization or have other significant adverse implications on our business, financial condition and&nbsp;results
of operations.</li>

<li style="margin: 0; text-align: justify">Delays in the commencement or completion of clinical trials could result in increased costs
to us and delay&nbsp;our ability to establish strategic collaborations.</li>

<li style="margin: 0; text-align: justify">A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially
and adversely affect our business and operations.</li>

<li style="margin: 0; text-align: justify">Results of earlier clinical trials may not be predictive of the results of later-stage clinical
trials.</li>

<li style="margin: 0; text-align: justify">We intend to rely on third parties to conduct our preclinical studies and clinical trials and
perform other tasks.&nbsp;If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply
with&nbsp;regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product&nbsp;candidates and
our business, financial condition and results of operations could be substantially harmed.</li>

<li style="margin: 0; text-align: justify">Our product candidates are subject to extensive regulation under the U.S. Food and Drug Administration
(the “FDA”), the European Medicines Agency (the “EMA”) or comparable foreign authorities, which can be costly
and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</li>

<li style="margin: 0; text-align: justify">If our competitors have product candidates that are approved faster, marketed more effectively,
are better&nbsp;tolerated, have a more favorable safety profile or are demonstrated to be more effective than ours, our&nbsp;commercial
opportunity may be reduced or eliminated.</li>

<li style="margin: 0; text-align: justify">We rely completely on third parties to manufacture our preclinical and clinical drug supplies,
and our&nbsp;business, financial condition and results of operations could be harmed if those third parties fail to provide us&nbsp;with
sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.</li>

<li style="margin: 0; text-align: justify">The commercial success of our product candidates depends upon their market acceptance among
physicians,&nbsp;patients, healthcare payors and the medical community.</li>

<li style="margin: 0; text-align: justify">If we fail to retain current members of our senior management and scientific personnel, or
to attract and&nbsp;keep additional key personnel, we may be unable to successfully develop or commercialize our product&nbsp;candidates.</li>

<li style="margin: 0; text-align: justify">We may not be successful in obtaining or maintaining necessary rights to our product candidates
through&nbsp;acquisitions and in-licenses.</li>
</ul>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">21</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<ul style="margin-top: 0in; list-style-type: disc">
<li style="margin: 0; text-align: justify">If we fail to comply with our obligations in the agreements under which we in-license intellectual
property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we
could lose intellectual property rights that are important to our business.</li>

<li style="margin: 0; text-align: justify">We may not be able to protect our proprietary or licensed technology in the marketplace.</li>

<li style="margin: 0; text-align: justify">The market price of our common stock is expected to be volatile.</li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risk Factors</b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>Risks Related to the Company</b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We are a clinical-stage company, we have a very limited operating
history, are not currently profitable, do not expect&nbsp;to become profitable in the near future and may never become profitable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a clinical-stage biopharmaceutical company. Since our incorporation,
we have focused primarily on the development and acquisition of clinical-stage therapeutic candidates. All of our therapeutic candidates
are in the clinical development stage and none of our pipeline therapeutic candidates have been approved for marketing or are being marketed
or commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As a result, we have no meaningful historical operations upon which to
evaluate our business and prospects and have not yet demonstrated an ability to obtain marketing approval for any of our product candidates
or successfully overcome the risks and uncertainties frequently encountered by companies in the biopharmaceutical industry. We also have
generated minimal revenues from collaboration and licensing agreements and no revenues from product sales to date and continue to incur
significant research and development and other expenses. As a result, we have not been profitable and have incurred significant operating
losses in every reporting period since our inception. We have incurred an accumulated deficit of $141.2 million from our inception through
December&nbsp;31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the foreseeable future, we expect to continue to incur losses, which
will increase significantly from historical levels as we expand our drug development activities, seek partnering and/or regulatory approvals
for our product candidates and begin to commercialize them if they are approved by the FDA, the EMA or comparable foreign authorities.
Even if we succeed in developing and commercializing one or more product candidates, we may never become profitable.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We are dependent on the success of one or more of our current
product candidates and we cannot be&nbsp;certain that any of them will receive regulatory approval or be commercialized.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have spent significant time, money and effort on the licensing and development
of our core assets, SLS-002, SLS-005 and SLS-006 and our other earlier-stage assets, SLS-004, SLS-007, SLS-008, SLS-010 and SLS-012. To
date, no pivotal clinical trials designed to provide clinically and statistically significant proof of efficacy, or to provide sufficient
evidence of safety to justify approval, have been completed with any of our pipeline product candidates. All of our product candidates
will require additional development, including clinical trials as well as further preclinical studies to evaluate their toxicology, carcinogenicity
and pharmacokinetics and optimize their formulation, and regulatory clearances before they can be commercialized. Positive results obtained
during early development do not necessarily mean later development will succeed or that regulatory clearances will be obtained. Our drug
development efforts may not lead to commercial drugs, either because our product candidates may fail to be safe and effective or because
we have inadequate financial or other resources to advance our product candidates through the clinical development and approval processes.
If any of our product candidates fail to demonstrate safety or efficacy at any time or during any phase of development, we would experience
potentially significant delays in, or be required to abandon, development of the product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We do not anticipate that any of our current product candidates will be
eligible to receive regulatory approval from the FDA, the EMA or comparable foreign authorities and begin commercialization for a number
of years, if ever. Even if we ultimately receive regulatory approval for any of these product candidates, we or our potential future partners,
if any, may be unable to commercialize them successfully for a variety of reasons. These include, for example, the availability of alternative
treatments, lack of cost-effectiveness, the cost of manufacturing the product on a commercial scale and competition with other drugs.
The success of our product candidates may also be limited by the prevalence and severity of any adverse side effects. If we fail to commercialize
one or more of our current product candidates, we may be unable to generate sufficient revenues to attain or maintain profitability, and
our financial condition and stock price may decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">22</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>If development of our product candidates does not produce favorable
results, or encounters challenges, we and our collaborators, if&nbsp;any, may be unable to commercialize these products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To receive regulatory approval for the commercialization of our core assets,
SLS-002, SLS-005 and SLS-006 and our earlier-stage assets, SLS-004, SLS-007, SLS-008, SLS-010 and SLS-012, or any other product candidates
that we may develop, adequate and well-controlled clinical trials must be conducted to demonstrate safety and efficacy in humans to the
satisfaction of the FDA, the EMA and comparable foreign authorities. In order to support marketing approval, these agencies typically
require successful results in one or more Phase III clinical trials, which our current product candidates have not yet reached and may
never reach. The development process is expensive, can take many years and has an uncertain outcome. Failure can occur at any stage of
the process. We may experience numerous unforeseen events during, or as a result of, the development process that could delay or prevent
commercialization of our current or future product candidates, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>clinical trials may produce negative or inconclusive results;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>preclinical studies conducted with product candidates during clinical development to, among other things, evaluate their toxicology,
carcinogenicity and pharmacokinetics and optimize their formulation may produce unfavorable results;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>we or our contract manufacturers may encounter manufacturing challenges or the FDA may raise concerns regarding Chemistry, Manufacturing,
and Controls (CMC) data or GMP compliance, or biocompatibility or drug-device interaction concerns for our combination product candidates;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>patient recruitment and enrollment in clinical trials may be slower than we anticipate;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>costs of development may be greater than we anticipate;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>our product candidates may cause undesirable side effects that delay or preclude regulatory approval or limit their commercial use
or market acceptance, if approved;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>collaborators who may be responsible for the development of our product candidates may not devote sufficient resources to these clinical
trials or other preclinical studies of these candidates or conduct them in a timely manner; or</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>we may face delays in obtaining regulatory approvals to commence one or more clinical trials.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Success in early development does not mean that later development will
be successful because, for example, product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy
despite having progressed through initial clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have licensed or acquired all of the intellectual property related to
our product candidates from third parties. All clinical trials, preclinical studies and other analyses performed to date with respect
to our product candidates have been conducted by their original owners. Therefore, as a company, we have limited experience in conducting
clinical trials for our product candidates. Since our experience with our product candidates is limited, we will need to train our existing
personnel and hire additional personnel in order to successfully administer and manage our clinical trials and other studies as planned,
which may result in delays in completing such planned clinical trials and preclinical studies. Moreover, to date our product candidates
have been tested in less than the number of patients that will likely need to be studied to obtain regulatory approval. The data collected
from clinical trials with larger patient populations may not demonstrate sufficient safety and efficacy to support regulatory approval
of these product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently do not have strategic collaborations in place for clinical
development of any of our current product candidates, except for our collaborative agreement with Team Sanfilippo Foundation (“TSF”),
which we assumed in connection with the asset purchase agreement with Bioblast Pharma Ltd. for IV Trehalose, which is now known as SLS-005.
Therefore, in the future, we or any potential future collaborative partner will be responsible for establishing the targeted endpoints
and goals for development of our product candidates. These targeted endpoints and goals may be inadequate to demonstrate the safety and
efficacy levels required for regulatory approvals. Even if we believe data collected during the development of our product candidates
are promising, such data may not be sufficient to support marketing approval by the FDA, the EMA or comparable foreign authorities. Further,
data generated during development can be interpreted in different ways, and the FDA, the EMA or comparable foreign authorities may interpret
such data in different ways than us or our collaborators. Our failure to adequately demonstrate the safety and efficacy of our product
candidates would prevent our receipt of regulatory approval, and ultimately the potential commercialization of these product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Since we do not currently possess the resources necessary to independently
develop and commercialize our product candidates or any other product candidates that we may develop, we may seek to enter into collaborative
agreements to assist in the development and potential future commercialization of some or all of these assets as a component of our strategic
plan. However, our discussions with potential collaborators may not lead to the establishment of collaborations on acceptable terms, if
at all, or it may take longer than expected to establish new collaborations, leading to development and potential commercialization delays,
which would adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">23</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
<!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;<b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We expect to continue to incur significant research and development
expenses, which may make it difficult&nbsp;for us to attain profitability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect to expend substantial funds in research and development, including
preclinical studies and clinical trials of our product candidates, and to manufacture and market any product candidates in the event they
are approved for commercial sale. We also may need additional funding to develop or acquire complementary companies, technologies and
assets, as well as for working capital requirements and other operating and general corporate purposes. Moreover, our planned increases
in staffing will dramatically increase our costs in the near and long-term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">However, our spending on current and future research and development programs
and product candidates for specific indications may not yield any commercially viable products. Due to our limited financial and managerial
resources, we must focus on a limited number of research programs and product candidates and on specific indications. Our resource allocation
decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Because the successful development of our product candidates is uncertain,
we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition, we may
not be able to generate sufficient revenue, even if we are able to commercialize any of our product candidates, to become profitable.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Given our lack of current cash flow, we may need to raise additional
capital; however, it may be unavailable&nbsp;to us or, even if capital is obtained, may cause dilution or place significant restrictions
on our ability to&nbsp;operate our business. If we fail to raise the necessary additional capital, we may be unable to complete the development
and commercialization of our product candidates, or continue our development programs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2021, we had a cash balance of approximately $78.7 million.
Since we will be unable to generate sufficient, if any, cash flow to fund our operations for the foreseeable future, we may need to seek
additional equity or debt financing to provide the capital required to maintain or expand our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As a result of our recurring losses from operations, there is uncertainty
regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about
our ability to continue as a going concern. If we are unsuccessful in our efforts to raise outside financing, we may be required
to significantly reduce or cease operations. The report of our independent registered public accounting firm on our audited financial
statements for the year ended December 31, 2021 included a “going concern” explanatory paragraph indicating that our recurring
losses from operations raise substantial doubt about our ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently have an effective shelf registration statement on Form S-3
filed with the SEC. We may use the shelf registration statement on Form S-3 to offer from time to time any combination of debt securities,
common and preferred stock and warrants, and, as of the date hereof, a total of $95.1 million of securities remains available for issuance
pursuant to the shelf registration statement. There can be no assurance that we will be able to raise sufficient additional capital on
acceptable terms or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">In addition, the impact of the COVID-19 pandemic
on the global financial markets may reduce our ability to access capital, which could negatively affect our liquidity and ability to continue
as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If such additional financing is not available on satisfactory terms, or
is not available in sufficient amounts, we may be required to delay, limit or eliminate the development of business opportunities and
our ability to achieve our business objectives, our competitiveness, and our business, financial condition and results of operations will
be materially adversely affected. In addition, we may be required to grant rights to develop and market product candidates that we would
otherwise prefer to develop and market ourselves. Our inability to fund our business could lead to the loss of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our future capital requirements will depend on many factors, including,
but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future product candidates;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the number and characteristics of the product candidates we seek to develop or commercialize;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the cost of commercialization activities if any of our current or future product candidates are approved for sale, including marketing,
sales and distribution costs;</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">24</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
<!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the expenses needed to attract and retain skilled personnel;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the costs associated with being a public company;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive
marketing approval; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation
costs and the outcome of any such litigation.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we raise additional capital by issuing equity securities, the
percentage ownership of our existing stockholders may be reduced, and accordingly these stockholders may experience substantial
dilution. We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common
stock. Given our need for cash and that equity issuances are the most common type of fundraising for similarly situated companies,
the risk of dilution is particularly significant for our stockholders. <span style="background-color: white">In addition, debt
financing may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our
assets.&nbsp;</span> For example, we granted to Lind Global Asset Management V, LLC (“Lind”), one of the holders of the
convertible promissory notes we issued in 2021 (the “Convertible Promissory Notes”), a first priority lien on our assets
and properties and the Convertible Promissory Notes include restrictive covenants and event of default provisions, including
restrictions on certain sales or other dispositions of company assets, restrictions on entering into certain variable-rate
transactions and a minimum cash requirement. In addition, although the Securities Purchase Agreement we entered into with Lind in
November 2021 provides that we may issue and sell to Lind additional convertible promissory notes, the issuances of such additional
notes are subject to the satisfaction of certain conditions and milestones, which we may not be able to satisfy or achieve. Our
inability to raise capital when needed may harm our business, financial condition and results of operations, and could cause our
stock price to decline or require that we wind down our operations altogether.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Our product candidates may cause undesirable side effects that
could delay or prevent their regulatory approval&nbsp;or commercialization or have other significant adverse implications on our business,
financial condition and&nbsp;results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Undesirable side effects observed in clinical trials or in supportive preclinical
studies with our product candidates could interrupt, delay or halt their development and could result in the denial of regulatory approval
by the FDA, the EMA or comparable foreign authorities for any or all targeted indications or adversely affect the marketability of any
such product candidates that receive regulatory approval. In turn, this could eliminate or limit our ability to commercialize our product
candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our product candidates may exhibit adverse effects in preclinical toxicology
studies and adverse interactions with other drugs. There are also risks associated with additional requirements the FDA, the EMA or comparable
foreign authorities may impose for marketing approval with regard to a particular disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our product candidates may require a risk management program that could
include patient and healthcare provider education, usage guidelines, appropriate promotional activities, a post-marketing observational
study, and ongoing safety and reporting mechanisms, among other requirements. Prescribing could be limited to physician specialists or
physicians trained in the use of the drug, or could be limited to a more restricted patient population. Any risk management program required
for approval of our product candidates could potentially have an adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Undesirable side effects involving our product candidates may have other
significant adverse implications on our business, financial condition and results of operations. For example:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>we may be unable to obtain additional financing on acceptable terms, if at all;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>our collaborators may terminate any development agreements covering these product candidates;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>if any development agreements are terminated, we may determine not to further develop the affected product candidates due to resource
constraints and may not be able to establish additional collaborations for their further development on acceptable terms, if at all;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>if we were to later continue the development of these product candidates and receive regulatory approval, earlier findings may significantly
limit their marketability and thus significantly lower our potential future revenues from their commercialization;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>we may be subject to product liability or stockholder litigation; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>we may be unable to attract and retain key employees.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">25</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, if any of our product candidates receive marketing approval
and we or others later identify undesirable side effects caused by the product:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>regulatory authorities may withdraw their approval of the product, or we or our partners may decide to cease marketing and sale of
the product voluntarily;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>we may be required to change the way the product is administered, conduct additional clinical trials or preclinical studies regarding
the product, change the labeling of the product, or change the product’s manufacturing facilities; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>our reputation may suffer.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Any of these events could prevent us from achieving or maintaining market
acceptance of the affected product and could substantially increase the costs and expenses of commercializing the product, which in turn
could delay or prevent us from generating significant revenues from the sale of the product.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Our efforts to discover product candidates beyond our current
product candidates may not succeed, and any&nbsp;product candidates we recommend for clinical development may not actually begin clinical
trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We intend to use our technology, including our licensed technology, knowledge
and expertise to develop novel drugs to address some of the world’s most widespread and costly central nervous system, respiratory
and other disorders, including orphan indications. We intend to expand our existing pipeline of core assets by advancing drug compounds
from current ongoing discovery programs into clinical development. However, the process of researching and discovering drug compounds
is expensive, time-consuming and unpredictable. Data from our current preclinical programs may not support the clinical development of
our lead compounds or other compounds from these programs, and we may not identify any additional drug compounds suitable for recommendation
for clinical development. Moreover, any drug compounds we recommend for clinical development may not demonstrate, through preclinical
studies, indications of safety and potential efficacy that would support advancement into clinical trials. Such findings would potentially
impede our ability to maintain or expand our clinical development pipeline. Our ability to identify new drug compounds and advance them
into clinical development also depends upon our ability to fund our research and development operations, and we cannot be certain that
additional funding will be available on acceptable terms, or at all.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Delays in the commencement or completion of clinical trials
could result in increased costs to us and delay&nbsp;our ability to establish strategic collaborations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Delays in the commencement or completion of clinical trials could significantly
impact our drug development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at
all. The commencement of clinical trials can be delayed for a variety of reasons, including, but not limited to, delays related to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>obtaining regulatory approval to commence one or more clinical trials;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>reaching agreement on acceptable terms with prospective third-party contract research organizations (“CROs”) and clinical
trial sites;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>manufacturing sufficient quantities of a product candidate or other materials necessary to conduct clinical trials;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>obtaining institutional review board approval to conduct one or more clinical trials at a prospective site;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>recruiting and enrolling patients to participate in one or more clinical trials; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the failure of our collaborators to adequately resource our product candidates due to their focus on other programs or as a result
of general market conditions.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, once a clinical trial has begun, it may be suspended or terminated
by us, our collaborators, the institutional review boards or data safety monitoring boards charged with overseeing our clinical trials,
the FDA, the EMA or comparable foreign authorities due to a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>inspection of the clinical trial operations or clinical trial site by the FDA, the EMA or comparable foreign authorities resulting
in the imposition of a clinical hold;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>unforeseen safety issues; or</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>lack of adequate funding to continue the clinical trial.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">26</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we experience delays in the completion, or termination, of any clinical
trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to commence product
sales and generate product revenues from any of our product candidates will be delayed. In addition, any delays in completing our clinical
trials will increase our costs and slow down our product candidate development and approval process. Delays in completing our clinical
trials could also allow our competitors to obtain marketing approval before we do or shorten the patent protection period during which
we may have the exclusive right to commercialize our product candidates. Any of these occurrences may harm our business, financial condition
and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical
trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>The COVID-19 pandemic, and any other pandemic, epidemic or outbreak
of an infectious disease, may materially and adversely affect our business and operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0">On March 11, 2020, the World Health Organization declared COVID-19
a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect our operations and those of third
parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of future clinical
trials. In addition, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays
of reviews and approvals, including with respect to our product candidates. Additionally, while the potential economic impact brought
by, and the duration of the COVID-19 pandemic, are difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial
markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. In addition, the
loss of any of our employees as a result of COVID-19 or another pandemic may have a material adverse effect on our operations. We are
actively monitoring the effect of the global situation on our financial condition, liquidity, operations, suppliers, industry and workforce.
While the spread of COVID-19 may eventually be contained or mitigated, we cannot predict the timing of the vaccine roll-out globally or
the continued efficacy of such vaccines, and we do not yet know how businesses or our partners will operate in a post COVID-19 environment.
The ultimate impact of the COVID-19 pandemic on our business, operations, or the global economy as a whole, remains highly uncertain,
and a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business,
financial condition, and operating results.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Results of earlier clinical trials may not be predictive of
the results of later-stage clinical trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The results of preclinical studies and early clinical trials of product
candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials
may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical trials.
Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to adverse safety
profiles or lack of efficacy, notwithstanding promising results in earlier studies. Similarly, our future clinical trial results may not
be successful for these or other reasons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">This product candidate development risk is heightened by any changes in
the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early
to late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program,
such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these
types of changes are common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization,
such changes carry the risk that they will not achieve these intended objectives. In addition, nonclinical studies may be requested or
required even after clinical trials have been commenced or completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Any of these changes could make the results of our planned clinical trials
or other future clinical trials we may initiate less predictable and could cause our product candidates to perform differently, including
causing toxicities, which could delay completion of our clinical trials, delay approval of our product candidates, and/or jeopardize our
ability to commence product sales and generate revenues.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>If we experience delays in the enrollment of patients in our
clinical trials, our receipt of necessary&nbsp;regulatory approvals could be delayed or prevented.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may not be able to initiate or continue clinical trials for our product
candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by
the FDA or other regulatory authorities. <span style="background-color: white">In addition, the COVID-19 pandemic may result in a reduction
of patient enrollment, a loss of patient enrollment and other delays affecting our clinical trials.&nbsp;</span> Patient enrollment, a
significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population,
the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical
trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other
available therapies, including any new drugs that may be approved for the indications we are investigating.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">27</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we fail to enroll and maintain the number of patients for which the
clinical trial was designed, the statistical power of that clinical trial may be reduced, which would make it harder to demonstrate that
the product candidate being tested in such clinical trial is safe and effective. Additionally, enrollment delays in our clinical trials
may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit
our ability to obtain additional financing. Our inability to enroll a sufficient number of patients for any of our current or future clinical
trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We intend to rely on third parties to conduct our preclinical
studies and clinical trials and perform other tasks.&nbsp;If these third parties do not successfully carry out their contractual duties,
meet expected deadlines, or comply with&nbsp;regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
our product&nbsp;candidates and our business, financial condition and results of operations could be substantially harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We intend to rely upon third-party CROs, medical institutions, clinical
investigators and contract laboratories to monitor and manage data for our ongoing preclinical and clinical programs. Nevertheless, we
maintain responsibility for ensuring that each of our clinical trials and preclinical studies is conducted in accordance with the applicable
protocol, legal, regulatory, and scientific standards and our reliance on these third parties does not relieve us of our regulatory responsibilities.
We and our CROs and other vendors are required to comply with current requirements on good manufacturing practices (“cGMP”)
good clinical practices (“GCP”) and good laboratory practice (“GLP”), which are a collection of laws and regulations
enforced by the FDA, the EMA and comparable foreign authorities for all of our product candidates in clinical development. Regulatory
authorities enforce these regulations through periodic inspections of preclinical study and clinical trial sponsors, principal investigators,
preclinical study and clinical trial sites, and other contractors. If we or any of our CROs or vendors fails to comply with applicable
regulations, the data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, the EMA or comparable
foreign authorities may require us to perform additional preclinical studies and clinical trials before approving our marketing applications.
We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced consistent with cGMP regulations.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the development and regulatory
approval processes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may not be able to enter into arrangements with CROs on commercially
reasonable terms, or at all. In addition, our CROs will not be our employees, and except for remedies available to us under our agreements
with such CROs, we will not be able to control whether or not they devote sufficient time and resources to our ongoing preclinical and
clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need
to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory
requirements, or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory
approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result,
our business, financial condition and results of operations and the commercial prospects for our product candidates could be materially
and adversely affected, our costs could increase, and our ability to generate revenue could be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Switching or adding additional CROs, medical institutions, clinical investigators
or contract laboratories involves additional cost and requires management time and focus. In addition, there is a natural transition period
when a new CRO commences work replacing a previous CRO. As a result, delays occur, which can materially impact our ability to meet our
desired clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays in the future
or that these delays or challenges will not have a material adverse effect on our business, financial condition or results of operations.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>Our product candidates are subject to extensive regulation
under the FDA, the EMA or comparable foreign&nbsp;authorities, which can be costly and time consuming, cause unanticipated delays or prevent
the receipt of the&nbsp;required approvals to commercialize our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The clinical development, manufacturing, labeling, storage, record-keeping,
advertising, promotion, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and
other U.S. regulatory agencies, the EMA or comparable authorities in foreign markets. In the U.S., neither we nor our collaborators are
permitted to market our product candidates until we or our collaborators receive approval of a new drug application (“NDA”)
from the FDA or receive similar approvals abroad. The process of obtaining these approvals is expensive, often takes many years, and can
vary substantially based upon the type, complexity and novelty of the product candidates involved. Approval policies or regulations may
change and may be influenced by the results of other similar or competitive products, making it more difficult for us to achieve such
approval in a timely manner or at all. Any guidance that may result from recent FDA advisory panel discussions may make it more expensive
to develop and commercialize such product candidates. In addition, as a company, we have not previously filed NDAs with the FDA or filed
similar applications with other foreign regulatory agencies. This lack of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">28</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">experience may impede our ability to obtain FDA or other foreign
regulatory agency approval in a timely manner, if at all, for our product candidates for which development and commercialization is our
responsibility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Despite the time and expense invested, regulatory approval is never guaranteed.
The FDA, the EMA or comparable foreign authorities can delay, limit or deny approval of a product candidate for many reasons, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>a product candidate may not be deemed safe or effective;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>agency officials of the FDA, the EMA or comparable foreign authorities may not find the data from non-clinical or preclinical studies
and clinical trials generated during development to be sufficient;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the FDA, the EMA or comparable foreign authorities may not approve our third-party manufacturers’ processes or facilities;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the FDA, the EMA or a comparable foreign authority may change its approval policies or adopt new regulations; or</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>our inability to obtain these approvals would prevent us from commercializing our product candidates.</td></tr></tbody></table>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are pursuing the FDA 505(b)(2) NDA pathway
for our lead product candidate, SLS-002, which presents certain additional development and commercialization risks as compared to a conventional
505(b)(1) NDA for an innovator product candidate. We may pursue this pathway for other product candidates as well. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For our lead product candidate (SLS-002) we are pursuing development in
order to seek potential FDA approval under an abbreviated regulatory pathway called a 505(b)(2) NDA, which permits the filing of an NDA
where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for
which the applicant has not obtained a right of reference. We may also pursue this pathway for other of our product candidates. Section
505(b)(2), if applicable to us for a particular product candidate, would allow an NDA we submit to the FDA to rely, in part, on data in
the public domain or the FDA’s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite
the development program for a product candidate by potentially decreasing the amount of clinical data that we would need to generate in
order to obtain FDA approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if the FDA allows us to rely on the 505(b)(2)
regulatory pathway, there is no assurance that such marketing approval will be obtained in a timely manner, or at all. The FDA may require
us to perform additional nonclinical studies and clinical trials, and conduct other development work, to support any change from the
reference listed drug (including with respect to the route of administration and drug delivery method and device), which presents uncertainty
about the data that may ultimately be necessary and could be time-consuming and substantially delay our application for or potential
receipt of marketing approval. Even if we are able to utilize the 505(b)(2) regulatory pathway, a drug approved via this pathway may
be subject to the same post-approval limitations, conditions and requirements as any other drug, including, for example a Risk Evaluation
and Mitigation Strategy (“REMS”), which we anticipate will be required for our lead product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Also, as has been the experience of others in our industry, our competitors
may file citizens’ petitions with the FDA to contest approval of our NDA, which may delay or even prevent the FDA from approving
any NDA that we submit under the 505(b)(2) regulatory pathway. If an FDA decision or action relative to our product candidate, or the
FDA’s interpretation of Section 505(b)(2) more generally, is successfully challenged, it could result in delays or even prevent
the FDA from approving a 505(b)(2) application for such product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, we may face Hatch-Waxman litigation in relation to our NDAs
submitted under the 505(b)(2) regulatory pathway, which may further delay or prevent the approval of our product candidate. The pharmaceutical
industry is highly competitive, and 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors
of previously approved drugs that are referenced in a 505(b)(2) NDA. If the previously approved drugs referenced in an applicant’s
505(b)(2) NDA are protected by patent(s) listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations publication,
or the Orange Book, the 505(b)(2) applicant is required to make a claim after filing its NDA that each such patent is invalid, unenforceable
or will not be infringed. The patent holder may thereafter bring suit for patent infringement, which will trigger a mandatory 30-month
delay (or the shorter of dismissal of the lawsuit or expiration of the patent(s)) in approval of the 505(b)(2) NDA application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If the FDA determines that our 505(b)(2) regulatory pathway is not viable
for SLS-002 or any other applicable product candidate for any reason, we would need to reconsider our plans and might not be able to commercialize
any such product candidate in a cost-efficient manner, or at all. If we were to pursue approval under the 505(b)(1) NDA pathway, we would
be subject to more extensive requirements and risks such as conducting additional clinical trials, providing additional data and information
or meeting additional standards for marketing approval. As a result, the time and financial resources required to obtain marketing approval
for our product candidates would likely increase substantially and further complications and risks</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">29</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">associated with our product candidates
may arise. Also, new competing products may reach the market faster than ours, which may materially and adversely affect our competitive
position, business and prospects.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>Even if our product candidates receive regulatory approval
in the U.S., we may never receive approval or&nbsp;commercialize our products outside of the U.S.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In order to market any products outside of the U.S., we must establish
and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary
among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval
in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include
all of the risks detailed above regarding FDA approval in the U.S. as well as other risks. Regulatory approval in one country does not
ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect
on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay seeking or obtaining such approval
would impair our ability to develop foreign markets for our product candidates.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>Even if any of our product candidates receive regulatory approval,
our product candidates may still face future&nbsp;development and regulatory difficulties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If any of our product candidates receive regulatory approval, the FDA,
the EMA or comparable foreign authorities may still impose significant restrictions on the indicated uses or marketing of the product
candidates or impose ongoing requirements for potentially costly post-approval studies and trials. In addition, regulatory agencies subject
a product, our manufacturer and the manufacturer’s facilities to continual review and periodic inspections. If a regulatory agency
discovers previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or problems with
the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, our collaborators or us,
including requiring withdrawal of the product from the market. Our product candidates will also be subject to ongoing FDA, EMA or comparable
foreign authorities’ requirements for the labeling, packaging, storage, advertising, promotion, record-keeping and submission of
safety and other post-market information on the drug. If our product candidates fail to comply with applicable regulatory requirements,
a regulatory agency may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>issue warning letters or other notices of possible violations;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>impose civil or criminal penalties or fines or seek disgorgement of revenue or profits;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>suspend any ongoing clinical trials;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>refuse to approve pending applications or supplements to approved applications filed by us or our collaborators;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>withdraw any regulatory approvals;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>impose restrictions on operations, including costly new manufacturing requirements, or shut down our manufacturing operations; or</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>seize or detain products or require a product recall.</td></tr></tbody></table>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>The FDA, the EMA and comparable foreign authorities actively
enforce the laws and regulations prohibiting the&nbsp;promotion of off-label uses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA, the EMA and comparable foreign authorities strictly regulate the
promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product
may not be promoted for uses that are not approved by the FDA, the EMA or comparable foreign authorities as reflected in the product’s
approved labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless
use our products for their patients in a manner that is inconsistent with the approved label, if the physicians personally believe in
their professional medical judgment that our products could be used in such manner. However, if we are found to have promoted our products
for any off-label uses, the federal government could levy civil, criminal or administrative penalties, and seek fines against us. Such
enforcement has become more common in the industry. The FDA, the EMA or comparable foreign authorities could also request that we enter
into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional
conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we
could become subject to significant liability, which would materially adversely affect our business, financial condition and results of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">30</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>If our competitors have product candidates that are approved
faster, marketed more effectively, are better&nbsp;tolerated, have a more favorable safety profile or are demonstrated to be more effective
than ours, our&nbsp;commercial opportunity may be reduced or eliminated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The biopharmaceutical industry is characterized by rapidly advancing technologies,
intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific
resources provide us with competitive advantages, we face potential competition from many different sources, including commercial biopharmaceutical
enterprises, academic institutions, government agencies and private and public research institutions. Any product candidates that we successfully
develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Many of our competitors have significantly greater financial resources
and expertise in research and development, manufacturing, preclinical studies, clinical trials, regulatory approvals and marketing approved
products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. Our competitors may succeed in developing technologies and therapies that are more
effective, better tolerated or less costly than any which we are developing, or that would render our product candidates obsolete and
noncompetitive. Even if we obtain regulatory approval for any of our product candidates, our competitors may succeed in obtaining regulatory
approvals for their products earlier than we do. We will also face competition from these third parties in recruiting and retaining qualified
scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring
and in-licensing technologies and products complementary to our programs or advantageous to our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The key competitive factors affecting the success of each of our product
candidates, if approved, are likely to be its efficacy, safety, tolerability, frequency and route of administration, convenience and price,
the level of branded and generic competition and the availability of coverage and reimbursement from government and other third-party
payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The pharmaceutical market for the treatment of major depressive disorder
includes selective serotonin reuptake inhibitors (“SSRIs”), serotonin and norepinephrine reuptake inhibitors (“SNRIs”)
and atypical antipsychotics. A number of these marketed antidepressants will be generic, and would be key competitors to SLS-002. These
products include Forest Laboratory’s Lexapro/Cipralex (escitalopram) and Viibryd (vilazodone), Pfizer, Inc.’s Zoloft (sertraline),
Effexor (venlafaxine) and Pristiq (desvenlafaxine), GlaxoSmithKline plc’s Paxil/Seroxat (paroxetine), Eli Lilly and Company’s
Prozac (fluoxetine) and Cymbalta (duloxetine), AstraZeneca plc’s Seroquel (quetiapine) and Bristol-Myers Squibb Company’s
Abilify (aripiprazole), among others.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Patients with treatment-resistant depression often require treatment with
several antidepressants, such as an SSRI or SNRI, combined with an “adjunct” therapy such as an antipsychotic compound, such
as AstraZeneca plc’s Seroquel (quetiapine) and Bristol-Myers Squibb Company’s Abilify (aripiprazole), or mood stabilizers,
such as Janssen Pharmaceutica’s Topamax (topiramate). In addition, Janssen’s Spravato (intranasal esketamine), which has been
approved for treatment-resistant depression and for depressive systems in adults with major depressive disorder with suicidal thoughts
or actions, targets the NMDA receptor and is expected to have a faster onset of therapeutic effect as compared to currently available
therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Current treatments for Parkinson’s Disease (“PD”) are
intended to improve the symptoms of patients. The cornerstone of PD therapy is levodopa, as it is the most effective therapy for reducing
symptoms of PD. There are other drug therapies in development that will target the disease, such as gene and stem cell therapy and A2A
receptor agonists.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We, or any future collaborators, may not be able to obtain
orphan drug designation or orphan drug exclusivity&nbsp;for our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Regulatory authorities in some jurisdictions, including the United States
and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate
a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population
of fewer than 200,000 individuals annually in the United States. In the United States and Europe, obtaining orphan drug approval may allow
us to obtain financial incentives, such as an extended period of exclusivity during which only we are allowed to market the orphan drug.
While we have received orphan drug designation for SLS-005 in Sanfilippo Syndrome and in spinocerebellar ataxia type 3 and in oculopharyngeal
muscular dystrophy and we plan to seek orphan drug designation from the FDA for SLS-008 for the treatment of a pediatric indication, we,
or any future collaborators, may not be granted orphan drug designations for our product candidates in the U.S. or in other jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">31</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Even if we, or any future collaborators, obtain orphan drug designation
for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product candidate. Generally, a product
with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication
for which it has such designation, in which case the FDA or the EMA will be precluded from approving another marketing application for
the same drug for that indication for the applicable exclusivity period. The applicable exclusivity period is seven years in the United
States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for
orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity
may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable
to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Even if we, or any future collaborators, obtain orphan drug exclusivity
for a product, that exclusivity may not effectively protect the product from competition because FDA has taken the position that, under
certain circumstances, another drug with the same active chemical and pharmacological characteristics, or moiety, can be approved for
the same condition. Specifically, the FDA’s regulations provide that it can approve another drug with the same active moiety for
the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or
makes a major contribution to patient care.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>The active ingredient of our lead product candidate, SLS-002,
ketamine hydrochloride, is recognized as having the potential for abuse, misuse and diversion and, as a result, is and will be subject
to extensive federal and state laws and regulations governing controlled substances and the entities involved in their research, manufacturing,
sale and distribution, and possession. In addition, we anticipate that if we obtain marketing approval for SLS-002 it will be the subject
of an FDA Risk Evaluation and Mitigation Strategy (REMS).</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Ketamine is listed by the Drug Enforcement Administration (“DEA”)
as a Schedule&nbsp;III controlled substance under the Controlled Substances Act. The DEA classifies substances as Schedule&nbsp;I, II,
III, IV or V controlled substances, with Schedule&nbsp;I controlled substances considered to present the highest risk of substance abuse
and Schedule&nbsp;V controlled substances the lowest risk. Scheduled controlled substances are subject to DEA regulations relating to
supply, procurement, manufacturing, storage, distribution and physician prescription procedures. In addition to federal scheduling, some
drugs may be subject to state-level controlled substance laws and regulations and in some cases more broadly applicable or more extensive
requirements than those determined by the DEA and FDA. Federal and state-level controlled substance laws impose a broad range of registration
and licensure requirements along with requirements for systems and controls intended to provide security and reduce the risk of diversion
and misuse, and to identify suspicious activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Compliance with these laws can be expensive and time consuming. Failure
to follow these requirements can lead to significant civil and/or criminal penalties and possibly even lead to a revocation of a DEA registration
and state-level licenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If SLS-002 receives marketing approval from the FDA or other regulatory
authority, we may be required to implement REMS to address the potential for abuse and misuse of our product candidate. As a result, our
product candidate may only be available through a restricted or limited distribution system to which only certain prescribing healthcare
professionals may have access for their patients or healthcare professionals may be limited in their prescribing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Furthermore, product candidates containing controlled substances may generate
public controversy. As a result, these products may be at risk of having their sale and distribution and marketing approvals further restricted
or in extreme cases withdrawn in the event that regulators were to assess that the benefits of a product no longer outweigh emerging risks.
Political pressures or adverse publicity could lead to delays in, and increased expenses for, and limit or restrict, the commercialization
of our product or product candidates.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to a multitude of manufacturing risks, any
of which could substantially increase our costs and&nbsp;limit supply of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The process of manufacturing our product candidates is complex, highly
regulated, and subject to several risks. For example, the process of manufacturing our product candidates is extremely susceptible to
product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error.
Even minor deviations from normal manufacturing processes for any of our product candidates could result in reduced production yields,
product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or
in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended
period of time to investigate and remedy the contamination. In addition, the manufacturing facilities in which our product candidates
are made could be adversely affected by equipment failures, labor shortages, natural disasters, public health crises, pandemics and epidemics,
such as the COVID-19 pandemic, power failures and numerous other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">32</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, any adverse developments affecting manufacturing operations
for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls or other interruptions
in the supply of our product candidates. We also may need to take inventory write-offs and incur other charges and expenses for product
candidates that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We rely completely on third parties to manufacture our preclinical
and clinical drug supplies, and our&nbsp;business, financial condition and results of operations could be harmed if those third parties
fail to provide us&nbsp;with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We do not currently have, nor do we plan to acquire, the infrastructure
or capability internally to manufacture our preclinical and clinical drug supplies for use in our clinical trials, and we lack the resources
and the capability to manufacture any of our product candidates on a clinical or commercial scale. We rely on our manufacturers to purchase
from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number
of suppliers for raw materials that we use to manufacture our product candidates, and there may be a need to identify alternate suppliers
to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials,
and, if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw
materials by our manufacturers. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a
product candidate to complete such clinical trial, any significant delay or discontinuity in the supply of a product candidate, or the
raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably
delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates, which could harm
our business, financial condition and results of operations.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Product candidates that are considered combination
products for FDA purposes, such as the SLS-002 drug-device combination product consisting of ketamine hydrocholoride and a USP aqueous
spray solution in a bi-dose nasal delivery device, may face additional challenges, risks and delays in the product development and regulatory
approval process.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0">SLS-002 is delivered by an intranasal delivery device and considered
a drug-device combination product (the device having been developed by a third party is subject to a license agreement). When
evaluating products that utilize a specific drug delivery system or device, the FDA will evaluate the characteristics of that delivery
system and its functionality, as well as the potential for undesirable interactions between the drug and the delivery system, including
the potential to negatively impact the safety or effectiveness of the drug. The FDA review process can be more complicated for combination
products, and may result in delays, particularly if novel delivery systems are involved. Additionally, quality or design concerns with
the delivery system could delay or prevent regulatory approval and commercialization of our product candidates.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We and our contract manufacturers are subject to significant
regulation with respect to manufacturing our&nbsp;product candidates. The manufacturing facilities on which we rely may not continue to
meet regulatory&nbsp;requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">All entities involved in the preparation of therapeutics for clinical trials
or commercial sale, including our contract manufacturers for our product candidates, are subject to extensive regulation. Components of
a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with
cGMP. These regulations govern manufacturing processes and procedures and the implementation and operation of quality systems to control
and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the
introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable
in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA or marketing authorization
application (“MAA”) on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA, the EMA or comparable
foreign authorities through their facilities inspection program. Some of our contract manufacturers may not have produced a commercially
approved pharmaceutical product and therefore may not have obtained the requisite regulatory authority approvals to do so. The facilities
and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable
regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory
authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or any
of our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being
conducted. Although we plan to oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely
dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval
plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected
to the satisfaction of the regulatory authority, if ever.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">33</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The regulatory authorities also may, at any time following approval of
a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure
to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of
such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly or time consuming
for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical trial or commercial sales
or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract
could materially harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we or any of our third-party manufacturers fail to maintain regulatory
compliance, the FDA, the EMA or comparable foreign authorities can impose regulatory sanctions including, among other things, refusal
to approve a pending application for a product candidate, withdrawal of an approval or suspension of production. As a result, our business,
financial condition and results of operations may be materially and adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Additionally, if supply from one manufacturer is interrupted, an alternative
manufacturer would need to be qualified through an NDA supplement or MAA variation, or equivalent foreign regulatory filing, which could
result in further delay. The regulatory agencies may also require additional studies or trials if a new manufacturer is relied upon for
commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical
and commercial timelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These factors could cause us to incur higher costs and could cause the
delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore,
if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production
at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>Any collaboration arrangement that we may enter into in the
future may not be successful, which could&nbsp;adversely affect our ability to develop and commercialize our current and potential future
product&nbsp;candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may seek collaboration arrangements with biopharmaceutical companies
for the development or commercialization of our current and potential future product candidates. To the extent that we decide to enter
into collaboration agreements, we will face significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements
are complex and time consuming to negotiate, execute and implement. We may not be successful in our efforts to establish and implement
collaborations or other alternative arrangements should we choose to enter into such arrangements, and the terms of the arrangements may
not be favorable to us. If and when we collaborate with a third party for development and commercialization of a product candidate, we
can expect to relinquish some or all of the control over the future success of that product candidate to the third party. The success
of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have
significant discretion in determining the efforts and resources that they will apply to these collaborations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Disagreements between parties to a collaboration arrangement can lead to
delays in developing or commercializing the applicable product candidate and can be difficult to resolve in a mutually beneficial manner.
In some cases, collaborations with biopharmaceutical companies and other third parties are terminated or allowed to expire by the other
party. Any such termination or expiration would adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>If we are unable to develop our own commercial organization
or enter into agreements with third parties to sell&nbsp;and market our product candidates, we may be unable to generate significant revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We do not have a sales and marketing organization, and we have no experience
as a company in the sales, marketing and distribution of pharmaceutical products. If any of our product candidates are approved for commercialization,
we may be required to develop our sales, marketing and distribution capabilities, or make arrangements with a third party to perform sales
and marketing services. Developing a sales force for any resulting product or any product resulting from any of our other product candidates
is expensive and time consuming and could delay any product launch. We may be unable to establish and manage an effective sales force
in a timely or cost-effective manner, if at all, and any sales force we do establish may not be capable of generating sufficient demand
for our product candidates. To the extent that we enter into arrangements with collaborators or other third parties to perform sales and
marketing services, our product revenues are likely to be lower than if we marketed and sold our product candidates independently. If
we are unable to establish adequate sales and marketing capabilities, independently or with others, we may not be able to generate significant
revenues and may not become profitable.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">34</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>The commercial success of our product candidates depends
upon their market acceptance among physicians,&nbsp;patients, healthcare payors and the medical community.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Even if our product candidates obtain regulatory approval, our products,
if any, may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance
of any of our approved product candidates will depend on a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the effectiveness of our approved product candidates as compared to currently available products;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>patient willingness to adopt our approved product candidates in place of current therapies;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>our ability to provide acceptable evidence of safety and efficacy;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>relative convenience and ease of administration;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the prevalence and severity of any adverse side effects;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>restrictions on use in combination with other products;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>availability of alternative treatments;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>pricing and cost-effectiveness assuming either competitive or potential premium pricing requirements, based on the profile of our
product candidates and target markets;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>effectiveness of us or our partners’ sales and marketing strategy;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>our ability to obtain sufficient third-party coverage or reimbursement; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>potential product liability claims.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, the potential market opportunity for our product candidates
is difficult to precisely estimate. Our estimates of the potential market opportunity for our product candidates include several key assumptions
based on our industry knowledge, industry publications, third-party research reports and other surveys. Independent sources have not verified
all of our assumptions. If any of these assumptions proves to be inaccurate, then the actual market for our product candidates could be
smaller than our estimates of the potential market opportunity. If the actual market for our product candidates is smaller than we expect,
our product revenue may be limited, it may be harder than expected to raise funds and it may be more difficult for us to achieve or maintain
profitability. If we fail to achieve market acceptance of our product candidates in the U.S. and abroad, our revenue will be limited and
it will be more difficult to achieve profitability.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>If we fail to obtain and sustain an adequate level of reimbursement
for our potential products by third-party&nbsp;payors, potential future sales would be materially adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There will be no viable commercial market for our product candidates, if
approved, without reimbursement from third-party payors. Reimbursement policies may be affected by future healthcare reform measures.
We cannot be certain that reimbursement will be available for our current product candidates or any other product candidate we may develop.
Additionally, even if there is a viable commercial market, if the level of reimbursement is below our expectations, our anticipated revenue
and gross margins will be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Third-party payors, such as government or private healthcare insurers,
carefully review and increasingly question and challenge the coverage of and the prices charged for drugs. Reimbursement rates from private
health insurance companies vary depending on the company, the insurance plan and other factors. Reimbursement rates may be based on reimbursement
levels already set for lower cost drugs and may be incorporated into existing payments for other services. There is a current trend in
the U.S. healthcare industry toward cost containment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Large public and private payors, managed care organizations, group purchasing
organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels
for, particular treatments. Such third-party payors, including Medicare, may question the coverage of, and challenge the prices charged
for, medical products and services, and many third-party payors limit coverage of or reimbursement for newly approved healthcare products.
In particular, third-party payors may limit the covered indications. Cost-control initiatives could decrease the price we might establish
for products, which could result in product revenues being lower than anticipated. We believe our drugs will be priced significantly higher
than existing generic drugs and consistent with current branded drugs. If we are unable to show a significant benefit relative to existing
generic drugs, Medicare, Medicaid and private payors may not be willing to provide reimbursement for our drugs, which would significantly
reduce the likelihood of our products gaining market acceptance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">35</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect that private insurers will consider the efficacy, cost-effectiveness,
safety and tolerability of our potential products in determining whether to approve reimbursement for such products and at what level.
Obtaining these approvals can be a time consuming and expensive process. Our business, financial condition and results of operations would
be materially adversely affected if we do not receive approval for reimbursement of our potential products from private insurers on a
timely or satisfactory basis. Limitations on coverage could also be imposed at the local Medicare carrier level or by fiscal intermediaries.
Medicare Part D, which provides a pharmacy benefit to Medicare patients as discussed below, does not require participating prescription
drug plans to cover all drugs within a class of products. Our business, financial condition and results of operations could be materially
adversely affected if Part D prescription drug plans were to limit access to, or deny or limit reimbursement of, our product candidates
or other potential products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Reimbursement systems in international markets vary significantly by country
and by region, and reimbursement approvals must be obtained on a country-by-country basis. In many countries, the product cannot be commercially
launched until reimbursement is approved. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental
control even after initial approval is granted. The negotiation process in some countries can exceed 12 months. To obtain reimbursement
or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products
to other available therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If the prices for our potential products are reduced or if governmental
and other third-party payors do not provide adequate coverage and reimbursement of our drugs, our future revenue, cash flows and prospects
for profitability will suffer.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>Current and future legislation may increase the difficulty
and cost of commercializing our product candidates&nbsp;and may affect the prices we may obtain if our product candidates are approved
for commercialization.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the U.S. and some foreign jurisdictions, there have been a number of
adopted and proposed legislative and regulatory changes regarding the healthcare system that could prevent or delay regulatory approval
of our product candidates, restrict or regulate post-marketing activities and affect our ability to profitably sell any of our product
candidates for which we obtain regulatory approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization
Act of 2003 (“MMA”) changed the way Medicare covers and pays for pharmaceutical products. Cost reduction initiatives and other
provisions of this legislation could limit the coverage and reimbursement rate that we receive for any of our approved products. While
the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar
reduction in payments from private payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In March 2010, the Patient Protection and Affordable Care Act, as amended
by the Health Care and Education Reconciliation Act of 2010 (collectively the “PPACA”), was enacted. The PPACA was intended
to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud
and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry
and impose additional health policy reforms. The PPACA increased manufacturers’ rebate liability under the Medicaid Drug Rebate
Program by increasing the minimum rebate amount for both branded and generic drugs and revised the definition of “average manufacturer
price”, which may also increase the amount of Medicaid drug rebates manufacturers are required to pay to states. The legislation
also expanded Medicaid drug rebates and created an alternative rebate formula for certain new formulations of certain existing products
that is intended to increase the rebates due on those drugs. The Centers for Medicare &amp; Medicaid Services, which administers the Medicaid
Drug Rebate Program, also has proposed to expand Medicaid rebates to the utilization that occurs in the territories of the U.S., such
as Puerto Rico and the Virgin Islands. Further, beginning in 2011, the PPACA imposed a significant annual fee on companies that manufacture
or import branded prescription drug products and required manufacturers to provide a 50% discount off the negotiated price of prescriptions
filled by beneficiaries in the Medicare Part D coverage gap, referred to as the “donut hole.” Legislative and regulatory proposals
have been introduced at both the state and federal level to expand post-approval requirements and restrict sales and promotional activities
for pharmaceutical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There have been public announcements by members of the U.S. Congress regarding
plans to repeal and replace or amend and expand the PPACA and Medicare. For example, on December 22, 2017 the Tax Cuts and Jobs Act of
2017 was signed into law, which, among other things, eliminated the individual mandate requiring most Americans (other than those who
qualify for a hardship exemption) to carry a minimum level of health coverage, effective January 1, 2019. We are not sure whether additional
legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of
such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress
of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product
labeling and post-marketing approval testing and other requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">36</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition to the PPACA, there will continue to be proposals by legislators
at both the federal and state levels, regulators and third-party payers to reduce costs while expanding individual healthcare benefits.
Certain of these changes could impose additional limitations on the prices we will be able to charge for our current and future solutions
or the amounts of reimbursement available for our current and future solutions from governmental agencies or third-party payers. While
in general it is difficult to predict specifically what effects the PPACA or any future healthcare reform legislation or policies will
have on our business, current and future healthcare reform legislation and policies could have a material adverse effect on our business
and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In Europe, the United Kingdom withdrew from the European Union on January
31, 2020 and began a transition period that ended on December 31, 2020. Although the ultimate effects of Brexit have yet to be seen, Brexit
has created additional uncertainties that may ultimately result in new regulatory costs and challenges for companies and increased restrictions
on imports and exports throughout Europe, which could adversely affect our ability to conduct and expand our operations in Europe and
which may have an adverse effect on our business, financial condition and results of operations. Additionally, Brexit may increase the
possibility that other countries may decide to leave the EU in the future.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>Changes in government funding for the FDA and other government
agencies could hinder their ability to hire and&nbsp;retain key leadership and other personnel, properly administer drug innovation, or
prevent our product&nbsp;candidates from being developed or commercialized, which could negatively impact our business, financial&nbsp;condition
and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The ability of the FDA to review and approve new products can be affected
by a variety of factors, including budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory and
policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other
agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2016, the 21<sup>st</sup>&nbsp;Century Cures Act was signed
into law. This new legislation is designed to advance medical innovation and empower the FDA with the authority to directly hire positions
related to drug and device development and review. However, government proposals to reduce or eliminate budgetary deficits may include
reduced allocations to the FDA and other related government agencies. These budgetary pressures may result in a reduced ability by the
FDA to perform their respective roles; including the related impact to academic institutions and research laboratories whose funding is
fully or partially dependent on both the level and timing of funding from government sources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Disruptions at the FDA and other agencies may also slow the time necessary
for our product candidates to be reviewed or approved by necessary government agencies, which could adversely affect our business, financial
condition and results of operations.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to “fraud and abuse” and similar
laws and regulations, and a failure to comply with such&nbsp;regulations or prevail in any litigation related to noncompliance could harm
our business, financial condition&nbsp;and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the U.S., we are subject to various federal and state healthcare “fraud
and abuse” laws, including anti-kickback laws, false claims laws and other laws intended, among other things, to reduce fraud and
abuse in federal and state healthcare programs. The federal Anti-Kickback Statute makes it illegal for any person, including a prescription
drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, receive, offer or pay any remuneration that is
intended to induce the referral of business, including the purchase, order or prescription of a particular drug, or other good or service
for which payment in whole or in part may be made under a federal healthcare program, such as Medicare or Medicaid. Although we seek to
structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and it is often difficult
to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged
under the federal Anti-Kickback Statute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The federal False Claims Act prohibits anyone from, among other things,
knowingly presenting or causing to be presented for payment to the government, including the federal healthcare programs, claims for reimbursed
drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed, or claims for medically
unnecessary items or services. Under the Health Insurance Portability and Accountability Act of 1996, we are prohibited from knowingly
and willfully executing a scheme to defraud any healthcare benefit program, including private payors, or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery
of or payment for healthcare benefits, items or services to obtain money or property of any healthcare benefit program. Violations of
fraud and abuse laws may be punishable by criminal or civil sanctions, including penalties, fines or exclusion or suspension from federal
and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private
individuals have the ability to bring actions on behalf of the government under the federal False Claims Act as well as under the false
claims laws of several states.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">37</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Many states have adopted laws similar to the federal Anti-Kickback Statute,
some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors. In addition,
some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance
Program Guidance for Pharmaceutical Manufacturers or the Pharmaceutical Research and Manufacturers of America’s Code on Interactions
with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing
or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail
to comply with an applicable state law requirement, we could be subject to penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Neither the government nor the courts have provided definitive guidance
on the application of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing these laws,
and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our business arrangements with
third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If we are found in violation
of one of these laws, we could be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from
governmental funded federal or state healthcare programs and the curtailment or restructuring of our operations. If this occurs, our business,
financial condition and results of operations may be materially adversely affected.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>If we face allegations of noncompliance with the law and encounter
sanctions, our reputation, revenues and&nbsp;liquidity may suffer, and any of our product candidates that are ultimately approved for
commercialization&nbsp;could be subject to restrictions or withdrawal from the market.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Any government investigation of alleged violations of law could require
us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory
requirements may significantly and adversely affect our ability to generate revenues from any of our product candidates that are ultimately
approved for commercialization. If regulatory sanctions are applied or if regulatory approval is withdrawn, our business, financial condition
and results of operations will be adversely affected. Additionally, if we are unable to generate revenues from product sales, our potential
for achieving profitability will be diminished and our need to raise capital to fund our operations will increase.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>If we fail to retain current members of our senior management
and scientific personnel, or to attract and&nbsp;keep additional key personnel, we may be unable to successfully develop or commercialize
our product&nbsp;candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our success depends on our continued ability to attract, retain and motivate
highly qualified management and scientific personnel. As of February 25, 2022, we have 16 employees. Our <span style="background-color: white">organization
will rely primarily on outsourcing research, development and clinical trial activities, and manufacturing operations, as well as other
functions critical to our business. We believe this approach enhances our ability to focus on our core product opportunities, allocate
resources efficiently to different projects and allocate internal resources more effectively. </span>We have filled several key open positions
and are currently recruiting for a few remaining positions. However, competition for qualified personnel is intense. We may not be successful
in attracting qualified personnel to fulfill our current or future needs and there is no guarantee that any of these individuals will
join us on a full-time employment basis, or at all. In addition, we may experience employee turnover as a result of the ongoing “great
resignation” occurring throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take
time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain
sufficient numbers of qualified individuals. In the event we are unable to fill critical open employment positions, we may need to delay
our operational activities and goals, including the development of our product candidates, and may have difficulty in meeting our obligations
as a public company. We do not maintain “key person” insurance on any of our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, competitors and others are likely in the future to attempt
to recruit our employees. The loss of the services of any of our key personnel, the inability to attract or retain highly qualified personnel
in the future or delays in hiring such personnel, particularly senior management and other technical personnel, could materially and adversely
affect our business, financial condition and results of operations. In addition, the replacement of key personnel likely would involve
significant time and costs, and may significantly delay or prevent the achievement of our business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">From time to time, our management seeks the advice and guidance of certain
scientific advisors and consultants regarding clinical and regulatory development programs and other customary matters. These scientific
advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that
may limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies
in developing products or technologies that may compete with us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">38</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We will need to increase the size of our organization and
may not successfully manage our growth.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a clinical-stage biopharmaceutical company with a small number of
planned employees, and our management system currently in place is not likely to be adequate to support our future growth plans. Our ability
to grow and to manage our growth effectively will require us to hire, train, retain, manage and motivate additional employees and to implement
and improve our operational, financial and management systems. These demands also may require the hiring of additional senior management
personnel or the development of additional expertise by our senior management personnel. Hiring a significant number of additional employees,
particularly those at the management level, would increase our expenses significantly. Moreover, if we fail to expand and enhance our
operational, financial and management systems in conjunction with our potential future growth, it could have a material adverse effect
on our business, financial condition and results of operations.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>Our management’s lack of public company experience could
put us at greater risk of incurring fines or&nbsp;regulatory actions for failure to comply with federal securities laws and could put
us at a competitive&nbsp;disadvantage, and could require our management to devote additional time and resources to ensure&nbsp;compliance
with applicable corporate governance requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our executive officers do not have prior experience as executive officers
in managing and operating a public company, which could have an adverse effect on their ability to quickly respond to problems or adequately
address issues and matters applicable to public companies. Any failure to comply with federal securities laws, rules or regulations could
subject us to fines or regulatory actions, which may materially adversely affect our business, financial condition and results of operations.
Further, since our executive officers do not have prior experience as executive officers managing and operating a public company, we may
need to dedicate additional time and resources to comply with legally mandated corporate governance policies relative to our competitors
whose management teams have more public company experience.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We are exposed to product liability, non-clinical and clinical
liability risks which could place a substantial&nbsp;financial burden upon us, should lawsuits be filed against us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our business exposes us to potential product liability and other liability
risks that are inherent in the testing, manufacturing and marketing of pharmaceutical formulations and products. In addition, the use
in our clinical trials of pharmaceutical products and the subsequent sale of these products by us or our potential collaborators may cause
us to bear a portion of or all product liability risks. A successful liability claim or series of claims brought against us could have
a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently carry product liability insurance for our clinical development
activities. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects.
A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed
our insurance coverage, could adversely affect our results of operations and business.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>Our research and development activities involve the use of
hazardous materials, which subject us to&nbsp;regulation, related costs and delays and potential liabilities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our research and development activities involve the controlled use of hazardous
materials and chemicals, and we will need to develop additional safety procedures for the handling and disposing of hazardous materials.
If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental,
health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and
the handling of biohazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted
in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate any of these laws or regulations.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We rely significantly on information technology and any failure,
inadequacy, interruption or security lapse&nbsp;of that technology, including any cybersecurity incidents, could harm our ability to operate
our business&nbsp;effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Despite the implementation of security measures, our internal computer
systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, unauthorized
access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches
could cause interruptions in our operations, and could result in a material disruption of our drug development and clinical activities
and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of drug development
or clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or
inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs and the development
of our product candidates could be delayed.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">39</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Our employees and consultants may engage in misconduct or other
improper activities, including&nbsp;noncompliance with regulatory standards and requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are exposed to the risk of employee or consultant fraud or other misconduct.
Misconduct by our employees or consultants could include intentional failures to comply with FDA regulations, provide accurate information
to the FDA, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations, report
financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements
in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other
abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion,
sales commissions, customer incentive programs and other business arrangements. Employee and consultant misconduct also could involve
the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm
to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent
this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations
or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect
on our business, financial condition and results of operations, and result in the imposition of significant fines or other sanctions against
us.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Business disruptions such as natural disasters could seriously
harm our future revenues and financial&nbsp;condition and increase our costs and expenses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We and our suppliers may experience a disruption in our and their business
as a result of natural disasters. A significant natural or man-made disaster, such as an earthquake, power outages, hurricane, flood or
fire, droughts and other extreme weather events and changing weather patterns, which are increasing in frequency due to the impacts of
climate change, could severely damage or destroy our headquarters or facilities or the facilities of our manufacturers or suppliers, which
could have a material and adverse effect on our business, financial condition and results of operations. In addition, terrorist acts or
acts of war targeted at the U.S., and specifically the greater New York, New York region, could cause damage or disruption to us, our
employees, facilities, partners and suppliers, which could have a material adverse effect on our business, financial condition and results
of operations.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We may engage in strategic transactions that could impact our
liquidity, increase our expenses and present&nbsp;significant distractions to our management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">From time to time, we may consider strategic transactions, such as acquisitions
of companies, asset purchases and out-licensing or in-licensing of products, product candidates or technologies. Additional potential
transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint
ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring
or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management
or business, which could adversely affect our business, financial condition and results of operations. For example, these transactions
may entail numerous operational and financial risks, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>exposure to unknown liabilities;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>disruption of our business and diversion of our management’s time and attention in order to develop acquired products, product
candidates or technologies;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>incurrence of substantial debt or dilutive issuances of equity securities to pay for any of these transactions;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>higher-than-expected transaction and integration costs;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>write-downs of assets or goodwill or impairment charges;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>increased amortization expenses;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>difficulty and cost in combining the operations and personnel of any acquired businesses or product lines with our operations and
personnel;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>impairment of relationships with key suppliers or customers of any acquired businesses or product lines due to changes in management
and ownership; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>inability to retain key employees of any acquired businesses.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Accordingly, although there can be no assurance that we will undertake
or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing
or other risks, and could have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">40</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Compliance with global privacy and data security requirements could
result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply
with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business,
financial condition or results of operations. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The regulatory framework for the collection, use, safeguarding, sharing,
transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future.
Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we
must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the
European Union, including personal health data, is subject to the EU General Data Protection Regulation (the “GDPR”), which
took effect across all member states of the European Economic Area (the “EEA”) in May 2018. The GDPR is wide-ranging in scope
and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other
sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding
data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification
of data breaches, and taking certain measures when engaging third-party processors. In addition, the GDPR also imposes strict rules on
the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny
that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered
to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require
destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can
be up to 4% of global revenues or €20 million, whichever is greater, and it also confers a private right of action on data subjects
and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages
resulting from violations of the GDPR. In addition, the GDPR provides that EU member states may make their own further laws and regulations
limiting the processing of personal data, including genetic, biometric or health data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Similar actions are either in place or under way in the United States.
There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both
the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws.
The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers.
New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act, which went
into effect on January 1, 2020, is creating similar risks and obligations as those created by the GDPR, though the California Consumer
Privacy Act does exempt certain clinical trial data. Many other states are considering similar legislation. A broad range of legislative
measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently
in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under
such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Given the breadth and depth of changes in data protection obligations,
preparing for and complying with these requirements is rigorous and time intensive and requires significant resources and a review of
our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants
that process or transfer personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with
the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials,
could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development,
regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions,
private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial
condition or results of operations. Similarly, failure to comply with federal and state laws regarding privacy and security of personal
information could expose us to fines and penalties under such laws. Even if we are not determined to have violated these laws, government
investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could
harm our reputation and our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">41</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are subject to certain U.S. and foreign anti-corruption, anti-money
laundering, export control, sanctions, and other trade laws and regulations. If we fail to comply with these laws, we could be subject
to civil or criminal liabilities, other remedial measures and legal expenses, be precluded from developing, manufacturing and selling
certain products outside the United States or be required to develop and implement costly compliance programs, which could adversely affect
our business, results of operations and financial condition. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our operations are subject to anti-corruption laws, including the U.S.
Foreign Corrupt Practices Act (the “FCPA”), the U.K. Bribery Act 2010 (the “Bribery Act”) and other anti-corruption
laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act and these other laws generally
prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government
officials or other persons to obtain or retain business or gain some other business advantage. Compliance with the FCPA, in particular,
is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular
challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other
hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have
been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may in the future operate in jurisdictions that pose a high risk of
potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions
could potentially subject us to liability under the FCPA, the Bribery Act or local anti-corruption laws. In addition, we cannot predict
the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in
which existing laws might be administered or interpreted. If we expand our operations outside of the United States, we will need to dedicate
additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are also subject to other laws and regulations governing our international
operations, including regulations administered by the governments of the United States, the United Kingdom and authorities in the European
Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency
exchange regulations (collectively referred to as “Trade Control Laws”). In addition, various laws, regulations and executive
orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information
classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our
presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may
preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could
limit our growth potential and increase our development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There is no assurance that we will be completely effective in ensuring
our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act or other legal requirements, including Trade
Control Laws. If we are not in compliance with the FCPA, the Bribery Act and other anti-corruption laws or Trade Control Laws, we may
be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have
an adverse impact on our business, financial condition, results of operations and liquidity. The Securities and Exchange Commission also
may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions. Any investigation
of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by U.S., United Kingdom or
other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Governments outside the United States tend to impose strict price
controls, which may adversely affect our revenue, if any.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In some countries, particularly member states of the European Union, the
pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental
authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be considerable pressure
by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic
and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has
been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced
and high-priced member states, can further reduce prices. In some countries, we, or our future collaborators, may be required to conduct
a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order
to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further
pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product
candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business
could be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">42</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We may not be successful in obtaining or maintaining necessary
rights to our product candidates through&nbsp;acquisitions and in-licenses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Because several of our programs require the use of proprietary rights held
by third parties, the growth of our business will likely depend in part on our ability to maintain and exploit these proprietary rights.
In addition, we may need to acquire or in-license additional intellectual property in the future. We may be unable to acquire or in-license
any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for
our product candidates. We face competition with regard to acquiring and in-licensing third-party intellectual property rights, including
from a number of more established companies. These established companies may have a competitive advantage over us due to their size, cash
resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor
may be unwilling to assign or license intellectual property rights to us. We also may be unable to acquire or in-license third-party intellectual
property rights on terms that would allow us to make an appropriate return on our investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may enter into collaboration agreements with U.S. and foreign academic
institutions to accelerate development of our current or future preclinical product candidates. Typically, these agreements include an
option for the company to negotiate a license to the institution’s intellectual property rights resulting from the collaboration.
Even with such an option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to
us. If we are unable to license rights from a collaborating institution, the institution may offer the intellectual property rights to
other parties, potentially blocking our ability to pursue our desired program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we are unable to successfully obtain required third-party intellectual
property rights or maintain our existing intellectual property rights, we may need to abandon development of the related program and our
business, financial condition and results of operations could be materially and adversely affected.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>If we fail to comply with our obligations in the agreements
under which we in-license intellectual property&nbsp;and other rights from third parties or otherwise experience disruptions to our business
relationships with&nbsp;our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our license agreement with Ligand Pharmaceuticals Incorporated, Neurogen
Corporation and CyDex Pharmaceuticals, Inc. (the “Ligand License Agreement”), our license agreement with the Regents of the
University of California (the “UC Regents License Agreement”), our license agreement with Duke University (the “Duke
License Agreement”) and our license agreement with iX Biopharma Ltd. (the “iX License Agreement”, together with the
Ligand License Agreement, the UC Regents License Agreement, and the Duke License Agreement, the “License Agreements”) are
important to our business and we expect to enter into additional license agreements in the future. The License Agreements impose, and
we expect that future license agreements will impose, various milestone payments, royalties and other obligations on us. If we fail to
comply with our obligations under these agreements, or if we file for bankruptcy, we may be required to make certain payments to the licensor,
we may lose the exclusivity of our license, or the licensor may have the right to terminate the license, in which event we would not be
able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses
could materially and adversely affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the terms of the Ligand License Agreement, the licensors each
have the right to terminate the Ligand License Agreement with respect to the programs licensed by such licensor under certain circumstances,
including, but not limited to: (i) if we do not pay an amount that is not disputed in good faith, (ii) if we willfully breach the Ligand
License Agreement in a manner for which legal remedies would not be expected to make such licensor whole, or (iii) if we file or have
filed against us a petition in bankruptcy or make an assignment for the benefit of creditors. In the event the Ligand License Agreement
is terminated by a licensor, all licenses granted to us by such licensor will terminate immediately. Further, pursuant to the terms of
the UC Regents License Agreement, the licensor has the right to terminate the UC Regents License Agreement or reduce our license to a
nonexclusive license if we fail to achieve certain milestones within a specified timeframe. Similarly, pursuant to the terms of the Duke
License Agreement and the iX License Agreement, each licensor has the right to terminate the Duke License Agreement or the iX License
Agreement, as applicable, if we fail to achieve certain milestones within a specified timeframe.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In some cases, patent prosecution of our licensed technology may be controlled
solely by the licensor. If our licensor fails to obtain and maintain patent or other protection for the proprietary intellectual property
we in-license, then we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors
could market competing products using the intellectual property. In certain cases, we may control the prosecution of patents resulting
from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability
to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business
and scientific issues. Disputes may arise regarding intellectual property subject to a licensing agreement, including, but not limited
to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">43</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the scope of rights granted under the license agreement and other interpretation-related issues;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
agreement;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the sublicensing of patent and other rights;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us, our licensors and
our collaborators; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the priority of invention of patented technology.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If disputes over intellectual property and other rights that we have in-licensed
prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop
and commercialize the affected product candidates. If we fail to comply with any such obligations to our licensor, such licensor may terminate
its licenses to us, in which case we would not be able to market products covered by these licenses. The loss of our licenses would have
a material adverse effect on our business.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We are required to make certain cash payments and may be required
to pay milestones and royalties pursuant to certain commercial agreements, which could adversely affect the overall profitability for
us of any products that we may seek to commercialize.</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0">Under the terms of the Ligand License Agreement, we may be obligated
to pay the licensor under the Ligand License Agreement up to an aggregate of approximately $126.7 million in development, regulatory and
sales milestones. Similarly, under the terms of the iX License Agreement, we may be obligated to pay the licensor under the iX License
Agreement up to an aggregate of approximately $239 million in development, regulatory and sales milestones. We will also be required to
pay royalties on future worldwide net product sales. In addition pursuant to the asset purchase agreement, as amended, with Phoenixus
AG f/k/a Vyera Pharmaceuticals AG and Turing Pharmaceuticals AG ("Vyera"), we may be obligated to pay an aggregate of approximately
$92.5 million in development, regulatory and sales milestones and we will be required to pay royalties to Vyera on any net sales of SLS-002.
We will also be required to pay up to an aggregate of approximately $17 million in development and regulatory milestones and royalties
on any net sales of SLS-005 pursuant to our asset purchase agreement with Bioblast Pharma Ltd. These cash, milestone and royalty payments
could adversely affect the overall profitability for us of any products that we may seek to commercialize.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may not be able to protect our proprietary or licensed technology
in the marketplace.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We depend on our ability to protect our proprietary or licensed technology.
We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and
third parties, all of which offer only limited protection. Our success depends in large part on our ability and any licensor’s or
licensee’s ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary or licensed
technology and products. We currently in-license some of our intellectual property rights to develop our product candidates and may in-license
additional intellectual property rights in the future. We cannot be certain that patent enforcement activities by our current or future
licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents
or other intellectual property rights. We also cannot be certain that our current or future licensors will allocate sufficient resources
or prioritize their or our enforcement of such patents. Even if we are not a party to these legal actions, an adverse outcome could prevent
us from continuing to license intellectual property that we may need to operate our business, which would have a material adverse effect
on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Although we believe we will be able to obtain, through prosecution of patent
applications covering our owned technology and technology licensed from others, adequate patent protection for our proprietary drug technology,
including those related to our in-licensed intellectual property, if we are compelled to spend significant time and money protecting or
enforcing our licensed patents and future patents we may own, designing around patents held by others or licensing or acquiring, potentially
for large fees, patents or other proprietary rights held by others, our business, financial condition and results of operations may be
materially and adversely affected. If we are unable to effectively protect the intellectual property that we own or in-license, other
companies may be able to offer the same or similar products for sale, which could materially adversely affect our business, financial
condition and results of operations. The patents of others from whom we may license technology, and any future patents we may own, may
be challenged, narrowed, invalidated or circumvented, which could limit our ability to stop competitors from marketing the same or similar
products or limit the length of term of patent protection that we may have for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">44</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Obtaining and maintaining patent protection depends on compliance
with various procedural, document&nbsp;submission, fee payment and other requirements imposed by governmental patent agencies, and our
patent&nbsp;protection for licensed patents, pending patent applications and potential future patent applications and patents&nbsp;could
be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Periodic maintenance fees, renewal fees, annuity fees and various other
governmental fees on patents and/or patent applications will be due to be paid to the U.S. Patent and Trademark Office (“USPTO”)
and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the applicable patent and/or patent
application. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment
of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
If this occurs with respect to our in-licensed patents or patent applications we may file in the future, our competitors might be able
to use our technologies, which would have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The patent positions of pharmaceutical products are often complex and uncertain.
The breadth of claims allowed in pharmaceutical patents in the U.S. and many jurisdictions outside of the U.S. is not consistent. For
example, in many jurisdictions, the support standards for pharmaceutical patents are becoming increasingly strict. Some countries prohibit
method of treatment claims in patents. Changes in either the patent laws or interpretations of patent laws in the U.S. and other countries
may diminish the value of our licensed or owned intellectual property or create uncertainty. In addition, publication of information related
to our current product candidates and potential products may prevent us from obtaining or enforcing patents relating to these product
candidates and potential products, including without limitation composition-of-matter patents, which are generally believed to offer the
strongest patent protection.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Patents that we currently license and patents that we may own or license
in the future do not necessarily ensure the protection of our licensed or owned intellectual property for a number of reasons, including,
without limitation, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the patents may not be broad or strong enough to prevent competition from other products that are identical or similar to our product
candidates;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>there can be no assurance that the term of a patent can be extended under the provisions of patent term extensions afforded by U.S.
law or similar provisions in foreign countries, where available;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the issued patents and patents that we may obtain or license in the future may not prevent generic entry into the market for our product
candidates;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>we, or third parties from whom we in-license or may license patents, may be required to disclaim part of the term of one or more patents;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>there may be prior art of which we are aware, which we do not believe affects the validity or enforceability of a patent claim, but
which, nonetheless, ultimately may be found to affect the validity or enforceability of a patent claim;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>there may be other patents issued to others that will affect our freedom to operate;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>if the patents are challenged, a court could determine that they are invalid or unenforceable;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>there might be a significant change in the law that governs patentability, validity and infringement of our licensed patents or any
future patents we may own that adversely affects the scope of our patent rights;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>a court could determine that a competitor’s technology or product does not infringe our licensed patents or any future patents
we may own; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations or could be subject to compulsory
licensing.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If we encounter delays in our development or clinical trials, the period
of time during which we could market our potential products under patent protection would be reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our competitors may be able to circumvent our licensed patents or future
patents we may own by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek
to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which our competitors
claim that our licensed patents or any future patents we may own are invalid, unenforceable or not infringed. Alternatively, our competitors
may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need
to defend or assert our licensed patents or any future patents we may own, including by filing lawsuits alleging patent infringement.
In any of these types of proceedings, a court or other agency with jurisdiction may find our licensed patents or any future patents we
may own invalid or unenforceable. We may also fail to identify patentable aspects of our</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">45</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">research and development before it is too late
to obtain patent protection. Even if we own or in-license valid and enforceable patents, these patents still may not provide protection
against competing products or processes sufficient to achieve our business objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The issuance of a patent is not conclusive as to its inventorship, scope,
ownership, priority, validity or enforceability. In this regard, third parties may challenge our licensed patents or any future patents
we may own in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate
or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others
from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology
and potential products. In addition, given the amount of time required for the development, testing and regulatory review of new product
candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We may infringe the intellectual property rights of others,
which may prevent or delay our drug development&nbsp;efforts and prevent us from commercializing or increase the costs of commercializing
our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our commercial success depends significantly on our ability to operate
without infringing the patents and other intellectual property rights of third parties. For example, there could be issued patents of
which we are not aware that our current or potential future product candidates infringe. There also could be patents that we believe we
do not infringe, but that we may ultimately be found to infringe.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Moreover, patent applications are in some cases maintained in secrecy until
patents are issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the
date on which the underlying discoveries were made and patent applications were filed. Because patents can take many years to issue, there
may be currently pending applications of which we are unaware that may later result in issued patents that our product candidates or potential
products infringe. For example, pending applications may exist that claim or can be amended to claim subject matter that our product candidates
or potential products infringe. Competitors may file continuing patent applications claiming priority to already issued patents in the
form of continuation, divisional, or continuation-in-part applications, in order to maintain the pendency of a patent family and attempt
to cover our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Third parties may assert that we are employing their proprietary technology
without authorization and may sue us for patent or other intellectual property infringement. These lawsuits are costly and could adversely
affect our business, financial condition and results of operations and divert the attention of managerial and scientific personnel. If
we are sued for patent infringement, we would need to demonstrate that our product candidates, potential products or methods either do
not infringe the claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity
is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption
of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and
attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse
effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. If a court holds that
any third-party patents are valid, enforceable and cover our products or their use, the holders of any of these patents may be able to
block our ability to commercialize our products unless we acquire or obtain a license under the applicable patents or until the patents
expire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may not be able to enter into licensing arrangements or make other arrangements
at a reasonable cost or on reasonable terms. Any inability to secure licenses or alternative technology could result in delays in the
introduction of our products or lead to prohibition of the manufacture or sale of products by us. Even if we are able to obtain a license,
it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including
by court order, to cease commercializing the infringing technology or product. In addition, in any such proceeding or litigation, we could
be found liable for monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed
a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business
operations, which could materially and adversely affect our business, financial condition and results of operations. Any claims by third
parties that we have misappropriated their confidential information or trade secrets could have a similar material and adverse effect
on our business, financial condition and results of operations. In addition, any uncertainties resulting from the initiation and continuation
of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">46</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Any claims or lawsuits relating to infringement of intellectual
property rights brought by or against us will be&nbsp;costly and time consuming and may adversely affect our business, financial condition
and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We may be required to initiate litigation to enforce or defend our licensed
and owned intellectual property. Lawsuits to protect our intellectual property rights can be very time consuming and costly. There is
a substantial amount of litigation involving patent and other intellectual property rights in the biopharmaceutical industry generally.
Such litigation or proceedings could substantially increase our operating expenses and reduce the resources available for development
activities or any future sales, marketing or distribution activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In any infringement litigation, any award of monetary damages we receive
may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover,
there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which
typically last for years before they are resolved. Further, any claims we assert against a perceived infringer could provoke these parties
to assert counterclaims against us alleging that we have infringed their patents. Some of our competitors may be able to sustain the costs
of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from
the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete
in the marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, our licensed patents and patent applications, and patents
and patent applications that we may apply for, own or license in the future, could face other challenges, such as interference proceedings,
opposition proceedings, re-examination proceedings and other forms of post-grant review. Any of these challenges, if successful, could
result in the invalidation of, or in a narrowing of the scope of, any of our licensed patents and patent applications and patents and
patent applications that we may apply for, own or license in the future subject to challenge. Any of these challenges, regardless of their
success, would likely be time consuming and expensive to defend and resolve and would divert our management and scientific personnel’s
time and attention.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Changes in U.S. patent law could diminish the value of patents
in general, thereby impairing our ability to&nbsp;protect our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As is the case with other biopharmaceutical companies, our success is heavily
dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both
technological and legal complexity and is costly, time-consuming and inherently uncertain. For example, the U.S. previously enacted and
is currently implementing wide-ranging patent reform legislation. Specifically, on September 16, 2011, the Leahy-Smith America Invents
Act (the “Leahy-Smith Act”) was signed into law and included a number of significant changes to U.S. patent law, and many
of the provisions became effective in March 2013. However, it may take the courts years to interpret the provisions of the Leahy-Smith
Act, and the implementation of the statute could increase the uncertainties and costs surrounding the prosecution of our licensed and
future patent applications and the enforcement or defense of our licensed and future patents, all of which could have a material adverse
effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, the U.S. Supreme Court has ruled on several patent cases in
recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners
in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination
of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the
federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability
to obtain new patents or to enforce patents that we might obtain in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may not be able to protect our intellectual property rights throughout
the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Filing, prosecuting and defending patents on product candidates throughout
the world would be prohibitively expensive. Competitors may use our licensed and owned technologies in jurisdictions where we have not
licensed or obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories
where we may obtain or license patent protection, but where patent enforcement is not as strong as that in the U.S. These products may
compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual
property rights may not be effective or sufficient to prevent them from so competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Many companies have encountered significant problems in protecting and
defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing
countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals,
which could make it difficult for us to stop the infringement of our licensed patents and future patents we may own, or marketing of competing
products in violation of our proprietary rights generally. Further, the laws of some foreign countries do not protect proprietary</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">47</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">rights
to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and
defending our licensed and owned intellectual property both in the U.S. and abroad. For example, China currently affords less protection
to a company’s intellectual property than some other jurisdictions. As such, the lack of strong patent and other intellectual property
protection in China may significantly increase our vulnerability regarding unauthorized disclosure or use of our intellectual property
and undermine our competitive position. Proceedings to enforce our future patent rights, if any, in foreign jurisdictions could result
in substantial cost and divert our efforts and attention from other aspects of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We may be unable to adequately prevent disclosure of trade secrets
and other proprietary information.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In order to protect our proprietary and licensed technology and processes,
we rely in part on confidentiality agreements with our corporate partners, employees, consultants, manufacturers, outside scientific collaborators
and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of our confidential information
and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently
discover our trade secrets and proprietary information. Failure to obtain or maintain trade secret protection could adversely affect our
competitive business position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If our trademarks and trade names are not adequately protected, then
we may not be able to build name recognition in our markets of interest and our business may be adversely affected</i></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We intend to use registered or unregistered trademarks or trade names
to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared
generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names,
which we need to build name recognition among potential partners or customers in our markets of interest, and it may be difficult and
costly to register, maintain and/or protect our rights to these trademarks and trade names in jurisdictions in and outside of the United
States. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity
and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by
owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade
names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be
able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related
to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial
costs and diversion of resources and could adversely affect our financial condition or results of operations.&nbsp;</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We may be subject to claims that our employees, consultants
or independent contractors have wrongfully&nbsp;used or disclosed confidential information of third parties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect to employ individuals who were previously employed at other biopharmaceutical
companies. Although we have no knowledge of any such claims against us, we may be subject to claims that we or our employees, consultants
or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’ former employers
or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these
claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.
To date, none of our employees have been subject to such claims.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We may be subject to claims challenging the inventorship of
our licensed patents, any future patents we may&nbsp;own and other intellectual property.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Although we are not currently experiencing any claims challenging the inventorship
of our licensed patents or our licensed or owned intellectual property, we may in the future be subject to claims that former employees,
collaborators or other third parties have an interest in our licensed patents or other licensed or owned intellectual property as an inventor
or co-inventor. For example, we may have inventorship disputes arising from conflicting obligations of consultants or others who are involved
in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business, financial condition and results of operations. Even if we are successful in defending against such claims, litigation could
result in substantial costs and be a distraction to management and other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">48</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>If we do not obtain additional protection under the Hatch-Waxman
Amendments and similar foreign&nbsp;legislation extending the terms of our licensed patents and any future patents we may own, our&nbsp;business,
financial condition and results of operations may be materially and adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Depending upon the timing, duration and specifics of FDA regulatory approval
for our product candidates, one or more of our licensed U.S. patents or future U.S. patents that we may license or own may be eligible
for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman
Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during
drug development and the FDA regulatory review process. This period is generally one-half the time between the effective date of an investigational
new drug application (“IND”) (falling after issuance of the patent), and the submission date of an NDA, plus the time between
the submission date of an NDA and the approval of that application. Patent term restorations, however, cannot extend the remaining term
of a patent beyond a total of 14 years from the date of product approval by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The application for patent term extension is subject to approval by the
USPTO, in conjunction with the FDA. It takes at least six months to obtain approval of the application for patent term extension. We may
not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration
of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent
protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any
such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened
and our competitors may obtain earlier approval of competing products, and our ability to generate revenues could be materially adversely
affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risks Related to Owning Our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>The market price of our common stock has been and will likely continue
to be volatile.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The trading price of our common stock has been and is likely to continue
to be volatile. For example, in 2021 our closing stock price ranged from $1.35 to $6.32 per share. Our stock price could be subject to
wide fluctuations in response to a variety of factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>results from, and any delays in, planned clinical trials for our product candidates, or any other future product candidates, and the
results of trials of competitors or those of other companies in our market sector;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>any delay in filing an NDA for any of our product candidates and any adverse development or perceived adverse development with respect
to the FDA’s review of that NDA;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>significant lawsuits, including patent or stockholder litigation;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>inability to obtain additional funding;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>failure to successfully develop and commercialize our product candidates;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>changes in laws or regulations applicable to our product candidates;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>inability to obtain adequate product supply for our product candidates, or the inability to do so at acceptable prices;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>unanticipated serious safety concerns related to any of our product candidates;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>adverse regulatory decisions;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>introduction of new products or technologies by our competitors;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>failure to meet or exceed drug development or financial projections we provide to the public;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>failure to meet or exceed the estimates and projections of the investment community;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the perception of the biopharmaceutical industry by the public, legislatures, regulators and the investment community;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent
protection for our licensed and owned technologies;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>additions or departures of key scientific or management personnel;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>changes in the market valuations of similar companies;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>general economic and market conditions and overall fluctuations in the U.S. equity market;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>public health crises, pandemics and epidemics, such as the COVID-19 pandemic;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>sales of our common stock by us or our stockholders in the future; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 38pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>trading volume of our common stock.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, the stock market in general, and small biopharmaceutical companies
in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating
performance of these companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">49</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Broad market and industry factors may negatively affect the market price of our common stock, regardless
of our actual operating performance. Further, a decline in the financial markets and related factors beyond our control may cause our
stock price to decline rapidly and unexpectedly.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If we fail to comply with the continued listing requirements of the
Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets
could be negatively impacted.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We must continue to satisfy the Nasdaq Capital Market’s continued
listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per share for 30 consecutive business
days. If a company fails for 30 consecutive business days to meet the $1.00 minimum closing bid price requirement, The Nasdaq Stock Market
LLC (“Nasdaq”) will send a deficiency notice to the company, advising that it has been afforded a “compliance period”
of 180 calendar days to regain compliance with the applicable requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A delisting of our common stock from the Nasdaq Capital Market could materially
reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition,
delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may
result in the potential loss of confidence by investors and employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 11, 2020, we received written notice from
Nasdaq indicating that, for the last thirty consecutive business days, the bid price for our common stock had closed below the minimum
$1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with
Nasdaq Listing Rule 5810(c)(3)(A), we were provided an initial period of 180 calendar days, or until May 10, 2021, to regain compliance.
We regained compliance after the closing bid price of our common stock had been at $1.00 per share or greater for twenty consecutive business
days, from December 10, 2020 through January 8, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0">In addition, we have previously received similar notices from Nasdaq
that our bid price of our common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital
Market under Nasdaq Listing Rule 5550(a)(2). Even though we regained compliance with the Nasdaq Capital Market’s minimum market
value of listed securities requirement and minimum closing bid price requirement, there is no guarantee that we will remain in compliance
with such listing requirements or other listing requirements in the future. Any failure to maintain compliance with continued listing
requirements of the Nasdaq Capital Market could result in delisting of our common stock from the Nasdaq Capital Market and negatively
impact our company and holders of our common stock, including by reducing the willingness of investors to hold our common stock because
of the resulting decreased price, liquidity and trading of our common stock, limited availability of price quotations and reduced news
and analyst coverage. Delisting may adversely impact the perception of our financial condition, cause reputational harm with investors,
our employees and parties conducting business with us and limit our access to debt and equity financing.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>We will incur significant costs as a result of operating as
a public company and our management will be required to devote substantial time to new compliance initiatives.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer
Protection Act of 2010 (the “Dodd-Frank Act”) as well as rules subsequently implemented by the SEC and Nasdaq have imposed
various requirements on public companies. There are significant corporate governance and executive compensation related provisions in
the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas. Stockholder activism, the current political
environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure
obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate) the manner in which we
operate our business. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives.
Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming
and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director
and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such insurance coverage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As a publicly traded company, we will incur legal, accounting and other
expenses associated with the SEC reporting requirements applicable to a company whose securities are registered under the Exchange Act,
as well as corporate governance requirements, including those under the Sarbanes-Oxley Act, the Dodd-Frank Act and other rules implemented
by the SEC and Nasdaq. The expenses incurred by public companies generally to meet SEC reporting, finance and accounting and corporate
governance requirements have been increasing in recent years as a result of changes in rules and regulations and the adoption of new rules
and regulations applicable to public companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">50</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Sales of a substantial number of shares of our common stock
in the public market by our existing stockholders, future issuances of our common stock or&nbsp;rights to purchase our common stock, could
cause our stock&nbsp;price to fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Sales of a substantial number of shares of our common stock by our existing
stockholders in the public market, or the perception that these sales might occur, could depress the market price of our common stock
and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that
such sales may have on the prevailing market price of our common stock. As of December 31, 2021, we have outstanding warrants to purchase
an aggregate of approximately 2.6 million shares of our common stock, which, if exercised, would further increase the number of shares
of our common stock outstanding and the number of shares eligible for resale in the public market. A<span style="background-color: white">s
of December 31</span>, 2021<span style="background-color: white">, 10,882,245 shares of our common stock were reserved for issuance under
our equity incentive plans, of which 7,305,420 shares of our common stock were subject to options outstanding at such date at a weighted-average
exercise price of $2.60 per share,&nbsp;1,405,011 shares of our common stock were reserved for future issuance pursuant to our Amended
and Restated 2012 Stock Long Term Incentive Plan, 646,465 shares of our common stock were reserved for future issuance pursuant to our
2019 Inducement Plan and 1,465,349 shares of our common stock were reserved for issuance pursuant to our 2020 Employee Stock Purchase
Plan. To the extent outstanding options are exercised, our existing stockholders may incur dilution. In addition, 2,400,000 shares of
our common stock are issuable upon the vesting of a performance restricted stock unit award granted to Dr. Mehra that will vest upon our
company achieving certain performance criteria established at the grant date and Dr. Mehra’s continued employment with us. Our stockholders
will incur dilution to the extent that this restricted stock unit award vests.</span> Furthermore, at any time following nine-months from
the date of issuance of the Convertible Promissory Notes, from time to time and before the maturity date of such Convertible Promissory
Note, each holder thereof will have the option to convert any portion of the then-outstanding principal amount of such holder’s
Convertible Promissory Note into shares of our common stock at a price per share of $6.00, subject to adjustment for stock splits, reverse
stock splits, stock dividends and similar transactions. We may also elect to make amortization payments on the Convertible Promissory
Notes in shares of our common stock. Any issuances of shares of our common stock pursuant to the Convertible Promissory Notes will result
in dilution to our then-existing stockholders and increase the number of shares eligible for resale in the public market. Sales of substantial
numbers of such shares in the public market could depress the market price of our common stock.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>The Financing Warrants contain price-based adjustment provisions
which, if triggered, may cause substantial&nbsp;additional dilution to our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On October 16, 2018, we entered into a Securities Purchase Agreement with
the investors listed on the Schedule of Buyers attached thereto, as amended, pursuant to which, among other things, we issued warrants
to purchase shares of our common stock (the “Financing Warrants”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The outstanding Financing <span style="background-color: white">Warrants</span>
contain price-based adjustment provisions, pursuant to which the exercise price of the Financing <span style="background-color: white">Warrants</span>
may be adjusted downward in the event of certain dilutive issuances by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If the Financing <span style="background-color: white">Warrants</span>
are exercised, additional shares of our common stock will be issued, which will result in dilution to our then-existing stockholders and
increase the number of shares eligible for resale in the public market. As of December 31, 2021, the Financing Warrants were exercisable
for approximately 0.3 million shares of our common stock at an exercise price of $0.2957 per share of common stock. Sales of substantial
numbers of such shares in the public market could depress the market price of our common stock.</p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b><i>Anti-takeover provisions in our governing documents and under
Nevada law could make an&nbsp;acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Provisions in our articles of incorporation and bylaws may delay or prevent
an acquisition or a change in management. These provisions include a classified board of directors and the ability of the board of directors
to issue preferred stock without stockholder approval. Although we believe these provisions collectively will provide for an opportunity
to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may
be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders
to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors,
which is responsible for appointing the members of management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain provisions of Nevada corporate law deter hostile takeovers. Specifically,
Nevada Revised Statutes (“NRS”) 78.411 through 78.444 prohibit a publicly held Nevada corporation from engaging in a “combination”
with an “interested stockholder” for a period of two years following the date the person first became an interested stockholder,
unless (with certain exceptions) the “combination” or the transaction by which the person became an interested stockholder
is approved in a prescribed manner. Generally, a “combination” includes a merger, asset or stock sale, or certain other transactions
resulting in a financial benefit to the interested stockholder. Generally, an “interested stockholder” is a person who, together
with affiliates and associates, beneficially owns or within two years prior to becoming an “interested stockholder” did own,
10% or more of a corporation’s</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">51</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">voting power. While these statutes permit a corporation to opt out of these protective provisions
in its articles of incorporation, our articles of incorporation do not include any such opt-out provision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Nevada’s “acquisition of controlling interest” statutes,
NRS 78.378 through 78.3793, contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These
“control share” laws provide generally that any person that acquires a “controlling interest” in certain Nevada
corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such
voting rights. These statutes provide that a person acquires a “controlling interest” whenever a person acquires shares of
a subject corporation that, but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth
or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power
of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares that it acquired in the transaction
taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire
a controlling interest become “control shares” to which the voting restrictions described above apply. While these statutes
permit a corporation to opt out of these protective provisions in its articles of incorporation or bylaws, our articles of incorporation
and bylaws do not include any such opt-out provision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Further, NRS 78.139 also provides that directors may resist a change or
potential change in control of the corporation if the board of directors determines that the change or potential change is opposed to
or not in the best interest of the corporation upon consideration of any relevant facts, circumstances, contingencies or constituencies
pursuant to NRS 78.138(4).</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>Our net operating loss carryforwards and certain other tax
attributes may be subject to limitations.&nbsp;The net operating loss carryforwards and certain other tax attributes of us&nbsp;may also
be subject to limitations as a result of certain prior ownership changes. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In general, a corporation that undergoes an “ownership change”
as defined in Section 382 of the United States Internal Revenue Code of 1986, as amended, is subject to limitations on its ability to
utilize its pre-change net operating loss carryforwards to offset future taxable income. In general, an ownership change occurs if the
aggregate stock ownership of certain stockholders, generally stockholders beneficially owning five percent or more of a corporation’s
common stock, applying certain look-through and aggregation rules, increases by more than 50 percentage points over such stockholders’
lowest percentage ownership during the testing period, generally three years. We may have experienced ownership changes in the past and
may experience ownership changes in the future. It is possible that our net operating loss carryforwards and certain other tax attributes
may also be subject to limitation as a result of ownership changes in the past. Consequently, even if we achieve profitability, we may
not be able to utilize a material portion of our net operating loss carryforwards and certain other tax attributes, which could have a
material adverse effect on cash flow and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We are a “smaller reporting company” and the reduced
disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a smaller reporting company, as defined in Rule 12b-2 under the
Exchange Act, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting
common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual
revenues are less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by
non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Smaller reporting companies are
permitted to rely on exemptions from certain disclosure requirements that are applicable to other public companies, including not being
required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting, reduced
disclosure obligations regarding executive compensation and not being required to provide disclosures regarding quantitative and qualitative
disclosures about market risk in our Annual Reports on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We have elected to take advantage of certain of these exemptions in the
past and may continue to choose to take advantage of some, but not all, of them in the future. We cannot predict whether investors will
find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive
as a result, there may be a less active trading market for our common stock, which may result in additional stock price volatility.</p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/11.5pt Times New Roman, Times, Serif; margin: 0"><b><i>We may never pay dividends on our common stock so any returns&nbsp;would
be limited to the appreciation of our stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently anticipate that we will retain future earnings for the development,
operation and expansion of our business and do not anticipate we will declare or pay any cash dividends for the foreseeable future. Any
return to stockholders will therefore be limited to the appreciation of their stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">52</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b>General Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b><i>An active trading market for
our common stock may not be sustained, and you may not&nbsp;be able to resell your common stock at a desired market price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">If no active trading market for our common stock
is sustained, you may be unable to sell your shares when you wish to sell them or at a price that you consider attractive or satisfactory.
The lack of an active market may also adversely affect our ability to raise capital by selling securities in the future or impair our
ability to acquire or in-license other product candidates, businesses or technologies using our shares as consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b><i>Our internal control over financial
reporting may not meet the standards required by&nbsp;Section 404 of the Sarbanes-Oxley Act, and failure to achieve and maintain effective
internal control over&nbsp;financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, could have a material adverse
effect&nbsp;on our business and share price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Our management is required to report on the effectiveness
of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our
internal control over financial reporting are complex and require significant documentation, testing and possible remediation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">In connection with the implementation of the necessary
procedures and practices related to internal control over financial reporting, we may identify deficiencies or material weaknesses that
we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of
Section 404. In addition, we may encounter problems or delays in completing the implementation of any requested improvements and, when
required, receiving a favorable attestation in connection with the attestation provided by our independent registered public accounting
firm. Failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business,
financial condition and results of operations and could limit our ability to report our financial results accurately and in a timely manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b><i>If securities or industry analysts
do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The trading market for our common stock depends, in part, on the research
and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade
our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our
operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease
coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price
and trading volume to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item1b"></span>ITEM 1B. UNRESOLVED STAFF
COMMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item2"></span>ITEM 2. PROPERTIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We currently lease one corporate office property
in New York, New York, as our corporate office space for approximately 300 square feet. We believe that our leased facility is generally
well maintained and in good operating condition and that the space is suitable and sufficient for our operational needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item3"></span>ITEM 3. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We may be a party to certain other litigation that
is either judged to be not material or that arises in the ordinary course of business from time to time. We intend to vigorously defend
our interests in these matters. We expect that the resolution of these matters will not have a material adverse effect on our business,
financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to
the outcome of these proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item4"></span>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">53</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>PART II.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item5"></span>ITEM 5. MARKET FOR REGISTRANT'S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Our common stock is traded on the Nasdaq Capital
Market under the symbol "SEEL." Before January 24, 2019, our common stock was trading under the ticker symbol "APRI".
The daily market activity and closing prices of our common stock can be found at www.nasdaq.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On February 25, 2022, the last reported
sales price for our common stock on the Nasdaq Capital Market was $1.06 per share, and we had approximately 109 holders of record of
our common stock. One of our shareholders is Cede&nbsp;&amp;&nbsp;Co., a nominee for Depository Trust Company ("DTC").
Shares of common stock that are held by financial institutions as nominees for beneficial owners are deposited into participant
accounts at DTC, and are considered to be held of record by Cede&nbsp;&amp;&nbsp;Co. as one stockholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Dividend Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We have never declared or paid cash dividends on
our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment of dividends on
our capital stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as
our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your
investment will only occur if the common stock price appreciates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Unregistered Sales of Equity Securities and Use
of Proceeds</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item6"></span>ITEM 6. [RESERVED]</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">54</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item7"></span>ITEM 7. MANAGEMENT'S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Overview</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">We are a clinical-stage biopharmaceutical company focused
on achieving efficient development of products that address significant unmet needs in Central Nervous System (“CNS”) disorders
and other rare disorders.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>Impact of COVID-19</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">In March 2020, we began taking precautionary measures to protect
the health and safety of our employees and contractors and further assessing the actual and potential impact of the coronavirus (“COVID-19”)
pandemic on our business, financial condition and operations. COVID-19 infections have been reported throughout the United States, along
with other jurisdictions in which our suppliers, partners and collaborators operate. In addition, COVID-19 has caused disruption and volatility
in the global capital markets, and has led to an economic slowdown. Certain national, provincial, state and local governmental authorities
have issued proclamations and/or directives aimed at minimizing the spread of COVID-19 and additional, more restrictive proclamations
and/or directives may be issued in the future. Before the COVID-19 outbreak, most of our employees worked remotely. Up until the fourth
quarter of 2021, we had not experienced any significant delays with our past or ongoing clinical trials for SLS-002, nor our start up
activities for clinical trials for SLS-005. During the fourth quarter of 2021 and through the issuance of this report, we have experienced
a slowdown in patient enrollment primarily due to staffing issues at our study sites related to the spike in COVID-19 cases due to the
Omicron variant. Additionally, the pandemic has not materially affected our liquidity as we maintain our resources in the form of cash.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">In addition, although we do not currently expect the preventative
measures taken to date to have a material adverse impact on our business for the first quarter of 2022, the continued impact of the COVID-19
pandemic on our business, financial condition and results of operations is unknown and will depend on future developments and risks, which
are highly uncertain and cannot be predicted. These developments and risks include, among others, the duration and severity of the COVID-19
pandemic, the emergence or spread of new COVID-19 variants, the impact on the capital markets, the impact on our partners and the regulatory
agencies that oversee our sector and any additional preventative and protective actions that governmental authorities, or we, may implement,
any of which may result in an extended period of business disruption, including potential delays in commencing future clinical trials,
or in completing enrollment for any clinical trials we may commence or in the FDA or other regulatory agencies conducting in-person inspections
or accommodations for alternatives to in-person inspections. Any resulting financial impact cannot be reasonably estimated at this time,
but the COVID-19 pandemic may force us to make adjustments to our business, our plans and our timeline for developing assets, including
our programs. In addition, the pandemic is currently not anticipated to have a material adverse impact on our business, financial condition
and results of operations, including our ability to raise additional capital, although, if the pandemic continues at its current rate
into the middle of 2022, it could have a material adverse impact on our business. See Part I, Item 1A, Risk Factors, for an additional
discussion of risks related to COVID-19.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">On January 24, 2019, our company (which was formerly named
“Apricus Biosciences, Inc.”), completed a business combination with Seelos Therapeutics, Inc., a Delaware corporation (“STI”),
in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into
on July 30, 2018. Pursuant to the Merger Agreement, (i) a former subsidiary of ours merged with and into STI, with STI (renamed “Seelos
Corporation”) continuing as a wholly-owned subsidiary of ours and the surviving corporation of the merger and (ii) our company was
renamed “Seelos Therapeutics, Inc.” (the “Merger”).</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Our business model is to advance multiple late-stage therapeutic
candidates with proven mechanisms of action that address large markets with unmet medical needs and for which there is a strong economic
and scientific rationale for development.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">55</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Our product development pipeline is as follows:</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Product</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Indication</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-size: 10pt"><b>Development
    Phase</b></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 42%; text-align: center"><span style="font-size: 10pt"><b>Development
    Status</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">SLS-002<br>
  Intranasal Racemic Ketamine</span></td>
  <td><span style="font-size: 10pt">&nbsp;<br>
  &nbsp;</span></td>
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Acute Suicidal Ideation and Behavior (ASIB) in Major
  Depressive Disorder (MDD)</span></td>
  <td><span style="font-size: 10pt">&nbsp; &nbsp;</span></td>
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Phase II<br>
  &nbsp;</span></td>
  <td><span style="font-size: 10pt">&nbsp;<br>
  &nbsp;</span></td>
  <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Completed open-label patient enrollment and announced
  the initial topline data from Part 1 of the proof-of-concept study on May 17, 2021 and initiated enrollment of Part 2 of a registration
  directed study&nbsp;</span></td>
</tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">SLS-005</span></p>
                                   <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">IV Trehalose</span></p></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Amyotrophic Lateral Sclerosis (ALS)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Phase II/III</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Startup activities completed; on February 28, 2022, we announced dosing
    of the first participants in the registrational study</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">&nbsp;Spinocerebellar Ataxia (SCA)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">Phase IIb/III</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">Startup activities initiated</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Sanfilippo Syndrome</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Phase II</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Obtaining natural history data</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">SLS-004</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Parkinson's Disease (PD)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Pre-IND</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical studies ongoing</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Gene Therapy</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">SLS-006</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Parkinson's Disease (PD)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Phase II/III</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Considering studies to advance into late stage trials</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Partial Dopamine Agonist</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">SLS-007</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Parkinson's Disease (PD)</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Pre-IND</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical study ongoing</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Peptide Inhibitor</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td>
    <td><span style="font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"><b>Lead Programs</b></p>


<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Our lead programs are currently SLS-002 for the potential
treatment of Acute Suicidal Ideation and Behavior (“ASIB”) in patients with Major Depressive Disorder (“MDD”)
and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”).
SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-002</span></b>&nbsp;is intranasal racemic ketamine
with two investigational new drug applications (“INDs”). The lead program is focused on the treatment of ASIB in MDD. SLS-002
was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500
subjects. SLS-002 addresses an unmet need for an efficacious drug to treat suicidality in the United States. Traditionally, anti-depressants
have been used in this setting but many of the existing treatments are known to contribute to an increased risk of suicidal thoughts in
some circumstances, and if and when they are effective, it often takes weeks for the full therapeutic effect to be manifested. We believe
there is a large opportunity in the United States and European markets for products in this space. Based on information gathered from
the databases of the Agency for Healthcare Research and Quality, there were approximately 1,000,000 visits to emergency rooms for suicide
attempts in 2013 in the United States alone. Experimental studies suggest ketamine has the potential to be a rapid, effective treatment
for refractory depression and suicidality.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">The clinical development program for SLS-002 includes two
parallel healthy volunteer studies (Phase I). We announced interim data from our Phase I study of SLS-002 during the quarterly period
ended March 31, 2020. As a result, in March 2020, we completed a Type C meeting with the U.S. Food and Drug Administration (“FDA”)
and received guidance to conduct a Phase II proof of concept (“PoC”) study of SLS-002 for ASIB in patients with MDD, to support
the further clinical development of this product candidate, together with nonclinical data under development.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">56</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">As a result of the Type C meeting and the Fast Track designation
for SLS-002 for the treatment of ASIB in patients with MDD, we believe we are well positioned to pursue the FDA's expedited programs for
drug development and review.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 4.5pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">On June 23, 2020, we announced the final safety data from
our Phase I pharmacokinetics/pharmacodynamics study of intranasal racemic ketamine (SLS-002) as well as the planned design of a Phase
II double blind, placebo-controlled PoC study for ASIB in subjects with MDD. We initiated this PoC study in two parts: Part 1 was an open-label
study of 17 subjects, and is being followed by Part 2, which is a double blind, placebo-controlled study of approximately 120 subjects.
On January 15, 2021, we announced dosing of the first subjects in Part 1 of the PoC study. On March 5, 2021, we announced the completion
of open-label enrollment of subjects in Part 1 of the PoC study. On May 17, 2021, we announced positive topline data from Part 1 of the
POC study, the open-label cohort, of our study of SLS-002 (intranasal racemic ketamine), demonstrating a significant treatment effect
and a well-tolerated safety profile for ASIB in patients with MDD. This study enrolled 17 subjects diagnosed with MDD requiring psychiatric
hospitalization due to significant risk of suicide with a baseline score of ≥ 28 points on the Montgomery-Åsberg Depression Rating
Scale ("MADRS"), a score of 5 or 6 on MADRS Item-10, a score of ≥ 15 points on the Sheehan-Suicidality Tracking Scale (S-STS)
total score and a history of previous suicide attempt(s), as confirmed on the Columbia Suicide Severity Rating Scale (C-SSRS) with a history
of at least one actual attempt, or if the attempt was interrupted or aborted, is judged to have been serious in intent. SLS-002 demonstrated
a 76.5% response rate (response meaning 50% reduction from baseline) in the primary endpoint on MADRS twenty-four hours after first dose,
with a mean reduction in total score from 39.4 to 14.5 points.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">On July 6, 2021, we announced dosing of the first subject
in Part 2 of the planned registration directed study. Based on feedback from a Type C meeting with the FDA in June 2021, we are planning
to increase the subjects in Part 2 to increase the sample size and power to support a potential marketing application.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-005</span></b> is IV trehalose, a protein stabilizer
that crosses the blood-brain-barrier and activates autophagy and the lysosomal pathway. Based on preclinical and in vitro studies, there
is a sound scientific rationale for developing trehalose for the treatment of ALS, SCA and other indications such as Sanfilippo Syndrome.
Trehalose is a low molecular weight disaccharide (0.342 kDa) that protects against pathological processes in cells. It has been shown
to penetrate muscle and cross the blood-brain-barrier. In animal models of several diseases associated with abnormal cellular protein
aggregation, it has been shown to reduce pathological aggregation of misfolded proteins as well as to activate autophagy pathways through
the activation of Transcription Factor EB ("TFEB"), a key factor in lysosomal and autophagy gene expression. Activation of TFEB
is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Trehalose 90.5 mg/mL IV solution has demonstrated promising
clinical potential in prior Phase II clinical development for oculopharyngeal muscular dystrophy ("OPMD") and spinocerebellar
ataxia type 3 ("SCA3"), also known as Machado Joseph disease, with no significant safety signals to date and encouraging efficacy
results. Pathological accumulation of protein aggregates within cells, whether in the CNS or in muscle, eventually leads to loss of function
and ultimately cell death. Prior preclinical studies indicate that this platform has the potential to prevent mutant protein aggregation
in other devastating PolyA/PolyQ diseases.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">57</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">We own three United States patents for parenteral
administration of trehalose for patients with OPMD and SCA3, all of which are expected to expire in 2034. In addition, Orphan Drug
Designation ("ODD") for OPMD and SCA3 has been secured in the United States and in the European Union ("EU"). In
February 2019, we assumed a collaborative agreement, turned subsequently into a research grant, with Team Sanfilippo Foundation
(“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome. On April 30,
2020, we were granted ODD for SLS-005 in Sanfilippo Syndrome from the FDA. SLS-005 was previously granted ODD from the FDA and
European Medicines Agency for SCA3 and OPMD as well as Fast Track designation for OPMD. On August 25, 2020, we were issued U.S.
patent number 10,751,353 titled "COMPOSITIONS AND METHODS FOR TREATING AN AGGREGATION DISEASE OR DISORDER" which relates to
trehalose (SLS-005). The issued patent covers the method of use for trehalose (SLS-005) formulation for treating a disease or
disorder selected from any one of the following: spinal and bulbar muscular atrophy, dentatombral-pallidoluysian atrophy, Pick's
disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia or parkinsonism linked to chromosome 17.
On May 15, 2020, we were granted Rare Pediatric Disease Designation ("RPDD") for SLS-005 in Sanfilippo Syndrome from the
FDA. RPDD is an incentive program created under the Federal Food, Drug, and Cosmetic Act to encourage the development of new
therapies for the prevention and treatment of certain rare pediatric diseases. On May 27, 2021, we announced that we were granted
ODD for SLS-005 in ALS from the European Medicines Agency. In December 2020, we announced the selection of SLS-005 for the Healey
ALS platform trial led by Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study multiple
potential treatments for ALS simultaneously. The platform trial model aims to greatly accelerate the study access, reduce costs and
shorten development timelines. On February 28, 2022, we announced the dosing of the first participants in the Healey ALS platform trial.
In November 2021, we announced the FDA acceptance of an IND and grant of Fast Track designation for SLS-005 for the treatment of
SCA. We have begun the start up activities for a Phase IIb/III study for SCA.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Additionally, we are developing several preclinical programs,
most of which have well-defined mechanisms of action, including SLS-004, licensed from Duke University, and SLS-007, licensed from The
Regents of the University of California, for the potential treatment of Parkinson’s Disease (“PD”), SLS-008, targeted
at chronic inflammation in asthma, atopic dermatitis and orphan indications such as pediatric esophagitis, SLS-010 in narcolepsy and related
disorders and SLS-012, an injectable therapy for post-operative pain management.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>Strategy and Ongoing Programs</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-002:</span></b> The clinical development program for
SLS-002 includes two parallel healthy volunteer studies (Phase I). Following these Phase I studies, we completed a Type C meeting with
the FDA in March 2020 and received guidance to conduct a Phase II PoC study of SLS-002 for ASIB in subjects with MDD. We released topline
data for Part 1 of our open-label study on May 17, 2021. We initiated enrollment in Part 2 of the registration directed study on July
6, 2021.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-005</span></b>
is undergoing startup activities for clinical studies in ALS and SCA. In December 2020, we announced the selection of SLS-005 for
the Healey ALS platform trial led by Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study
multiple potential treatments for ALS simultaneously. The platform trial model aims to greatly accelerate the study access, reduce
costs, and shorten development timelines. On February 28, 2022, we announced dosing of the first participants in the Healey ALS
platform trial. In November 2021, we announced the FDA acceptance of an IND and grant of Fast Track designation for SLS-005 for the
treatment of SCA. We have begun the start up activities for a Phase IIb/III study for SCA. We are continuing to consider trials in
Sanfilippo Syndrome and are seeking more natural history data based on the guidance from regulatory agencies.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">58</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-004</span></b> is an all-in-one lentiviral vector,
targeted for gene editing through DNA methylation within intron 1 of the synuclein alpha ("SNCA") gene responsible for expressing
alpha-synuclein protein. SLS-004, when delivered to dopaminergic neurons derived from human induced pluripotent stem cells of a PD patient,
modified the expression on alpha-synuclein ("α-synuclein") and exhibited reversal of the disease-related cellular-phenotype
characteristics of the neurons. The role of mutated SNCA in PD pathogenesis and the need to maintain the normal physiological levels of
α-synuclein protein emphasize the yet unmet need to develop new therapeutic strategies, such as SLS-004, targeting the regulatory
mechanism of α-synuclein expression. On May 28, 2020, we announced the initiation of a preclinical study of SLS-004 in PD through
an all-in-one lentiviral vector targeting the SNCA gene. We are constructing a bimodular viral system harboring an endogenous α-synuclein
transgene and inducible regulated repressive CRISPR/Cas9-unit to achieve constitutive activation and inducible suppression of PD-related
pathologies. On July 7, 2021, we announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein expression under
this study.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-006</span></b> is a true partial dopamine agonist,
originally developed by Wyeth Pharmaceuticals, Inc., with previous clinical studies on 340 subjects in various Phase I and Phase II studies.
It is a potent D2/D3 agonist/antagonist that has shown promising efficacy with statistical significance in Phase II studies in early-stage
PD patients and an attractive safety profile. Moreover, it has also shown synergistic effect with reduced doses of L-DOPA. We are considering
studies to advance the product candidate into late-stage trials.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b><span style="text-decoration: underline">SLS-007</span></b> is a rationally designed peptide-based
approach, targeting the nonamyloid component core ("NACore") of α-synuclein to inhibit the protein from aggregation. Recent
in vitro and cell culture research has shown that SLS-007 has the ability to stop the propagation and seeding of α-synuclein aggregates.
We will evaluate the potential for in vivo delivery of SLS-007 in a PD transgenic mice model. The goal will be to establish in vivo pharmacokinetics/pharmacodynamics
and target engagement parameters of SLS-007, a family of anti-α-synuclein peptidic inhibitors. On June 25, 2020, we announced
the initiation of a preclinical study of SLS-007 in PD delivered through an adeno associated viral ("AAV") vector targeting
the non-amyloid component core of α-synuclein. We have initiated an in vivo preclinical study of SLS-007 in rodents to assess the
ability of two specific novel peptides, S62 and S71, delivered via AAV1/2 viral vector, to protect dopaminergic function in the preformed
α-synuclein fibril rodent model of PD. Production of AAV1/2 vectors encoding each of the two novel peptides incorporating hemagglutinin
tags has already been completed. This preclinical study is designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles
and target engagement parameters of SLS-007.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">We intend to become a leading biopharmaceutical company focused
on neurological and psychiatric disorders, including orphan indications. Our business strategy includes:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">advancing SLS-002 in ASIB in MDD and post-traumatic stress disorder;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">advancing SLS-004 in PD;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">advancing SLS-005 in ALS, SCA and Sanfilippo Syndrome;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">advancing SLS-007 in PD as a monotherapy; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="padding-right: 1pt">acquiring synergistic assets in the CNS therapy space through licensing and partnerships.</td></tr></tbody></table>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">We also have two legacy product candidates: a product candidate
in the United States for the treatment of erectile dysfunction, which we in-licensed from Warner Chilcott Company, Inc., now a subsidiary
of Allergan plc; and a product candidate which has completed a Phase IIa clinical trial for the treatment of Raynaud’s Phenomenon,
secondary to scleroderma, for which we own worldwide rights.&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">59</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Operating Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Operating expense for the years ended December 31, 2021 and 2020 was as
follows (in thousands, except percentages):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="4" style="background-color: white; text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; background-color: white; text-align: center"><span style="font-size: 10pt"><b>2021 vs 2020</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; background-color: white; text-align: center"><span style="font-size: 10pt"><b>$ Change</b></span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; background-color: white; text-align: center"><span style="font-size: 10pt"><b>% Change</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 41%"><span style="font-size: 10pt">Operating expense</span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 13%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 13%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 13%; background-color: white; text-align: right">&nbsp;</td>
    <td style="width: 1%; background-color: white; text-align: right">&nbsp;</td>
    <td style="width: 13%; background-color: white; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Research and development</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">46,649&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">10,984&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">35,665</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right"><span style="font-size: 10pt">325%</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; General and administrative</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">15,020&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">7,775&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">7,245&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right"><span style="font-size: 10pt">93%</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Total operating expense</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">61,669&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">18,759&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">42,910</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right"><span style="font-size: 10pt">229%</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Research and development (“R&amp;D”) costs are expensed
as they are incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct R&amp;D
on our behalf. The $35.7 million increase in R&amp;D expense during the year ended December 31, 2021, as compared to the same period in
2020, is detailed as follows (in thousands, except percentages):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="4" style="background-color: white; text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; background-color: white; text-align: center"><span style="font-size: 10pt"><b>2021 vs 2020</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; background-color: white; text-align: center"><span style="font-size: 10pt"><b>$ Change</b></span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; background-color: white; text-align: center"><span style="font-size: 10pt"><b>% Change</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 41%"><span style="font-size: 10pt">Research and development expenses</span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 13%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 13%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 13%; background-color: white; text-align: right">&nbsp;</td>
    <td style="width: 1%; background-color: white; text-align: right">&nbsp;</td>
    <td style="width: 13%; background-color: white; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;  License payments</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">18,140&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">193&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">17,947</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">n/a</span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Clinical trial expenses</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">17,382&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,868&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">12,514&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">257%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Manufacturing expenses</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5,592&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,792&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,800</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">212%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Employee compensation</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,370&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,828&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,542&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">84%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Contract consulting expenses</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,454&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,837&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(383)&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-21%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Other research and development expenses</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">711&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">466&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">245&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">53%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">Total research and development expenses</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">46,649&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">10,984&nbsp;</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="background-color: white; text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">35,665</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">325%</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The $35.7 million increase in R&amp;D expense during the year ended
December 31, 2021, as compared to the same period in 2020, resulted primarily from an increase in license fees of approximately $17.9
million, clinical trial costs of approximately $12.5 million, and manufacturing costs to support increased clinical activity of $3.8 million.
These increases were partially offset by a decrease in external consulting costs of approximately $0.4 million.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>General and Administrative Expenses</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">General and administrative (“G&amp;A”) costs include
expenses for personnel, finance, legal, business development and investor relations. G&amp;A expenses increased by $7.2 million
during the year ended December 31, 2021, as compared to the same period in 2020. This increase was primarily due to non-cash
stock-based compensation of approximately $6.0 million, of which $4.9 million relates to vesting of a performance stock unit award
in the fourth quarter of 2021, and additional costs including, but not limited to, legal fees costs of approximately $0.5
million during the year ended December 31, 2021. This increase was partially offset by decreases in investor relations costs during
the year ended December 31, 2021 of $0.1 million.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">60</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Other Income and Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Other income and expense for the years ended
December 31, 2021 and 2020 was as follows (in thousands):</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Year Ended December 31,</td>
    <td style="font-weight: bold; vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="font-weight: bold; vertical-align: middle">&nbsp;</td></tr>
  <tr style="vertical-align: middle">
    <td style="width: 52%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="background-color: white; width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 14%">2021</td>
    <td style="background-color: white; width: 1%">&nbsp;</td>
    <td style="border-top-color: Black; border-top-width: 1pt; background-color: white; width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 14%">2020</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="background-color: white; width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 14%">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Other income (expense)</td>
    <td style="background-color: white">&nbsp;</td>
    <td style="background-color: white">&nbsp;</td>
    <td style="border-top-color: Black; border-top-width: 1pt; background-color: white">&nbsp;</td>
    <td style="background-color: white">&nbsp;</td>
    <td style="background-color: white">&nbsp;</td>
    <td style="border-top-color: Black; border-top-width: 1pt; background-color: white">&nbsp;</td>
    <td style="background-color: white">&nbsp;</td>
    <td style="background-color: white">&nbsp;</td>
    <td style="border-top-color: Black; border-top-width: 1pt">&nbsp;</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;113</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;68</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1,598)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(164)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1,434)</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liability</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(369)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(369)</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of convertible notes</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;230</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;230</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss on extinguishment of debt</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2,387)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2,387)</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on forgiveness of debt</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;149</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;149</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrant liabilities</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(517)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(223)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(294)</td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expense)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4,379)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(342)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4,037)</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Interest Income</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Interest income was $113,000 and $45,000 for the years ended December
31, 2021 and 2020, respectively. The increase in interest income was primarily related to higher average cash balances during the year
ended December 31, 2021 compared to the year ended December 31, 2020.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Interest Expense</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Interest expense was $1.6 million and $0.2 million for the years ended
December 31, 2021 and 2020, respectively. The increase was due to the issuance of convertible notes in December 2020.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Change in Fair Value of Derivative Liability</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Change in fair value of derivative liability was $0.4 million for
the years ended December 31, 2021. This change is due to the revaluation of the embedded derivative resulting from our license agreement
with iX Biopharma Europe Ltd., which is required to be revalued at each reporting period, with changes in fair value reflected in earnings.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Change in Fair Value of Convertible Notes</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Change in fair value of convertible notes was $0.2 million and $0
for the years ended December 31, 2021 and 2020, respectively. This change is due to our 2021 convertible notes issued in November 2021
and December 2021, which have been accounted for under the fair value option and are revalued at each reporting period, with changes in
fair value reflected in earnings.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss on Extinguishment of Debt</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">Net loss on extinguishment of
debt was $2.4 million and $0 for the years ended December 31, 2021 and 2020, respectively. This loss was primarily due to the termination
agreement with Lind Global Asset Management II, LLC (“Lind”), whereby we issued Lind 406,250 shares with a fair value of $1.4
million, as well as losses on extinguishments recognized on other principal payments on our 2020 convertible notes during the period.</span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Gain on Forgiveness of Debt</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">Gain on forgiveness of debt
was $149,000 and $0 for the years ended December 31, 2021 and 2020, respectively. This gain was due to the forgiveness of our outstanding
PPP loan, which we received in June 2021.</span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">61</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Change in Fair Value of Warrant Liability</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The fair value of warrant liability was $0.4 million and $1.0 million
at December 31, 2021 and 2020, respectively. The change in fair value of warrant liabilities of $0.5 million during the year ended December
31, 2021 is due to revaluation of the Series A warrants during such period. The change in fair value of warrant liabilities of $0.2 million
during the year ended December 31, 2020 was due to revaluation of the Series A and Series B warrants during such period.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Liquidity, Capital Resources and Financial Condition</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We have generated limited revenues, incurred operating losses since
inception, and we expect to continue to incur significant operating losses for the foreseeable future and may never become profitable.
As of December 31, 2021, we had $78.7 million in cash and an accumulated deficit of $141.2 million. We have historically funded our operations
through the issuance of convertible notes (the “Notes”) (see Note 9 to our consolidated financial statements), the sale of
common stock (see Note 6 to our consolidated financial statements) and the exercise of warrants (see Note 10 to our consolidated financial
statements).</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On November 23, 2021, we entered into a Securities Purchase Agreement
(the “Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among
other things, on November 23, 2021 (the “Closing Date”), we issued and sold to Lind V, in a private placement transaction
(the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (1) a convertible promissory note (the
“2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest
until the first anniversary of the issuance of the First Note and will thereafter bear interest at a rate of 5% per annum, and mature
on November 23, 2024 (the “Maturity Date”), and (2) 534,759 shares (the “2021 Closing Shares”) of our common stock.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">At the first anniversary of the Closing Date, we shall have the
option, at our sole discretion, to issue to Lind V a convertible promissory note (the “Second Note”) in the principal
amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of
the Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of us and Lind V, we shall issue to Lind V a convertible promissory note (the “Third Note”) in the principal amount of $11.0
million in exchange for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S.
Food &amp; Drug Administration for either SLS-002 or SLS-005, and subject to the mutual agreement of us and Lind V, we shall issue
to Lind a convertible promissory note (the “Fourth Note”) in the principal amount of $11.0 million in exchange for the
payment by Lind V of $10.0 million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the
same form as the 2021 Note. See Note 9 to our consolidated financial statements for further discussion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">On December 2, 2021, we
entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the
Securities Purchase Agreement, pursuant to which we sold, in private placement transactions, in exchange for the payment by the
accredited investors of an aggregate of $201,534, (i) convertible promissory notes (the “December 2021 Notes”) in an
aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388
shares of our common stock. These notes have substantially the same terms as the 2021 Note.</span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">On May 24, 2021, we completed
an underwritten public offering pursuant to which we sold 22,258,066 shares of our common stock at a price to the public of $3.10 per
share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock.
The net proceeds to us from the offering were $64.5 million, after deducting underwriting discounts and commissions and other estimated
offering expenses payable by us (see Note 6 to our consolidated financial statements). We used $7.3 million of the net proceeds from the
offering for the partial repayment of the Notes (as defined below).</span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">62</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On January 28, 2021, we completed an underwritten public offering
pursuant to which we sold 17,530,488 shares of our common stock at a price to the public of $2.05 per share, which included the exercise
in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to us from the
offering were approximately $33.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses
payable by us. We used $3.8 million of the net proceeds from the offering for the partial repayment of the Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On December 11, 2020, we entered into a Securities Purchase
Agreement (the “Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the "Investor")
pursuant to which, among other things, on December 11, 2020, we issued and sold to the Investor, in a private placement transaction,
in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the "2020 Note") in an
aggregate principal amount of $12,000,000 (the "Principal Amount"), which did not bear interest and was to mature on
December 11, 2022 (the "Maturity Date"), and (2) 975,000 shares (the "2020 Closing Shares") of our common stock. At
any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion
of the then-outstanding Principal Amount of the 2020 Note into shares of common stock at a price per share of $1.60, subject to
adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the "Conversion Price"). Prior
to June 11, 2021, we had the right to prepay up to sixty-six and two-thirds percent (662/3%) of the then-outstanding Principal
Amount of the 2020 Note with no penalty. Subject to certain exceptions, we were required to direct proceeds from any subsequent debt
financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money
debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless
waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments
equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining
until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. <span style="background-color: white">On
June 14, 2021, we and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which we agreed to issue to
the Investor an aggregate of 406,250 additional shares of our common stock (the “Lind Shares”) and to pay the Investor
the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of our remaining obligations to
the Investor under the 2020 Note. We issued the Lind Shares and made the Final Payment to the Investor, and the Lind Securities
Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.</span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On December 17, 2020, we entered into three separate securities purchase
agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the "December
17 SPAs"), pursuant to which we sold, in private placement transactions, in exchange for the payment by the accredited investors
of an aggregate of $1,138,023, (1) convertible promissory notes (the "December 17 Notes") in an aggregate principal amount
of $1,365,628, which did not bear interest and was to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of our common
stock. On December 18, 2020, we entered into an additional securities purchase agreement with an accredited investor on substantially
the same terms as the Lind Securities Purchase Agreement (the "December 18 SPA" and, together with the December 17 SPAs, the
"Subsequent Securities Purchase Agreements"), pursuant to which we sold, in a private placement transaction, in exchange for
the payment by the accredited investor of $269,373, (1) a convertible promissory note (the "December 18 Note" and, together
with the December 17 Notes, the "Subsequent Notes," and, together with the Note, the "Notes") in an aggregate principal
amount of $323,247, which did not bear interest and was to mature on December 18, 2022, and (2) 26,263 shares of our common stock. The
Subsequent Securities Purchase Agreements were entered into with certain accredited investors pursuant to the right to participate in
future offerings provided to the accredited investors in connection with the registered direct offering we completed in September 2020.
The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement, and the Subsequent
Notes had substantially the same terms as the Note. In connection with the Subsequent Securities Purchase Agreements, we repaid $1.4 million
of principal amount of the Note on January 8, 2021. On July 7, 2021, we and the holder of the December 18 Note (the “December 18
Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed
to return to us $42,777 in cash (the “Repayment”) previously paid by us to the December 18 Note Holder as a payment against
our obligations under the December 18 Note, and (ii) we agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional
shares of our common stock (the “December 18 Note Shares”) in full satisfaction of our remaining obligations to the December
18 Note Holder under the December 18 Note. The December 18 Note Holder paid us the Repayment and we issued the December Note Shares, and
the December 18 SPA and the December 18 Note terminated, effective July 7, 2021.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">63</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On September 4, 2020, we entered into a Securities Purchase Agreement
with certain institutional investors (the “September 2020 Securities Purchase Agreement”), pursuant to which we issued and
sold an aggregate of 8,865,000 shares of common stock in a registered direct offering, resulting in total gross proceeds of approximately
$6.4 million, after deducting the placement agent's fees and offering expenses (see Note 6 to our consolidated financial statements).
We also agreed to issue to the investors unregistered warrants to purchase up to 6,648,750 shares of common stock in a concurrent private
placement (the “September 2020 Warrants”). The September 2020 Warrants have an exercise price of $0.84 per share of common
stock, will be exercisable six months from the date of issuance and will expire on March 9, 2026. The combined purchase price for one
share and one warrant to purchase half of a share of common stock in the offerings was $0.79.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On May 4, 2020, we qualified for and received a loan pursuant to the
Paycheck Protection Program, a program implemented by the U.S. Small Business Administration under the Coronavirus Aid, Relief, and Economic
Security Act, from a qualified lender (the "PPP Lender"), for an aggregate principal amount of approximately $147,000 (the "PPP
Loan"). The PPP Loan bore interest at a fixed rate of 1.0% per annum, with the first six months of interest deferred, had a term
of two years and was unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan was subject
to forgiveness under the Paycheck Protection Program upon our request to the extent that the PPP Loan proceeds are used to pay expenses
permitted by the Paycheck Protection Program, including payroll costs, covered rent and mortgage obligations and covered utility payments
incurred by us. We applied for and received full forgiveness of the PPP Loan with respect to those covered expenses and recorded a gain
on forgiveness of debt during the year ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On March 16, 2020, we completed an underwritten public offering pursuant
to which we sold 7,500,000 shares of our common stock at a price to the public of $0.60 per share. The net proceeds to us from this offering
were approximately $4.0 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">On February 13, 2020, we completed an underwritten public offering,
pursuant to which we sold 6,666,667 shares of our common stock at a price to the public of $0.75 per share. On February 19, 2020, we sold
an additional 999,999 shares of our common stock at a price to the public of $0.75 per share pursuant to the full exercise of the underwriters’
option to cover over-allotments. The net proceeds to us from this offering were approximately $5.0 million, after deducting underwriting
discounts and commissions and other offering expenses payable by us.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">During the years ended December 31, 2021 and 2020, we received approximately
$7.3 million and $45 thousand, respectively, in proceeds from the exercise of warrants to purchase approximately 7.4 million and 154 thousand
shares of our common stock, respectively.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect to use the net proceeds from the above transactions primarily
for general corporate purposes, which may include financing our normal business operations, developing new or existing product candidates,
and funding capital expenditures, acquisitions and investments. In addition, pursuant to the amended and restated license agreement with
Stuart Weg, M.D., we made an additional cash payment of $0.2 million to Stuart Weg in January 2022. We believe that in order for us to
meet our obligations arising from normal business operations for the next twelve months, we will require additional capital in the form
of equity, debt or both. Without additional capital, our ability to continue to operate will be limited. Our accompanying audited consolidated
financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification
of liabilities that might be necessary should we not be able to continue as a going concern.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We currently have an effective shelf registration statement on Form
S-3 filed with the SEC. We may use the shelf registration statement on Form S-3 to offer from time to time any combination of debt securities,
common and preferred stock and warrants, and, as of the date hereof, a total of $95.1 million of securities remains available for issuance
pursuant to the shelf registration statement.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The accompanying audited consolidated financial statements have been
prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities
in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and
classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability to
continue as a going concern.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">64</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Our future liquidity and capital funding requirements will depend
on numerous factors, including:</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="width: 94%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">our ability to raise additional funds to finance our operations;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">our ability to maintain compliance with the listing requirements of The Nasdaq Capital Market;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">the outcome, costs and timing of any clinical trial results for our current or future product candidates;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">potential litigation expenses;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">the emergence and effect of competing or complementary products or product candidates;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">the terms and timing of any collaborative, licensing or other arrangements that we have or may establish;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">the trading price of our common stock;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">our ability to secure a development partner for our product candidate in the United States for the treatment of ED; and</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">•</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">our ability to increase the number of authorized shares outstanding to facilitate future financing events.</td></tr>
  </tbody></table>
<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We may need to raise substantial additional funds, and if we do so,
we may do so through one or more of the following: issuance of additional debt, equity, or both and/or the completion of a licensing
or other commercial transaction for one or more of our product candidates. If we are unable to maintain sufficient financial resources,
our business, financial condition and results of operations will be materially and adversely affected. This could adversely affect future
development and business activities, operations and business plans, such as future clinical studies and/or other future ventures. There
can be no assurance that we will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible
debt financings may have a dilutive effect on the holdings of our existing stockholders. No assurances can be given that we will be able
to obtain additional financing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Cash Flow Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following table summarizes selected items in
our consolidated statements of cash flows&nbsp;(in thousands):</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: middle; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white; width: 60%">&nbsp;</td>
    <td style="vertical-align: middle; background-color: white; width: 2%">&nbsp;</td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 2%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 16%">2021</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 2%">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right; width: 2%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 16%">2020</td></tr>
  <tr style="vertical-align: middle">
    <td>Net cash (used in) provided by operations</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="font-weight: bold; text-align: right; background-color: white">&nbsp;</td>
    <td style="font-weight: bold; text-align: center; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="font-weight: bold; text-align: right; background-color: white">&nbsp;</td>
    <td style="font-weight: bold; text-align: center; background-color: white">&nbsp;</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(48,995)</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(20,913)</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;112,067</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26,314</td></tr>
  <tr style="vertical-align: middle">
    <td>Net increase (decrease) in cash</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63,072</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5,401</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Operating Activities</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Cash used in operating activities of $49.0 million in the year ended
December 31, 2021 was primarily due to the net loss of $66.0 million and changes in operating assets and liabilities of $1.4 million,
which was partially offset by $8.3 million in stock compensation expense and $5.6 million in non-cash research and development expense
of licenses acquired.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Cash used in operating activities of $20.9 million in the year ended
December 31, 2020 was primarily due to the net loss of $19.1 million and changes in operating assets and liabilities of $4.5 million,
which was partially offset by $2.0 million in stock compensation expense.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">65</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Investing Activities</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">No cash was used in investing activities during the years ended December
31, 2021 or 2020.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Financing Activities</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Cash provided by financing activities of $112.1 million in the year
ended December 31, 2021 was primarily due to the proceeds from our May 2021 and January 2021 public offerings, as well as proceeds from
the issuance and sale of the 2021 Note and the 2021 Closing Shares.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Cash provided by financing activities of $26.3 million in the year
ended December 31, 2020 was primarily due to the proceeds from the exercise of warrants, the proceeds from the issuance and sale of the
2020 Note and the 2020 Closing Shares, the issuance and sale of common stock pursuant to the September 2020 Securities Purchase Agreement,
the PPP Loan, and proceeds from our February 2020 and March 2020 public offerings.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Contractual Obligations</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">We have entered into long-term agreements
with certain manufacturers and suppliers that require us to make contractual payment to these organizations. Further, we have
entered into certain material contracts with contract research organizations for our SLS-002, SLS-005, and other clinical programs,
which include varying cancellation fees in the event we delay or cancel our studies with them. We expect to enter into additional
collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments
and long-term commitments of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Recent Accounting
Pronouncements</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">See Note 1 to our consolidated financial statements for a discussion
of recent accounting pronouncements and their effect, if any, on us.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Critical Accounting Estimates and Policies</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in accordance with United
States generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect
the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience,
market and other conditions, and various other assumptions it believes to be reasonable. Although these estimates are based on management’s
best knowledge of current events and actions that may impact us in the future, the estimation process is, by its nature, uncertain given
that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate,
our consolidated financial statements may be materially affected. In addition, if our assumptions change, we may need to revise our estimates,
or take other corrective actions, either of which may also have a material effect in our consolidated financial statements. We review
our estimates, judgments, and assumptions used in our accounting practices periodically and reflect the effects of revisions in the period
in which they are deemed to be necessary. We believe that these estimates are reasonable; however, our actual results may differ from
these estimates.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We believe that the following critical accounting policies and estimates
have a higher degree of inherent uncertainty and require our most significant judgments:</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">66</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Accrual of Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Research and development costs are expensed as incurred and include
salaries and benefits; costs paid to third-party contractors to perform research, conduct clinical trials, develop and manufacture pre-approval
drug materials and delivery devices. Clinical trial costs are a significant component of research and development expenses and include
costs associated with third-party contractors. Invoicing from third-party contractors for services performed can lag several months. We
accrue the costs of services rendered in connection with third-party contractor activities based on our estimate of management fees, site
management and monitoring costs and data management costs. Differences between actual clinical trial costs from estimated clinical trial
costs have not been material and are adjusted for in the period in which they become known.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Stock Based Compensation</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Stock based compensation expense includes charges related to options
awards to employees and directors. The estimated grant date fair value of stock options granted to employees and directors is calculated
based upon the closing stock price of our common stock on the date of the grant and recognized as stock-based compensation expense over
the expected service period, which is typically approximated by the vesting period.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">We estimate the fair value of each option award on the date of grant
using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires us to estimate our dividend yield rate,
expected volatility and risk-free interest rate over the life of the option.&nbsp;The use of estimates on these factors may cause the
fair value of the option to be under or overestimated (see Note 11 to our consolidated financial statements for the current estimates
used in the Black-Scholes option pricing model).</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Valuation of Warrant Liability</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Our outstanding Series A Warrants are classified as liabilities in
the accompanying consolidated balance sheets as they contain provisions that are considered outside of our control, such as requiring
us to maintain active registration of the shares underlying such warrants. The warrants were recorded at fair value using the Black-Scholes
option pricing model. The fair value of these warrants is re-measured at each financial reporting period with any changes in fair value
being recognized as a component of other income (expense) in the accompanying consolidated statements of operations.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>Valuation of Convertible Notes</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our outstanding Note and December 2021 Notes are accounted for under
the fair value option in the accompanying consolidated balance sheets, as permitted under Accounting Standards Codification Topic
825, Financial Instruments. The convertible notes were recorded at fair value using a Monte-Carlo simulation model. The convertible
notes are re-measured at each financial reporting period with any changes in fair value being recognized as a component of other
income (expense) in the accompanying consolidated statements of operations.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item7a"></span>ITEM 7A. QUANTITATIVE AND
QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">67</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->









<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item8"></span>ITEM 8. FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>INDEX TO FINANCIAL STATEMENTS</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="width: 93%">&nbsp;</td>
    <td style="width: 7%; text-align: center"><span style="font-size: 7.5pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm (<span id="xdx_90D_edei--AuditorName_c20210101__20211231_zk8SqHrB0OO9"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorName" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">KPMG LLP</ix:nonnumeric></span></span>, <span id="xdx_908_edei--AuditorLocation_c20210101__20211231_zUSNZ09JmDtd"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorLocation" inside-table="true" id="fact-identifier-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Short Hills, NJ</ix:nonnumeric></span></span>, Auditor Firm ID: <span id="xdx_906_edei--AuditorFirmId_c20210101__20211231_zIIUJ38844d9"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorFirmId" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">185</ix:nonnumeric></span></span>)</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">69</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Financial Statements:</span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-indent: 10pt"><span style="font-size: 10pt">Consolidated Balance Sheets as of December 31, 2021 and 2020</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 10pt"><span style="font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2021 and 2020</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: 10pt"><span style="font-size: 10pt">Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the years ended December 31, 2021 <br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and 2020</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">73</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-indent: 10pt"><span style="font-size: 10pt">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">74</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-indent: 10pt"><span style="font-size: 10pt">Notes to the Consolidated Financial Statements</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">75</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">68</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</p>




<p style="font: bold 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 20pt; text-align: center"><b>Report of Independent Registered
Public Accounting Firm</b></p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">To the Stockholders and Board of Directors<br>
Seelos Therapeutics, Inc.:</p>

<p style="font: italic 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 5pt; text-indent: 0.5in"><i>Opinion on the Consolidated Financial
Statements</i></p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">We have audited the accompanying consolidated balance
sheets of Seelos Therapeutics, Inc.&nbsp;and subsidiaries (the Company) as of December&nbsp;31,&nbsp;2021 and 2020,
the related consolidated statements of operations and comprehensive loss, stockholders’ equity (deficit), and cash flows for each
of the years in the two-year period ended December&nbsp;31,&nbsp;2021, and the related notes (collectively, the consolidated financial
statements).&nbsp;In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position
of the Company as of December&nbsp;31,&nbsp;2021 and 2020, and the results of its operations and its cash flows for each of the years
in the two-year period ended December&nbsp;31,&nbsp;2021, in conformity with U.S. generally accepted accounting principles.</p>

<p style="font: italic 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 5pt; text-indent: 0.5in"><i>Going Concern</i></p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">The accompanying consolidated financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial
statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial
doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note
2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: italic 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 5pt; text-indent: 0.5in"><i>Basis for Opinion</i></p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">These consolidated financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">We conducted our audit in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Our audit included performing procedures to assess the risks of material
misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial
statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for
our opinion.</p>
<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</p>
<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">69</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->


<p style="font: italic 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 5pt; text-indent: 0.5in"><i>Critical Audit Matter</i></p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">The critical audit matter communicated below is a matter arising
from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit
committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved
our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our
opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below,
providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>

<p style="font: italic 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 5pt 0.25in; text-indent: 0.5in">Assessment
of the measurement of fair value of the convertible note with Lind V</p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt 0.25in">As discussed in Notes&nbsp;4 and&nbsp;9 to the consolidated
financial statements, the Company completed several convertible note offerings during the year ended December 31, 2021, including an offering
with Lind Global Asset Management V, LLC (Lind V). The Company received aggregate gross proceeds of $20.2 million from the convertible
note offerings and elected to account for these convertible notes at fair value. The estimated fair value of the convertible notes as
of December 31, 2021 was $18.9 million, which included the convertible note with Lind V. The Company used a Monte Carlo simulation model
to estimate the fair value of the convertible notes.</p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt 0.25in">We identified the assessment of the measurement of fair
value of the convertible note with Lind V as of December 31, 2021 as a critical audit matter. This matter required the involvement of
valuation professionals with specialized skills and knowledge to assess the Company’s model used to value the convertible note.</p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt 0.25in">The following is the primary procedure we performed to address this critical
audit matter. We assessed the valuation model by involving valuation professionals with specialized skills and knowledge who assisted
by independently developing a range of fair values of the convertible note with Lind V and comparing it to the amount recorded by the
Company.</p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt 0.25in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 40%; padding-top: 3pt">&nbsp;</td>
    <td style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; width: 20%; padding-bottom: 10pt; text-align: center"><img alt="" style="height: 28px; width: 131px" data-src="https://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/image_001.gif" src="https://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/image_001.gif"></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; width: 40%; padding-top: 3pt">&nbsp;</td></tr>
  </tbody></table>
<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">We have served as the Company’s auditor since 2017.</p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">Short Hills, New Jersey<br>
March&nbsp;4,&nbsp;2022</p>

<p style="font: 10pt/12pt Arial, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;&nbsp;</p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">70</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>Seelos Therapeutics, Inc.
and Subsidiaries<br>
Consolidated Balance Sheets<br>
(In thousands, except share and per share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 172.15pt 0 172.25pt; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table border="0" cellpadding="0" cellspacing="0" id="xdx_30E_111_pn3n3_zfXqpNQWTkml" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="vertical-align: top; background-color: white; width: 66%"></td>
    <td style="vertical-align: top; background-color: white; width: 1%"></td>
    <td style="vertical-align: top; width: 1%"></td>
    <td id="xdx_494_20211231_zczYAhDr5kc5" style="font-weight: bold; vertical-align: top; text-align: center; background-color: white; width: 15%"></td>
    <td style="vertical-align: top; width: 1%"></td>
    <td style="vertical-align: top; width: 1%"></td>
    <td id="xdx_490_20201231_zJtpkvFm1f9i" style="font-weight: bold; vertical-align: top; text-align: center; background-color: white; width: 15%">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white">&nbsp;</td>
    <td style="vertical-align: middle; background-color: white">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">December 31,</td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">2021</td>
    <td style="vertical-align: bottom"></td>
    <td style="vertical-align: bottom"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">2020</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_z9wioUcTNWw6">
    <td style="font-weight: bold; vertical-align: middle; background-color: white">Assets</td>
    <td style="font-weight: bold; vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td style="vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td style="vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white"></td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_iB_zppNRc48tux9" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold">Current assets</td>
    <td style="font-weight: bold"></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td></tr>
  <tr id="xdx_409_eus-gaap--Cash_i01I_maACzKPF_maACzYR4_z7s6bf9J4125" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Cash</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,734</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,662</ix:nonfraction></span></td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_maACzKPF_maACzYR4_z0697NrIss0h" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Prepaid expenses and other current assets</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,727</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,832</ix:nonfraction></span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrent_i02TI_mtACzKPF_maAzJVm_mtACzYR4_zKMEWyCq50Wk" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 20pt; font-weight: bold">Total current assets</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">83,461</ix:nonfraction></span></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,494</ix:nonfraction></span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_maAzJVm_maAzekD_zXj8IDuxWoS7" style="vertical-align: middle; background-color: white">
    <td style="text-align: left">Operating lease right-of-use asset</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0065"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2020-12-31" id="fact-identifier-46" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0065" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_403_eus-gaap--Assets_i02TI_mtAzJVm_mtAzekD_zLCMa1FPHUx7" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold">Total assets</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">83,500</ix:nonfraction></span></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,494</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white">&nbsp;</td>
    <td style="font-weight: bold; text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="font-weight: bold; text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zFVG0EC1znmi" style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white">Liabilities and stockholders’ equity</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_iB_zzTAaSNSTYJk" style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white">Current liabilities</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i01I_maLCzx7x_zpNe0ELRfOb9" style="vertical-align: middle">
    <td style="text-indent: 10pt; background-color: white">Accounts payable</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,693</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right; background-color: white"><span><ix:nonfraction name="us-gaap:AccountsPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,887</ix:nonfraction></span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_i01I_maLCzx7x_zKcrav58wiY4" style="vertical-align: middle">
    <td style="text-indent: 10pt; background-color: white">Accrued expenses</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,728</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,924</ix:nonfraction></span></td></tr>
  <tr id="xdx_400_ecustom--LicensesPayable_i01I_maLCzx7x_zt4iNrVa9By7" style="vertical-align: middle">
    <td style="text-indent: 10pt">Licenses payable</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:LicensesPayable" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">200</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:LicensesPayable" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">125</ix:nonfraction></span></td></tr>
  <tr id="xdx_404_eus-gaap--ConvertibleDebtCurrent_i01I_maLCzx7x_zFXFSuGO8Pj" style="vertical-align: middle">
    <td style="text-indent: 10pt">Convertible debt</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085"><span><ix:nonfraction name="us-gaap:ConvertibleDebtCurrent" contextref="AsOf2021-12-31" id="fact-identifier-55" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0085" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleDebtCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,431</ix:nonfraction></span></td></tr>
  <tr id="xdx_404_eus-gaap--ConvertibleSubordinatedDebtCurrent_i01I_maLCzx7x_zzhYHV6HUEK3" style="vertical-align: middle">
    <td style="text-indent: 10pt">Short-term portion of convertible notes payable, at fair value</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleSubordinatedDebtCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,030</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0089"><span><ix:nonfraction name="us-gaap:ConvertibleSubordinatedDebtCurrent" contextref="AsOf2020-12-31" id="fact-identifier-58" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0089" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilities_i01I_maLCzx7x_zfmdiZKAQhs3" style="vertical-align: middle">
    <td style="text-indent: 10pt">Derivative liability</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,174</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilitiesCurrent_i01I_maLCzx7x_zkIhhBnsJQ63" style="vertical-align: middle">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">424</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,062</ix:nonfraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maLCzx7x_z1M8bjgPJ0Nj" style="vertical-align: middle">
    <td style="text-indent: 10pt">Operating lease liability</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0098"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextref="AsOf2020-12-31" id="fact-identifier-63" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0098" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzx7x_maLzbDW_zTuyZOEqiH7i" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold">Total current liabilities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,287</ix:nonfraction></span></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,429</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr id="xdx_408_ecustom--LicensesPayableLongterm_iI_zLfHFI4r72ub" style="vertical-align: middle">
    <td>Licenses payable, long-term</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0103"><span><ix:nonfraction name="SEEL:LicensesPayableLongterm" contextref="AsOf2021-12-31" id="fact-identifier-66" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:LicensesPayableLongterm" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">200</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_403_eus-gaap--OtherLongTermNotesPayable_iI_maLzkBU_maLzbDW_zVti9bmSAky" style="vertical-align: middle">
    <td>Note payable</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0106"><span><ix:nonfraction name="us-gaap:OtherLongTermNotesPayable" contextref="AsOf2021-12-31" id="fact-identifier-68" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherLongTermNotesPayable" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147</ix:nonfraction></span></td></tr>
  <tr id="xdx_403_eus-gaap--ConvertibleSubordinatedDebtNoncurrent_iI_maLzbDW_zVUDNBeaV5g4" style="vertical-align: middle">
    <td>Convertible notes payable, at fair value</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleSubordinatedDebtNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,890</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0110"><span><ix:nonfraction name="us-gaap:ConvertibleSubordinatedDebtNoncurrent" contextref="AsOf2020-12-31" id="fact-identifier-71" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--ConvertibleDebtNoncurrent_iI_maLzbDW_zwWkUuIonUgd" style="vertical-align: middle">
    <td>Convertible debt, long-term</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0112"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2021-12-31" id="fact-identifier-72" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,146</ix:nonfraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--Liabilities_i02I_maLASEzvXX_mtLzbDW_zmMcy8ctpuSi" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold">Total liabilities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,177</ix:nonfraction></span></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,922</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="visibility: hidden; vertical-align: middle; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="visibility: hidden; vertical-align: middle; text-align: right">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_iI_zZC8wt13ZoT2" style="vertical-align: middle">
    <td>Commitments and contingencies (note 13)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="visibility: hidden; vertical-align: middle; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0118"><span><ix:nonfraction name="us-gaap:CommitmentsAndContingencies" contextref="AsOf2021-12-31" id="fact-identifier-76" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>

    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="visibility: hidden; vertical-align: middle; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0119"><span><ix:nonfraction name="us-gaap:CommitmentsAndContingencies" contextref="AsOf2020-12-31" id="fact-identifier-77" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-indent: 0pt; font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquityAbstract_iB_zDDkEcusPBNd" style="vertical-align: middle">
    <td style="text-indent: 0pt; font-weight: bold">Stockholders’ equity</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockValue_i01I_maSEzNe3_zVojd25Oo4G9" style="vertical-align: middle">
    <td style="text-indent: 10pt">Preferred stock, $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20211231_zBrsUfUySluc" title="Preferred stock, per value (in usd per share)"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20201231_ztPxfWl9Zdw2"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value,
    <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20201231_zQDCvo0vXIRa" title="Preferred stock, authorized (in shares)">
    <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20211231_zP8w763z6Lbd" title="Preferred stock, authorized (in shares)"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span></ix:nonfraction></span></span> </span>shares
    authorized, <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231_zho2eV5xme38"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20201231_zFsPRgBVXmig" title="Preferred stock, issued (in shares)"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zKLJtyzYkXC3" title="Preferred stock, issued (in shares)"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20201231_zQmnZotwnUgc" title="Preferred stock, outstanding (in shares)"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span></span>
    shares<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued or outstanding as of December 31, 2021 and December 31, 2020</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0124"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-12-31" id="fact-identifier-86" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0125"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-12-31" id="fact-identifier-87" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0125" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_402_eus-gaap--CommonStockValue_i01I_maSEzZnz_maSEzNe3_zuBhAQQ3Ixef" style="vertical-align: middle">
    <td style="text-indent: 10pt">Common stock, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_zPBSL7vipYz4" title="Common stock, par value (in usd per share)"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231_zl1vJ7fAFthc" title="Common stock, par value (in usd per share)"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20211231_zD1n0unnmKv5" title="Common stock, authorized (in shares)"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">240,000,000</ix:nonfraction></span></span> and <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20201231_zmOAsrX5I74l" title="Common stock, authorized (in shares)"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">120,000,000</ix:nonfraction></span></span> shares
    authorized,<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pp0p0_c20211231_z990hXmveFf2" title="Common stock, issued (in shares)"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pp0p0_c20211231_zdZRzE8dU3e7" title="Common stock, outstanding (in shares)"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,500,445</ix:nonfraction></span></ix:nonfraction></span></span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pp0p0_c20201231_z1l9Nm1H9b0g" title="Common stock, issued (in shares)"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pp0p0_c20201231_zfZiDfA4rIu9" title="Common stock, outstanding (in shares)"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54,535,891</ix:nonfraction></span></ix:nonfraction></span></span></span> issued and outstanding
    as of<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;December 31, 2021 and December 31, 2020, respectively</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54</ix:nonfraction></span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maSEzZnz_maSEzNe3_zOEyj4yIkKLg" style="vertical-align: middle">
    <td style="text-indent: 10pt">Additional paid-in-capital</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">198,428</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77,680</ix:nonfraction></span></td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i01NI_di_maSEzZnz_maSEzNe3_zK1v1WzW2dPh" style="vertical-align: middle">
    <td style="text-indent: 10pt">Accumulated deficit</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">141,210</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,162</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquity_i02TI_mtSEzZnz_mtSEzNe3_zoZrdrBrLMo3" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold">Total stockholders’ equity</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,323</ix:nonfraction></span></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,572</ix:nonfraction></span></td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i02TI_mtLASEzvXX_zgVfdgv2jDKc" style="vertical-align: middle">
    <td style="font-weight: bold; background-color: white">Total liabilities and stockholders’ equity</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">83,500</ix:nonfraction></span></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt; background-color: white"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,494</ix:nonfraction></span></td></tr>
  </tbody></table>

<p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">The accompanying notes are an
integral part of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">71</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; text-align: center; margin-right: 0; margin-left: 0"><b>Seelos Therapeutics, Inc.
and Subsidiaries<br>
Consolidated Statements of Operations and Comprehensive Loss<br>
(In thousands, except per share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></p><p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="xdx_30B_113_pn3n3_z3bZ4uKanK1a" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: middle">
    <td style="vertical-align: middle; text-align: left">&nbsp;</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_492_20210101__20211231_zI6IkB9t2yN5" style="vertical-align: top; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_492_20200101__20201231_zlopNdO72DE5" style="vertical-align: top; text-align: center"></td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle"></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: bottom"></td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year
Ended December 31,</p></td></tr>
  <tr>
    <td style="vertical-align: middle; width: 66%"></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; width: 14%">2021</td>
    <td style="vertical-align: middle; text-align: right; width: 1%"></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; width: 14%">2020</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpensesAbstract_iB_z2qN9R4D0Xm5" style="vertical-align: middle">
    <td style="font-weight: bold">Operating expense</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top-color: Black; border-top-width: 1pt"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top-color: Black; border-top-width: 1pt"></td></tr>
  <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzp2P_zPkpP0yDJsff" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Research and development</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,649</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,984</ix:nonfraction></span></td></tr>
  <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzp2P_zzDqITPUE1Kb" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">General and administrative</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,020</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,775</ix:nonfraction></span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingExpenses_i02T_mtOEzp2P_msOILzQ93_z5YQGayKTlG2" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold; text-align: left">Total operating expense</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,669</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,759</ix:nonfraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_mtOILzQ93_maNILzVt0_maNILzPx1_zoARbHk1paY" style="vertical-align: middle">
    <td style="font-weight: bold">Loss from operations</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; border-top-color: Black; border-top-width: 1pt">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,669</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; border-top-color: Black; border-top-width: 1pt">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,759</ix:nonfraction></span>)</td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z6BDpatWVred" style="vertical-align: middle">
    <td style="font-weight: bold">Other income (expense)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_409_eus-gaap--InterestIncomeDomesticDeposits_i01_maNIEz6Xd_zi0x9GAuZ6Gi" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Interest income</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeDomesticDeposits" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeDomesticDeposits" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45</ix:nonfraction></span></td></tr>
  <tr id="xdx_407_eus-gaap--InterestExpense_i01N_di_msNIEz6Xd_zVk3cQ8cxXRe" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Interest expense</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,598</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">164</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeLossOnDerivative_i01N_di_msNIEz6Xd_zH3CnT5xYN1h" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Change in fair value of derivative  liability</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DerivativeLossOnDerivative" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">369</ix:nonfraction></span>)</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0197"><span><ix:nonfraction name="us-gaap:DerivativeLossOnDerivative" contextref="From2020-01-012020-12-31" id="fact-identifier-119" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40C_ecustom--GainLossInFairValueOfConvertibleNotes_i01_maNIEz6Xd_zEcmObNm4LN8" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Change in fair value of convertible notes</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">230</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0200"><span><ix:nonfraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextref="From2020-01-012020-12-31" id="fact-identifier-121" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01N_di_maNIEz6Xd_zCi9MMkA8KAd" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Net loss on extinguishment of debt</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,387</ix:nonfraction></span>)</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2020-01-012020-12-31" id="fact-identifier-123" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_400_eus-gaap--GainLossOnContractTermination_i01_maNIEz6Xd_zznEHhdFR3Oa" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Gain on forgiveness of debt</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:GainLossOnContractTermination" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">149</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0206"><span><ix:nonfraction name="us-gaap:GainLossOnContractTermination" contextref="From2020-01-012020-12-31" id="fact-identifier-125" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEz6Xd_zLLFPpdE5wn" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left">Change in fair value of warrant liabilities</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OtherNonoperatingIncomeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">517</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OtherNonoperatingIncomeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">223</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpense_i02T_maNILzPx1_mtNIEz6Xd_ztpNxchFowQd" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold; text-align: left">Total other income (expense)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,379</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">342</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i02T_mtNILzPx1_zZf71aNWZY99" style="vertical-align: middle">
    <td style="text-indent: 20pt; font-weight: bold; text-align: left">Net loss and comprehensive loss</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; border-top-color: Black; border-top-width: 1pt">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,048</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; border-top-color: Black; border-top-width: 1pt">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,101</ix:nonfraction></span>)</td></tr>
  <tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: bottom"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="border-top: Black 2pt double; vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="border-top: Black 2pt double; vertical-align: middle; text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: left">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareBasicAndDiluted_pii_zGEbyipgMQA7" style="vertical-align: middle">
    <td style="text-align: left">Net loss per share basic and diluted</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.73</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.43</ix:nonfraction></span>)</td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: middle; text-align: right">&nbsp;</td>
    <td style="vertical-align: middle; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: middle; text-align: right">&nbsp;</td>
    <td style="vertical-align: middle; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pip0_zSkNRrMJvMo3">
    <td style="vertical-align: middle">Weighted-average common shares outstanding basic and diluted</td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="border-bottom: Black 2pt double; vertical-align: bottom; text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,890,061</ix:nonfraction></span></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="border-bottom: Black 2pt double; vertical-align: bottom; text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">44,766,640</ix:nonfraction></span></td></tr>
  </tbody></table>

<p style="font: 9pt Sans-Serif; margin: 7.7pt 0 0; color: Red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 7.7pt 0 0 63.95pt">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">The accompanying notes are an
integral part of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">72</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>Seelos Therapeutics, Inc.
and Subsidiaries<br>
Consolidated Statements of Changes in Stockholders' Equity (Deficit)<br>
(In thousands, except share data)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="xdx_308_114_pn3n3_zq5KE4YOCzB6" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="vertical-align: top; text-align: left; background-color: white; width: 49%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zy14jp0Fowwe" style="font-weight: bold; vertical-align: middle; text-align: center; width: 5%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zZBhz5mqdaK" style="font-weight: bold; vertical-align: middle; text-align: center; width: 8%"><span style="font-size: 9pt">Additional</span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z58Fmjn5VjX1" style="font-weight: bold; vertical-align: middle; text-align: center; width: 9%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"><span style="font-size: 9pt"></span></td>
    <td id="xdx_4B8_z6qmNnvV3krj" style="font-weight: bold; vertical-align: middle; text-align: center; width: 10%"><span style="font-size: 9pt">Total</span></td></tr>
  <tr>
    <td style="vertical-align: middle; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td colspan="4" style="border-bottom: Black 1.5pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Common
    Stock</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Paid-In</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Accumulated</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Stockholders'</span></td></tr>
  <tr>
    <td style="vertical-align: middle; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: middle; text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">(Shares)</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">(Amount)</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center"><span style="font-size: 9pt">Capital</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">Deficit</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white"><span style="font-size: 9pt">Equity</span></td></tr>
  <tr id="xdx_43F_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zShEm9FU6789" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span style="font-size: 9pt">Balance as of December 31, 2019</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_98D_eus-gaap--CommonStockSharesOutstanding_iS_pp0p0_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUUrDkWs4Hfk" style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,028,533</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,027</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,061</ix:nonfraction></span>)</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonfraction></span>)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zxU7VyaBcRtl" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Stock-based compensation expense</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">-</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0229"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-141" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-142" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,044</ix:nonfraction></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0231"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-143" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,044</ix:nonfraction></span></td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfCommonStockForPrepaidServices_zuER5Y3kR4Tj" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Issuance of common stock for prepaid services</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_986_ecustom--IssuanceOfCommonStockForPrepaidServicesShares_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zheXdRaqECAg" style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForPrepaidServicesShares" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">400,000</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0234"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForPrepaidServices" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-146" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForPrepaidServices" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">330</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0236"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForPrepaidServices" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-148" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForPrepaidServices" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">330</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfCommonStockForLicenseAcquired_zWdWlZuXS1O2" style="vertical-align: middle">
    <td><span style="font-size: 9pt">Issuance of common stock for license acquired</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_98C_ecustom--Issuanceofcommonstockforlicenseacquiredshares_iP3custom--IssuanceOfCommonStockForLicenseAcquired_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4bSeWF2GCR4" title="Issuance of common stock for license acquired, shares" style="text-align: right; background-color: white"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:Issuanceofcommonstockforlicenseacquiredshares" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,809,845</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForLicenseAcquired" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForLicenseAcquired" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,441</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0242"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForLicenseAcquired" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-153" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForLicenseAcquired" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,443</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_iP2us-gaap--NetIncomeLoss_zMZXYxCXZq48" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Issuance of common stock, net of issuance costs</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7eWi77rv8r5" style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,166,666</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,835</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0249"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-158" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,850</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_zeJQjkjIyHs" style="vertical-align: middle; background-color: white">
    <td>Warrants exercised for cash</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><p id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2UpextHJyja" style="margin-top: 0; margin-bottom: 0"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">153,628</ix:nonfraction></span>&nbsp;</p></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-161" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">169</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-163" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">169</ix:nonfraction></span></td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts_zJ1yC0YZBLJ" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Issuance of common stock and warrants, pursuant to<br> &nbsp;&nbsp;&nbsp;&nbsp;Securities Purchase
    Agreement, net of issuance costs</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98A_ecustom--IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu0u82uRcTl6" title="Issuance of common stock and warrants, pursuant to Securities Purchase Agreement, net of issuance costs, shares" style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCostsShares" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,112,219</ix:nonfraction></span></span></td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,378</ix:nonfraction></span></span></td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-168" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSecuritiesPurchaseAgreementNetOfIssuanceCosts" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,379</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts_zo3MWHEwIPp2" style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 9pt">Issuance of common stock and warrants, pursuant to<br> &nbsp;&nbsp;&nbsp;&nbsp;September 2020 Securities Purchase
    Agreement,<br> &nbsp;&nbsp;&nbsp;&nbsp;net of issuance costs</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td id="xdx_982_ecustom--IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8VGbOqI3zU7" title="Issuance of common stock and warrants, pursuant to September 2020 Securities Purchase Agreement, net of issuance costs" style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCostsShares" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8,865,000</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,356</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0268"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-173" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockAndWarrantsPursuantToSeptember2020SecuritiesPurchaseAgreementNetOfIssuanceCosts" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,365</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_ztDuuRJc0EV6" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Net loss</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">-</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0273"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-175" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0274"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-176" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,101</ix:nonfraction></span>)</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,101</ix:nonfraction></span>)</span></td></tr>

  <tr id="xdx_439_c20210101__20211231_eus-gaap--StockholdersEquity_iS_ztAPtTKAQB3a" style="vertical-align: middle">
    <td style="background-color: white"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt"><b>Balance as of December
31, 2020</b></span></p></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td id="xdx_982_eus-gaap--CommonStockSharesOutstanding_iE_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8dfXOWMS3Bj" style="text-align: right; background-color: white"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54,535,891</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77,680</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,162</ix:nonfraction></span>)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,572</ix:nonfraction></span></td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zf55M7ZcSx8b" style="vertical-align: middle">
    <td style="background-color: white"><span style="font-size: 9pt">Stock-based compensation expense</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">-</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0284"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-184" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-185" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,347</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0286"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-186" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,347</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zOtQ7Njq2s35" style="vertical-align: middle">
    <td><span style="font-size: 9pt">Issuance of common stock, options exercised</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iP3us-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2R5K5ZllNVk" title="Issuance of common stock, options exercised, shares" style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79,138</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0289"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-189" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">102</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0291"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-191" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0291" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-192" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">102</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_406_ecustom--ExtinguishmentOfBeneficialConversionFeature_iPus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zpgE5P6tCL5c" style="vertical-align: middle">
    <td><span style="font-size: 9pt">Extinguishment of beneficial conversion feature</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td title="Issuance of common stock, ESPP, shares" style="text-align: right">-</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296"><span><ix:nonfraction name="SEEL:ExtinguishmentOfBeneficialConversionFeature" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-193" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">(<span><ix:nonfraction name="SEEL:ExtinguishmentOfBeneficialConversionFeature" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,519</ix:nonfraction></span>)</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298"><span><ix:nonfraction name="SEEL:ExtinguishmentOfBeneficialConversionFeature" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-195" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right">(<span><ix:nonfraction name="SEEL:ExtinguishmentOfBeneficialConversionFeature" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,519</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfCommonStockForLicenseAcquired_zwATrcIluXn9" style="vertical-align: middle">
    <td><p><span style="font-size: 9pt">Issuance of common stock for license acquired</span></p></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_982_ecustom--Issuanceofcommonstockforlicenseacquiredshares_iP3custom--IssuanceOfCommonStockForLicenseAcquired_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt8O2vvyVgV6" style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:Issuanceofcommonstockforlicenseacquiredshares" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,570,266</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForLicenseAcquired" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForLicenseAcquired" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,830</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForLicenseAcquired" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-200" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForLicenseAcquired" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,832</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_401_ecustom--IssuanceOfCommonStockForSettlementOfDebt_iPs-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zn89rU0Sgcma" style="vertical-align: middle">
    <td><span style="font-size: 9pt">Issuance of common stock for settlement of debt</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98C_ecustom--IssuanceOfCommonStockForExtinguishmentOfDebtShares_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8r840rvc4gg" style="text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForExtinguishmentOfDebtShares" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">406,250</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForSettlementOfDebt" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-203" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForSettlementOfDebt" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,377</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForSettlementOfDebt" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-205" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForSettlementOfDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,377</ix:nonfraction></span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zHkx05Iri3Sl" style="vertical-align: middle">
    <td><span style="font-size: 9pt">Issuance of common stock for conversion of debt</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_989_ecustom--IssuanceOfCommonStockForConversionOfDebtShares_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z854XEzYxnMf" style="text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForConversionOfDebtShares" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">69,065</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-208" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">138</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-210" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">138</ix:nonfraction></span></td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_z1rBrTg3TfP3" style="vertical-align: middle">
    <td><span style="font-size: 9pt">Issuance of common stock, ESPP</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFizwIJeiFe4" title="Issuance of common stock, ESPP, shares" style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,009</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0319"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-213" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">104</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0321"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-215" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">104</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfCommonStockPursuantTo2021SecuritiesPurchaseAgreement_zG0nt2KgVuA3" style="vertical-align: middle">
    <td><span style="font-size: 9pt">Issuance of common stock, pursuant to 2021<br>&nbsp;&nbsp;&nbsp;&nbsp;Securities Purchase Agreements</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98D_ecustom--Customissuanceofcommonstockpursuantto2021securitiespurchaseagreement_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTlDwNayfZ8k" title="custom:IssuanceOfCommonStockPursuantTo2021SecuritiesPurchaseAgreement" style="vertical-align: bottom; text-align: right"><span><ix:nonfraction name="SEEL:Customissuanceofcommonstockpursuantto2021securitiespurchaseagreement" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">540,147</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockPursuantTo2021SecuritiesPurchaseAgreement" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockPursuantTo2021SecuritiesPurchaseAgreement" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,051</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockPursuantTo2021SecuritiesPurchaseAgreement" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-220" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0328" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockPursuantTo2021SecuritiesPurchaseAgreement" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-221" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,052</ix:nonfraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_zPLXYKTf4ffj" style="vertical-align: middle">
    <td><span style="font-size: 9pt">Warrants exercised for cash</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_iP3us-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpzG9Kf4Arii" title="Warrants exercised for cash, shares" style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,431,125</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,401</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0335"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-225" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-226" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,408</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zzeir5BKQV2g" style="vertical-align: middle">
    <td colspan="2" style="background-color: white"><span style="font-size: 9pt">Issuance of common stock, net of issuance
    costs</span></td>
    <td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfHlCNXQAu4a" title="Issuance of common stock, net of issuance costs, shares" style="text-align: right; background-color: white"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,788,554</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-228" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97,917</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0342"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-230" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97,957</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zZy6DF0ib4ek" style="vertical-align: middle; background-color: white">
    <td><span style="font-size: 9pt">Net loss</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">-</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0347"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-232" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0348"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-233" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0348" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,048</ix:nonfraction></span>)</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,048</ix:nonfraction></span>)</span></td></tr>
  <tr id="xdx_431_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zWi6JlAMbUq4" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span style="font-size: 9pt">Balance as of December 31, 2021</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font-size: 9pt"></span></td>
    <td id="xdx_98B_eus-gaap--CommonStockSharesOutstanding_iE_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znJEi5AyuBk2" style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="true" id="fact-identifier-236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,500,445</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-237" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-238" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">198,428</ix:nonfraction></span></span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span style="font-size: 9pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-239" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">141,210</ix:nonfraction></span>)</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"></span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,323</ix:nonfraction></span></td></tr>
  </tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 4.6pt 0 0; text-align: left">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">The accompanying notes are an
integral part of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">73</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>Seelos Therapeutics, Inc.
and Subsidiaries<br>
Consolidated Statements of Cash Flows<br>
(In thousands)</b></p>

<p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0.45pt 2pt 0 0; text-align: left">&nbsp;<b>&nbsp;</b></p>

<table border="0" cellpadding="0" cellspacing="0" id="xdx_308_112_pn3n3_zOqFgSStlHha" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left; vertical-align: top"></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"></td>
    <td id="xdx_491_20210101__20211231_zitKK0fveX7c" style="vertical-align: top; text-align: center; border-top-color: Black; border-top-width: 2pt"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_492_20200101__20201231_zAkbaPmFunGb" style="vertical-align: top; text-align: center; border-top-color: Black; border-top-width: 2pt"></td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white"></td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: middle; background-color: white"></td>
    <td style="vertical-align: bottom"></td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Year
    Ended December 31,</td></tr>
  <tr>
    <td style="vertical-align: middle; background-color: white; width: 70%"></td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 13%">2021</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 13%">2020</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zfFjzPMXk2vg" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold">Cash flows from operating activities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top-color: Black; border-top-width: 1pt"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top-color: Black; border-top-width: 1pt"></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_zqgTOrOXwEJ1" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Net loss</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-241" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,048</ix:nonfraction></span>)</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,101</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_ztiRLAoPWQ63" style="vertical-align: middle">
    <td style="text-indent: 10pt; font-weight: bold; text-align: left; background-color: white">Adjustments to reconcile net loss to net cash used in operating activities</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_zDC4uDzbnF31" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left; background-color: white">Stock-based compensation expense</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-243" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,347</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-244" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,044</ix:nonfraction></span></td></tr>
  <tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_zurOXqGc6yR8" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left; background-color: white">Shares issued for services</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370"><span><ix:nonfraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextref="From2021-01-01to2021-12-31" id="fact-identifier-245" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124</ix:nonfraction></span></td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_i02_zCwBg7vIHFQ7" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Research and development expenses - license acquired</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,637</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">192</ix:nonfraction></span></td></tr>
  <tr id="xdx_407_eus-gaap--FairValueAdjustmentOfWarrants_i02_zM2tHfO37HC5" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Change in fair value of warrant liability</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">517</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:FairValueAdjustmentOfWarrants" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">223</ix:nonfraction></span></td></tr>
  <tr id="xdx_40D_ecustom--GainLossInFairValueOfConvertibleNotes_i02N_di_zhDtriszszUh" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Change in fair value of convertible notes payable</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">230</ix:nonfraction></span>)</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380"><span><ix:nonfraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextref="From2020-01-012020-12-31" id="fact-identifier-252" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--DerivativeLossOnDerivative_i01_zGzSbLdY6Tc7" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Change in fair value of derivative liability</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLossOnDerivative" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">369</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383"><span><ix:nonfraction name="us-gaap:DerivativeLossOnDerivative" contextref="From2020-01-012020-12-31" id="fact-identifier-254" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40C_ecustom--GainLossOnForgivenessOfNotePayable_i02_zKbdJqD8mP6e" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Gain on forgiveness of note payable</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">(<span><ix:nonfraction name="SEEL:GainLossOnForgivenessOfNotePayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">149</ix:nonfraction></span>)</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386"><span><ix:nonfraction name="SEEL:GainLossOnForgivenessOfNotePayable" contextref="From2020-01-012020-12-31" id="fact-identifier-256" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_zwuF1FFdvoZd" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left"> Net loss on extinguishment of convertible debt</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,387</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389"><span><ix:nonfraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextref="From2020-01-012020-12-31" id="fact-identifier-258" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40F_eus-gaap--AmortizationOfDebtDiscountPremium_i02_zXXCi2c7UP" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Amortization of debt discount</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,582</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150</ix:nonfraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zrSBdKuaJPD8" style="vertical-align: middle">
    <td style="text-indent: 10pt; font-weight: bold; text-align: left">Changes in operating assets and liabilities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02_zwmddgZuYS1c" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Prepaid expenses and other current assets</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,894</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">791</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_zRjWzhVsCzP9" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Accounts payable</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">194</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-264" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,091</ix:nonfraction></span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_zrtZRknJri79" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left; background-color: white">Accrued expenses</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,806</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-266" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span></td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i02_zDODPA9h06Ji" style="vertical-align: middle">
    <td style="text-indent: 20pt; text-align: left">Licenses payable</td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125</ix:nonfraction></span>)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,850</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_i03T_zAaM6Q1MzKSi" style="vertical-align: middle">
    <td style="text-indent: 30pt; font-weight: bold; text-align: left; background-color: white">Net cash used in operating activities</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,995</ix:nonfraction></span>)</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,913</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zm0IZJ1RUL23" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; text-align: left">Cash flows provided by financing activities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_40E_eus-gaap--RepaymentsOfNotesPayable_iN_di_msNCPBUzunm_zhybmi9ITDR" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Payment of convertible note</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:RepaymentsOfNotesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,551</ix:nonfraction></span>)</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416"><span><ix:nonfraction name="us-gaap:RepaymentsOfNotesPayable" contextref="From2020-01-012020-12-31" id="fact-identifier-272" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfCommonStock_maNCPBUzunm_zswubf0Z88wl" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from issuance of common stock, net of issuance costs</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97,957</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,850</ix:nonfraction></span></td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromConvertibleDebt_maNCPBUzunm_zWdDbyF7reg1" style="vertical-align: middle">
    <td style="vertical-align: bottom; text-indent: 10pt; text-align: left; background-color: white">Proceeds from issuance of common stock and convertible notes payable</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-275" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,203</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,907</ix:nonfraction></span></td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_maNCPBUzunm_zLdJesCsrDPa" style="text-align: right; vertical-align: bottom">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from issuance of common stock and warrants, pursuant to<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Securities Purchase Agreement, net of issuance costs</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextref="From2021-01-01to2021-12-31" id="fact-identifier-277" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,365</ix:nonfraction></span></td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromWarrantExercises_maNCPBUzunm_zjcN9CKeCc6c" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from exercise of warrants</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,252</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45</ix:nonfraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromStockOptionsExercised_maNCPBUzunm_z14hEz3zU8P2" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from exercise of options</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromStockOptionsExercised" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">102</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431"><span><ix:nonfraction name="us-gaap:ProceedsFromStockOptionsExercised" contextref="From2020-01-012020-12-31" id="fact-identifier-282" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromStockPlans_maNCPBUzunm_zcdb21JgWnii" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from sales of common stock under ESPP</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromStockPlans" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">104</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434"><span><ix:nonfraction name="us-gaap:ProceedsFromStockPlans" contextref="From2020-01-012020-12-31" id="fact-identifier-284" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromNotesPayable_maNCPBUzunm_zLuNdKNhOLM9" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Proceeds from note payable</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436"><span><ix:nonfraction name="us-gaap:ProceedsFromNotesPayable" contextref="From2021-01-01to2021-12-31" id="fact-identifier-285" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromNotesPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147</ix:nonfraction></span></td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i03_maCCERCzfGQ_mtNCPBUzunm_ztlIM9o0tcx6" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 30pt; font-weight: bold; text-align: left">Net cash provided by financing activities</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; border-top-color: Black; border-top-width: 1pt"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">112,067</ix:nonfraction></span></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; border-top-color: Black; border-top-width: 1pt"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,314</ix:nonfraction></span></td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_i03_mtCCERCzfGQ_zHLR7WOFfb4b" style="vertical-align: middle; background-color: white">
    <td>Net increase  in cash</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63,072</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-290" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,401</ix:nonfraction></span></td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zj9eaAwnb2X8" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; text-align: left">Cash, beginning of period</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-291" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,662</ix:nonfraction></span></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-292" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,261</ix:nonfraction></span></td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zWeXOdTWHIf2" style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold">Cash, end of period</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,734</ix:nonfraction></span></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,662</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; border-top-color: Black; border-top-width: 2pt"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right; border-top-color: Black; border-top-width: 2pt"></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationAbstract_iB_ziYJR0v5o9Ak" style="vertical-align: middle; background-color: white">
    <td><b>Supplemental disclosure of cash flow information</b>:</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_402_eus-gaap--InterestPaidNet_i01_zXup1UJY9lg9" style="vertical-align: middle">
    <td style="text-indent: 10pt; text-align: left; background-color: white">Cash paid for interest</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11</ix:nonfraction></span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxesPaid_i01_zQVZD3DUFHQk" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Cash paid for income taxes</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaid" contextref="From2021-01-01to2021-12-31" id="fact-identifier-297" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0457" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaid" contextref="From2020-01-012020-12-31" id="fact-identifier-298" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0458" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z3YSTLCVxtC2" style="vertical-align: middle; background-color: white">
    <td><b>Non-cash investing and financing activities:</b></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td></tr>
  <tr id="xdx_403_ecustom--ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash_i01_zq9L5nvJxA29" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Reclass of warrant liabilities related to Series A warrants exercised for cash</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-299" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,155</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">124</ix:nonfraction></span></td></tr>
  <tr id="xdx_409_eus-gaap--CapitalLeaseObligationsIncurred_i01_zTQPeDSSSLIg" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Right-of-use assets obtained in exchange for operating lease liabilities</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:CapitalLeaseObligationsIncurred" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467"><span><ix:nonfraction name="us-gaap:CapitalLeaseObligationsIncurred" contextref="From2020-01-012020-12-31" id="fact-identifier-302" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40E_ecustom--NonCashIssuanceOfCommonStockForConvertibleNotes_i01_zUHpXskbYsbd" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Issuance of common stock for convertible notes</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:NonCashIssuanceOfCommonStockForConvertibleNotes" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">69</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470"><span><ix:nonfraction name="SEEL:NonCashIssuanceOfCommonStockForConvertibleNotes" contextref="From2020-01-012020-12-31" id="fact-identifier-304" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0470" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40E_ecustom--NonCashIssuanceOfCommonStockForSettlementOfDebt_i01_zIw54POegEbh" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Issuance of common stock for settlement of debt</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:NonCashIssuanceOfCommonStockForSettlementOfDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,377</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473"><span><ix:nonfraction name="SEEL:NonCashIssuanceOfCommonStockForSettlementOfDebt" contextref="From2020-01-012020-12-31" id="fact-identifier-306" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_407_ecustom--NonCashExtinguishmentOfBeneficialConversionFeature_i01_z4VoxdQ4cUog" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Extinguishment of beneficial conversion feature</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:NonCashExtinguishmentOfBeneficialConversionFeature" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,519</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476"><span><ix:nonfraction name="SEEL:NonCashExtinguishmentOfBeneficialConversionFeature" contextref="From2020-01-012020-12-31" id="fact-identifier-308" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0476" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_406_ecustom--IssuanceOfCommonStockForIxBiopharmaLicense_i01_zjlbyscYLCS8" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Issuance of common stock for iX Biopharma license</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForIxBiopharmaLicense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,832</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479"><span><ix:nonfraction name="SEEL:IssuanceOfCommonStockForIxBiopharmaLicense" contextref="From2020-01-012020-12-31" id="fact-identifier-310" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssued1_i01_z05rQzayONM" style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt; text-align: left">Issuance of common stock for license payable</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481"><span><ix:nonfraction name="us-gaap:StockIssued1" contextref="From2021-01-01to2021-12-31" id="fact-identifier-311" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0481" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssued1" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,443</ix:nonfraction></span></td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 1.9pt 0 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"><b>&nbsp;&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">The accompanying notes are an
integral part of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">74</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><b>Seelos Therapeutics, Inc. and Subsidiaries</b><br>
<b>Notes to Consolidated Financial Statements</b></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zuX7QNqCOsIe" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>1. Organization and Summary of Significant Accounting
Policies</b></p>

<span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NatureOfOperations" inside-table="false" id="fact-identifier-314" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84E_eus-gaap--NatureOfOperations_zbh1OLHtEaa9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Organization</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 1pt 0 0">Seelos Therapeutics, Inc. and its subsidiaries (the “Company”)
is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs
in Central Nervous System (“CNS”) disorders and other rare disorders. The Company’s lead programs are SLS-002 for the
potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (“ASIB in MDD”) and
SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”).
SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered.
Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including:
SLS-004, SLS-006, SLS-007 for the potential treatment of Parkinson’s Disease (“PD”) and SLS-008, which is being developed
for the potential treatment of an undisclosed indication, but may also be targeted at chronic inflammation in asthma and orphan indications
such as pediatric esophagitis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zSj8hTWylB28" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Basis of Presentation and Principles of Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The consolidated financial statements include the
accounts of the Company and its wholly-owned subsidiaries.&nbsp;All significant intercompany accounts and transactions have been eliminated
in consolidation.</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" id="fact-identifier-316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_848_eus-gaap--UseOfEstimates_zm2sDEjm2iEe" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The preparation of these consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation
of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on
current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily
apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material
differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>



</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" inside-table="false" id="fact-identifier-317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zXOqGPEeK3J" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Fair Value of Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The carrying amounts of financial instruments such
as accounts payable and accrued expenses approximate their related fair values due to the short-term nature of these
instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">75</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zs3iIruCYpFj" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Leases</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">The Company determines if an
arrangement is a lease at inception.&nbsp;</span> Operating leases are included in operating lease right-of-use (“ROU”) asset,
operating lease liability, current and operating lease liability, long-term in the Company’s condensed consolidated balance sheets.
ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liability represents its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based
on the present value of the lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company
uses an incremental borrowing rate based on the information available at the transition date and commencement date in determining the
present value of lease payments. This is the rate the Company would have to pay if it borrowed on a collateralized basis over a similar
term to each lease. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s
lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.
Lease expense for lease payments is recognized on a straight-line basis over the lease term.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal; background-color: white"></span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueTransferPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_847_eus-gaap--FairValueTransferPolicyPolicyTextBlock_zgWi1XChP06i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="background-color: white"><b>Fair Value
Option</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="background-color: white"><b>&nbsp;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As permitted under Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”) Topic 825, Financial Instruments (“ASC 825”), the Company elected the
fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”).
In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Consolidated
Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible
notes were expensed as incurred and were not deferred.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z9R5ZTduvmsj" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company follows the accounting guidance in the FASB ASC Topic 820,
Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured
at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that
would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would
use in pricing an asset or a liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accounting guidance requires fair value measurements be classified
and disclosed in one of the following three categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Level 1: Quoted prices in active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Level 2: Observable inputs other than Level 1 prices, for similar assets
or liabilities that are directly or indirectly observable in the marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Level 3: Unobservable inputs which are supported by little or no market
activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar
techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value hierarchy also requires an entity to maximize the use of
observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value
are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" inside-table="false" id="fact-identifier-321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_zu81PV01om9b" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Research and development costs are expensed as incurred
and include milestone and upfront payments for license arrangements, the cost of employee compensation and related expenses, as well as
expenses for third parties who conduct research and development on the Company's behalf, pursuant to development and consulting agreements
in place.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">76</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-322" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zc2fG5WkCHB3" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Income taxes are accounted for under the asset and liability method.&nbsp;Deferred
income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&nbsp;Deferred
tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&nbsp;A
valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company also follows the provisions of accounting for uncertainty in
income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return,
and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-323" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zTCcvTiGwXwg" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Income (Loss) Per Common Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Basic loss per share is computed by dividing net loss applicable to common
stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes
the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that
would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to
common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss
exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following potentially dilutive securities outstanding for
the year ended December 31, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding,
as they would be anti-dilutive (in thousands):</p>

<p id="xdx_8BB_zaSYSOgneGG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td colspan="4" style="font-weight: bold; vertical-align: middle; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center"></td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center">Year Ended
    December 31,</td></tr>
  <tr>
    <td style="vertical-align: middle; width: 62%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2021</td>
    <td style="vertical-align: bottom; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: center; width: 2%"></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%">2020</td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding stock options</td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zZf44FT3b2Z1" title="Outstanding stock options" style="text-align: right; border-top-color: Black; border-top-width: 1pt"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,306</ix:nonfraction></span></td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zBVRqNzUoCO4" title="Outstanding stock options" style="text-align: right; border-top-color: Black; border-top-width: 1pt"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,120</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle">
    <td>Restricted stock units</td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zaruYXGvegp4" title="Restricted stock units" style="text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-327" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,400</ix:nonfraction></span></td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zMcIpR1QQGnk" title="Restricted stock units" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="fact-identifier-328" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0514" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr style="vertical-align: middle">
    <td>Outstanding warrants</td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zolHXX0rngi4" title="Outstanding warrants" style="text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,635</ix:nonfraction></span></td>
    <td></td>
    <td style="text-align: right"></td>
    <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5Wof5SqYk53" title="Outstanding Warrants" style="text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,066</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle">
    <td>Convertible debt </td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zcodDCBoo8a3" style="text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_us-gaap_ConvertibleDebtSecuritiesMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,704</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zuj9B8PxIhJe" style="text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_us-gaap_ConvertibleDebtSecuritiesMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,556</ix:nonfraction></span></td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td style="vertical-align: bottom; text-align: right"></td></tr>
  <tr>
    <td style="vertical-align: middle"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20210101__20211231_zez6t4eyJPph" title="Antidilutive securities excluded" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,045</ix:nonfraction></span></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td style="vertical-align: middle; text-align: right"></td>
    <td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_i01_pin3_c20200101__20201231_zH0bKiw9x1F6" title="Antidilutive securities excluded" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; vertical-align: middle; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,742</ix:nonfraction></span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A9_zKZPpjg80Pv8" style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; color: Red"><b>&nbsp;</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>


</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" inside-table="false" id="fact-identifier-335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zNQyk1SmEoY" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company expenses stock-based compensation to employees, non-employees
and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates.
The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line
basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock
option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards
represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All
stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations
based upon the underlying individual’s role at the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">Performance share awards are
initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that
vest will be determined based on the achievement of specified performance milestones by the end of the performance period.
Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the
performance period. If achievement of the performance milestone is not probable of achievement during the performance period,
compensation expense is reversed. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z3D9mzfVSIx9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Segment Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company operates under one segment which develops
pharmaceutical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">77</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqs3mRKCT6nl" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2019, the FASB issued Accounting Standards Update (“ASU”) No.
2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to
simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in
Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal
years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company
adopted ASU 2019-12 effective January 1, 2021. The adoption of ASU 2019-12 did not have a material effect on the Company’s
financial statements.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In August 2020, the FASB issued ASU 2020-06: Debt – Debt with
Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the
accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature,
as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt
instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest
expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU
2020-06. Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share,
and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for
fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December
15, 2020, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company does not expect the
adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_ztauKF4yfbO1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>2. Liquidity and Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying consolidated financial statements have been prepared assuming
the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in
the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification
of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going
concern.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has limited revenues, has incurred operating losses since inception,
and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December
31, 2021, the Company had $<span id="xdx_908_eus-gaap--Cash_iI_pn5n6_c20211231_zcHXxgdImvkl"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-339" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78.7</ix:nonfraction></span></span> million in cash and an accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn5n6_c20211231_zj9i5ci4KZg"><span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">141.2</ix:nonfraction></span></span> million. The Company has historically funded its
operations through the issuance of convertible notes (see Note 9), the sale of common stock (see Note 6) and the exercise of warrants
(see Note 10).</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company evaluated whether there are any conditions and events, considered
in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the release date
of this Annual Report on Form 10-K. Based on such evaluation and the Company's current plans (including the ongoing clinical programs
for SLS-002, SLS-005; and other product candidates), which are subject to change, management believes that the Company’s existing
cash and cash equivalents as of December 31, 2021 are not sufficient to satisfy its operating cash needs for at least one year.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company may raise substantial additional funds, and if it does so,
it may do so through one or more of the following: issuance of additional debt or equity and/or the completion of a licensing or other
commercial transaction for one or more of the Company’s product candidates. If the Company is unable to maintain sufficient financial
resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future
development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity
or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the
Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings
will likely have a dilutive effect on the holdings of the Company’s existing stockholders.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_808_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_z2eUq4xnITBk" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>3. Business Combination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 24, 2019, the Company (which was formerly known as “Apricus
Biosciences, Inc.”) (“Apricus”) completed the business combination with Seelos Therapeutics, Inc., a Delaware corporation
(“STI”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization entered into on July 30, 2018
(the “Merger Agreement”). Pursuant to the Merger Agreement, (i) a former subsidiary of the Company merged with and into STI,
with STI (renamed “Seelos Corporation”) continuing as a wholly-owned subsidiary of the Company and the surviving corporation
of the merger and (ii) the Company was renamed “Seelos Therapeutics, Inc.” (the “Merger”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">78</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Merger was accounted for as a reverse recapitalization under U.S. GAAP
because the primary assets of Apricus were nominal at the close of the Merger. STI was determined to be the accounting acquirer based
upon the terms of the Merger and other factors, including: (i) STI stockholders and other persons holding securities convertible, exercisable
or exchangeable directly or indirectly for STI common stock owned the majority of the Company immediately following the effective time
of the Merger, (ii) STI holds the majority (four of five) of board seats of the combined company, and (iii) STI’s management holds
all key positions in the management of the combined company.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">STI acquired no tangible assets and assumed no employees or operation from
Apricus. Additionally, Apricus’ intellectual property was considered to have no value. The remaining Apricus liabilities had a fair
value of approximately $300 thousand.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Merger, the Company and STI entered into a Contingent
Value Rights Agreement (the “CVR Agreement”). Pursuant to the CVR Agreement, Apricus stockholders received one contingent
value right (“CVR”) for each share of Apricus common stock held of record immediately prior to the closing of the Merger.
Each CVR represents the right to receive payments based on Apricus’ U.S. assets related to products in development, intended for
the topical treatment of erectile dysfunction, which are known as Vitaros in certain countries outside of the United States (the “CVR
Product Candidate”). In particular, CVR holders will be entitled to receive 90% of any cash payments (or the fair market value of
any non-cash payments) exceeding $500,000 received, during a period of ten years from the closing of the Merger, based on the sale or
out-licensing of Apricus’ CVR Product Candidate intangible asset, including any milestone payments (the “Contingent Payments”),
less reasonable transaction expenses. The Company is entitled to retain the first $500,000 and 10% of any Contingent Payments. The Company
has agreed to pay up to $500,000 of such Contingent Payments that it receives to a third party pursuant to a settlement agreement between
the Company and the third party. The Company assigned no value to the CVR Product Candidate intangible asset as of December 31, 2021 or
the CVR in the acquisition accounting.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_808_eus-gaap--FairValueDisclosuresTextBlock_ztlU5aWE8O6h" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>4. Fair Value Measurement</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zEOiYvW1990c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The
following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring
basis and indicate the level of the fair value hierarchy utilized to determine such fair values. At time of issuance, the derivative
liability at fair value was recognized using Level 3 inputs as no observable inputs were available at the time in the market. At December
31, 2021, the derivative liability has been reclassed as a Level 1 input as the significant inputs were known and observable. There were
<span id="xdx_902_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_do_c20210101__20211231_zj15Zf57s37l"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_do_c20200101__20201231_zQQQ7DiKO6q8">no</span></span>
transfers between fair value measurement levels during the years ended December 31, 2021 and 2020 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"><span id="xdx_8BE_zLdsggSUjfL6" style="display: none">Schedule of Fair Value Hierarchy Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold; width: 44%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: right; width: 2%"></td>
    <td style="font-weight: bold; text-align: center; width: 10%"></td></tr>
</tbody></table>


<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Fair Value Measurements</td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">as of December 31, 2021</td></tr>
  <tr>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 1)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 2)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 3)</td>
    <td style="vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">Total</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90C_eus-gaap--AssetsAbstract_iB_c20210101__20211231_z1NdZhfsyYU6">Assets</span>:</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Cash</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zphNLgkyaaSg" style="border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,734</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTrI2Jcn3cac" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-345" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0543" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0vhW9igOboi" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-346" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0544" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZ0sFf2PIsVd" style="border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,734</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_90E_eus-gaap--LiabilitiesAbstract_iB_c20210101__20211231_zqbnatmsvCN5">Liabilities</span>:</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Convertible notes payable, at fair value</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z1Dji7GN6VXc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" id="fact-identifier-348" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zZc1eDPalm1i" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0548"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" id="fact-identifier-349" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0548" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6iymzVEu8el" style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-350" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,920</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zMlyQogvhvz5" style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,920</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Derivative liability, at fair value</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zB0e9XsEXIV7" style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-352" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,174</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z3vyQwT75uk1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="fact-identifier-353" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0552" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zBPGwAQ3cEei" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="fact-identifier-354" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0553" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98A_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zai4h0Tys5Ud" style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-355" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,174</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZKHP2KXgNKf" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="fact-identifier-356" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0555" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zpHSbRNVJiJi" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="fact-identifier-357" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0556" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z2rtoturi0K1" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-358" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">424</ix:nonfraction></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zW1Y23DafrH3" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">424</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="text-indent: 10pt">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkxlXzVGYAY6" style="border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,174</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYs6Is3hVU9l" style="border-bottom: Black 2pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-361" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zDyahd65sJWd" style="border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,344</ix:nonfraction></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwS6h5ca1G24" style="border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,518</ix:nonfraction></span></td></tr>
  </tbody></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&nbsp;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">Fair Value Measurements</td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white"></td>
    <td style="vertical-align: bottom; text-align: right"></td>
    <td colspan="10" style="font-weight: bold; vertical-align: middle; text-align: center; background-color: white">as of December 31, 2020</td></tr>
  <tr>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%"></td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 1)</td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 2)</td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">(Level 3)</td>
    <td style="font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%"></td>
    <td style="vertical-align: bottom; text-align: right; width: 1%"></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%">Total</td></tr>
  <tr style="vertical-align: middle; background-color: white">
    <td style="font-weight: bold"><span id="xdx_904_eus-gaap--AssetsAbstract_iB_c20200101__20201231_zvgjQ3VeP7K9">Assets</span>:</td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: right"></td>
    <td style="font-weight: bold; text-align: center"></td>
    <td style="font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-indent: 10pt">Cash</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z50SyCguuPRb" style="border-bottom: Black 2pt double; text-align: right; background-color: white"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,662</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_985_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKOQaKdemBBl" style="border-bottom: Black 2pt double; text-align: right; background-color: white"><span style="-sec-ix-hidden: xdx2ixbrl0565"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-365" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0565" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_98A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTOLkvZnvEAk" style="border-bottom: Black 2pt double; text-align: right; background-color: white"><span style="-sec-ix-hidden: xdx2ixbrl0566"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="fact-identifier-366" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_988_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5H1PLXJwB88" style="border-bottom: Black 2pt double; text-align: right; background-color: white"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,662</ix:nonfraction></span></td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold"><span id="xdx_90D_eus-gaap--LiabilitiesAbstract_iB_c20200101__20201231_z7Gm9RWcWDJ9">Liabilities</span>:</td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; text-align: center; background-color: white"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; text-align: center; background-color: white"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; text-align: center; background-color: white"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; text-align: right; background-color: white"></td>
    <td style="font-weight: bold; text-align: center; background-color: white"></td></tr>
  <tr style="vertical-align: middle">
    <td style="text-indent: 10pt">Warrant liabilities, at fair value</td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_981_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zgvJtJ3fRxzd" style="border-bottom: Black 2pt double; text-align: right; background-color: white"><span style="-sec-ix-hidden: xdx2ixbrl0569"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="fact-identifier-368" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0569" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_983_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z1Z7MvOJRFzk" style="border-bottom: Black 2pt double; text-align: right; background-color: white"><span style="-sec-ix-hidden: xdx2ixbrl0570"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="fact-identifier-369" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0570" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_ztlbtmJ0jali" style="border-bottom: Black 2pt double; text-align: right; background-color: white"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,062</ix:nonfraction></span></td>
    <td style="text-align: right; background-color: white"></td>
    <td style="text-align: right; background-color: white">$</td>
    <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zU9qLmSSddgj" style="border-bottom: Black 2pt double; text-align: right; background-color: white"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,062</ix:nonfraction></span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AD_zWf1Uyzwva4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="background-color: white">The fair
value of the Company’s money market funds is based on quoted active market prices for the funds and is determined using the market
approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">79</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="background-color: white">&nbsp;&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Company measures the 2021 Convertible Notes,
derivative liability and warrant liabilities <span style="background-color: white">at fair value based on significant inputs not observable
in the market, which causes them to be classified as a Level&nbsp;3 measurement within the fair value hierarchy.&nbsp;</span>These valuations
use assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses
these assumptions and estimates on&nbsp;an&nbsp;on-going&nbsp;basis as additional data impacting the assumptions and estimates are obtained.
Changes in the fair value of the convertible notes payable, derivative liability and warrant liabilities related to updated assumptions
and estimates are recognized within the Consolidated Statements of Operations and Comprehensive Loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The fair value of the convertible notes payable,
derivative liability and warrant liabilities may change significantly as additional data is obtained, impacting the Company’s assumptions
regarding probabilities of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of
the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different
valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s
results of operations in future periods.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Derivative Liability</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The derivative liability represents the fair value of the “Shortfall
Amount” provision provided for in the license agreement with iX Biopharma Europe Limited. See Note 7.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_894_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z20vY1nYK26g" style="font: 10pt Times New Roman, Times, Serif; margin: 0">At issuance, the fair value of the embedded derivative was estimated by
using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall Amount
in cash and estimated the fair value based on a probability weighted market approach.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p id="xdx_8BD_zGlmURkNZTLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Summary of Fair Value Measurements Derivative Valuation
Assumptions</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tbody><tr style="vertical-align: middle">
    <td style="width: 62%">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 2%">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 35%">Year Ended</td></tr>
  <tr style="vertical-align: middle">
    <td>&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">December 31, 2021</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Risk-free interest rate</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zV9WEr8CcoM" style="text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.13</ix:nonfraction></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Volatility</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z9uj4ZTMaIEc" style="text-align: center; background-color: white"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110</ix:nonfraction></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Dividend yield</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center; background-color: white"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zkeJAir1v29c"><span style="-sec-ix-hidden: xdx2ixbrl0577"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" id="fact-identifier-375" unitref="Pure" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0577" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Expected term (years)</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zOUM2z3c3VS" style="text-align: center; background-color: white"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.11</ix:nonnumeric></span></td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Stock price</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z8ebGxP0lcoe" style="vertical-align: bottom; text-align: center; background-color: white"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.88</ix:nonfraction></span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A7_z0GaY9meUUgc" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>2021 Convertible Notes</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_LongTermDebtMember" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zobZdwvz86B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2021 Convertible Notes are valued using a Monte Carlo simulation model.
The following assumptions were used in determining the fair value of the 2021 Convertible Notes as of December 31, 2021:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p id="xdx_8B1_ziFuTHcOTBZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Summary of Fair Value Measurements Convertible Notes Valuation
Assumptions</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: middle">
    <td style="width: 68%">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 2%">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 2%">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 28%">Year Ended</td></tr>
  <tr style="vertical-align: middle">
    <td>&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">December 31, 2021</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Risk-free interest rate</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zZeGHvgGJ9s4"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.90</ix:nonfraction></span></span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z37XKizL0Gw7"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.95</ix:nonfraction></span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Volatility</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td style="text-align: center; background-color: white"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zg5wBGRG8c44"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="2" unitref="Pure" inside-table="true" id="fact-identifier-381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113</ix:nonfraction></span></span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_zErzf8T2zyUi"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_LongTermDebtMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="2" unitref="Pure" inside-table="true" id="fact-identifier-382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">114</ix:nonfraction></span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Dividend yield</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center; background-color: white"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_ziWfoJRwIme7"><span style="-sec-ix-hidden: xdx2ixbrl0586"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" id="fact-identifier-383" unitref="Pure" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0586" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span>%</td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Contractual term (years)</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zmlt9elrKnbd" style="vertical-align: bottom; text-align: center; background-color: white"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonnumeric></span></td></tr>
  <tr style="vertical-align: middle">
    <td style="background-color: white">Stock price</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="vertical-align: bottom; text-align: center; background-color: white"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zljLj7MQFzwe"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="2" unitref="USDPShares" inside-table="true" id="fact-identifier-385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.74</ix:nonfraction></span></span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z3kkv8fM9Zpa"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_us-gaap_LongTermDebtMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="2" unitref="USDPShares" inside-table="true" id="fact-identifier-386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.95</ix:nonfraction></span></span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AF_zrGUII808ble" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">80</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Warrant Liabilities</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The common stock warrant liabilities were recorded at fair value using
the Black-Scholes option pricing model. &nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_WarrantMember329729531" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-387" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO2vSCDX6qTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">The following assumptions were used in determining the fair value of the
warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2021 and 2020:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">&nbsp;</span></span></p>

<p id="xdx_8BD_zAZ6sU0ZV6p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"><span style="display: none; background-color: white">Summary
of Fair Value Measurements Warrant Valuation Assumptions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">&nbsp;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tbody><tr style="vertical-align: middle">
    <td style="width: 55%">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: center; width: 19%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 20%">&nbsp;</td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"></td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"></td>
    <td colspan="4" style="font-size: 9pt; font-weight: bold; text-align: center">Year Ended December 31,</td></tr>
  <tr style="vertical-align: middle">
    <td></td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">2021</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td></tr>
  <tr style="vertical-align: middle">
    <td>Risk-free interest rate</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zsAfqJtti995" style="text-align: center; border-top-color: Black; border-top-width: 1pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>%</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zDIdnWbjCrCc" style="text-align: center; border-top-color: Black; border-top-width: 1pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.18</ix:nonfraction></span>%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Volatility</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zo2u1DQLegci" style="text-align: center"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110.55</ix:nonfraction></span>%</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zg5C8eM64s5j" style="text-align: center"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">116.77</ix:nonfraction></span>%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td><p style="margin-top: 0; margin-bottom: 0">Dividend yield</p></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zGCEcHAMa6pl" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0597"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="fact-identifier-392" unitref="Pure" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0597" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span>%</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zhtybNHJWSnb" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0599"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="fact-identifier-393" unitref="Pure" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0599" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span>%</td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Expected term (years)</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zgyud3Xzj1Rj" style="text-align: center"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.07</ix:nonnumeric></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zvwWtuUKxclc" style="text-align: center"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.07</ix:nonnumeric></span></td>
    </tr>
  <tr style="vertical-align: middle">
    <td>Weighted-average fair value</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zlm7VpGbRQq6" style="text-align: center"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.40</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td style="text-align: right">$</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zdsYOCgj612a" style="text-align: center"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-397" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.40</ix:nonfraction></span></td>
    </tr>
  </tbody></table>

<p style="font: bold 9pt Sans-Serif; margin: 0 0 0 6pt; text-align: left; color: Red"></p>

</ix:nonnumeric></span><p id="xdx_8A1_zU3M9zd0geK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">&nbsp;</p>






<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCPml5pFNX89" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The
following table is a reconciliation for the common stock warrant liabilities, derivative liability, and convertible notes measured at
fair value using Level 3 unobservable inputs (in thousands):&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal; background-color: white">&nbsp;</span></p>

<p id="xdx_8BF_z141aSNXGWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="display: none; font-weight: normal; background-color: white; font-style: normal">Schedule of Fair Value Level 3 Reconciliation</span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&nbsp;</p>



<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: right; width: 58%"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; width: 1%"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; width: 1%"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; width: 8%"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; width: 1%"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; width: 10%"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; width: 1%"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; width: 18%"><span style="font-size: 9pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Warrant</b></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Derivative</b></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 9pt"><b>Convertible notes,</b></span></td></tr>
  <tr>
    <td style="vertical-align: middle"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">liabilities</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">liability</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center"><span style="font-size: 9pt">at
    fair value</span></td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of December 31, 2019</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20191231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zLDetD01hKwd" style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextref="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">963</ix:nonfraction></span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td></tr>
  <tr>
    <td style="vertical-align: middle"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant liability reclassified to stockholders'
    equity</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_i01_pn3n3_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaJFDgjDPJ6">(<span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextref="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124</ix:nonfraction></span>)</span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td></tr>
  <tr>
    <td style="vertical-align: middle"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value measurement of
    warrant liability</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 0.5pt solid; vertical-align: middle; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9iVni2QBl92"><span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextref="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">223</ix:nonfraction></span></span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 0.5pt solid; vertical-align: middle; text-align: right"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 0.5pt solid; vertical-align: middle; text-align: right"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td style="font-weight: bold"><span style="font-size: 9pt">Balance as of December 31, 2020</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zEF1LGDvnPL6" style="text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,062</ix:nonfraction></span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant liability reclassified to stockholders' equity</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zy3q2RQ3tfl9">(<span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,155</ix:nonfraction></span>)</span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuance of convertible notes, at fair value</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2l9ITqAdDS3"><span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,150</ix:nonfraction></span></span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuance of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeSjkKoJkkxe"><span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">805</ix:nonfraction></span></span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value measurement of derivative liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsnriOmehMg3"><span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">369</ix:nonfraction></span></span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value measurement of convertible notes</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1bOcwLgc6ni">(<span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitref="USD" inside-table="true" id="fact-identifier-407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">230</ix:nonfraction></span>)</span></span></td></tr>
  <tr style="vertical-align: middle">
    <td><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value measurement of warrant liability</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ZMDiklTg95"><span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextref="From2021-01-012021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">517</ix:nonfraction></span></span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; background-color: white"><span style="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</span></td></tr>
  <tr>
    <td style="font-weight: bold; vertical-align: middle"><span style="font-size: 9pt">Balance as of December 31, 2021</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZOckZD8d9d6" style="border-bottom: Black 2pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt"><span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-409" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">424</ix:nonfraction></span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zqO3PH8nHf3a" style="border-bottom: Black 2pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt">&nbsp;<span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-410" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,174</ix:nonfraction></span></span></td>
    <td><span style="font-size: 9pt">&nbsp;</span></td>
    <td style="vertical-align: middle; text-align: right"><span style="font-size: 9pt">$</span></td>
    <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zzTtUmRpTS0k" style="border-bottom: Black 2pt double; vertical-align: middle; text-align: right"><span style="font-size: 9pt">&nbsp;<span><ix:nonfraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_LongTermDebtMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,920</ix:nonfraction></span></span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A9_zTkGNxX2rtf6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify">&nbsp;</p>
<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">For the years ended December
31, 2021 and 2020, the changes in fair value of the convertible notes, derivative liability and warrant liability primarily resulted
from the volatility of the Company’s common stock. </span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_807_eus-gaap--OtherCurrentAssetsTextBlock_zxTYFBXSMjbi" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>5. Prepaid Expenses and Other Current Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z2quCZanxsAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Prepaid expenses and other current assets are comprised of the following
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p id="xdx_8BB_zFwXqZpjjEH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Schedule of Prepaid Expenses and Other Current Assets</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
  <tbody><tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&nbsp;</td>
    <td id="xdx_494_20211231_zG3m1WnohvGh" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&nbsp;</td>
    <td colspan="2" id="xdx_498_20201231_zS2z3MiqH6Jl" style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&nbsp;</td>
    <td colspan="4" style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">December 31,</td></tr>
  <tr>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">2021</td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center">2020</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzj4M_zj6iYj33ahr1" style="vertical-align: middle">
    <td style="width: 66%">Prepaid insurance</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="vertical-align: top; text-align: right; width: 1%">$</td>
    <td style="text-align: right; background-color: white; width: 15%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:PrepaidInsurance" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="vertical-align: top; text-align: right; width: 1%">$</td>
    <td style="text-align: right; width: 15%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:PrepaidInsurance" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50</ix:nonfraction></span></td></tr>
  <tr id="xdx_409_ecustom--PrepaidClinicalCosts_iI_pn3n3_maPEAOAzj4M_zdLnkA0OVshh" style="vertical-align: middle">
    <td>Prepaid clinical costs</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="SEEL:PrepaidClinicalCosts" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,481</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td style="vertical-align: top; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="SEEL:PrepaidClinicalCosts" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,743</ix:nonfraction></span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzj4M_zDuzsVMSYJ83">
    <td style="vertical-align: middle">Other</td>
    <td style="vertical-align: bottom; text-align: right">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:OtherPrepaidExpenseCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-418" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">187</ix:nonfraction></span></td>
    <td style="vertical-align: middle">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: right">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: middle; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:OtherPrepaidExpenseCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39</ix:nonfraction></span></td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_maACzKPF_maACzYR4_mtPEAOAzj4M_zuIdy9vqOoKd" style="vertical-align: middle">
    <td style="padding-left: 24px; text-align: left">Prepaid expenses and other current assets</td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-420" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,727</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: Black 2pt double; vertical-align: top; text-align: right">$</td>
    <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 1pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,832</ix:nonfraction></span></td></tr>
  </tbody></table>
</ix:nonnumeric></span><p id="xdx_8A9_z5E5zcgHzLMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">81</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>



</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="SEEL:CommonStockOfferings" inside-table="false" id="fact-identifier-422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_806_ecustom--CommonStockOfferings_zBIm3LrRJh9h" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>6. Common Stock Offerings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Securities Purchase Agreements</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>November 2021 and December 2021 Convertible Notes and Private Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Between November 2021 and December 2021, the Company issued an aggregate
of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20211101__20211231__us-gaap--StatementClassOfStockAxis__custom--NovemberAndDecember2021Member_z3qK1MgABEA7"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-11-012021-12-31_custom_NovemberAndDecember2021Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">540,147</ix:nonfraction></span></span> shares of common stock in conjunction with the issuance of convertible notes at a discount for aggregate gross proceeds of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20211101__20211231__us-gaap--StatementClassOfStockAxis__custom--NovemberAndDecember2021Member_zyYmJvYPIQ18"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-11-012021-12-31_custom_NovemberAndDecember2021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.2</ix:nonfraction></span></span>
million (see Note 9).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>December 2020 Convertible Note and Private Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In December 2020, the Company sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20201201__20201231__us-gaap--StatementClassOfStockAxis__custom--December2020Member_zQvJatJ3Swo9"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-12-012020-12-31_custom_December2020Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,112,219</ix:nonfraction></span>
</span>shares of common stock in conjunction with the issuance of convertible notes at a discount for aggregate net proceeds of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20201201__20201231__us-gaap--StatementClassOfStockAxis__custom--December2020Member_zcmmNvYIOnFk"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-12-012020-12-31_custom_December2020Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.9</ix:nonfraction></span>
</span>million (see Note 9).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>2020 Registered Direct Offering and Concurrent
Private Placement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On September 4, 2020, the Company entered into a
Securities Purchase Agreement with certain institutional investors (the “2020 Securities Purchase Agreement”) pursuant to
which the Company issued and sold an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200901__20200930__us-gaap--StatementClassOfStockAxis__custom--September42020Member_zVn9Y9OT3Nwg"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-09-012020-09-30_custom_September42020Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,865,000</ix:nonfraction></span>
</span>shares of common stock in a registered direct offering, resulting in total net proceeds of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--September42020Member_zSzYrW9mxDhj"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_custom_September42020Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.4</ix:nonfraction></span>
</span>million, after deducting the placement agent’s fees and other offering expenses. The shares were offered by the Company
pursuant to the Company’s shelf registration statement on Form S-3 filed with the SEC on November 2, 2017, as amended. <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--September42020Member_z4UACK1Rl0wj"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_September42020Member" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" inside-table="false" id="fact-identifier-429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The
Company also issued to the investors warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the
"September 2020 Warrants"). The September 2020 Warrants have an exercise price of $0.84 per share of common stock, became exercisable
beginning on March 9, 2021 and will expire on March 9, 2026.&nbsp;</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The combined purchase price for one share and one warrant to purchase
0.75 of a share of common stock in the offerings was $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20200909__us-gaap--StatementClassOfStockAxis__custom--September42020Member_zXiYySIYc5B7"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2020-09-09_custom_September42020Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.79</ix:nonfraction></span></span>.
The closing of the offerings occurred on September 9, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>2019 Registered Direct Offering and Concurrent Private Placement</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 23, 2019, the Company entered into a Securities Purchase Agreement
with certain institutional investors, pursuant to which the Company issued and sold an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20190801__20190831__us-gaap--StatementClassOfStockAxis__custom--August2019Member_zFjGa0hxedKe"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-08-012019-08-31_custom_August2019Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,475,000</ix:nonfraction></span></span> shares of common stock
in a registered direct offering, resulting in total gross proceeds of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20190801__20190830__us-gaap--StatementClassOfStockAxis__custom--August2019Member_zjzTk6mK7NV4"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2019-08-012019-08-30_custom_August2019Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-432" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.7</ix:nonfraction></span></span> million, before deducting the placement agents’
fees and other estimated offering expenses. The shares were offered by the Company pursuant to the Company’s shelf registration
statement on Form S-3 filed with the SEC on November 2, 2017, as amended. <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20190801__20190830__us-gaap--StatementClassOfStockAxis__custom--August2019Member_zLGZxnRRiUae"><span><ix:nonnumeric contextref="From2019-08-012019-08-30_custom_August2019Member" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" inside-table="false" id="fact-identifier-433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Company issued to the investors warrants to purchase up
to 2,237,500 shares of common stock in a concurrent private placement (the “August 2019 Warrants”). The August 2019 Warrants
have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of issuance and will expire four
years following the date of issuance. The combined purchase price for one share and one warrant to purchase half of a share of common
stock in the offerings was $1.50. Roth Capital Partners, LLC (“Roth”) served as the placement agent for the issuance and
sale of the shares and the warrants, and the Company paid Roth an aggregate fee equal to 7.0% of the gross proceeds received by the Company
in the offerings.</ix:nonnumeric></span></span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Public Offerings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 24, 2021, the Company completed an underwritten public
offering, pursuant to which the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zPVRgA5RMaM1" title="Number of shares of common stock issued"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-01-012021-12-31_custom_May242021Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,258,066</ix:nonfraction></span></span> shares of its common stock, at a price to the public of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210524__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zkYUNTkLxcd1" title="Shares Issued, Price Per Share"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2021-05-24_custom_May242021Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-435" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.10</ix:nonfraction></span></span> per share, which
included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net
proceeds to the Company from the offering were approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zhylCscaQiz" title="Cash received from stock sale"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_custom_May242021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">64.5</ix:nonfraction></span></span> million, after deducting underwriting discounts, commissions and
other offering expenses. The Company used $<span id="xdx_90E_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zbSSnmJkeCOh" title="Offering proceeds used to partially repay certain convertible promissory notes"><span><ix:nonfraction name="SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" contextref="From2021-01-012021-12-31_custom_May242021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.3</ix:nonfraction></span></span> million of the net proceeds from the offering for the partial repayment
of certain outstanding convertible promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 28, 2021, the Company completed an underwritten public
offering, pursuant to which the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_ziiVbkN1rM35"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-01-012021-12-31_custom_January282021Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,530,488</ix:nonfraction></span>
</span>shares of its common stock, at a price to the public of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210128__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zhwuTBDaRzq1"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2021-01-28_custom_January282021Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-439" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.05</ix:nonfraction></span>
</span>per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares
of common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z86SClZKrcwl"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_custom_January282021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33.5</ix:nonfraction></span>
</span>million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $<span id="xdx_907_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z7HAPFqbneJ7"><span><ix:nonfraction name="SEEL:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes" contextref="From2021-01-012021-12-31_custom_January282021Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-441" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.8</ix:nonfraction></span>
</span>million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">82</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 16, 2020, the Company completed an underwritten public
offering pursuant to which it sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200301__20200331__us-gaap--StatementClassOfStockAxis__custom--March162020Member_z1hIlryMdwk9" title="Number of shares of common stock issued"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-03-012020-03-31_custom_March162020Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-442" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,500,000</ix:nonfraction></span></span> shares of its common stock at a price to the public of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20200316__us-gaap--StatementClassOfStockAxis__custom--March162020Member_zNcNUHhDFlOf" title="Shares Issued, Price Per Share"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2020-03-16_custom_March162020Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.60</ix:nonfraction></span></span> per share. The net proceeds
to the Company from this offering were approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20200301__20200331__us-gaap--StatementClassOfStockAxis__custom--March162020Member_z5PSPMiIdI3c" title="Cash received from stock sale"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-03-012020-03-31_custom_March162020Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.0</ix:nonfraction></span></span> million, after deducting underwriting discounts and commissions and other offering
expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On February 13, 2020, the Company completed an underwritten public offering,
pursuant to which it sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200201__20200228__us-gaap--StatementClassOfStockAxis__custom--February132020Member_zJSuqhbZK8Zk"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-02-012020-02-28_custom_February132020Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-445" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,666,667</ix:nonfraction></span>
</span>shares of its common stock at a price to the public of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20200213__us-gaap--StatementClassOfStockAxis__custom--February132020Member_zXJ2JDqr6uh3"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2020-02-13_custom_February132020Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-446" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span>per share. On February 19, 2020, the Company sold an additional <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200201__20200228__us-gaap--StatementClassOfStockAxis__custom--February192020Member_zYbPSOUDLR4a"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-02-012020-02-28_custom_February192020Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">999,999</ix:nonfraction></span>
</span>shares of its common stock at a price to the public of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20200219__us-gaap--StatementClassOfStockAxis__custom--February192020Member_z1THJ1JIgLii"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2020-02-19_custom_February192020Member" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-448" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span>
</span>per share pursuant to the full exercise of the underwriters’ option to cover over-allotments. The net proceeds to the Company
from this offering were approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20200201__20200228__us-gaap--StatementClassOfStockAxis__custom--February132020Member_zVqCD0NjCAZi"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2020-02-012020-02-28_custom_February132020Member" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.8</ix:nonfraction></span>
</span>million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company.<i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock Purchase Agreement with iX Biopharma Europe Limited</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 24, 2021, the Company entered in an exclusive license agreement
and stock purchase agreement (the “iXBEL Stock Purchase Agreement”) with iX Biopharma Europe Limited (“iXBEL”).
As consideration for the license under the license agreement, the Company paid iXBEL an upfront fee of $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zbhykfLuIVV3"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.0</ix:nonfraction></span></span> million, comprised of $<span id="xdx_904_ecustom--NonrefundableCashPayment_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zmPI9QRGhjX2"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.5</ix:nonfraction></span></span>
million in cash and <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zW4EhQQTZYA3"><span><ix:nonfraction name="SEEL:Issuanceofcommonstockforlicenseacquiredshares" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-452" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,570,266</ix:nonfraction></span></span> restricted shares of the Company’s common stock. Pursuant to the iXBEL Stock Purchase Agreement, the
Company agreed to reimburse iXBEL for the difference in value (the “Shortfall Amount”) in the event the aggregate value of
the <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_znU54BEBumsl"><span><ix:nonfraction name="SEEL:Issuanceofcommonstockforlicenseacquiredshares" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-453" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,570,266</ix:nonfraction></span></span> shares of the Company’s common stock at the time of registration and issuance was less than $<span id="xdx_900_ecustom--MinimumStockValueOfSharesIssued_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zNsqGgWak0V3"><span><ix:nonfraction name="SEEL:MinimumStockValueOfSharesIssued" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-454" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.5</ix:nonfraction></span></span> million. The initial
fair value of this Shortfall Amount was $<span id="xdx_90E_ecustom--InitialStockValuationShortfallFrom5.5MillionValue_pn5n6_c20211101__20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zZf7snEttr1j"><span><ix:nonfraction name="SEEL:InitialStockValuationShortfallFrom5.5MillionValue" contextref="From2021-11-012021-12-31_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-455" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.8</ix:nonfraction></span></span> million and in January 2022, the Company settled the Shortfall Amount by the payment of $<span id="xdx_906_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zwDR1YtqtHq3"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2022-01-012022-01-31_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-456" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.2</ix:nonfraction></span></span>
million in cash to iXBEL. The change in fair value of the Shortfall Amount is included in Change in fair value of derivative liability
on the Consolidated Statement of Operations and Comprehensive Loss (see Note 4).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><b>Stock
Purchase Agreement with Vyera</b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 2, 2020, the Company entered into a stock purchase agreement
(the “Stock Purchase Agreement”) with Vyera, pursuant to which the Company issued to Vyera <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200101__20200131__us-gaap--StatementClassOfStockAxis__custom--January22020Member_zRXm5NSiiLl4"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-01-012020-01-31_custom_January22020Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-457" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,809,845</ix:nonfraction></span>
</span>registered shares of the Company's common stock (the “Shares”). The Company entered into the Stock Purchase Agreement
in accordance with an asset purchase agreement with Vyera , as amended by the amendment entered into
on October 15, 2019 (see Note 7). As partial consideration for the assets of Vyera, the Company agreed to issue the Shares pursuant to
the Stock Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Consulting Agreement</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 11, 2020, the Company entered into a consulting agreement
(the “Consulting Agreement”) with an advisory firm, pursuant to which the advisory firm agreed to provide the Company with
certain management consulting, business and advisory services. The Company agreed to issue the advisory firm <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200501__20200531__us-gaap--StatementClassOfStockAxis__custom--May112020Member_zmai1bIDkKCk"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-05-012020-05-31_custom_May112020Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-458" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000</ix:nonfraction></span>
</span>unregistered shares of the Company’s common stock, which shares were issued on May 11, 2020, plus $80,000 in cash. On June
9, 2020, the Company and the advisory firm entered into an amendment to the Consulting Agreement (the “Amendment”). Pursuant
to the Amendment, the advisory firm agreed to provide the Company with additional services and, in consideration, the Company agreed
to issue the advisory firm an additional 200,000 unregistered shares of the Company’s common stock (the “Additional Shares”),
plus $20,000 in cash. The Additional Shares were issued to the advisory firm on June 9, 2020 and were subject to certain vesting restrictions.</p>



<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the year ended December 31, 2020, the Company recognized approximately
$<span id="xdx_90C_eus-gaap--OtherNonrecurringExpense_pip0_c20200511__20201231__us-gaap--StatementClassOfStockAxis__custom--May112020Member_zBpaDB49RnEi"><span><ix:nonfraction name="us-gaap:OtherNonrecurringExpense" contextref="From2020-05-112020-12-31_custom_May112020Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">431,000</ix:nonfraction></span>
</span>of consulting expense under this Consulting Agreement. On July 9, 2020, the Company cancelled the Consulting Agreement with an
effective date of August 9, 2020. The Company also canceled 100,000 shares that did not vest due to the cancellation of the Consulting
Agreement.&nbsp;</p>



<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Pre-Merger Financing</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 24, 2019, STI and Apricus closed
a private placement transaction with certain accredited investors (the “Investors”), whereby, among other things, STI issued
to investors shares of STI’s common stock immediately prior to the Merger in a private placement transaction (the “Financing”),
pursuant to a Securities Purchase Agreement, made and entered into as of October 16, 2018, by and among STI, Apricus and the investors,
as amended (the “Purchase Agreement”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">83</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January242019Member_zQl9IfUapU51" title="Warrant terms and provisions"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_January242019Member" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" inside-table="false" id="fact-identifier-460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Pursuant
to the Purchase Agreement, STI (i) issued and sold to the Investors an aggregate of 2,374,672 shares of STI’s common stock
which converted pursuant to the exchange ratio in the Merger into the right to receive 1,829,407 shares of the Company’s
common stock and (ii) issued warrants representing the right to acquire 1,463,519 shares of common stock at a price per share of
$4.15, subject to adjustment as provided therein (the “Series A Warrants”), most recently adjusted to a price per share
of $0.2957 per share, and additional warrants initially representing the right to acquire no shares of common stock at a price per
share of $0.001, subject to adjustment as provided therein (the “Series B Warrants” together with the Series A Warrants,
the “Investor Warrants”), for aggregate gross proceeds of $18.0 million, or $16.5 million net of financing fees. The
terms of the Investor Warrants included certain provisions that could result in adjustments to both the number of warrants issued
and the exercise price of each warrant, which resulted in the warrants being classified as a liability upon issuance (see Note 10).
The Investor Warrants were recorded at fair value of $21.5 million upon issuance and given that the liability exceeded the proceeds
received, a loss of $5.0 million was recognized.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--March72019Member_zY4DpAzSIR4e" title="Warrant terms and provisions"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_March72019Member" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" inside-table="false" id="fact-identifier-461" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On March 7, 2019, the Company entered
into Amendment Agreements (collectively, the “Amendment Agreements”) with each Investor amending: (i) the Purchase Agreement,
(ii) the Series A Warrants, and (iii) the Series B Warrants. The Amendment Agreements, among other things, fixed the aggregate number
of shares of common stock issued and issuable pursuant to the Series A Warrants at 3,629,023 (none of which were exercised as of March
7, 2019). The terms of the Investor Warrants continue to include certain provisions that could result in a future adjustment to the exercise
price of the Investor Warrants and accordingly, they continue to be classified as a liability after the Amendment Agreements.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At December 31, 2021, <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pin6_c20211231__us-gaap--StatementClassOfStockAxis__custom--March72019Member_znc9c50XJvG6" title="Series A Warrants unexercised"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextref="AsOf2021-12-31_custom_March72019Member" format="ixt:numdotdecimal" decimals="INF" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-462" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span></span> million Series A
Warrants remain unexercised. All Series B Warrants were exercised during the year ended December 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80D_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zcNC7WqOqb51" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>7. License Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Acquisition of License from Ligand Pharmaceuticals Incorporated</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90C_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20160901__20160930__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zmZpi00GmQ61" title="License agreement description"><span><ix:nonnumeric contextref="From2016-09-012016-09-30_custom_LicensefromLigandPharmaceuticalsMember" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription" inside-table="false" id="fact-identifier-464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On September 21, 2016, the Company entered into a License Agreement
(the “License Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”), Neurogen Corporation and CyDex
Pharmaceuticals, Inc. (collectively, the “Licensors”), pursuant to which, among other things, the Licensors granted to the
Company an exclusive, perpetual, irrevocable, worldwide, royalty-bearing, nontransferable right and license under (i) patents related
to a product known as Aplindore, which is now known as SLS-006, acetaminophen (as it may have been or may be modified for use in a product
to be administered by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical
ingredient of which is acetaminophen), which is now known as SLS-012, an H3 receptor antagonist, which is now known as SLS-010, and either
or both of the Licensors’ two proprietary CRTh2 antagonists, which are now known collectively as SLS-008 (collectively, the “Licensed
Products”), and (ii) copyrights, trade secrets, moral rights and all other intellectual and proprietary rights related thereto.
The Company is obligated to use commercially reasonable efforts to (a) develop the Licensed Products, (b) obtain regulatory approval for
the Licensed Products in the European Union (either in its entirety or including at least one of France, Germany or, if at the time the
United Kingdom is a member of the European Union, the United Kingdom), the United Kingdom, if at the time the United Kingdom is not a
member of the European Union, Japan or the People’s Republic of China (each, a “Major Market”) or the United States,
and (c) commercialize the Licensed Products in each country where regulatory approval is obtained. The Company has the exclusive right
and sole responsibility and decision-making authority to research and develop any Licensed Products and to conduct all clinical trials
and non-clinical studies the Company believes appropriate to obtain regulatory approvals for commercialization of the Licensed Products.
The Company also has the exclusive right and sole responsibility and decision-making authority to commercialize any of the Licensed Products.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the closing of the Merger, the Company issued
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20190101__20190331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zb51CPyfg4Qj" title="Shares of common stock issued"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-01-012019-03-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-465" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">801,253</ix:nonfraction></span></span> shares of common stock to Ligand and recognized research and development expense totaling approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20190101__20190331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zEjlYFaBt0Sl" title="Research and development expense"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2019-01-012019-03-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-466" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.2</ix:nonfraction></span></span> million during the
three months ended March 31, 2019 for this License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company also agreed to pay to Ligand certain one-time,
non-refundable regulatory milestone payments in connection with the Licensed Products, other than in connection with Aplindore for the
indication of PD or Restless Leg Syndrome, consisting of (i) $<span id="xdx_905_ecustom--ContingentNonrefundableRegulatoryMilestonePaymentUponSubmissionOfApplicationWithFdaOrEquivalentForeignBodyForParticularLicensedProduct_iI_pp0p0_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_z0CaoBHDuiI" title="Contingent non-refundable regulatory milestone payment upon submission of an application with the FDA or equivalent foreign body for a particular Licensed Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableRegulatoryMilestonePaymentUponSubmissionOfApplicationWithFdaOrEquivalentForeignBodyForParticularLicensedProduct" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">750,000</ix:nonfraction></span></span> upon submission of an application with the FDA or equivalent foreign
body for a particular Licensed Product, (ii) $<span id="xdx_900_ecustom--ContingentNonrefundableRegulatoryMilestonePaymentUponFdaApprovalOfApplicationForParticularLicensedProduct_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zvY2gYhWhjA3" title="Contingent non-refundable regulatory milestone payment upon FDA approval of an application for a particular Licensed Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableRegulatoryMilestonePaymentUponFdaApprovalOfApplicationForParticularLicensedProduct" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span></span> million upon FDA approval of an application for a particular Licensed Product, (iii)
$<span id="xdx_903_ecustom--ContingentNonrefundableRegulatoryMilestonePaymentUponRegulatoryApprovalInMajorMarketForParticularLicensedProduct_iI_pp3n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zm3REqXtHjJi" title="Contingent non-refundable regulatory milestone payment upon regulatory approval in a Major Market for a particular Licensed Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableRegulatoryMilestonePaymentUponRegulatoryApprovalInMajorMarketForParticularLicensedProduct" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="3" scale="6" unitref="USD" inside-table="false" id="fact-identifier-469" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.125</ix:nonfraction></span></span> million upon regulatory approval in a Major Market for a particular Licensed Product, and (iv) $<span id="xdx_905_ecustom--ContingentNonrefundableRegulatoryMilestonePaymentUponRegulatoryApprovalInSecondMajorMarketForParticularLicensedProduct_iI_pp3n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zDEGmFrIBT47" title="Contingent non-refundable regulatory milestone payment upon regulatory approval in a second Major Market for a particular Licensed Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableRegulatoryMilestonePaymentUponRegulatoryApprovalInSecondMajorMarketForParticularLicensedProduct" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="3" scale="6" unitref="USD" inside-table="false" id="fact-identifier-470" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.125</ix:nonfraction></span></span> million upon regulatory approval
in a second Major Market for a particular Licensed Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">84</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company also agreed to pay to Ligand certain one-time,
non-refundable regulatory milestone payments in connection with the Licensed Products in connection with Aplindore for the indication
of PD or Restless Leg Syndrome, consisting of (i) $<span id="xdx_900_ecustom--ContingentNonrefundableRegulatoryMilestonePaymentInConnectionWithAplindoreUponSubmissionOfApplicationWithFdaOrEquivalentForeignBodyForSuchParticularLicensedProduct_iI_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zQudF4ntHo8" title="Contingent non-refundable regulatory milestone payment in connection with Aplindore upon submission of an application with the FDA or equivalent foreign body for such a particular Licensed Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableRegulatoryMilestonePaymentInConnectionWithAplindoreUponSubmissionOfApplicationWithFdaOrEquivalentForeignBodyForSuchParticularLicensedProduct" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-471" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000</ix:nonfraction></span></span> upon submission of an application with the FDA or equivalent foreign body for
such a particular Licensed Product, (ii) $<span id="xdx_909_ecustom--ContingentNonrefundableRegulatoryMilestonePaymentInConnectionWithAplindoreUponFdaApprovalOfApplicationForSuchParticularLicensedProduct_iI_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zyNmLeLHMYgi" title="Contingent non-refundable regulatory milestone payment in connection with Aplindore upon FDA approval of an application for such a particular Licensed Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableRegulatoryMilestonePaymentInConnectionWithAplindoreUponFdaApprovalOfApplicationForSuchParticularLicensedProduct" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-472" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">350,000</ix:nonfraction></span></span> upon FDA approval of an application for such a particular Licensed Product, (iii) $<span id="xdx_90D_ecustom--ContingentNonrefundableRegulatoryMilestonePaymentInConnectionWithAplindoreUponRegulatoryApprovalInMajorMarketForSuchParticularLicensedProduct_iI_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zPGt9dKpRuT7" title="Contingent non-refundable regulatory milestone payment in connection with Aplindore upon regulatory approval in a Major Market for such a particular Licensed Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableRegulatoryMilestonePaymentInConnectionWithAplindoreUponRegulatoryApprovalInMajorMarketForSuchParticularLicensedProduct" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">125,000</ix:nonfraction></span></span>
upon regulatory approval in a Major Market for such a particular Licensed Product, and (iv) $<span id="xdx_902_ecustom--ContingentNonrefundableRegulatoryMilestonePaymentInConnectionWithAplindoreUponRegulatoryApprovalInSecondMajorMarketForSuchParticularLicensedProduct_iI_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zbKGaMGzogS2" title="Contingent non-refundable regulatory milestone payment in connection with Aplindore upon regulatory approval in a second Major Market for such a particular Licensed Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableRegulatoryMilestonePaymentInConnectionWithAplindoreUponRegulatoryApprovalInSecondMajorMarketForSuchParticularLicensedProduct" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">125,000</ix:nonfraction></span></span> upon regulatory approval in a second
Major Market for such a particular Licensed Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company agreed to pay to Ligand certain one-time, non-refundable
commercial milestone payments in connection with the Licensed Products, consisting of (i) $<span id="xdx_90F_ecustom--ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf1.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponAplindore_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zUiYHrBlgZx2" title="Contingent non-refundable commercial milestone payments in connection with the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore"><span><ix:nonfraction name="SEEL:ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf1.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponAplindore" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-475" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.0</ix:nonfraction></span></span> million upon the achievement of $1.0 billion
of cumulative worldwide net sales of Licensed Products based upon Aplindore, (ii) $<span id="xdx_90C_ecustom--ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf1.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponH3ReceptorAntagonist_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zhf2Vb3OAXd9" title="Contingent non-refundable commercial milestone payments in connection with the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist"><span><ix:nonfraction name="SEEL:ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf1.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponH3ReceptorAntagonist" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-476" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.0</ix:nonfraction></span></span> million upon the achievement of $1.0 billion of
cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist, (iii) $<span id="xdx_90D_ecustom--ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf1.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponAcetaminophen_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zYeTQYIY5dk3" title="Contingent non-refundable commercial milestone payments in connection with the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen"><span><ix:nonfraction name="SEEL:ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf1.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponAcetaminophen" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-477" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.0</ix:nonfraction></span></span> million upon the achievement of
$1.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may be modified for
use in a product to be administered by any method in any form including, without limitation injection and intravenously, the sole active
pharmaceutical ingredient of which is acetaminophen), (iv) $<span id="xdx_904_ecustom--ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf1.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponCrth2Antagonists_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zswvV9RiYsb8" title="Contingent non-refundable commercial milestone payments in connection with the achievement of $1.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists"><span><ix:nonfraction name="SEEL:ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf1.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponCrth2Antagonists" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-478" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.0</ix:nonfraction></span></span> million upon the achievement of $1.0 billion of cumulative worldwide
net sales of Licensed Products based upon CRTh2 antagonists, (v) $<span id="xdx_904_ecustom--ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf2.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponAplindore_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zDgoIBEdnRW7" title="Contingent non-refundable commercial milestone payments in connection with the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon Aplindore"><span><ix:nonfraction name="SEEL:ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf2.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponAplindore" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20.0</ix:nonfraction></span></span> million upon the achievement of $2.0 billion of cumulative worldwide
net sales of Licensed Products based upon Aplindore, (vi) $<span id="xdx_90F_ecustom--ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf2.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponH3ReceptorAntagonist_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zATSeHDmChf7" title="Contingent non-refundable commercial milestone payments in connection with the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon an H3 receptor antagonist"><span><ix:nonfraction name="SEEL:ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf2.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponH3ReceptorAntagonist" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-480" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20.0</ix:nonfraction></span></span> million upon the achievement of $2.0 billion of cumulative worldwide net
sales of Licensed Products based upon an H3 receptor antagonist, (vii) $<span id="xdx_90F_ecustom--ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf2.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponAcetaminophen_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zO3TOYSmaeza" title="Contingent non-refundable commercial milestone payments in connection with the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon acetaminophen"><span><ix:nonfraction name="SEEL:ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf2.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponAcetaminophen" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-481" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20.0</ix:nonfraction></span></span> million upon the achievement of $2.0 billion of cumulative
worldwide net sales of Licensed Products based upon acetaminophen (as it may have been or may be modified for use in a product to be administered
by any method in any form including, without limitation injection and intravenously, the sole active pharmaceutical ingredient of which
is acetaminophen), and (viii) $<span id="xdx_906_ecustom--ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf2.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponCrth2Antagonists_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zGWHSHWNnWX4" title="Contingent non-refundable commercial milestone payments in connection with the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products based upon CRTh2 antagonists"><span><ix:nonfraction name="SEEL:ContingentNonrefundableCommercialMilestonePaymentsInConnectionWithAchievementOf2.0BillionOfCumulativeWorldwideNetSalesOfLicensedProductsBasedUponCrth2Antagonists" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-482" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20.0</ix:nonfraction></span></span> million upon the achievement of $2.0 billion of cumulative worldwide net sales of Licensed Products
based upon CRTh2 antagonists.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company will also pay to Ligand middle single-digit
royalties on aggregate annual net sales of Licensed Products other than in connection with Aplindore for the indication of PD or
Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed patent and a tiered incremental royalty
in the upper single digit to lower double digit range on aggregate annual net sales of Licensed Products in connection with
Aplindore for the indication of PD n or Restless Leg Syndrome in a country where such Licensed Products are covered under a licensed
patent. Additionally, the Company will pay to Ligand low single digit royalties on aggregate annual net sales of Licensed Products
other than in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a country where such Licensed Products
are not covered under a licensed patent and a tiered incremental royalty in the lower single digit to middle single digit range on
aggregate annual net sales of Licensed Products in connection with Aplindore for the indication of PD or Restless Leg Syndrome in a
country where such Licensed Products are not covered under a licensed patent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The potential regulatory and commercial milestones are not
yet considered probable, and <span id="xdx_90B_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--LicensefromLigandPharmaceuticalsMember_zRSuzJeG5Ztk" title="Milestone payments accrued"><span><ix:nonfraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextref="AsOf2021-12-31_custom_LicensefromLigandPharmaceuticalsMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-483" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></span> milestone payments have been accrued at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><i></i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals,
AG and Turing Pharmaceuticals AG (“Vyera”)</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90E_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20180301__20180331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zu5GGoARaQW4"><span><ix:nonnumeric contextref="From2018-03-012018-03-31_custom_AssetsfromVyeraPharmaceuticalsMember" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription" inside-table="false" id="fact-identifier-484" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On March 6, 2018, the Company entered into the Vyera Agreement
with Vyera, pursuant to which the Company acquired the assets (the “Vyera Assets”) and liabilities (the “Vyera Assumed
Liabilities”), of Vyera related to TUR-002 (intranasal ketamine), which is now known as SLS-002. The Company is obligated to use
commercially reasonable efforts to seek regulatory approval in the United States for and commercialize SLS-002</ix:nonnumeric></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As consideration for the Vyera Assets, the Company paid to
Vyera a non-refundable cash payment of $<span id="xdx_900_ecustom--NonrefundableCashPayment_pip0_c20180501__20180531__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zWq0a5xIRSQ3"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2018-05-012018-05-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-485" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span>
</span>on May 21, 2018. As further consideration for the Vyera Assets, upon public announcement of the entry by Apricus and STI into
the Merger Agreement, the Company paid to Vyera a non-refundable cash payment of $<span id="xdx_904_ecustom--NonrefundableCashPayment_pip0_c20190101__20190131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zipzpSOvh8bb"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2019-01-012019-01-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-486" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span></span>.
As further consideration for the Vyera Assets, the Company issued to Vyera <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20190101__20190331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zhvVoqsCWt54"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-01-012019-03-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-487" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">191,529</ix:nonfraction></span>
</span>shares of common stock and paid Vyera a non-refundable cash payment of $<span id="xdx_90B_ecustom--NonrefundableCashPayment_pip0_c20190101__20190331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zyYtBNL6NKX8"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2019-01-012019-03-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-488" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,000,000</ix:nonfraction></span>
</span>on January 29, 2019.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the amendment to the Asset Purchase Agreement entered
into by the Company and Vyera on October 15, 2019, the Company issued Vyera <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200101__20200131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_z3qntZ7VWY57" title="Shares of common stock issued"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-01-012020-01-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,809,845</ix:nonfraction></span></span> registered shares of the Company’s common
stock on January 2, 2020 and made cash payments to Vyera in the amounts of $<span id="xdx_90E_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pp0p0_c20191001__20191031__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_z98i4mEQf3q1" title="Cash payments agreed to in Amendment to the Asset Purchase Agreement"><span><ix:nonfraction name="SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" contextref="From2019-10-012019-10-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-490" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">750,000</ix:nonfraction></span></span>, $<span id="xdx_90F_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pp0p0_c20200101__20200131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zx9NiG5EVBG7" title="Cash payments agreed to in Amendment to the Asset Purchase Agreement"><span><ix:nonfraction name="SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" contextref="From2020-01-012020-01-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">750,000</ix:nonfraction></span></span>, $<span id="xdx_904_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20200401__20200430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zJafOFR8Kle6" title="Cash payments agreed to in Amendment to the Asset Purchase Agreement"><span><ix:nonfraction name="SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" contextref="From2020-04-012020-04-30_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-492" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.0</ix:nonfraction></span></span> million and $<span id="xdx_902_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20200701__20200731__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zsBO0x2v9R87" title="Cash payments agreed to in Amendment to the Asset Purchase Agreement"><span><ix:nonfraction name="SEEL:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement" contextref="From2020-07-012020-07-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-493" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.0</ix:nonfraction></span></span> million in October
2019, January 2020, April 2020 and July 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the amendment to the asset purchase agreement entered into
with Vyera on February 15, 2021, the Company made cash payments to Vyera in the amount of $<span id="xdx_904_ecustom--CashPaymentsforLowerRoyaltyPercentageonPotentialNetSalesofSLS002_pn5n6_c20210901__20210930__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_z6LRsqLPjfFj"><span><ix:nonfraction name="SEEL:CashPaymentsforLowerRoyaltyPercentageonPotentialNetSalesofSLS002" contextref="From2021-09-012021-09-30_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-494" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span>
</span>million in each of February 2021, June 2021 and September 2021 in exchange for a lower royalty percentage on potential net sales
of SLS-002.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">85</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the event that the Company sells, directly or indirectly,
all or substantially all of the Vyera Assets to a third party, then the Company must pay Vyera an amount equal to 4% of the net proceeds
actually received by the Company as an upfront payment in such sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company agreed to pay to Vyera certain one-time, non-refundable
milestone payments consisting of (i) $<span id="xdx_90D_ecustom--ContingentNonrefundableMilestonePaymentUponApprovalByFdaOfNdaWithRespectToSls002_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_z0QROWwwzRpj" title="Contingent non-refundable milestone payment upon approval by the FDA of an NDA, with respect to SLS-002"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponApprovalByFdaOfNdaWithRespectToSls002" contextref="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.0</ix:nonfraction></span></span> million upon approval by the FDA of a new drug application (an “NDA”), with respect
to SLS-002, (ii) $<span id="xdx_908_ecustom--ContingentNonrefundableMilestonePaymentUponApprovalByEmaOfForeignEquivalentToNdaWithRespectToSls002InMajorMarket_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zkQvskISzyw3" title="Contingent non-refundable milestone payment upon approval by the EMA of the foreign equivalent to an NDA with respect to SLS-002 in a Major Market"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponApprovalByEmaOfForeignEquivalentToNdaWithRespectToSls002InMajorMarket" contextref="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-496" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.0</ix:nonfraction></span></span> million upon approval by the European Medicines Agency (the “EMA”) of the foreign equivalent to an NDA
with respect to SLS-002 in a Major Market, (iii) $<span id="xdx_90B_ecustom--ContingentNonrefundableMilestonePaymentUponApprovalByEmaOfForeignEquivalentToNdaWithRespectToSls002InSecondMajorMarket_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zJ0TsaaiXk04" title="Contingent non-refundable milestone payment upon approval by the EMA of the foreign equivalent to an NDA with respect to SLS-002 in a second Major Market"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponApprovalByEmaOfForeignEquivalentToNdaWithRespectToSls002InSecondMajorMarket" contextref="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-497" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.5</ix:nonfraction></span></span> million upon approval by the EMA of the foreign equivalent to an NDA with respect
to SLS-002 in a second Major Market, (iv) $<span id="xdx_909_ecustom--ContingentNonrefundableMilestonePaymentUponAchievementOf250.0MillionInNetSalesOfSls002_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zIy7fS1wP0o" title="Contingent non-refundable milestone payment upon the achievement of $250.0 million in net sales of SLS-002"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponAchievementOf250.0MillionInNetSalesOfSls002" contextref="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-498" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.0</ix:nonfraction></span></span> million upon the achievement of $250.0 million in net sales of SLS-002, (v) $<span id="xdx_90D_ecustom--ContingentNonrefundableMilestonePaymentUponAchievementOf500.0MillionInNetSalesOfSls002_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zcdOuYLyB6Jl" title="Contingent non-refundable milestone payment upon  the achievement of $500.0 million in net sales of SLS-002"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponAchievementOf500.0MillionInNetSalesOfSls002" contextref="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-499" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.0</ix:nonfraction></span></span> million
upon the achievement of $500.0 million in net sales of SLS-002, (vi) $<span id="xdx_90E_ecustom--ContingentNonrefundableMilestonePaymentUponAchievementOf1.0BillionInNetSalesOfSls002_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zPU1SrdKNyBj" title="Contingent non-refundable milestone payment upon the achievement of $1.0 billion in net sales of SLS-002"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponAchievementOf1.0BillionInNetSalesOfSls002" contextref="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-500" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15.0</ix:nonfraction></span></span> million upon the achievement of $1.0 billion in net sales of
SLS-002, (vii) $<span id="xdx_90B_ecustom--ContingentNonrefundableMilestonePaymentUponAchievementOf1.5BillionInNetSalesOfSls002_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zpmiatMiAJF7" title="Contingent non-refundable milestone payment upon the achievement of $1.5 billion in net sales of SLS-002"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponAchievementOf1.5BillionInNetSalesOfSls002" contextref="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-501" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20.0</ix:nonfraction></span></span> million upon the achievement of $1.5 billion in net sales of SLS-002, and (viii) $<span id="xdx_906_ecustom--ContingentNonrefundableMilestonePaymentUponAchievementOf2.0BillionInNetSalesOfSls002_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_z21f4KK307r3" title="Contingent non-refundable milestone payment upon the achievement of $2.0 billion in net sales of SLS-002"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponAchievementOf2.0BillionInNetSalesOfSls002" contextref="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-502" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25.0</ix:nonfraction></span></span> million upon the achievement
of $2.0 billion in net sales of SLS-002. The Company will also pay to Vyera a royalty percentage in the mid-single digits on aggregate
annual net sales of SLS-002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The potential regulatory and commercial milestones are not
yet considered probable, and <span id="xdx_901_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zk1aoEnai0R1" title="Milestone payments accrued"><span><ix:nonfraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextref="AsOf2021-12-31_custom_AssetsfromVyeraPharmaceuticalsMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-503" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></span> milestone payments have been accrued at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Acquisition of License from Stuart
Weg, MD</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_907_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20190801__20190831__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zlZ8kLOosFO2" title="License agreement description"><span><ix:nonnumeric contextref="From2019-08-012019-08-31_custom_WegLicenseAgreementMember" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription" inside-table="false" id="fact-identifier-504" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On August 29, 2019, the Company entered into an amended and
restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was
granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of
the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay
additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii)
in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $<span id="xdx_905_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zGva1W1wyXU" title="Non-refundable cash payment"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2022-01-012022-01-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-505" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.2</ix:nonfraction></span></span> million
on January 2, 2022. The Company paid the required $<span id="xdx_90E_ecustom--NonrefundableCashPayment_pn5n6_c20200101__20200131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zL51DBdLIJ7i" title="Non-refundable cash payment"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2020-01-012020-01-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-506" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span></span> million on January 2, 2020 and $<span id="xdx_90E_ecustom--NonrefundableCashPayment_pn3n6_c20210101__20210131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zip73Tm54JPj" title="Non-refundable cash payment"><span id="xdx_90A_ecustom--NonrefundableCashPayment_pp3n6_c20210101__20210131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zMzcpsO2NU67" title="Non-refundable cash payment"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2021-01-012021-01-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitref="USD" inside-table="false" id="fact-identifier-507" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2021-01-012021-01-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="3" scale="6" unitref="USD" inside-table="false" id="fact-identifier-508" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.125</ix:nonfraction></span></ix:nonfraction></span></span></span> million on January 2, 2021. As further consideration,
the Company agreed to pay Dr. Weg certain milestone payments consisting of (i) $<span id="xdx_900_ecustom--ContingentNonrefundableMilestonePaymentUponIssuanceOfFirstPatentDirectedToAnxietyIndication_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zB9k8dO4hyi8" title="Contingent non-refundable milestone payment upon the issuance of the first patent directed to an anxiety indication"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponIssuanceOfFirstPatentDirectedToAnxietyIndication" contextref="AsOf2021-12-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-509" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span></span> million and shares of common stock equal to $<span id="xdx_901_ecustom--ContingentNonrefundableMilestoneShareValueOfCommonStockPaymentUponIssuanceOfFirstPatentDirectedToAnxietyIndication_iI_pp2n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_z2GfwwH0x1Qb" title="Contingent non-refundable milestone share value of common stock payment upon the issuance of the first patent directed to an anxiety indication"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestoneShareValueOfCommonStockPaymentUponIssuanceOfFirstPatentDirectedToAnxietyIndication" contextref="AsOf2021-12-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="2" scale="6" unitref="USD" inside-table="false" id="fact-identifier-510" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.15</ix:nonfraction></span></span>
million divided by the closing sales price of the Company’s common stock upon the issuance of the first patent directed to an anxiety
indication, (ii) $<span id="xdx_902_ecustom--ContingentNonrefundableMilestonePaymentAfterLockingOfDatabaseAndUnblindingDataForStatisticallySignificantReadoutOfPhaseIiiTrialOfIntranasalRacemicKetamineProductThatHasBeenConductedForSubmissionUnder_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zingPp1T7xSi" title="Contingent non-refundable milestone payment after the locking of the database and unblinding the data for the statistically significant readout of a Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission unde"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentAfterLockingOfDatabaseAndUnblindingDataForStatisticallySignificantReadoutOfPhaseIiiTrialOfIntranasalRacemicKetamineProductThatHasBeenConductedForSubmissionUnder" contextref="AsOf2021-12-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-511" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.5</ix:nonfraction></span></span> million after the locking of the database and unblinding the data for the statistically significant readout of a
Phase III trial of an intranasal racemic ketamine product that has been conducted for the submission under an NDA or equivalent seeking
regulatory approval in the United States, the United Kingdom, France, Germany, Italy, Spain, China or Japan, or seeking regulatory approval
from the EMA in the EU, for such product (the “Milestone Product”), (iii) $<span id="xdx_905_ecustom--ContingentNonrefundableMilestonePaymentUponFdaApprovalOfNdaForMilestoneProduct_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zE0rcmq82kCd" title="Contingent non-refundable milestone payment upon FDA approval of an NDA for the Milestone Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponFdaApprovalOfNdaForMilestoneProduct" contextref="AsOf2021-12-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-512" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span></span> million upon FDA approval of an NDA for the
Milestone Product, (iv) $<span id="xdx_909_ecustom--ContingentNonrefundableMilestonePaymentUponRegulatoryApprovalByEmaForMilestoneProduct_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zZgdyzVX7EC4" title="Contingent non-refundable milestone payment upon regulatory approval by the EMA for the Milestone Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponRegulatoryApprovalByEmaForMilestoneProduct" contextref="AsOf2021-12-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-513" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span></span> million upon regulatory approval by the EMA for the Milestone Product, and (v) $<span id="xdx_903_ecustom--ContingentNonrefundableMilestonePaymentUponRegulatoryApprovalInJapanForMilestoneProduct_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zapuIy0bPfY2" title="Contingent non-refundable milestone payment upon regulatory approval in Japan for the Milestone Product"><span><ix:nonfraction name="SEEL:ContingentNonrefundableMilestonePaymentUponRegulatoryApprovalInJapanForMilestoneProduct" contextref="AsOf2021-12-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-514" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.5</ix:nonfraction></span></span> million upon regulatory
approval in Japan for the Milestone Product; provided, however, that the maximum amount to be paid by the Company under milestones (i)-(v)
will be $<span id="xdx_90A_ecustom--MaximumAmountToBePaidUnderMilestones_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zDGXuTKWKaQg" title="Maximum amount to be paid under milestones"><span><ix:nonfraction name="SEEL:MaximumAmountToBePaidUnderMilestones" contextref="AsOf2021-12-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.6</ix:nonfraction></span></span> million. The Company will also pay to Dr. Weg a royalty percentage equal to <span id="xdx_903_ecustom--PercentageOfRoyaltyPayments_iI_pid_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zsk7QhSj74Ph" title="Percentage of royalty payments"><span><ix:nonfraction name="SEEL:PercentageOfRoyaltyPayments" contextref="AsOf2021-12-31_custom_WegLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-516" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.25</ix:nonfraction></span>%</span> on the sale of each product containing
ketamine in any dosage</ix:nonnumeric></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The potential regulatory and commercial milestones are not
yet considered probable, and <span id="xdx_90A_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_ze8GOPx7q3xh" title="Milestone payments accrued"><span><ix:nonfraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextref="AsOf2021-12-31_custom_WegLicenseAgreementMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></span> milestone payments have been accrued at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Acquisition of Assets from Bioblast
Pharma Ltd. (“Bioblast”)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_907_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20190201__20190228__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromBioblastPharmaMember_zIdzJZG6Youf" title="License agreement description"><span><ix:nonnumeric contextref="From2019-02-012019-02-28_custom_AssetsfromBioblastPharmaMember" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription" inside-table="false" id="fact-identifier-518" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On February 15, 2019, the Company entered into an Asset Purchase
Agreement (the “Bioblast Asset Purchase Agreement”) with Bioblast. Pursuant to the Bioblast Asset Purchase Agreement, the
Company acquired all of the assets of Bioblast relating to a therapeutic platform known as Trehalose (the “Bioblast Asset Purchase”).
The Company paid to Bioblast $<span id="xdx_90F_ecustom--NonrefundableCashPayment_pn5n6_c20190201__20190228__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromBioblastPharmaMember_zKT2GztEHPZg" title="Non-refundable cash payment"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2019-02-012019-02-28_custom_AssetsfromBioblastPharmaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-519" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.5</ix:nonfraction></span></span> million in February 2019 and an additional $<span id="xdx_902_ecustom--NonrefundableCashPayment_pn5n6_c20200201__20200229__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromBioblastPharmaMember_zJR2eRdIkrQ1" title="Non-refundable cash payment"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2020-02-012020-02-29_custom_AssetsfromBioblastPharmaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-520" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span></span> million in February 2020. Accordingly, the Company recognized
a $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20190101__20190331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromBioblastPharmaMember_zGdbBDuPDfbc" title="Research and development expense"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2019-01-012019-03-31_custom_AssetsfromBioblastPharmaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.5</ix:nonfraction></span></span> million charge to research and development expense during the three months ended March 31, 2019. Under the terms of the Bioblast
Asset Purchase Agreement, the Company agreed to pay additional consideration to Bioblast upon the achievement of certain milestones in
the future, as follows: (i) within 15 days following the completion of the Company’s first Phase II(b) clinical trial of Trehalose
satisfying certain criteria, the Company will pay to Bioblast $<span id="xdx_90B_ecustom--ContingentAdditionalMilestoneConsiderationWithin15DaysFollowingCompletionOfCompanysFirstPhaseIibClinicalTrialOfTrehaloseSatisfyingCertainCriteria_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromBioblastPharmaMember_zVTK0VB6giSa" title="Contingent additional milestone consideration within 15 days following the completion of the Company's first Phase II(b) clinical trial of Trehalose satisfying certain criteria"><span><ix:nonfraction name="SEEL:ContingentAdditionalMilestoneConsiderationWithin15DaysFollowingCompletionOfCompanysFirstPhaseIibClinicalTrialOfTrehaloseSatisfyingCertainCriteria" contextref="AsOf2021-12-31_custom_AssetsfromBioblastPharmaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-522" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.5</ix:nonfraction></span></span> million; and (ii) within 15 days following the approval for commercialization
by the FDA or the Health Products and Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose
filed by the Company or its affiliates, the Company will pay to Bioblast $<span id="xdx_909_ecustom--ContingentAdditionalMilestoneConsiderationWithin15DaysFollowingApprovalForCommercializationByFdaOrHealthProductsAndFoodBranchOfHealthCanadaOfFirstNdaOrNewDrugSubmissionRespectivelyOfTrehaloseFiledByC_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromBioblastPharmaMember_zborLxR2Hvpi" title="Contingent additional milestone consideration within 15 days following the approval for commercialization by the FDA or the Health Products and Food Branch of Health Canada of the first NDA or New Drug Submission, respectively, of Trehalose filed by the Company or its affiliates"><span><ix:nonfraction name="SEEL:ContingentAdditionalMilestoneConsiderationWithin15DaysFollowingApprovalForCommercializationByFdaOrHealthProductsAndFoodBranchOfHealthCanadaOfFirstNdaOrNewDrugSubmissionRespectivelyOfTrehaloseFiledByC" contextref="AsOf2021-12-31_custom_AssetsfromBioblastPharmaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-523" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.5</ix:nonfraction></span></span> million. In addition, the Company agreed to pay Bioblast
a cash royalty equal to <span id="xdx_902_ecustom--PercentageOfRoyaltyPayments_iI_pid_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromBioblastPharmaMember_zHRfM5Nnra1f" title="Percentage of royalty payments"><span><ix:nonfraction name="SEEL:PercentageOfRoyaltyPayments" contextref="AsOf2021-12-31_custom_AssetsfromBioblastPharmaMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-524" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span>%</span> of the net sales of Trehalose. Under the terms of the Bioblast Asset Purchase, the Company assumed a collaborative
agreement with Team Sanfilippo Foundation (“TSF”), a nonprofit medical research foundation founded by parents of children
with Sanfilippo Syndrome. TSF, upon approval by the FDA, planned to begin an open label, Phase II(b) clinical trial in up to 20 patients
with Sanfilippo Syndrome, which is now known under the study name SLS-005. The Company will provide the clinical supply of Trehalose.
The terms of the Bioblast Asset Purchase Agreement entitle the Company access to all clinical data from this trial. On July 15, 2019,
TSF and the Company amended the agreement whereby the Company agreed to assume responsibility for the Phase II(b)/III clinical trial and
TSF agreed to provide a grant of up to $<span id="xdx_909_ecustom--FutureGrantRevenueContingentOnPhaseIiBiiiSanfilippoClinicalTrial_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromBioblastPharmaMember_zrklL7ZUr0W6" title="Future grant revenue contingent on Phase II (b)/III Sanfilippo clinical trial"><span><ix:nonfraction name="SEEL:FutureGrantRevenueContingentOnPhaseIiBiiiSanfilippoClinicalTrial" contextref="AsOf2021-12-31_custom_AssetsfromBioblastPharmaMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-525" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.5</ix:nonfraction></span></span> million towards the funding of the trial.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">&nbsp;
    <!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The potential regulatory and commercial milestones are not
yet considered probable, and <span id="xdx_90B_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromBioblastPharmaMember_zL98hBwaiXKd" title="Milestone payments accrued"><span><ix:nonfraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextref="AsOf2021-12-31_custom_AssetsfromBioblastPharmaMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></span> milestone payments have been accrued at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Acquisition of License from The Regents of the University
of California</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_906_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_pn5n6_c20190301__20190331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_z2nwLnVLAqr9" title="License agreement description"><span><ix:nonnumeric contextref="From2019-03-012019-03-31_custom_UCRegentsLicenseAgreementMember" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription" inside-table="false" id="fact-identifier-527" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On March 7, 2019, the Company entered into an exclusive license
agreement (the “UC Regents License Agreement”) with The Regents of the University of California (“The UC Regents”)
pursuant to which the Company was granted an exclusive license to intellectual property owned by The UC Regents pertaining to a technology
that was created by researchers at the University of California, Los Angeles (UCLA). Such technology relates to a family of rationally-designed
peptide inhibitors that target the aggregation of alpha-synuclein (α-synuclein). The Company plans to study this initial approach
in PD and will further evaluate the potential clinical approach in other disorders affecting the CNS.
This program is now known as SLS-007. Upon entry into the UC Regents License Agreement, the Company paid to The UC Regents $<span id="xdx_908_ecustom--NonrefundableCashPayment_pn5n6_c20190301__20190331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_zjpAcEQGuskc" title="Non-refundable cash payment"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2019-03-012019-03-31_custom_UCRegentsLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span></span> million
and recognized a $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20190101__20190331__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_zaSVWgv99Q55" title="Research and development expense"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2019-01-012019-03-31_custom_UCRegentsLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-529" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span></span> million charge to research and development expense during the three months ended March 31, 2019. Under the terms
of the UC Regents License Agreement, the Company agreed to pay additional consideration upon the achievement of certain milestones in
the future, as follows: (i) within 90 days following the completion of dosing of the first patient in a Phase I clinical trial, the Company
will pay $<span id="xdx_901_ecustom--IContingentMilestonePaymentWithin90DaysFollowingCompletionOfDosingOfFirstPatientInPhaseIClinicalTrial_iI_pp0p0_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_z9cI5oUfpD37" title="Contingent milestone payment within 90 days following the completion of dosing of the first patient in a Phase I clinical trial"><span><ix:nonfraction name="SEEL:IContingentMilestonePaymentWithin90DaysFollowingCompletionOfDosingOfFirstPatientInPhaseIClinicalTrial" contextref="AsOf2021-12-31_custom_UCRegentsLicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-530" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50,000</ix:nonfraction></span></span>; (ii) within 90 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $<span id="xdx_906_ecustom--ContingentMilestonePaymentWithin90DaysFollowingDosingOfFirstPatientInPhaseIiClinicalTrial_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_zFm2fq9h3f63" title="Contingent milestone payment within 90 days following dosing of the first patient in a Phase II clinical trial"><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin90DaysFollowingDosingOfFirstPatientInPhaseIiClinicalTrial" contextref="AsOf2021-12-31_custom_UCRegentsLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span></span> million;
(iii) within 90 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $<span id="xdx_909_ecustom--ContingentMilestonePaymentWithin90DaysFollowingDosingOfFirstPatientInPhaseIiiClinicalTrial_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_zjBaLbSCXtf4" title="Contingent milestone payment within 90 days following dosing of the first patient in a Phase III clinical trial"><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin90DaysFollowingDosingOfFirstPatientInPhaseIiiClinicalTrial" contextref="AsOf2021-12-31_custom_UCRegentsLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-532" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.3</ix:nonfraction></span></span> million; (iv) within
90 days following the first commercial sales in the U.S., the Company will pay $<span id="xdx_905_ecustom--ContingentMilestonePaymentWithin90DaysFollowingFirstCommercialSalesInU.s._iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_zF5yILapnOO8" title="Contingent milestone payment within 90 days following the first commercial sales in the U.S."><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin90DaysFollowingFirstCommercialSalesInU.s." contextref="AsOf2021-12-31_custom_UCRegentsLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-533" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.0</ix:nonfraction></span></span> million; (v) within 90 days following the first commercial
sales in any European market, the Company will pay $<span id="xdx_901_ecustom--ContingentMilestonePaymentWithin90DaysFollowingFirstCommercialSalesInAnyEuropeanMarket_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_zFNuQTRh9c5" title="Contingent milestone payment within 90 days following the first commercial sales in any European market"><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin90DaysFollowingFirstCommercialSalesInAnyEuropeanMarket" contextref="AsOf2021-12-31_custom_UCRegentsLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-534" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.0</ix:nonfraction></span></span> million; and (vi) within 90 days following $250 million in cumulative worldwide
net sales of a licensed product, the Company will pay $<span id="xdx_90D_ecustom--ContingentMilestonePaymentWithin90DaysFollowing250MillionInCumulativeWorldwideNetSalesOfLicensedProduct_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_zP0XFQ5iRlxc" title="Contingent milestone payment within 90 days following $250 million in cumulative worldwide net sales of a licensed product"><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin90DaysFollowing250MillionInCumulativeWorldwideNetSalesOfLicensedProduct" contextref="AsOf2021-12-31_custom_UCRegentsLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-535" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.5</ix:nonfraction></span></span> million. The Company is also obligated to pay a single digit royalty on sales
of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified timeframe, The UC Regents may
terminate the agreement or reduce the Company’s license to a nonexclusive license.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The potential regulatory and commercial milestones are not
yet considered probable, and <span id="xdx_901_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--UCRegentsLicenseAgreementMember_zZiEqVKWLIRd" title="Milestone payments accrued"><span><ix:nonfraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextref="AsOf2021-12-31_custom_UCRegentsLicenseAgreementMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-536" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></span> milestone payments have been accrued at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Acquisition of License from Duke University</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_905_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_pn5n6_c20190601__20190630__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--DukeLicenseAgreementMember_zOX6zEeWGkSg" title="License agreement description"><span><ix:nonnumeric contextref="From2019-06-012019-06-30_custom_DukeLicenseAgreementMember" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription" inside-table="false" id="fact-identifier-537" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On
June 27, 2019, the Company entered into an exclusive license agreement (the “Duke License Agreement”) with Duke
University pursuant to which the Company was granted an exclusive license to a gene therapy program targeting the regulation of the
synuclein alpha (“SNCA”) gene, which encodes alpha-synuclein expression. The Company plans to study this initial approach in PD and will
further evaluate the potential clinical approach in other disorders affecting the CNS. This program is now known as SLS-004. Upon
entry into the Duke License Agreement, the Company paid to Duke University $<span id="xdx_90C_ecustom--NonrefundableCashPayment_pn5n6_c20190601__20190630__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--DukeLicenseAgreementMember_zqjAcHVEiKUh" title="Non-refundable cash payment"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2019-06-012019-06-30_custom_DukeLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-538" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span></span>
million and recognized $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20190401__20190630__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--DukeLicenseAgreementMember_z4GNqWW7FOv" title="Research and development expense"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2019-04-012019-06-30_custom_DukeLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-539" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span></span>
million charge to research and development expense during the three months ended September 30, 2019. The Company agreed to pay additional
consideration to Duke University upon the achievement of certain milestones in the future, as follows: (i) within 30 days following
filing of an IND following the completion of preclinical studies including comprehensive validation of the platform, the Company
will pay $<span id="xdx_90F_ecustom--ContingentMilestonePaymentWithin30DaysFollowingFilingOfIndFollowingCompletionOfPreclinicalStudiesIncludingComprehensiveValidationOfPlatform_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--DukeLicenseAgreementMember_zGFLUNmsov71" title="Contingent milestone payment within 30 days following filing of an IND following the completion of preclinical studies including comprehensive validation of the platform"><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin30DaysFollowingFilingOfIndFollowingCompletionOfPreclinicalStudiesIncludingComprehensiveValidationOfPlatform" contextref="AsOf2021-12-31_custom_DukeLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span></span> million; (ii) within 30 days following dosing of the first patient in a Phase I clinical trial, the Company will pay
$<span id="xdx_900_ecustom--ContingentMilestonePaymentWithin30DaysFollowingDosingOfFirstPatientInPhaseIClinicalTrial_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--DukeLicenseAgreementMember_zfJgGsWcE4Rl" title="Contingent milestone payment within 30 days following dosing of the first patient in a Phase I clinical trial"><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin30DaysFollowingDosingOfFirstPatientInPhaseIClinicalTrial" contextref="AsOf2021-12-31_custom_DukeLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-541" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.2</ix:nonfraction></span></span> million; (iii) within 30 days following dosing of the first patient in a Phase II clinical trial, the Company will pay $<span id="xdx_90D_ecustom--ContingentMilestonePaymentWithin30DaysFollowingDosingOfFirstPatientInPhaseIiClinicalTrial_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--DukeLicenseAgreementMember_zvA9R5cPWfpa" title="Contingent milestone payment within 30 days following dosing of the first patient in a Phase II clinical trial"><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin30DaysFollowingDosingOfFirstPatientInPhaseIiClinicalTrial" contextref="AsOf2021-12-31_custom_DukeLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-542" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.5</ix:nonfraction></span></span>
million; (iv) within 30 days following dosing of the first patient in a Phase III clinical trial, the Company will pay $<span id="xdx_908_ecustom--ContingentMilestonePaymentWithin30DaysFollowingDosingOfFirstPatientInPhaseIiiClinicalTrial_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--DukeLicenseAgreementMember_zInuSI6Fz9d3" title="Contingent milestone payment within 30 days following dosing of the first patient in a Phase III clinical trial"><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin30DaysFollowingDosingOfFirstPatientInPhaseIiiClinicalTrial" contextref="AsOf2021-12-31_custom_DukeLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-543" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.0</ix:nonfraction></span></span> million;
and (v) within 30 days following an NDA approval, the Company will pay $<span id="xdx_905_ecustom--ContingentMilestonePaymentWithin30DaysFollowingNdaApproval_iI_pn5n6_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--DukeLicenseAgreementMember_zsrIWyJkL174" title="Contingent milestone payment within 30 days following an NDA approval"><span><ix:nonfraction name="SEEL:ContingentMilestonePaymentWithin30DaysFollowingNdaApproval" contextref="AsOf2021-12-31_custom_DukeLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-544" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span></span> million. The Company is also obligated to pay a single
digit royalty on sales of the product, if any. In addition, if the Company fails to achieve certain milestones within a specified
timeframe, Duke University may terminate the agreement.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The potential regulatory and commercial
milestones are not yet considered probable, and <span id="xdx_901_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--DukeLicenseAgreementMember_zXVTmVLHWMi6" title="Milestone payments accrued"><span><ix:nonfraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextref="AsOf2021-12-31_custom_DukeLicenseAgreementMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-545" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></span> milestone payments have been accrued at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">87</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Acquisition of License from iX Biopharma Europe Limited</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90B_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_ztXgZGihoTSf"><span><ix:nonnumeric contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription" inside-table="false" id="fact-identifier-546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On November 24, 2021, the Company entered into an exclusive license agreement
(the “iX License Agreement”) with iXBEL and the iXBEL Stock Purchase Agreement. Pursuant to the iX License Agreement, among
other things, iXBEL granted the Company an exclusive, sublicensable, perpetual, worldwide (excluding certain jurisdictions identified
in the iX License Agreement) and irrevocable right and license to certain of iXBEL’s licensed patents, know-how, and technological
information, including access to iXBEL’s research, development and manufacturing capabilities, to enable the further development,
manufacture, promotion and commercialization of Wafermine<sup>™</sup> and certain other existing and to be developed iXBEL wafer-based delivery
technologies, in all cases for sublingual administration of ketamine. In addition, iXBEL will supply the Company with sufficient product
for the potential treatment of 400 patients, with further supplied amounts to be determined by the parties. The Company granted iXBEL
an exclusive license to exploit technology developed under the iX License Agreement outside of the licensed territory and to undertake
limited, non-exclusive research and development activities in the territory. The Company further agreed not to undertake certain activities
with respect to products competitive with those licensed under the iX License Agreement during the term of the iX License Agreement.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As consideration for the license under the iX License Agreement, the Company
agreed to (i) pay iXBEL an upfront fee of $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zjVGj4DG7zli"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.0</ix:nonfraction></span></span> million, comprised of $<span id="xdx_904_ecustom--NonrefundableCashPayment_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_z2XYRnCDruOc"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-548" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.5</ix:nonfraction></span></span> million in cash and <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zyFzPTBNe0U9"><span><ix:nonfraction name="SEEL:Issuanceofcommonstockforlicenseacquiredshares" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-549" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,570,266</ix:nonfraction></span></span> restricted shares of its common
stock; (ii) pay certain development, regulatory and commercial milestones,
which, if achieved, aggregate to a total of $239.0 million; and (iii) pay royalty payments of ten percent on net sales, if any, as further
set out in the iX License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the iXBEL Stock Purchase Agreement, the Company also agreed
to reimburse iXBEL for the Shortfall Amount in the event the aggregate value of the <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zs1cT229JRy8"><span><ix:nonfraction name="SEEL:Issuanceofcommonstockforlicenseacquiredshares" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-550" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,570,266</ix:nonfraction></span></span> shares of its common stock issued to iXBEL
pursuant to the iXBEL Stock Purchase Agreement was less than $<span id="xdx_900_ecustom--MinimumStockValueOfSharesIssued_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_z9l8OszA7mZ2" title="Minimum stock value of shares issued"><span><ix:nonfraction name="SEEL:MinimumStockValueOfSharesIssued" contextref="From2021-11-012021-11-30_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-551" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.5</ix:nonfraction></span></span> million. The Shortfall Amount could be paid in cash, additional shares
of common stock or a combination of both. As of December 31, 2021, the Company calculated the Shortfall Amount to be $<span id="xdx_90D_ecustom--StockValuationShortfallFrom5.5MillionValue_pn5n6_c20211101__20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zTSZUEccSrpj" title="Stock valuation shortfall from 5.5 million value"><span><ix:nonfraction name="SEEL:StockValuationShortfallFrom5.5MillionValue" contextref="From2021-11-012021-12-31_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-552" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.2</ix:nonfraction></span></span> million. The
Company paid the Shortfall Amount of $<span id="xdx_906_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zsEuR97FHZu4"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2022-01-012022-01-31_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-553" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.2</ix:nonfraction></span></span> million to iXBEL in cash in January 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-554" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zIsKhPRNio92" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>8. Accrued Expenses</b></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-555" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLbnzvITG1p5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accrued expenses are comprised of the following (in
thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0"><span><span id="xdx_8BD_z6KWwFfJHuHk">Schedule of Accrued Liabilities</span></span></p>




<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td id="xdx_492_20211231_zS8lnADjM4F" style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td id="xdx_498_20201231_z7CTT0lm55Lh" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31,</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 74%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZt1_ziFqceZp8kCd" style="vertical-align: top">
    <td><span style="font-size: 10pt">Professional fees</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccruedProfessionalFeesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-556" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">181</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccruedProfessionalFeesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-557" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">292</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zct9paxXbfkh" style="vertical-align: top">
    <td><span style="font-size: 10pt">Personnel related</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-558" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,303</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-559" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">756</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_403_ecustom--OutsideResearchAndDevelopmentServicesCurrent_iI_pn3n3_zO2P7csp6146" style="vertical-align: top">
    <td><span style="font-size: 10pt">Outside research and development services</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="SEEL:OutsideResearchAndDevelopmentServicesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,219</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="SEEL:OutsideResearchAndDevelopmentServicesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">764</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zVwREZNxc5Fc" style="vertical-align: top">
    <td><span style="font-size: 10pt">Other</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-562" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-563" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">112</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZt1_ztGJO0fQsEb3" style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Accrued expenses, net</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-564" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,728</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-565" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,924</ix:nonfraction></span>&nbsp;</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A6_zJtCCx3fxOm9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>


</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zANXrcphKVbl" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>9. Debt</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Convertible Notes</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>November 2021 and December 2021 Convertible Notes and Private Placement</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_905_eus-gaap--LongTermDebtDescription_c20211101__20211130__us-gaap--DebtInstrumentAxis__custom--Vovember2021LindSecuritiesPurchaseAgreementMember_zkR7SeEeeOGi"><span><ix:nonnumeric contextref="From2021-11-012021-11-30_custom_Vovember2021LindSecuritiesPurchaseAgreementMember" name="us-gaap:LongTermDebtDescription" inside-table="false" id="fact-identifier-567" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On November 23, 2021, the Company entered into a Securities Purchase Agreement
(the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant
to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private
placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible
promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”),
which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate
of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock.</ix:nonnumeric></span></span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">88</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;At the first anniversary of the Closing Date, the Company shall
have the option, at its sole discretion, to issue to Lind V a convertible promissory note (the “Second Note”) in the principal
amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the
Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company
shall issue to Lind V a convertible promissory note (the “Third Note”) in the principal amount of $11.0 million in exchange
for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food &amp; Drug Administration
for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible
promissory note (the “Fourth Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0
million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At any time following August 23, 2022, from time to time and before the
Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares
of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar
transactions (the “Conversion Price”). At any time prior August 23, 2022, the Company shall have the right to prepay, in whole
or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the
outstanding Principal Amount of the 2021 Note with no penalty. If the Company does not prepay any amounts of the 2021 Note prior to August
23, 2022 then, commencing August 23, 2022, the Company shall have the right to prepay, in whole or in part (exercisable by the Company
at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty;
however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent
(33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. If the Company prepays any amounts of the 2021 Note
prior to August 23, 2022 then, commencing November 23, 2022, the Company shall not have the right to prepay any amounts of the 2021 Note
between August 23, 2022 to November 23, 2022 and, commencing November 23, 2022, the Company shall have the right to prepay, in whole or
in part (exercisable by the Company at any time or from time to time prior to the Maturity Date) up to the full remaining Principal Amount
of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to
thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to certain exceptions, the Company will be required to direct proceeds
from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other
than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the
2021 Notes, unless waived by Lind V in advance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four
monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of
months remaining until the Maturity Date. All amortization payments shall be payable, at the Company’s sole option, in cash, shares
of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022,
the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of
the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90%
of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date
of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the
Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note,
on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the
Company’s assets and properties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90F_eus-gaap--LongTermDebtDescription_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zJXT89faIVld"><span><ix:nonnumeric contextref="From2021-12-012021-12-31_custom_December2021SPAsMember" name="us-gaap:LongTermDebtDescription" inside-table="false" id="fact-identifier-568" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On December 2, 2021, the Company entered into two separate securities purchase
agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant
to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate
of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on
December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021
Note.</ix:nonnumeric></span></span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company received aggregate gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zwqXfHkzQ9i7"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2021-12-012021-12-31_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-569" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.2</ix:nonfraction></span></span> million from
the convertible note offerings. The Company elected to account for these notes under the fair value option. At time of issuance, the
Company recorded a liability of $<span id="xdx_90F_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211202__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_z9w6y8VcH4hc"><span><ix:nonfraction name="us-gaap:ConvertibleSubordinatedDebt" contextref="AsOf2021-12-02_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-570" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19.2</ix:nonfraction></span></span> million, which was determined to be the fair value at time of issuance. As of December 31,
2021, the Company recognized a $<span id="xdx_907_ecustom--GainLossInFairValueOfConvertibleNotes_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zzMEJPzlPW65"><span><ix:nonfraction name="SEEL:GainLossInFairValueOfConvertibleNotes" contextref="From2021-12-012021-12-31_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-571" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.2</ix:nonfraction></span></span> million gain on change in fair value of convertible notes, recognizing a total convertible note
liability of $<span id="xdx_907_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zVMjFwqdvbzl"><span><ix:nonfraction name="us-gaap:ConvertibleSubordinatedDebt" contextref="AsOf2021-12-31_custom_December2021SPAsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-572" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18.9</ix:nonfraction></span></span> million.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">89</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2021, the principal contractual balance of the notes
totaled $22.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-573" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zGOgr283Io92" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Scheduled maturities with respect to the 2021 Convertible Notes are as
follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p id="xdx_8B0_z4kbFAHjHJMj" style="font: 12pt Times New Roman, Times, Serif; margin: 0; display: none"><span style="font-size: 10pt">Maturities of Long-term Debt</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tbody><tr style="vertical-align: middle">
    <td style="background-color: white">&nbsp;</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right">&nbsp;</td>
    <td style="text-align: right; background-color: white">&nbsp;</td>
    <td id="xdx_49D_20211231_zkhNISrbth1b" style="text-align: center; background-color: white">&nbsp;</td></tr>
  <tr id="xdx_40E_ecustom--YearEndingDecember31_iB_zPT3b61TXHb9" style="vertical-align: middle">
    <td style="background-color: white; width: 75%">Year Ending December 31:</td>
    <td style="font-size: 9pt; font-weight: bold; text-align: right; width: 1%">&nbsp;</td>
    <td style="text-align: right; background-color: white; width: 2%">&nbsp;</td>
    <td style="text-align: center; background-color: white; width: 22%">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_zU0TsI9cdLvl" style="vertical-align: middle">
    <td style="padding-left: 24px; text-align: left; background-color: white">2022</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-574" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">917</ix:nonfraction></span></td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_zGvqClP9A5mg" style="vertical-align: middle">
    <td style="padding-left: 24px; text-align: left; background-color: white">2023</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-575" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,111</ix:nonfraction></span></td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_zAu4ER3NnGwj" style="vertical-align: middle">
    <td style="padding-left: 24px; text-align: left; background-color: white">2024</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-576" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,194</ix:nonfraction></span></td></tr>
  <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_zyNYMhCFiw06" style="vertical-align: middle">
    <td style="padding-left: 24px; text-align: left; background-color: white">2025</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: center; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0895"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextref="AsOf2021-12-31" id="fact-identifier-577" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0895" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_pn3n3_zBFYMeRJc2bb" style="vertical-align: middle">
    <td style="padding-left: 24px; text-align: left; background-color: white">2026</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: center; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0897"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextref="AsOf2021-12-31" id="fact-identifier-578" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0897" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--LongTermDebt_iI_pn3n3_zp6YVOBvCwyd" style="vertical-align: middle">
    <td style="background-color: white">Total</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; font-weight: bold; text-align: right; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span><ix:nonfraction name="us-gaap:LongTermDebt" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-579" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,222</ix:nonfraction></span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A6_zCHLoqU36ts1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span>&nbsp;</span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>December 2020 Convertible Note and Private Placement</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 20pt; text-indent: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span id="xdx_901_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--LindSecuritiesPurchaseAgreementMember_zM4f5isFyqNg"><span><ix:nonnumeric contextref="From2020-12-012020-12-31_custom_LindSecuritiesPurchaseAgreementMember" name="us-gaap:LongTermDebtDescription" inside-table="false" id="fact-identifier-580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On
December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase
Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on
December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by
the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of
$12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the
“Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and
from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal
Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock
splits, stock dividends and similar transactions (the “Conversion Price”). Prior to June 11, 2021, the Company
had the right to prepay up to sixty-six and two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the
2020 Note with no penalty. Subject to certain exceptions, the Company was required to direct proceeds from any subsequent debt
financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money
debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless
waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments
equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining
until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of
2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the
Company and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to
the Investor an aggregate of 406,250 additional shares of its common stock (the “Lind Shares”) and to pay the Investor
the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of our remaining obligations to
the Investor under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind
Securities Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_906_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_zOgv5jqXw7tf"><span><ix:nonnumeric contextref="From2020-12-012020-12-31_custom_December17SPAsMember" name="us-gaap:LongTermDebtDescription" inside-table="false" id="fact-identifier-581" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On December 17, 2020, the Company entered into three separate securities
purchase agreements with certain accredited investors on substantially the same terms as the Lind Securities Purchase Agreement (the “December
17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited
investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal
amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its
common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with
an accredited investor on substantially the same terms as the Lind Securities Purchase Agreement (the “December 18 SPA” and,
together with the December 17 SPAs, the "Subsequent Securities Purchase Agreements"), pursuant to which the Company sold, in
a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note
in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December
18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s
common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the Lind Securities Purchase Agreement,
and the Subsequent Notes had substantially the same terms as the Note. During the first half of 2021, the Company made certain repayments
on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the
“December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December
18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December
18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to
the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in
full satisfaction of our remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder
paid the Company the Repayment and the Company issued the December Note Shares, and the December 18 SPA and the December 18 Note terminated,
effective July 7, 2021.</ix:nonnumeric></span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">90</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white">The Company received aggregate net proceeds
of $10.9 million from the convertible note offering, net of $0.5 million of issuance costs. The total gross proceeds were allocated to
the convertible notes and common stock issued under the agreements based on their relative fair values. Due to the principal payments
made during the year, the Company remeasured the beneficial conversion feature discount at each payment date and recorded a loss on extinguishment
of debt of approximately $1.0 million during the year ended December 31, 2021 as well as a reduction in additional paid-in capital of
$1.5 million as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white">During the year ended December 31, 2021,
the Company paid approximately $13.6 million in principal payments on the outstanding convertible notes and issued an aggregate of 475,315
shares of its common stock upon conversion of the convertible notes, and none of the 2020 convertible notes remain outstanding as of December
31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><b>PPP
Loan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><br>
<span id="xdx_90D_eus-gaap--LongTermDebtDescription_c20200501__20200531__us-gaap--DebtInstrumentAxis__custom--PPPLoanMember_zk8oq0QVifIh"><span><ix:nonnumeric contextref="From2020-05-012020-05-31_custom_PPPLoanMember" name="us-gaap:LongTermDebtDescription" inside-table="false" id="fact-identifier-582" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On
May 4, 2020, the Company qualified for and received a loan pursuant to the Paycheck Protection Program, a program implemented by the
U.S. Small Business Administration under the Coronavirus Aid, Relief, and Economic Security Act, from a qualified lender (the “PPP
Lender”), for an aggregate principal amount of approximately $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200531__us-gaap--DebtInstrumentAxis__custom--PPPLoanMember_zolUJbm7lfG2"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-05-31_custom_PPPLoanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-583" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147,000</ix:nonfraction></span></span>
(the “PPP Loan”). The PPP Loan bore interest at a fixed rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_c20200531__us-gaap--DebtInstrumentAxis__custom--PPPLoanMember_zWSfcnN2Afk8"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-05-31_custom_PPPLoanMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-584" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span></span>%
per annum, with the first six months of interest deferred, had a term of two years, and was unsecured and guaranteed by the U.S. Small
Business Administration. The principal amount of the PPP Loan was subject to forgiveness under the Paycheck Protection Program upon the
Company’s request to the extent that the PPP Loan proceeds were used to pay expenses permitted by the Paycheck Protection Program,
including payroll costs, covered rent and mortgage obligations and covered utility payments incurred by the Company. The Company applied
for and received full forgiveness of the PPP Loan with respect to these covered expenses and recorded a gain on forgiveness of debt during
the year ended December 31, 2021</ix:nonnumeric></span></span>.</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></p>



</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-585" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zsHcb8KCiMV1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>10. Stockholders' Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company is authorized to issue <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20211231_zoHUob9LwPu9"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-586" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span></span> shares
of preferred stock, par value $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20211231_zYKAccOsEG94"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-587" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></span>. <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zIaDBLZSRU5e"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20201231_zgkO03XaOQJ5"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-588" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-589" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonfraction></span></ix:nonfraction></span></span></span> shares of preferred stock were outstanding as of December 31, 2021 or 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has authorized <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20211231_zQ9PVhHjzcYb" title="Common stock, authorized (in shares)"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-590" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">240,000,000</ix:nonfraction></span></span>
and <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20201231_zKAw4cQWQTHi" title="Common stock, authorized (in shares)"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-591" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">120,000,000</ix:nonfraction></span></span>
shares of common stock as of December 31, 2021 and 2020, respectively. <span id="xdx_90F_eus-gaap--CommonStockVotingRights_c20210101__20211231_zesv2VP8EqN4" title="Common stock voting right"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="us-gaap:CommonStockVotingRights" inside-table="false" id="fact-identifier-592" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Each
share of common stock is entitled to one voting right</ix:nonnumeric></span></span>. Common stock owners are entitled to dividends when funds are legally
available and declared by the Board of Directors.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Warrants</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>September 2020
Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zH1B4svAAJsh" title="Warrant description"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_September2020WarrantsMember" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" inside-table="false" id="fact-identifier-593" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The September 2020 Warrants are exercisable for
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20190801__20190831__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_zGyqjRT9CNG3" title="Number of shares of common stock issued"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-08-012019-08-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-594" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,648,750</ix:nonfraction></span></span> shares of common stock at an exercise price per share equal to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zcMg07k6tSD3"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.84</ix:nonfraction></span></span>. The September 2020 Warrants became exercisable beginning
on <span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zbSbWsOvBvF2" title="Date on which warrants became exercisable"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_September2020WarrantsMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" inside-table="false" id="fact-identifier-596" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">March 9, 2021</ix:nonnumeric></span></span> and will expire on March 9, 2026.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">During the year ended December 31, 2021, September 2020 Warrants
were exercised for <span id="xdx_90B_ecustom--NumberofWarrantsExercisedDuringPeriod_pin6_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zMXuJkbi8nVe"><span><ix:nonfraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextref="From2021-01-012021-12-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-597" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.6</ix:nonfraction></span> </span>million
shares of common stock for approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pin6_uUSD_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zfzXoJkbMQVj"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2021-01-012021-12-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-598" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.7</ix:nonfraction></span> </span>million.
As of December 31, 2021, September 2020 Warrants exercisable for <span id="xdx_902_ecustom--WarrantsExercisable_iI_pin6_c20211231__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_zwq1d91o1ape"><span><ix:nonfraction name="SEEL:WarrantsExercisable" contextref="AsOf2021-12-31_custom_September2020WarrantsMember329739390" format="ixt:numdotdecimal" decimals="INF" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-599" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.0</ix:nonfraction></span>
million </span>shares of common stock remain outstanding at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zkR68TIt7IIk"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_September2020WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-600" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.84</ix:nonfraction></span> </span>per
share.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">91</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>





<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>August 2019 Warrants&nbsp;&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zGC7U2UhuDAb"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_August2019WarrantsMember" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" inside-table="false" id="fact-identifier-601" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On
August 23, 2019, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the
Company issued and sold an aggregate of</ix:nonnumeric></span> </span><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20190801__20190831__us-gaap--StatementClassOfStockAxis__custom--August232019Member_znZJGncD8xFc"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-08-012019-08-31_custom_August232019Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,475,000</ix:nonfraction></span>
</span>shares
of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent
private placement (the “August 2019 Warrants”). The August 2019 Warrants were initially exercisable for 2,237,500 shares
of common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zQHQtogphdF4"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_August2019WarrantsMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" inside-table="false" id="fact-identifier-603" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">February
27, 2020</ix:nonnumeric></span></span> and
will expire on August 28, 2023.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the year ended December 31, 2021, August
2019 Warrants for <span id="xdx_906_ecustom--NumberofWarrantsExercisedDuringPeriod_pin6_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zqCAvUVWaQp"><span><ix:nonfraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextref="From2021-01-012021-12-31_custom_August2019WarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-604" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.3</ix:nonfraction></span>
</span>million shares of common stock were exercised for approximately $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_pin6_uUSD_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zEWLi2hsYNTa"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2021-01-012021-12-31_custom_August2019WarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-605" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.4</ix:nonfraction></span>
</span>million. As of December 31, 2021, August 2019 Warrants exercisable for <span id="xdx_90C_ecustom--WarrantsExercisable_iI_pip0_c20211231__us-gaap--StatementClassOfStockAxis__custom--August2019WarrantsMember_zjZBDjOCyMo7"><span><ix:nonfraction name="SEEL:WarrantsExercisable" contextref="AsOf2021-12-31_custom_August2019WarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-606" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">900,000</ix:nonfraction></span>
</span>shares of common stock remain outstanding at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_z6PENrONWdr4"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_August2019WarrantsMember329739468" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-607" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.78</ix:nonfraction></span>
</span>per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>Series A Warrants</i>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zx9vvr8Zxao8"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_SeriesAWarrantsMember" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" inside-table="false" id="fact-identifier-608" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The
Series A Warrants were initially exercisable
for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to the terms
thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the
exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement
of the offerings pursuant to the September 2020 Securities Purchase Agreement. The Series A Warrants were immediately exercisable upon
issuance and will expire on January 31, 2024.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">During
the year ended December 31, 2021 and 2020, Series A Warrants for <span id="xdx_90B_ecustom--NumberofWarrantsExercisedDuringPeriod_pin6_uShares_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z3dd77hSPhEj" style="background-color: White"><span><ix:nonfraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextref="From2021-01-012021-12-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-609" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.5</ix:nonfraction></span> </span><span style="background-color: White">million
and <span id="xdx_906_ecustom--NumberofWarrantsExercisedDuringPeriod_pin6_uShares_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zi8kC3NjLU3a"><span><ix:nonfraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextref="From2020-01-012020-12-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-610" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.2</ix:nonfraction></span> </span></span><span style="background-color: White">million
shares of common stock, respectively, were exercised for approximately $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pin6_uUSD_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z0tnKgoqeFy1"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2021-01-012021-12-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-611" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> </span></span><span style="background-color: White">million
and $<span id="xdx_906_eus-gaap--ProceedsFromWarrantExercises_pp0p0_uUSD_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zyEObKbBdVo2"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2020-01-012020-12-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-612" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,000</ix:nonfraction></span></span></span><span style="background-color: White">,
respectively. As of December 31, 2021, Series A Warrants exercisable for <span id="xdx_90C_ecustom--WarrantsExercisable_iI_pin6_uShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_ztzOuFvenF8b"><span><ix:nonfraction name="SEEL:WarrantsExercisable" contextref="AsOf2021-12-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="INF" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-613" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.3</ix:nonfraction></span> </span></span><span style="background-color: White">million
shares of common stock remain outstanding at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zeCxL8lA8hYg"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_SeriesAWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-614" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2957</ix:nonfraction></span> </span></span><span style="background-color: White">per
share</span>.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>


<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-615" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zs8Q6k4l1Xo1" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of warrant activity during the year ended
December 31, 2021 is as follows (in thousands):</p>


<p id="xdx_8B2_z2LIccTdlgrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; display: none">Summary of Warrant Activity</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Weighted-</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Weighted-</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Average</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Average</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Remaining</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>Contractual Life</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><span style="font-size: 10pt"><b>Warrants</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 13%; text-align: center"><span style="font-size: 10pt"><b>Price</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><span style="font-size: 10pt"><b>(in years)</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Outstanding as of December 31, 2019</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pin3_c20191231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zL8Eay8H5Xfj" title="Outstanding as of December 31, 2019" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextref="AsOf2019-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-616" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,584</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pp2p0_uUSDPShares_c20191231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zUZEbWxbyZf5" title="Outstanding as of December 31, weighted-average exercise price (in usd per share)" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2019-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-617" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.86</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right; font-size: 10pt"></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Issued</span></td>
    <td>&nbsp;</td>
    <td id="xdx_98F_ecustom--NumberofWarrantsIssuedDuringPeriod_i01_pin3_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zAUb0Jln5yFg" title="Warrants issued" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="SEEL:NumberofWarrantsIssuedDuringPeriod" contextref="From2020-01-012020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-618" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,648</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_ecustom--ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zJtEr0kLdOx9" title="Warrants issued, warrant exercise price" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="SEEL:ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" contextref="From2020-01-012020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-619" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.84</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Exercised</span></td>
    <td>&nbsp;</td>
    <td id="xdx_989_ecustom--NumberofWarrantsExercisedDuringPeriod_i01_pin3_uShares_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zK2vQP1qYqj3" title="Warrants exercised" style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextref="From2020-01-012020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">154</ix:nonfraction></span>)</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zVcpS6XEwd87" title="Warrants exercised, exercise price of warrants" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="SEEL:ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" contextref="From2020-01-012020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-621" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.30</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Cancelled</span></td>
    <td>&nbsp;</td>
    <td id="xdx_985_ecustom--NumberofWarrantsCancelledDuringPeriod_i01_pin3_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zPGYKSu9hAlb" title="Warrants cancelled" style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="SEEL:NumberofWarrantsCancelledDuringPeriod" contextref="From2020-01-012020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-622" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12</ix:nonfraction></span>)</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98E_ecustom--ClassOfWarrantOrRightCanceledExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_z86sYuoYrfbc" title="Warrants cancelled, exercise price of warrants" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="SEEL:ClassOfWarrantOrRightCanceledExercisePriceOfWarrantsOrRights" contextref="From2020-01-012020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-623" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">18.00</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Outstanding as of December 31, 2020</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pin3_c20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zCAjuDVWjeU" title="Outstanding as of December 31, 2020" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextref="AsOf2020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-624" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,066</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
<td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pp2p0_uUSDPShares_c20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_z24H1LDNVw9b" title="Outstanding as of December 31, weighted-average exercise price (in usd per share)" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-625" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.84</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td id="xdx_98C_ecustom--ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_dtY_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zB6vdxSHCA4l" style="text-align: right; font-size: 10pt"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt-sec:duryear" name="SEEL:ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" inside-table="true" id="fact-identifier-626" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.4</ix:nonnumeric></span></td></tr>
    <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Issued</span></td>
    <td>&nbsp;</td>
    <td id="xdx_983_ecustom--NumberofWarrantsIssuedDuringPeriod_i01_pin3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zL0zkSXddAwa" title="Warrants issued" style="text-align: right"><span style="font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0966"><span><ix:nonfraction name="SEEL:NumberofWarrantsIssuedDuringPeriod" contextref="From2021-01-012021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="fact-identifier-627" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0966" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">&nbsp;</ix:nonfraction></span></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zTIvJZzhjmke" title="Warrants issued, warrant exercise price" style="text-align: right"><span style="font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0968"><span><ix:nonfraction name="SEEL:ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights" contextref="From2021-01-012021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="fact-identifier-628" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0968" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">&nbsp;</ix:nonfraction></span></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Exercised</span></td>
    <td>&nbsp;</td>
    <td id="xdx_98A_ecustom--NumberofWarrantsExercisedDuringPeriod_i01_pin3_uShares_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zNm4g2P9M1u2" title="Warrants exercised" style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="SEEL:NumberofWarrantsExercisedDuringPeriod" contextref="From2021-01-012021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-629" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,431</ix:nonfraction></span>)</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_i01_pp2n2_uUSDPShares_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zIkhSz6SIFi2" title="Warrants exercised, exercise price of warrants" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="SEEL:ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights" contextref="From2021-01-012021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="2" unitref="USDPShares" inside-table="true" id="fact-identifier-630" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.98</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; Cancelled</span></td>
    <td>&nbsp;</td>
    <td id="xdx_987_ecustom--NumberofWarrantsCancelledDuringPeriod_i01_pin3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zCFeEQULRwMc" title="Warrants cancelled" style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0974"><span><ix:nonfraction name="SEEL:NumberofWarrantsCancelledDuringPeriod" contextref="From2021-01-012021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="fact-identifier-631" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0974" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">-</ix:nonfraction></span></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightCanceledExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_z86UFWV9H6Pa" style="text-align: right"><span style="font-size: 10pt">-<span style="-sec-ix-hidden: xdx2ixbrl0975"><span><ix:nonfraction name="SEEL:ClassOfWarrantOrRightCanceledExercisePriceOfWarrantsOrRights" contextref="From2021-01-012021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" id="fact-identifier-632" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0975" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">&nbsp;</ix:nonfraction></span></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Outstanding as of December 31, 2021</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pin3_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zhVTHNyWlKDc" title="Outstanding as of December 31, 2021" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextref="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-633" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,635</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pp2p0_uUSDPShares_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zRD3fEZECHu" title="Outstanding as of December 31, weighted-average exercise price (in usd per share)" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-634" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.29</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_dtY_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zc2kdD1Im4ch" style="text-align: right; font-size: 10pt"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt-sec:duryear" name="SEEL:ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife" inside-table="true" id="fact-identifier-635" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.4</ix:nonnumeric></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Exercisable as of December 31, 2021</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_985_ecustom--WarrantsExercisable_iI_pin3_uShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zeJXfgRoZEj8" title="Warrants exercisable as of December 31" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="SEEL:WarrantsExercisable" contextref="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-636" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,635</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_iI_pp2p0_uUSDPShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zKJ5DgKvuLw6" title="Warrants exercisable, weighted-average exercise price (in usd per share)" style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="SEEL:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-637" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.29</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td id="xdx_982_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_dtY_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zrV8DjMBYaql" title="Warrants exercisable as of December 31, 2021, weighted-average remaining contractual life (in years)" style="text-align: right; font-size: 10pt"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember" format="ixt-sec:duryear" name="SEEL:ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife" inside-table="true" id="fact-identifier-638" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.4</ix:nonnumeric></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><p id="xdx_8A3_z9wrwBGnAEY4" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Series A Warrants were recognized as a
liability at their fair value upon issuance. The warrant liability is remeasured to the then fair value prior to their exercise or
at period end for warrants that are unexercised and the gain or loss recognized in earnings during the period.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">92</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>







<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-639" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z4euioaKD8ha" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>11. Stock-Based Compensation</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7dlVtOZgYHi"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" inside-table="false" id="fact-identifier-640" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Company has the Amended and Restated Apricus 2012 Stock Long Term
Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted
and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest
over a period of one to four years and have a maximum term of ten years from the date of grant. As of December 31, 2021, an aggregate
of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4FZDHXwbxR9"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextref="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-641" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,110,431</ix:nonfraction></span></span> shares of common stock were authorized under the Apricus 2012 Plan, of which <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pin6_c20211231_zLUTkbRHY6Il"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-642" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.4</ix:nonfraction></span></span> million shares of common stock were available
for future grants. Upon completion of the Merger, the Company assumed the Seelos Therapeutics, Inc. 2016 Equity Incentive Plan (the “2016
Plan”) and awards outstanding under the 2016 Plan became awards for common stock. Effective as of the Merger, no further awards
may be issued under the 2016 Plan.</ix:nonnumeric></span></span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210101__20211231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zjWd15bXaash"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" inside-table="false" id="fact-identifier-643" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On May 15, 2020, the Company’s stockholders approved the Company’s
2020 Employee Stock Purchase Plan (the “ESPP”), whereby qualified employees are allowed to purchase limited amounts of the
Company’s common stock at the lesser of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pip2_dp_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zG2ZeKcmMav3"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextref="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-4" unitref="Pure" inside-table="false" id="fact-identifier-644" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85</ix:nonfraction></span></span>% of the market price at the beginning or end of the offering period. The stockholders
authorized an initial amount of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zgnqUdAw8Ve4"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextref="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-645" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span></span> million shares for purchase by employees under the ESPP. The ESPP provides that an additional number
of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing
on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to the lesser of (i) 1% of the number of
shares of the Company’s common stock issued and outstanding on the immediately preceding December 31, and (ii) a number of shares
of common stock set by the Company’s Board of Directors or the Compensation Committee of the Board of Directors (the “Compensation
Committee”) of the Company on or prior to each such January 1. <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20210101__20211231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zTnZDtsAYU4"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" inside-table="false" id="fact-identifier-646" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On January 1, 2021, the Company added 545,358 shares for purchase
by employees under the ESPP.</ix:nonnumeric></span></span> During the year ended December 31, 2021, the Company sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zDpws2Q4fQ1h"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextref="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-647" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,009</ix:nonfraction></span></span> shares under the ESPP. The compensation
costs are calculated as the fair value of the 15% discount from market price and were approximately $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zWjwR8FgLPP5"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextref="From2021-01-012021-12-31_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-648" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72,000</ix:nonfraction></span></span> for the year ended December
31, 2021.</ix:nonnumeric></span></span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210101__20211231__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_ztrN7flWMuhc"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_InducementPlanof2019Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" inside-table="false" id="fact-identifier-649" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">On July 28, 2019, the Compensation Committee adopted the Seelos Therapeutics,
Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan
is substantially similar to the 2016 Plan. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock
options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units
and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met.
Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into
employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona
fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20211231__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_zNM0va6Gdss4"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextref="AsOf2021-12-31_custom_InducementPlanof2019Member" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-650" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000,000</ix:nonfraction></span></span>
shares of the Company’s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August
12, 2029.</ix:nonnumeric></span></span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Stock options</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTlT0Gyjt5C7"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" inside-table="false" id="fact-identifier-651" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">During the year ended December 31, 2021, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zySPq6YMbbm1"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-652" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,210,000</ix:nonfraction></span></span>
stock options to employees with a weighted average exercise price per share of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrVjSAPnDbr9"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-653" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.04</ix:nonfraction></span></span> and a 10-year term, subject to the terms and conditions
of the 2012 Plan above. The stock
options are subject to time vesting requirements. The stock options granted to employees vest 25% on the first anniversary of the grant
and monthly thereafter over the next three years.</ix:nonnumeric></span></span></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zZgWT6RK096k"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" inside-table="false" id="fact-identifier-654" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">During
the year ended December 31, 2021, the Company also granted</ix:nonnumeric></span> </span><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zGNNGM3ERehl"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-655" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">106,000</ix:nonfraction></span>
</span>non-qualified
stock options to non-employee directors with a weighted average exercise price per share of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zE5oStEzJIEj"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-656" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.67</ix:nonfraction></span>
</span>and
a 10-year term, subject to the terms and conditions of the 2012 Plan above. 64,000 of the stock options granted to non-employee directors
vest monthly over the 12 months following the grant and 42,000 of these stock options vest 25% on the first anniversary of the grant
and monthly thereafter over the next two years.&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">93</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The fair value of stock option grants are estimated on the date of
grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked sufficient company-specific
historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility
of a publicly traded set of peer companies. Additionally, due to an insufficient history with respect to stock option activity and post-vesting
cancellations, the expected term assumption for employee grants is based on a permitted simplified method, which is based on the vesting
period and contractual term for each tranche of awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield
curve in effect for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the
fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-657" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z7IUk0xIRtRj" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following assumptions were used in determining
the fair value of the stock options granted during the years ended December 31, 2021 and 2020:</p>
<p id="xdx_8BF_zXfcPsXzw2Jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Valuation Assumptions for Stock Options</p>



<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: right; width: 70%">&nbsp;</td>
    <td style="text-align: right; width: 1%">&nbsp;</td>
    <td style="text-align: right; width: 1%">&nbsp;</td>
    <td style="text-align: center; width: 13%">&nbsp;</td>
    <td style="text-align: right; width: 1%">&nbsp;</td>
    <td style="text-align: right; width: 1%">&nbsp;</td>
    <td style="text-align: center; width: 13%"></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="4" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white">&nbsp;</td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>2021</b></span></p></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgVDIVGkQpZ8"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-658" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span></span>%-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgjgOWoVrrL4"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-659" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.2</ix:nonfraction></span></span>%</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5G4K94SNEFj"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextref="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember329742015" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-660" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span></span>%-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1nN2YHCslq3"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextref="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember329742015" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="true" id="fact-identifier-661" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.7</ix:nonfraction></span></span>%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">Volatility</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zb5nF4ibOLGb"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-662" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">118</ix:nonfraction></span></span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zo1Mrs00hqh"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-663" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125</ix:nonfraction></span></span>%</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zF4IT7LBrmz6"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextref="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-664" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">109</ix:nonfraction></span></span>%-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zztvjpqML6W4"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextref="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-665" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">119</ix:nonfraction></span></span>%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">Dividend yield</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSEwLhk3MI45"><span style="-sec-ix-hidden: xdx2ixbrl1016"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000" id="fact-identifier-666" unitref="Pure" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1016" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span> %</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX8xOeEVRX7g"><span style="-sec-ix-hidden: xdx2ixbrl1017"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember329742015" id="fact-identifier-667" unitref="Pure" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1017" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></span> %</span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">Expected term (years)</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zkVOHHZ4sN02"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-668" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span></span>-<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zEw9y4CbMHM"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-669" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonnumeric></span></span></span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zYAQbwNw3rI4"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-670" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span></span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zbR433gLyEU7"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-671" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonnumeric></span></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="background-color: white"><span style="font-size: 10pt">Weighted-average fair value</span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zg2XLuQI9Rvb"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-672" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.46</ix:nonfraction></span></span></span></td>
    <td style="background-color: white; text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0AjFIEi6UF3"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember329742015" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-673" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.97</ix:nonfraction></span></span></span></td></tr>
  </tbody></table>
</ix:nonnumeric></span><p id="xdx_8A5_zur2nXGsmGE1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"></p>




<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-674" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zGwXtKjiCYWg" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A summary of stock option activity during the year
ended December 31, 2021 is as follows (in thousands, except exercise prices and years):</p>
<p id="xdx_8BF_zHOdoRenQ5rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Valuation Assumptions for Stock Options</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Weighted</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Weighted</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Total</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Average</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Average Remaining</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Aggregate</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Stock</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Exercise</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Contractual</b></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 9.5pt"><b>Intrinsic</b></span></td></tr>
  <tr>
    <td style="width: 42%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 9.5pt"><b>Options</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 9.5pt"><b>Price</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><span style="font-size: 9.5pt"><b>Life (in years)</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 9.5pt"><b>Value</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Outstanding as of December 31, 2020</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_uShares_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zWpBxzdXI1Cl" style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2020-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-675" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,120</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2p0_uUSDPShares_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zXc5DkaDn7bk" style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-676" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.97</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right; font-size: 9.5pt"></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span style="font-size: 9.5pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Granted</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_z9pDHndpdMLa" style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-677" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,316</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zm5lX5OkIdod" style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-678" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.94</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right; font-size: 9.5pt"></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Exercised</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zEt4wfBG18k8" style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-679" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">81</ix:nonfraction></span>)</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zs2xVSGBwLMf" style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-680" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.40</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Cancelled</span></td>
    <td>&nbsp;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pin3_di_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_z0kQVfNo3DL6" style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 9.5pt">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-681" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49</ix:nonfraction></span>)</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zVueHKDPDabb" style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextref="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-682" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.06</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"> &nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Outstanding as of December 31, 2021</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_uShares_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zx2N2EaV07J7" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-683" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,306</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2p0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zPboptHsdHi1" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-684" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.60</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zxrqnIL5Ytqb" style="text-align: right; font-size: 9.5pt"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-685" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.5</ix:nonnumeric></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_uUSD_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zw0Q5xvBE7xi" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-686" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,180</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Vested and expected to vest as of December 31, 2021</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pin3_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_z1yg8tHivt55" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextref="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-687" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,306</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zCla0wQtyRuc" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-688" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.60</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_ztXwWlD6SJe" style="text-align: right; font-size: 9.5pt"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-689" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.5</ix:nonnumeric></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pn3n3_uUSD_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zV6W6Q4Lwju2" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextref="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-690" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,180</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Exercisable as of December 31, 2021</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pin3_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_z9laGM8ZelMh" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitref="Shares" inside-table="true" id="fact-identifier-691" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,245</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zBavhrolh2Tg" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="true" id="fact-identifier-692" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.99</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_znK0JBaVEXll" style="text-align: right; font-size: 9.5pt"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-693" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.1</ix:nonnumeric></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_uUSD_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsandDirectorOptionsMember_zxdTk1UdOoe8" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextref="AsOf2021-12-31_custom_StockOptionsandDirectorOptionsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-694" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">856</ix:nonfraction></span>&nbsp;</span></td></tr>
  </tbody></table>
</ix:nonnumeric></span><p id="xdx_8A7_zCEiN3zSl7D3" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The intrinsic value of options exercised during the years ended December
31, 2021 and 2020 was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm2n6QybU1L4"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-695" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span></span> million and $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHwQlKDO2QIa"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-696" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span>, respectively. As of December 31, 2021, unrecognized stock-option compensation expense of $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqZwwEgiKfMg"><span><ix:nonfraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextref="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-697" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.4</ix:nonfraction></span></span>
million is expected to be realized over a weighted-average period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_pid_dtY_uYears_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0cDI9iB3Oqd"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember329741000" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" inside-table="false" id="fact-identifier-698" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.1</ix:nonnumeric></span></span> years.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 0 6pt"><i>Performance Stock Award</i></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 0 6pt"><span style="background-color: white"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_pip0_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zaSjlw208Zpl"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" inside-table="false" id="fact-identifier-699" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">During
the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the
Company’s Chief Executive Officer for <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pp0p0_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zT3trg7CuhOb"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextref="From2019-01-012019-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="Shares" inside-table="false" id="fact-identifier-700" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,400,000</ix:nonfraction></span></span>
shares of common stock, with a grant date fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zxDRWvxt6fFf"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2019-01-012019-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt:numdotdecimal" decimals="2" scale="0" unitref="USDPShares" inside-table="false" id="fact-identifier-701" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.31</ix:nonfraction></span></span>
per unit. Vesting of this award is subject to the Company achieving certain performance criteria established at the grant date and
the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards are
unvested and three of the five performance conditions have been satisfied. The Company recognized stock-based compensation related
to this award of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zTdRxZs5lGaa"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2019-01-012019-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-702" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.9</ix:nonfraction></span></span>
million during the fourth quarter of 2021, which was recorded in general and administrative expense. The Company does not believe that the
achievement of the remaining two performance criteria is probable at this time. Unrecognized compensation expense will be recognized
only once the performance condition is probable of being achieved and only for the cumulative amount related to the service
condition that has been fulfilled. As of December 31, 2021, the Company had $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pn5n6_c20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zrEqOR3R6coe"><span><ix:nonfraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextref="AsOf2021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-703" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span></span>
million of unrecognized compensation expense related to performance conditions considered probable which will be recognized over <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_pid_dtY_uYears_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_z32FZkfUPYN2"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" inside-table="false" id="fact-identifier-704" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonnumeric></span></span>
years. As of December 31, 2021, the Company had unrecognized compensation expense of $<span id="xdx_90D_ecustom--SharebasedPaymentArrangementNonvestedAwardExcludingOptionCostNotYetRecognizedForPerformanceNotProbableAmount_iI_pn5n6_c20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zsFl7rpAI1pa" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized for Performance Not Probable, Amount"><span><ix:nonfraction name="SEEL:SharebasedPaymentArrangementNonvestedAwardExcludingOptionCostNotYetRecognizedForPerformanceNotProbableAmount" contextref="AsOf2021-12-31_us-gaap_PerformanceSharesMember_custom_PSUtoExecutivesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-705" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.1</ix:nonfraction></span></span>
million for performance conditions that were considered not probable of achievement.</ix:nonnumeric></span></span></span>&nbsp;&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">&nbsp;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">94</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>







<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-706" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zI97LS1e4ur8" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The following table summarizes the total stock-based
compensation expense resulting from share-based awards recorded in the Company's consolidated statements of operations (in thousands):</p>

<p id="xdx_8B3_zQZmeL0hn6J1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Stock-Based Compensation Expense</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 9.5pt"><b>Year Ended December 31,</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 74%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 9.5pt"><b>2021</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 9.5pt"><b>2020</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Research and development</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9clW4XAjdU" style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-707" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">717</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zcoOdvd8rzx8" style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-708" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">394</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 9.5pt">General and administrative</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zRIWsxjI1Mmh" style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-012021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-709" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,630</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zCLSOGN6C3T8" style="border-bottom: black 1.5pt solid; text-align: right; font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-710" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,650</ix:nonfraction></span>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20211231_zlDq7lSgonEh" title="Stock-based compensation expense" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-711" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,347</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20200101__20201231_z7hrx084Fikc" title="Stock-based compensation expense" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-712" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,044</ix:nonfraction></span>&nbsp;</span></td></tr>
  </tbody></table>
</ix:nonnumeric></span><p id="xdx_8A2_zRfXcWjGllSd" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-713" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zUuRkvwWnzya" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>12. Income Taxes</b></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has incurred net operating losses
since inception. At December 31, 2021, the Company has available net operating loss carryforwards of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z0lt5HTdho24" title="Operating loss carryforward"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-714" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89.4</ix:nonfraction></span></span>
million for federal income tax reporting purposes and approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zi2Hy5qbErRi" title="Operating loss carryforward"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-715" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">175.5</ix:nonfraction></span></span>
million for state and local income tax reporting purposes. The federal net operating loss carryover includes $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_znFZndbF9zJg"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextref="AsOf2021-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-716" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.4</ix:nonfraction></span></span>
million that will begin expiring in <span id="xdx_905_eus-gaap--OperatingLossCarryforwardsExpirationDate_dxL_uYears_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zJbP23eaY2v4" title="::XDX::12%2F31%2F2036"><span style="-sec-ix-hidden: xdx2ixbrl1075"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_DomesticCountryMember" format="ixt:datemonthdayyear" id="fact-identifier-717" name="us-gaap:OperatingLossCarryforwardsExpirationDate" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="xdx2ixbrl1075" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">2036</ix:nonnumeric></span></span></span>.
The remaining net operating loss carryover of $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zlk5wNNYPnc7"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" contextref="AsOf2021-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-718" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89.0</ix:nonfraction></span></span>
million will be carried forward indefinitely. The state net operating loss carryover of $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zBEdB6b2AAk"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-719" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">175.5</ix:nonfraction></span></span>
million will begin expiring in <span id="xdx_90C_eus-gaap--OperatingLossCarryforwardsExpirationDate_ddxL_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z1AZTTivlb1" title="::XDX::12%2F31%2F2036"><span style="-sec-ix-hidden: xdx2ixbrl1078"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:datemonthdayyear" id="fact-identifier-720" name="us-gaap:OperatingLossCarryforwardsExpirationDate" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="xdx2ixbrl1078" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">2036</ix:nonnumeric></span></span></span>.</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-721" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zxeZiEvWmcd7" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Deferred tax assets consist of the following (in
thousands):</p>

<p id="xdx_8B7_zTkfdcL65NF4" style="font: 9.5pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0">Schedule of Deferred Tax Assets</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td id="xdx_497_20211231_zNS4ARpzgJtd" style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td id="xdx_49D_20201231_zqIPXHWbDFt8" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 9.5pt"><b>December 31,</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 74%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 9.5pt"><b>2021</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 9.5pt"><b>2020</b></span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzWS4_zXEBlihbeZR6" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Net operating tax loss carryforwards</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-722" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,751</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-723" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,223</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzWS4_zvpFFPpkrMdb" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Accrued expenses</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"> - <span style="-sec-ix-hidden: xdx2ixbrl1085"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextref="AsOf2021-12-31" id="fact-identifier-724" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1085" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-725" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_pn3n3_maDTAGzWS4_zMcXwQJshjkg" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Contingent payment obligations</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-726" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">407</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">- <span style="-sec-ix-hidden: xdx2ixbrl1089"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextref="AsOf2020-12-31" id="fact-identifier-727" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1089" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzWS4_zOUdt9htAqm3" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Stock-based compensation</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-728" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,208</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-729" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">521</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzWS4_zBOsdr7PbnR1" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Intangible assets</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-730" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,970</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-731" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,320</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_mtDTAGzWS4_maDTANzkos_zB4PiGTIvlqd" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">&nbsp;&nbsp;&nbsp;&nbsp; Total deferred tax asset</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-732" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,336</ix:nonfraction></span>&nbsp;</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-733" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,130</ix:nonfraction></span>&nbsp;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzkos_zWaSI8kvRV1" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Less valuation allowance</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 9.5pt">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-734" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,336</ix:nonfraction></span>)</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 9.5pt">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-735" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,130</ix:nonfraction></span>)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_mtDTANzkos_z6nLqqtpTJua" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">&nbsp;&nbsp;&nbsp;&nbsp; Net deferred tax asset</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt">- <span style="-sec-ix-hidden: xdx2ixbrl1103"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2021-12-31" id="fact-identifier-736" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt">- <span style="-sec-ix-hidden: xdx2ixbrl1104"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2020-12-31" id="fact-identifier-737" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></span></td></tr>
  </tbody></table>
</ix:nonnumeric></span><p id="xdx_8AC_z6tJRonnkeDj" style="font: 9.5pt Times New Roman, Times, Serif; margin: 6pt 0">&nbsp;</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin: 6pt 0">The federal and state net operating loss carryforwards, not subject
to the annual limitation under Internal Revenue Code Section 382, resulted in a noncurrent deferred tax asset as of December 31, 2021
and 2020 of approximately $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsGrossNoncurrent_iI_pn5n6_c20211231_zHRTS44cUA3g" title="Noncurrent deferred tax asset, gross"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGrossNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-738" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30.8</ix:nonfraction></span></span> million and $<span id="xdx_908_eus-gaap--DeferredTaxAssetsGrossNoncurrent_iI_pn5n6_c20201231_z2u9WXVhsIOk" title="Noncurrent deferred tax asset, gross"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGrossNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-739" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15.2</ix:nonfraction></span></span> million, respectively.&nbsp;In consideration of the Company's accumulated losses and
the uncertainty of its ability to utilize this deferred tax asset in the future, the Company has recorded a full valuation allowance as
of such dates.</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin: 6pt 0">The Company follows&nbsp;the provisions of income tax guidance
which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in
income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the
financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax
positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the
largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company's federal
income tax returns for <span id="xdx_900_eus-gaap--OpenTaxYear_c20210101__20211231_zZuLumIoN6ge"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="us-gaap:OpenTaxYear" inside-table="false" id="fact-identifier-740" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2018</ix:nonnumeric></span></span> to 2021 are still open
and subject to audit.&nbsp;In addition, net operating losses arising from prior years are also subject to examination at the time
they are utilized in future years.&nbsp;Unrecognized tax benefits, if recognized, would have no effect on the Company's effective
tax rate. The Company's policy is to recognize interest and penalties related to income tax matters in income tax expense. For the
years ended December 31, 2021 and 2020, the Company has <span id="xdx_904_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pip0_do_c20210101__20211231_zkR2m9a6Art5" title="Tax examination penalties and interest expense"><span id="xdx_90E_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pip0_do_c20200101__20201231_zOxnQsRTk2Ia"><span><ix:nonfraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextref="From2021-01-01to2021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-741" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextref="From2020-01-012020-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-742" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></span></span>
recorded interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax
benefits within the next twelve months.</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin: 6pt 0">The Company did not have any unrecognized tax benefits for the years ended December 31, 2021 and 2020.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">95</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>









<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0">&nbsp;&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-743" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zezo3XDceuIj" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The reconciliation of income taxes computed using
the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31, 2021 and 2020,
are as follows:</p>

<p id="xdx_8BF_z2cp8TKICrwf" style="font: 9.5pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0">Schedule of Effective Income Tax Rate Reconciliation</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td id="xdx_494_20210101__20211231_zps18fkbQmWj" style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td id="xdx_491_20200101__20201231_zegDx7mW8pY6" style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 9.5pt"><b>Year Ended December 31,</b></span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="width: 73%">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 9.5pt"><b>2021</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="width: 1%; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 9.5pt"><b>2020</b></span></td>
    <td style="width: 1%; text-align: right">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pp1p0_z6D9ugBN3lje" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Federal statutory tax rate</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-744" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span>&nbsp;</span></td>
    <td><span style="font-size: 9.5pt">%</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-745" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span>&nbsp;</span></td>
    <td><span style="font-size: 9.5pt">%</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pp1p0_zWXqnecGpFfj" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">State and local taxes, net of federal benefit</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-746" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.9</ix:nonfraction></span>&nbsp;</span></td>
    <td><span style="font-size: 9.5pt">%</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-747" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.2</ix:nonfraction></span>&nbsp;</span></td>
    <td><span style="font-size: 9.5pt">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsOther_pp1p0_z92tdVnBokab" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Permanent items</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-748" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.1</ix:nonfraction></span>)</span></td>
    <td><span style="font-size: 9.5pt">%</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-749" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span>)</span></td>
    <td><span style="font-size: 9.5pt">%</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pp1p0_zkTmhBThFZQf" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Deferred rate changes</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-750" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span>&nbsp;</span></td>
    <td><span style="font-size: 9.5pt">%</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-751" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> &nbsp;</span></td>
    <td><span style="font-size: 9.5pt">%</span></td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pp1p0_zUn2MQD33dK6" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Other</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-752" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0</ix:nonfraction></span>&nbsp;</span></td>
    <td><span style="font-size: 9.5pt">%</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 9.5pt"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitref="Pure" inside-table="true" id="fact-identifier-753" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59.3</ix:nonfraction></span></span></td>
    <td><span style="font-size: 9.5pt">%</span></td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pp1p0_zXryR2Pipcmi" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">Change in valuation allowance</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 9.5pt">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-754" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35.1</ix:nonfraction></span>)</span></td>
    <td><span style="font-size: 9.5pt">%</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 9.5pt">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-755" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90.6</ix:nonfraction></span>)</span></td>
    <td><span style="font-size: 9.5pt">%</span></td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_zSbGlc0VvUqc" style="vertical-align: top">
    <td><span style="font-size: 9.5pt">&nbsp;&nbsp;&nbsp;&nbsp; Income tax provision (benefit)</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt">- <span style="-sec-ix-hidden: xdx2ixbrl1134"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2021-01-01to2021-12-31" id="fact-identifier-756" unitref="Pure" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></span></td>
    <td><span style="font-size: 9.5pt">%</span></td>
    <td style="text-align: right">&nbsp;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 9.5pt">- <span style="-sec-ix-hidden: xdx2ixbrl1135"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2020-01-012020-12-31" id="fact-identifier-757" unitref="Pure" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">&nbsp;</ix:nonfraction></span></span></span></td>
    <td><span style="font-size: 9.5pt">%</span></td></tr>
  </tbody></table>
</ix:nonnumeric></span><p id="xdx_8AC_zeSvgWMqVNdl" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-758" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80A_eus-gaap--CommitmentsDisclosureTextBlock_zPeoTg8AMwFk" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>13.</b>&nbsp;<b>Commitments and Contingencies</b></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>Leases</i></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0"><span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20210101__20211231__us-gaap--LeaseContractualTermAxis__custom--March2019LeaseMember_z0aqwr6d1jQk"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_March2019LeaseMember" name="us-gaap:LesseeOperatingLeaseDescription" inside-table="false" id="fact-identifier-759" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">In
March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November
2019. In November 2019 the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000
per month. In November 2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately
$3,800 per month. In March 2021, the Company was notified that the counterparty’s right to occupy the space at 300 Park Avenue,
New York, NY was terminated, and the Company was required to vacate by March 26, 2021. The Company vacated the premises and has advised
the counterparty that the counterparty is in breach of this rental agreement and therefore, the Company has no further obligations thereunder.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0"><span id="xdx_900_eus-gaap--LesseeOperatingLeaseDescription_c20210101__20211231__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_z5XGESwi08Qj"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_March2021LeaseMember" name="us-gaap:LesseeOperatingLeaseDescription" inside-table="false" id="fact-identifier-760" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">In
March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New York,
NY, expiring July 2022. The rental agreement contains a base rent of approximately $4,000 per month.</ix:nonnumeric></span> </span><span id="xdx_906_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20210101__20211231__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_znBWQipFSuS"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_March2021LeaseMember" name="us-gaap:LesseeOperatingLeaseOptionToExtend" inside-table="false" id="fact-identifier-761" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">This
agreement includes one or more renewal options.</ix:nonnumeric></span></span> At December 31, 2021, the Company has right-of-use assets of $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_z0HaYBldbYWd"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2021-12-31_custom_March2021LeaseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-762" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,000</ix:nonfraction></span>
</span>and a total lease liability for operating leases of $<span id="xdx_90F_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20211231__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zhphEBI2FtU5"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiability" contextref="AsOf2021-12-31_custom_March2021LeaseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-763" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,000</ix:nonfraction></span></span>,
of which all is included in current lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0">Upon the commencement of the 300 Park Avenue, New York,
NY office space in March 2021,
in exchange for the new operating lease liability, the Company recognized a right-of-use asset of $<span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210331_zwHad2h693F4"><span><ix:nonfraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextref="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-764" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74,000</ix:nonfraction></span></span>.
As December 31, 2021, the weighted-average remaining lease term of the operating lease is <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_pp1p0_dtxL_uYears_c20211231_zMgZ6HWt8X1f" title="::XDX::P292D"><span style="-sec-ix-hidden: xdx2ixbrl1144"><span><ix:nonnumeric contextref="AsOf2021-12-31" id="fact-identifier-765" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="xdx2ixbrl1144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">0.8
</ix:nonnumeric></span></span></span>years, and the weighted-average discount rate is <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pp1p0_uPure_c20211231_zrhbpACvLyrk"><span><ix:nonfraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitref="Pure" inside-table="false" id="fact-identifier-766" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.0</ix:nonfraction></span></span>%.&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-767" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_89B_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zXhLn9nS7Ama" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0">As
of December 31, 2021, future minimum lease payments for the Company’s operating leases with a non-cancelable term of more
than one year is as follows (in thousands):</p>

<p id="xdx_8BF_z1KRk18BYi8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; display: none">Schedule of future minimum operating lease payments</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="width: 79%"></td>
    <td style="width: 2%"></td>
    <td style="width: 2%"></td>
    <td id="xdx_49E_20211231_zruIgLM5ZKec" style="font-weight: bold; text-align: center; width: 17%">Operating</td></tr>
  <tr style="vertical-align: bottom">
    <td></td>
    <td></td>
    <td></td>
    <td style="border-bottom: Black 0.5pt solid; font-weight: bold; text-align: center">Leases</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPz53j_zrpgG7zHWwA3" style="vertical-align: bottom">
    <td>Remaining Period Ended December 31, 2021</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149"><span><ix:nonfraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextref="AsOf2021-12-31" id="fact-identifier-768" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl1149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false">-</ix:nonfraction></span></span></td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPz53j_zcfG0jf8lnZj" style="vertical-align: bottom">
    <td>Year Ended December 31, 2022</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right"><span><ix:nonfraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-769" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40</ix:nonfraction></span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_i01TI_pn3n3_mtLOLLPz53j_zQwz4jjjjnJc" style="vertical-align: bottom">
    <td style="text-indent: 10pt">Total</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="border-top: Black 0.5pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-770" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40</ix:nonfraction></span></td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_i01NI_pn3n3_di_maOLLzeMS_zz6HdRwECwrl" style="vertical-align: bottom">
    <td>Less present value discount</td>
    <td style="text-align: right"></td>
    <td style="text-align: right"></td>
    <td style="text-align: right">(<span><ix:nonfraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-771" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzeMS_zuijHUAWEMd6" style="vertical-align: bottom">
    <td>Operating lease liabilities</td>
    <td style="text-align: right"></td>
    <td style="text-align: right">$</td>
    <td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingLeaseLiability" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitref="USD" inside-table="true" id="fact-identifier-772" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38</ix:nonfraction></span></td></tr>
  </tbody></table>

<p style="font: 9pt Sans-Serif; margin: 0 5.85pt 0 5pt; text-align: left; color: Red"></p>

</ix:nonnumeric></span><p id="xdx_8A6_zLVHyMAiaLE2" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0">For the years ended December 31, 2021 and 2020, rent expense totaled
$<span id="xdx_902_eus-gaap--OperatingLeaseExpense_pn5n6_c20210101__20211231_zol13YoQn0w5"><span id="xdx_903_eus-gaap--OperatingLeaseExpense_pn5n6_c20200101__20201231_zlb1Hvmu88d1"><span><ix:nonfraction name="us-gaap:OperatingLeaseExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-773" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:OperatingLeaseExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-774" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span></ix:nonfraction></span></span></span> million.</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><i>Contractual Commitments</i></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has entered into long-term agreements
with certain manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects to enter
into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front
payments and long-term commitments of cash.&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">96</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>











<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Litigation</b></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of December 31, 2021, there was no material litigation
against the Company.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-775" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_z66whnoU24a3" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>14. Subsequent Events</b></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">In January 2022, the Company paid to iXBEL the
Shortfall Amount (as described in Note 4) of $<span id="xdx_906_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zDzfctKQt45g"><span><ix:nonfraction name="SEEL:NonrefundableCashPayment" contextref="From2022-01-012022-01-31_custom_IXLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitref="USD" inside-table="false" id="fact-identifier-776" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.2</ix:nonfraction></span></span>
million in cash.</p>

</ix:nonnumeric></span><p id="xdx_815_zOylwdswL3Ig" style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item9"></span>ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span id="item9a"></span><b>ITEM 9A.</b>&nbsp;<b>CONTROLS
AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Evaluation of Disclosure Controls and Procedures</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Our disclosure controls and procedures are designed to ensure that
information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, communicated to our management
to allow timely decisions regarding required disclosure, summarized and reported within the time periods specified in the SEC’s
rules and forms.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">Under the supervision and with the
participation of our management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”),
we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e)
and 15d-15(e) under the Exchange Act, as of December 31, 2021. Based on this evaluation, our CEO and CFO concluded that our disclosure
controls and procedures were effective as of December 31, 2021 at the reasonable assurance level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Management's Report on Internal Control Over
Financial Reporting</i></b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Management is responsible for establishing and maintaining adequate
internal control over financial reporting, as such term is defined in Exchange Act Rule 13a 15(f). Our internal control over financial
reporting is a process designed, under the supervision and, with the participation of our CEO who serves as our principal executive officer
and principal financial officer, overseen by our Board of Directors and implemented by our management and other personnel, to provide
reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external
purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes policies
and procedures that:</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of
our assets;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations
of our management and directors; and</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/120% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">•</td><td>Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets
that could have a material effect on our financial statements.</td></tr></tbody></table>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">97</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->









<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Because of our inherent limitations, our internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate. Management performed an assessment of the effectiveness of our internal control over financial reporting
as of December&nbsp;31, 2021 using criteria established in the&nbsp;<i>Internal Control-Integrated Framework (2013)</i>&nbsp;issued by
the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this assessment, management determined
that, as of December&nbsp;31, 2021, our internal control over financial reporting was effective. Because we are a smaller reporting company,
KPMG, an independent registered public accounting firm, is not required to attest to or issue a report on the effectiveness of our internal
control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"><i>Inherent Limitations on Effectiveness
of Controls</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">A control system, no matter how well conceived and
operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent
limitations, internal control over financial reporting may not prevent or detect misstatements.&nbsp;Accordingly, our disclosure controls
and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure system are met. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of
changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><i>Changes in Internal Control over Financial
Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">There were no material changes to our internal control over financial reporting
during the three months ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item9b"></span>ITEM 9B. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item9c"></span>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</b></p>


<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>PART III.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item10"></span>ITEM 10. DIRECTORS, EXECUTIVE
OFFICERS AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The information required by this item is incorporated
by reference from the information contained in our Definitive Proxy Statement to be filed with the SEC within 120 days after the end of
the fiscal year ended December 31, 2021 in connection with the Annual Meeting of Stockholders to be held in 2022 (the "2022 Proxy
Statement"). To the extent that we do not file the 2022 Proxy Statement by such date, we will file an amendment to this Annual Report
on Form 10-K that includes the information required by this Item 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">We have adopted a Code of Ethics for Officers
(the "Code of Ethics") that is available at the Investors/Media/Corporate Governance Documents section of our website at
www.seelostherapeutics.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item11"></span>ITEM 11. EXECUTIVE COMPENSATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The information required by this item is incorporated
by reference from the information contained in the 2022 Proxy Statement. The 2022 Proxy Statement will be filed within 120 days after
the end of the fiscal year ended December 31, 2021. To the extent that we do not file the 2022 Proxy Statement by such date, we will file
an amendment to this Annual Report on Form 10-K that includes the information required by this Item 11.</p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">98</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->









<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item12"></span>ITEM 12.&nbsp;SECURITY OWNERSHIP
OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The information required by this item is incorporated
by reference from the information contained in the 2022 Proxy Statement. The 2022 Proxy Statement will be filed within 120 days after
the end of the fiscal year ended December 31, 2021. To the extent that we do not file the 2022 Proxy Statement by such date, we will
file an amendment to this Annual Report on Form 10-K that includes the information required by this Item 12.&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item13"></span>ITEM 13. CERTAIN RELATIONSHIPS
AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The information required by this item is incorporated
by reference from the information contained in the 2022 Proxy Statement. The 2022 Proxy Statement will be filed within 120 days after
the end of the fiscal year ended December 31, 2021. To the extent that we do not file the 2022 Proxy Statement by such date, we will file
an amendment to this Annual Report on Form 10-K that includes the information required by this Item 13.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item14"></span>ITEM 14. PRINCIPAL ACCOUNTANT
FEES AND SERVICES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The information required by this item is incorporated
by reference from the information contained in the 2022 Proxy Statement. The 2022 Proxy Statement will be filed within 120 days after
the end of the fiscal year ended December 31, 2021. To the extent that we do not file the 2022 Proxy Statement by such date, we will file
an amendment to this Annual Report on Form 10-K that includes the information required by this Item 14.</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>PART IV.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0.5in"></p>



<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b><span id="item15"></span>ITEM 15. EXHIBITS</b></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">(a) 1.&nbsp;<span style="text-decoration: underline">Financial Statements:</span></p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0.5in">The information required by this item is included
in Item 8 of Part II of this Form 10-K.</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;&nbsp;&nbsp;&nbsp; 2. Financial Statement
Schedules</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0.5in">The information required by this item is included
in Item 8 of Part II of this Form 10-K.</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;&nbsp;&nbsp;&nbsp; 3. Exhibits</p>

<p style="font: 9.5pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0.5in">The following exhibits are incorporated by reference
or filed as part of this report:</p>

<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; width: 5%"><span style="font-size: 7.5pt"><b>EXHIBITS<br>
NO.</b></span></td>
    <td style="border-bottom: black 1.5pt solid; padding: 0.75pt; width: 95%"><span style="font-size: 7.5pt"><b>&nbsp; DESCRIPTION</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000069/exhibit21agreementandplano.htm" tabindex="18">2.1</a>+</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Agreement and Plan of Merger and Reorganization, dated July 30, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 30, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000092/ex21to8-kon10x16x18.htm" tabindex="18">2.2</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment No. 1 Agreement and Plan of Merger and Reorganization, dated October 16, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312518349990/d602430dex21.htm" tabindex="18">2.3</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment No. 2 Agreement and Plan of Merger and Reorganization, dated December 14, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 14, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  </tbody></table>


<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">99</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001204/ex2_1.htm" tabindex="18">2.4</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment No. 3 Agreement and Plan of Merger and Reorganization, dated January 16, 2019, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 16, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000068/exh2-1.htm" tabindex="18">2.5</a>+</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Asset Purchase Agreement, dated February 15, 2019, by and between the Company and Bioblast Pharma Ltd. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 19, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/0001005477-97-000778.txt" tabindex="18">3.1</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amended and Restated Articles of Incorporation of the Company (incorporated herein by reference to Exhibit 2.1 to the Company's Registration Statement on Form 10- SB filed with the Securities and Exchange Commission on March 14, 1997).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 6%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000095013603000741/file002.txt" tabindex="18">3.2</a></span></td>
    <td style="padding: 0.75pt; width: 94%"><span style="font-size: 10pt">Certificate of Amendment to Articles of Incorporation of the Company, dated June 22, 2000 (incorporated herein by reference to Exhibit 3.2 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2003).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420406010273/v037542_ex3-4.htm" tabindex="18">3.3</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to Articles of Incorporation of the Company, dated June 14, 2005 (incorporated herein by reference to Exhibit 3.4 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2006).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-6.htm" tabindex="18">3.4</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated March 3, 2010 (incorporated herein by reference to Exhibit 3.6 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420410017441/v178249_ex3-7.htm" tabindex="18">3.5</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Correction to Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated March 3, 2010 (incorporated herein by reference to Exhibit 3.7 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420411016743/v215636_ex3-1.htm" tabindex="18">3.6</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Designation for Series D Junior-Participating Cumulative Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-A filed with the Securities and Exchange Commission on March 24, 2011).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420410034002/v188471_ex3-1.htm" tabindex="18">3.7</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 17, 2010).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420410048909/v196361_ex3-1.htm" tabindex="18">3.8</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated September 10, 2010 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2010).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312513224446/d539505dex31.htm" tabindex="18">3.9</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Withdrawal of Series D Junior Participating Cumulative Preferred Stock, dated May&nbsp;15, 2013 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May&nbsp;16, 2013).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749116000227/exhibit31to8-konreversesto.htm" tabindex="18">3.10</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2016).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000091/apri63017ex310.htm" tabindex="18">3.11</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.10 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 2, 2017).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  </tbody></table>


<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">100</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000075/apri63018ex312.htm" tabindex="18">3.12</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.12 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_1.htm" tabindex="18">3.13</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment related to the Share Increase Amendment, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_2.htm" tabindex="18">3.14</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment related to the Name Change, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 6%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/ex3_3.htm" tabindex="18">3.15</a></span></td>
    <td style="padding: 0.75pt; width: 94%"><span style="font-size: 10pt">Amended and Restated Bylaws, dated January 24, 2019 (incorporated herein by reference to Exhibit 3.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000114/exh3-16.htm" tabindex="18"><span style="font-size: 10pt">3.16</span></a></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Correction to Certificate of Amended and Restated Articles of Incorporation of the Company, dated March 25, 2020 (incorporated herein by reference to Exhibit 3.16 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2020)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000124/exh3-1.htm" tabindex="18"><span style="font-size: 10pt">3.17</span></a></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed May 18, 2020 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 19, 2020).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; text-align: left; vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000131/exh3-1.htm" tabindex="18"><span style="font-size: 10pt">3.18</span></a></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Correction to Certificate of Amended and Restated Articles of Incorporation of the Company, filed May 20, 2020 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2020).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; text-align: left; vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000080/exh3-1.htm" tabindex="18"><span style="font-size: 10pt">3.19</span></a></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certificate of Amendment to the Amended and Restated
    Articles of Incorporation of the Company, filed May 21, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company's
    Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114420411016740/v215638_ex4-1.htm" tabindex="18">4.1</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2011).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312514375645/d806711dex42.htm" tabindex="18">4.2</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant issued to the lenders under the Loan and Security Agreement, dated as of October 17, 2014, by and among the Company, NexMed (U.S.A.), Inc., NexMed Holdings, Inc. and Apricus Pharmaceuticals USA, Inc., as borrowers, Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time including Oxford Finance LLC and Silicon Valley Bank (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 20, 2014).</span></td></tr>

  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312516428442/d224777dex41.htm" tabindex="18">4.3</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant issued to Sarissa Capital Domestic Fund LP and Sarissa Capital Offshore Master Fund LP (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312516428442/d224777dex42.htm" tabindex="18">4.4</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant issued to other purchasers (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).</span></td></tr>

  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  </tbody></table>


<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">101</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000119312516722474/d444660dex41.htm" tabindex="18">4.5</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2016).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000048/exhibit49formofwarrant.htm" tabindex="18">4.6</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant (incorporated herein by reference to Exhibit 4.9 of Amendment No. 1 to Company's Registration Statement on Form S-1 (File No. 333-217036) filed with the Securities and Exchange Commission on April 17, 2017).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 6%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000063/exhibit41formofwarrantamen.htm" tabindex="18">4.7</a></span></td>
    <td style="padding: 0.75pt; width: 94%"><span style="font-size: 10pt">Form of Warrant Amendment (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 21, 2017).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000034/ex412amendmenttowarranttop.htm" tabindex="18">4.8</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.12 of Amendment No. 1 to the Company's Registration Statement on Form S-3 (File No. 333-223353) filed with the Securities and Exchange Commission on March 22, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000050/exhibit41to8-kon3x29x18.htm" tabindex="18">4.9</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to Warrant to Purchase Common Stock, dated as of March 27, 2018 (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000050/exhibit42to8-kon3x29x18.htm" tabindex="18">4.10</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000050/exhibit43to8-kon3x29x18.htm" tabindex="18">4.11</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000065/exhibit41to8-kjune2018warr.htm" tabindex="18">4.12</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to Warrant to Purchase Common Stock, dated as of June 22, 2018, by and between the Company and Sarissa Offshore (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000085/ex41to8-konsept2018pipe.htm" tabindex="18">4.13</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000085/ex42to8-konsept2018pipe.htm" tabindex="18">4.14</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Wainwright Warrant (incorporated by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000092/ex41to8-kon10x16x18.htm" tabindex="18">4.15</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Investor Warrants (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000092/ex42to8-kon10x16x18.htm" tabindex="18">4.16</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Registration Rights Agreement, dated October 16, 2018, by and among the Company and certain investors named therein (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000038/exh4-1.htm" tabindex="18">4.17</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Series A Warrant, issued to investors on January 31, 2019 (incorporated by reference to Exhibit 4.1 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 6, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000232/exh4-1.htm" tabindex="18">4.18</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant, issued to investors on August 27, 2019 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  </tbody></table>


<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">102</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000167/exh4-1.htm" tabindex="18">4.19</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Warrant, issued to investors on September 9, 2020 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 9, 2020).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 6%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000248/exh4-1.htm" tabindex="18">4.20</a></span></td>
    <td style="padding: 0.75pt; width: 94%"><span style="font-size: 10pt">Form of Convertible Promissory Note due November 13, 2024
    (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange
    Commission at 7:27 a.m. Eastern Time on November 24, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/exh4-21.htm" tabindex="18">4.21</a>*</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Description of Securities of Seelos Therapeutics, Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/exh4-22.htm" tabindex="18">4.22</a>*</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to Convertible Promissory Note, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC, dated December 10, 2021.</span></td></tr>

  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749114000079/apri-2014630xex101.htm" tabindex="18">10.1</a>#</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Stock Option Grant Notice and Stock Option Agreement under the Company's 2012 Stock Long Term Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2014).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749117000104/ex42formofregistrationrigh.htm" tabindex="18">10.2</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Registration Rights Agreement (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 11, 2017).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000065/exhibit101to8-kjune2018war.htm" tabindex="18">10.3</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment No. 1 to Subscription Agreement, dated as of June 22, 2018, by and between the Investors and the Company (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000069/exhibit101formofcvragreeme.htm" tabindex="18">10.4</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of CVR Agreement (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 30, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 6%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1032toapris-4.htm" tabindex="18">10.5</a></span></td>
    <td style="padding: 0.75pt; width: 94%"><span style="font-size: 10pt">Form of Indemnification Agreement for the Company's Directors and Officers (incorporated by reference to Exhibit 10.32 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1033toapris-4.htm" tabindex="18">10.6</a>†</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">License Agreement, dated September 21, 2016, by and among Seelos Therapeutics, Inc., Ligand Pharmaceuticals Incorporated, Neurogen Corporation and CyDex Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.33 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1034toapris-4.htm" tabindex="18">10.7</a>+†</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Asset Purchase Agreement, dated as of March 6, 2018, by and between Seelos Therapeutics, Inc. and Vyera Pharmaceuticals AG f/k/a Turing Pharmaceuticals AG (incorporated by reference to Exhibit 10.34 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1035toapris-4.htm" tabindex="18">10.8</a>†</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to Asset Purchase Agreement, dated as of May 18, 2018, by and between Seelos Therapeutics, Inc. and Vyera Pharmaceuticals AG f/k/a Turing Pharmaceuticals AG (incorporated by reference to Exhibit 10.35 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1036toapris-4.htm" tabindex="18">10.9</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Indemnity Agreement, dated July 8, 2016, by and between Seelos Therapeutics, Inc. and Raj Mehra, Ph.D. (incorporated by reference to Exhibit 10.36 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1039toapris-4.htm" tabindex="18">10.10</a>#</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Seelos Therapeutics, Inc. 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.39 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  </tbody></table>


<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">103</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000101749118000081/exhibit1040toapris-4.htm" tabindex="18">10.11</a>#</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Option Agreement under the Seelos Therapeutics, Inc. 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.40 of the Company's Registration Statement on Form S-4 filed on August 31, 2018).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119000397/ex10_1.htm" tabindex="18">10.12</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Second Amendment Agreement, dated as of January 4, 2019, by and among Seelos Therapeutics, Inc., the Company and the investors party thereto (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036119001204/ex10_1.htm" tabindex="18">10.13</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Third Amendment Agreement, dated as of January 16, 2019, by and among Seelos Therapeutics, Inc., the Company and the investors party thereto (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 16, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000064/exh10-2.htm" tabindex="18">10.14</a>#</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 30, 2021).</span></td></tr>

  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000215/exh10-1.htm" tabindex="18">10.15</a>#</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Seelos Therapeutics, Inc. 2019 Inducement Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 14, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000264/exh10-1.htm" tabindex="18">10.16</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment No. 2 to Asset Purchase Agreement, dated as of December 31, 2018, by and between Seelos Therapeutics, Inc. and Phoenixus AG f/k/a Vyera Pharmaceuticals AG and Turing Pharmaceuticals AG. (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000220/exh4-3.htm" tabindex="18">10.17</a>#</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Form of Stock Option Agreement under the Seelos Therapeutics, Inc. 2019 Inducement Plan (incorporated herein by reference to Exhibit 4.3 to the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on August 15, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>

  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 6%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000264/exh10-7.htm" tabindex="18">10.18^</a></span></td>
    <td style="padding: 0.75pt; width: 94%"><span style="font-size: 10pt">Amended and Restated Exclusive License Agreement, dated August 29, 2019, by and between Seelos Therapeutics, Inc. and Stuart Weg, MD. (incorporated herein by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000239/exh10-1.htm" tabindex="18">10.19</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment No. 3 to Asset Purchase Agreement, dated October 15, 2019, by and between Seelos Therapeutics, Inc. and Phoenixus AG (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 21, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626120000092/exh10-30.htm" tabindex="18">10.20</a>*</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment to License Agreement, dated as of February 8, 2019, by and among Ligand Pharmaceuticals Incorporated, Neurogen Corporation, CyDex Pharmaceuticals, Inc., and Seelos Corporation (incorporated herein by reference to Exhibit 10.30 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2020).</span></td></tr>

  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/nc10010435x2_def14a.htm#tAPPB" tabindex="18">10.21</a>#</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan, effective May 15, 2020 (incorporated herein by reference to Appendix B to the Registrant's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 13, 2020).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/nc10010435x2_def14a.htm#tAPPA" tabindex="18">10.22</a>#</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Seelos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (incorporated herein by reference to Appendix A to the Registrant's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 13, 2020).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000027/exh10-1.htm" tabindex="18">10.23</a>**</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amendment No. 4 to Asset Purchase Agreement, dated February 15, 2021, by and between Seelos Corporation and Phoenixus AG (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 18, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  </tbody></table>


<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">104</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="1" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000248/exh10-1.htm" tabindex="18">10.24</a>^</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Securities Purchase Agreement, dated as of November 23, 2021, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC. (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission at 7:27 a.m. Eastern Time on November 24, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000248/exh10-2.htm" tabindex="18">10.25</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Security Agreement, dated as of November 23, 2021, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC. (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission at 7:27 a.m. Eastern Time on November 24, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000250/exh10-1.htm" tabindex="18">10.26</a>^**</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">License Agreement, dated as of November 24, 2021, by and between Seelos Therapeutics, Inc. and iX Biopharma Europe Limited (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission at 8:20 a.m. Eastern Time on November 24, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626121000250/exh10-2.htm" tabindex="18">10.27</a>**</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Common Stock Purchase Agreement, dated as of November 24, 2021, by and between Seelos Therapeutics, Inc. and iX Biopharma Europe Limited (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission at 8:20 a.m. Eastern Time on November 24, 2021).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626122000035/exh10-1.htm" tabindex="18">10.28</a>#</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Amended and Restated Employment Agreement by and between Seelos Therapeutics, Inc. and Raj Mehra, Ph.D., dated as of January 10, 2022 (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 10, 2022).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1017491/000113626119000121/exh21-1.htm" tabindex="18">21.1</a></span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 28, 2019).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/exh23-1.htm" tabindex="18">23.1</a>*</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Consent of KPMG, LLP, independent registered public accounting firm.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/exh31-1.htm" tabindex="18">31.1</a>*</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certification of Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/exh31-2.htm" tabindex="18">31.2</a>*</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt; width: 6%"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/exh32-1.htm" tabindex="18">32.1</a>*</span></td>
    <td style="padding: 0.75pt; width: 94%"><span style="font-size: 10pt">Certification of Principal Executive Officer, pursuant to 18
    U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (1)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1017491/000113626122000156/exh32-2.htm" tabindex="18">32.2</a>*</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section
    1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (1)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.INS</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.SCH</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.CAL</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.DEF</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.LAB</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">101.PRE</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt">&nbsp;</td>
    <td style="padding: 0.75pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.75pt"><span style="font-size: 10pt">104</span></td>
    <td style="padding: 0.75pt"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></td></tr>
  </tbody></table>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">105</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0.5in">(1) &nbsp;&nbsp; Furnished, not filed.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%"><span style="background-color: white">+</span></td>
    <td style="width: 95%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%"><span style="background-color: white">All schedules and exhibits to the agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities Exchange Commission upon request.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">†</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">Confidential treatment has been granted for portions of this exhibit.&nbsp;&nbsp;Those portions have been omitted and filed separately with the Securities and Exchange Commission.</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">*</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">Filed herewith.</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">#</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 120%">Management compensatory plan or arrangement</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">^&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">Non-material schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the Securities and Exchange Commission.</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">**</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain identified information has been omitted pursuant to Item 601(b)(10)
    of Regulation S-K because such information is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly
    disclosed. The Company hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the Securities and Exchange
    Commission.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></td></tr>
  </tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span id="item16"></span><b>ITEM 16.</b>&nbsp;<b>FORM 10-K SUMMARY</b></p>



<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">106</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;<b>SIGNATURES</b></p>

<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Pursuant to&nbsp;the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="vertical-align: top; width: 61%; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; width: 39%; padding-right: 2pt; padding-left: 9pt">Seelos Therapeutics, Inc.</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-left: 9pt">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 2pt; padding-left: 3pt">Date: March 4, 2022</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">/s/ Raj Mehra, Ph.D.</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">Raj Mehra, Ph.D.</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">President and Chief Executive Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 3pt">Date: March 4, 2022</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">/s/ Michael Golembiewski</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">Michael Golembiewski</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></td></tr>
  </tbody></table>
<p style="font: 10pt/9pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/9pt Times New Roman, Times, Serif; margin: 0; text-align: center">POWER OF ATTORNEY</p>

<p style="font: 10pt/9pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/9pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><span style="font-variant: small-caps"><b>Know All
Persons By These Presents</b></span>, that each person whose signature appears below constitutes and appoints Raj Mehra, Ph.D. his or
her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments
to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities
and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may
do or cause to be done by virtue hereof.</p>

<p style="font: 10pt/9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/9pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons, on behalf of the registrant on the dates and the capacities
indicated.</p>

<p style="font: 10pt/9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/9pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 30%; padding-right: 3pt; padding-left: 3pt">Signature</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 53%; padding-right: 3pt; padding-left: 3pt">Title</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 15%; padding-right: 3pt; padding-left: 3pt">Date</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">/s/ Raj Mehra, Ph.D.</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">President, Chief Executive Officer, and Chairman of the Board</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">March 4, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">Raj Mehra, Ph.D.</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt"><i>(Principal Executive Officer)</i></td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt">/s/ Michael Golembiewski</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">Chief Financial Officer</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">March 4, 2022</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">Michael Golembiewski</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt"><i>(Principal Financial and Accounting Officer)</i></td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">/s/ Margaret Dalesandro</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">Director</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">March 4, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">Margaret Dalesandro</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">/s/ Brian Lian, Ph.D.</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">Director</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">March 4, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">Brian Lian, Ph.D.</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">/s/ Daniel J. O’Connor, J.D.</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">Director</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">March 4, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">Daniel J. O’Connor, J.D.</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">/s/ Richard W. Pascoe</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 3pt; padding-left: 3pt">Director</td>
    <td style="vertical-align: bottom; padding-left: 3pt">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 3pt; padding-left: 3pt">March 4, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">Richard W. Pascoe</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td>
    <td style="padding-left: 3pt">&nbsp;</td>
    <td style="padding-right: 3pt; padding-left: 3pt">&nbsp;</td></tr>
  </tbody></table>
<p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span id="Signatures"></span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 18 --><div style="border-bottom: Black thin solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="font-size: 9pt; text-align: center; width: 100%">107</td></tr></tbody></table></div><div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->





<p style="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</p>




</body>
</html>